<SEC-DOCUMENT>0001824293-24-000105.txt : 20240814
<SEC-HEADER>0001824293-24-000105.hdr.sgml : 20240814
<ACCEPTANCE-DATETIME>20240813200547
ACCESSION NUMBER:		0001824293-24-000105
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240814
DATE AS OF CHANGE:		20240813

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GRI BIO, Inc.
		CENTRAL INDEX KEY:			0001824293
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				824369909
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40034
		FILM NUMBER:		241203707

	BUSINESS ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(619) 400-1171

	MAIL ADDRESS:	
		STREET 1:		2223 AVENIDA DE LA PLAYA
		STREET 2:		SUITE 208
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Vallon Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20200910
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ck0001824293-20240630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4b2bd8b8-7391-472c-baa6-f4915a4212d0,g:cfdabf3d-48ec-4ec5-a4ba-2606592f7687,d:442ee3de1de54639845a81d9f3db661d-->
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ck0001824293="http://www.vallon-pharma.com/20240630" xmlns:srt="http://fasb.org/srt/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ck0001824293-20240630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-29">0001824293</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-30">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-31">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-32">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-33">FALSE</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-49" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-267">0.0333</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-50" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-268">0.14290</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-51" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="f-269">0.07690</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ck0001824293-20240630.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="closing"><xbrli:measure>ck0001824293:closing</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-08-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-29</xbrli:startDate><xbrli:endDate>2024-01-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-17</xbrli:startDate><xbrli:endDate>2024-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-20</xbrli:startDate><xbrli:endDate>2024-05-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-21</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-26</xbrli:startDate><xbrli:endDate>2024-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesCCommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesCCommonWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:GRIOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-13</xbrli:startDate><xbrli:endDate>2022-12-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-14</xbrli:startDate><xbrli:endDate>2022-12-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-09</xbrli:startDate><xbrli:endDate>2023-03-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-21</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ThePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ThePlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsNotExpiringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInDecember2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001824293</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-21</xbrli:startDate><xbrli:endDate>2023-04-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i442ee3de1de54639845a81d9f3db661d_1"></div><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:2.5pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1"><ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-2">10-Q</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-3">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5">June 30, 2024</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.150%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from_________to_________</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number:&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-7">001-40034</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:center"><img src="ck0001824293-20240630_g1.jpg" alt="GRI_ LOGO SELECT_ColorJPG.jpg" style="height:101px;margin-bottom:5pt;vertical-align:text-bottom;width:201px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-8">GRI BIO, INC.</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">____________________________________</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.622%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-9">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-10">82-4369909</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Identification No.)&#160;</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-11">2223 Avenida de la Playa</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-12">#208</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-13">La Jolla</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-14">CA</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-15">92037</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-16">619</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-17">400-1170</ix:nonNumeric></span></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.650%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.513%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-18">Common Stock, par value $0.0001<br/>per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-19">GRI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">The Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.372%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-24">x</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-true" id="f-25">x</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act.&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityExTransitionPeriod" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-27">x</ix:nonNumeric></span></div><div style="margin-bottom:8pt;margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of August&#160;6, 2024, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-28">2,927,707</ix:nonFraction> shares of the Registrant&#8217;s common stock were outstanding.</span></div><div style="margin-bottom:8pt;margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><span><br/></span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_7"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:8pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.066%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_13">PART&#160;I. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_13">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_16">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_19">Balance Sheets as of </a>June 30, 2024<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_19"> (unaudited) and </a>December 31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated Statements of Operations (unaudited) for the three and six <a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_22">months ended</a> June 30, 2024<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_22"> and</a> 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_25">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) (unaudited) for the three and six months ended June 30, 202</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_25">4</a><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_25"> and 202</a>3</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2024<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_28"> and </a>2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_28">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_31">Notes to Unaudited Interim Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_85">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_85">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_109">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_109">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_109">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_112">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_112">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_112">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_115">PART&#160;II. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_115">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_115">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_118">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_118">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_118">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_121">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_121">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_121">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_124">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_124">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_124">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_127">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_127">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_127">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_130">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_130">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_130">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_133">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_133">30</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_136">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_136">31</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_139">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i442ee3de1de54639845a81d9f3db661d_139">33</a></span></div></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_13"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div id="i442ee3de1de54639845a81d9f3db661d_16"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Financial Statements.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_19"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:71.589%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-34">6,353</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-35">1,808</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="f-36">531</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">1,126</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">6,884</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">2,934</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">6</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-41">8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-42">141</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="f-43">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-44">7,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">1,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">1,410</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-48">935</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">1,270</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:WarrantLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-50">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:WarrantLiabilityCurrent" scale="3" id="f-51">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-52">45</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-53">14</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">2,216</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">2,697</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-56">96</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-57">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-58">2,312</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-59">2,697</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-60"/></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-61"/></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, <ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-62"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-63">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-64"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-65">250,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of June&#160;30, 2024 and December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-66"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-67">801,914</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-69">49,663</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June&#160;30, 2024 and December&#160;31, 2023, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-70">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in-capital</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-72">40,389</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-73">31,792</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-74">35,670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-75">31,533</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-76">4,719</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-77">259</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-78">7,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-79">2,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_22"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.043%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:10pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-80">877</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-81">880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-82">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="f-83">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-85">5,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">2,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-87">5,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28.35pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-88">2,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-89">5,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-90">4,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-91">6,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">2,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-93">5,934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-94">4,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">6,923</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-96">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-97">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-98">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ChangeInFairValueOfWarrantLiability" scale="3" id="f-99">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-100">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-101">934</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="f-102">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-103">2,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-104">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">4,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">8,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share of common stock, basic and diluted</span></div></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-108"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-109">4.92</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-110"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-111">239.37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-112"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113">8.82</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-114"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-115">433.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-117">457,742</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-118"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-119">28,181</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-120"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-121">469,100</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-122"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-123">20,536</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_25"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.876%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity (Deficit)</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-124">10,987</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-125">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-126">16,871</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-127">18,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-128">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-129">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-130">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock vesting</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="f-131">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-132">532</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" id="f-133">532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-134">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-135">2,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-136">10,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-138">17,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-139">20,646</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-140">3,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-141">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-142">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted stock vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="f-143">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" scale="0" id="f-144">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-145">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueWarrantExercises" scale="3" id="f-146">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock in pre-closing financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing" format="ixt:num-dot-decimal" scale="0" id="f-147">13,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-148">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing" format="ixt:num-dot-decimal" scale="3" id="f-149">11,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for settlement of bridge note</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt" scale="0" id="f-150">596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-151">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-152">3,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock for reverse recapitalization expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" scale="0" id="f-153">335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-154">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="3" id="f-155">1,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to Vallon stockholders in reverse recapitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization" format="ixt:num-dot-decimal" scale="0" id="f-156">4,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-157">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-158">2,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">6,746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-161">32,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-163">31,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-164">27,392</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-165">4,038</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.205%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.876%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Additional&#160;Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance,&#160;December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-166">49,663</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-167">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">31,792</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">31,533</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-170">259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-171">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-172">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-173">19</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants in financing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-174">25,419</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-175">4,389</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-176">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prefunded warrant exercise</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-177">170,812</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-178">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-179">1,887</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, March 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-180">245,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">36,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">33,420</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-184">2,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-185">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="f-186">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fractional share adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment" scale="0" id="f-187">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock and prefunded warrants in financing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-188">353,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-189">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-190">4,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prefunded warrant exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise" format="ixt:num-dot-decimal" scale="0" id="f-191">202,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-192">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-193">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-194">801,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-196">40,389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-197">35,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-198">4,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_28"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">4,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">8,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-201">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-202">2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discounts and issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="f-203">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-204">2,104</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-205">74</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="f-206">26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-207">3</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-208">63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition" scale="3" id="f-209">127</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="f-210">26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-211">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-212">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-213">400</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-214">4,179</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-215">250</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-216">1,157</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-217">127</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-218">30</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-219">4,344</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-220">2,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-221">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-222">8</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-223">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-224">8</ix:nonFraction>)</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Advances from employees</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:ProceedsFromAdvancesFromEmployees" scale="3" id="f-226">190</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment of advances from employees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" format="ixt:fixed-zero" scale="3" id="f-227">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:RepaymentOfAdvancesFromEmployees" scale="3" id="f-228">195</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in financing</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-229">9,499</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-230">12,250</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-231">961</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-232">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from issuance of bridge promissory note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:fixed-zero" scale="3" id="f-233">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-234">1,250</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from warrant exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-236">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net liabilities assumed in connection with reverse recapitalization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:fixed-zero" scale="3" id="f-237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" format="ixt:num-dot-decimal" scale="3" id="f-238">2,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of reverse recapitalization costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:PaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-240">2,984</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of deferred stock issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-241">1,571</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="f-242">517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-244">150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-245">8,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-246">6,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-247">4,545</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-248">4,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-249">1,808</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-250">9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-251">6,353</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-252">4,799</ix:nonFraction></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of stock for repayment of bridge promissory note</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:fixed-zero" scale="3" id="f-253">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuedForRepaymentOfNotesPayable" format="ixt:num-dot-decimal" scale="3" id="f-254">3,333</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the<br/>&#160;&#160;issuance of promissory notes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" format="ixt:fixed-zero" scale="3" id="f-255">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" scale="3" id="f-256">532</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of stock for payment of reverse recapitalization costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts" format="ixt:num-dot-decimal" scale="3" id="f-258">1,875</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Issuance of warrants for payment of stock issuance costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:WarrantsIssued" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:WarrantsIssued" scale="3" id="f-260">18</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Stock issuance costs in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:StockIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-261">367</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:StockIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-262">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;Merger costs included in accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ck0001824293:NoncashMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-263">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ck0001824293:NoncashMergerRelatedCostsFinancingActivities" scale="3" id="f-264">72</ix:nonFraction></span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to unaudited interim consolidated financial statements.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_31"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GRI Bio, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Unaudited Interim Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div id="i442ee3de1de54639845a81d9f3db661d_34"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:NatureOfOperations" id="f-265" continuedAt="f-265-1" escape="true">ORGANIZATION AND DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-265-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to an Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among the Company, GRI Bio Operations, Inc., formerly known as GRI Bio, Inc. (GRI Operations), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI Operations (the Merger), with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company (Note 4). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and amended its bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization                              </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, and immediately prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-48" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-266">0.0001</ix:nonFraction> (Common Stock), at a ratio of  one-for-thirty (the April 2023 Reverse Stock Split). On January 29, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split and together with the April 2023 Reverse Stock Split and the January 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, GRI Operations. All Common Stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio (as defined below) and the Reverse Stock Splits for all periods presented, to the extent applicable.</span></div></ix:continuation><div id="i442ee3de1de54639845a81d9f3db661d_40"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock" id="f-270" continuedAt="f-270-1" escape="true">LIQUIDITY</ix:nonNumeric></span></div><ix:continuation id="f-270-1" continuedAt="f-270-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and, as a result, has incurred $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-271">35,670</ix:nonFraction> in accumulated deficit through June&#160;30, 2024. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2024, the Company had cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-272">6,353</ix:nonFraction>. </span></div></ix:continuation><div style="margin-bottom:8pt;margin-top:8pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-270-2" continuedAt="f-270-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium Growth Fund, LP (Altium) entered into a Securities Purchase Agreement, dated December 13, 2022 (the Equity SPA), pursuant to which Altium agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-273">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes (as defined below) in return for the issuance of shares of GRI Operations common stock (GRI Operations Common Stock) immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued <ix:nonFraction unitRef="shares" contextRef="c-53" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-274">74,584</ix:nonFraction> shares of GRI Operations Common Stock (the Initial Shares) to Altium and <ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="ck0001824293:CommonStockHeldIntoEscrowAccount" format="ixt:num-dot-decimal" scale="0" id="f-275">298,339</ix:nonFraction> shares of GRI Operations Common Stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-276">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-277">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-278">2,789</ix:nonFraction> shares of the Company&#8217;s Common Stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" format="ixt:num-dot-decimal" scale="0" id="f-279">11,157</ix:nonFraction> shares of the Company&#8217;s Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Company&#8217;s Common Stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-280">25,419</ix:nonFraction> shares (the February 2024 Shares) of  Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-281">359,196</ix:nonFraction> pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-282">359,196</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-283">384,615</ix:nonFraction> Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-284">384,615</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-285">384,615</ix:nonFraction> Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-286">384,615</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-287">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-288">1,110</ix:nonFraction>. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-289">one</ix:nonFraction> February 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-290">one</ix:nonFraction> February 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-291">one</ix:nonFraction> Series B-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-292">one</ix:nonFraction> Series B-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-293">14.30</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-294">0.0013</ix:nonFraction> for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants became exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-295">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-296">0.0013</ix:nonFraction> and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-297">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-298">14.30</ix:nonFraction> for a <ix:nonNumeric contextRef="c-61" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-299">five-year</ix:nonNumeric> period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-300">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-301">14.30</ix:nonFraction> for an <ix:nonNumeric contextRef="c-62" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-302">18</ix:nonNumeric>-month period after February 6, 2024 the date of issuance. As of June&#160;30, 2024, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the February 2024 Shares and February 2024 Warrants pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-63" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-303">0.0001</ix:nonFraction>, per share pursuant to the terms of the Series A-1 Warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-304">10.0</ix:nonFraction>&#160;million of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-64" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-305">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-306">293,892</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-307">3.27</ix:nonFraction> per share, raising $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-308">961</ix:nonFraction> of gross proceeds and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="f-309">923</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, the Company filed a prospectus supplement to its registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="3" id="f-310">2,644</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-311">961</ix:nonFraction> that have been sold under the ATM Offering.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-270-3" continuedAt="f-270-4"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering (the June 2024 Offering), (i) <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-312">60,000</ix:nonFraction> shares (the June 2024 Shares) of  Common Stock, (ii) <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-313">2,125,793</ix:nonFraction> pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-314">2,125,793</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-315">2,185,793</ix:nonFraction> Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-316">2,185,793</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-317">2,185,793</ix:nonFraction> Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-318">2,185,793</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-319">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-320">1,057</ix:nonFraction>. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-321">one</ix:nonFraction> June 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-322">one</ix:nonFraction> June 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-323">one</ix:nonFraction> Series C-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-324">one</ix:nonFraction> Series C-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-72" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-325">1.83</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-326">0.0001</ix:nonFraction> for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants are exercisable for <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-327">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-328">0.0001</ix:nonFraction>, are exercisable immediately and will expire when exercised in full. Each Series C Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-329">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-330">1.83</ix:nonFraction> and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series C Common Warrants (Warrant Stockholder Approval). The Series C-1 Common Warrants will expire on the <ix:nonNumeric contextRef="c-76" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-331">five-year</ix:nonNumeric> anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the <ix:nonNumeric contextRef="c-77" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-332">18</ix:nonNumeric>-month anniversary of the Warrant Stockholder Approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025. </span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-270-4">The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of Common Stock have a value weighted average price of at least $<ix:nonFraction unitRef="usdPerShare" contextRef="c-78" decimals="2" name="us-gaap:SharePrice" scale="0" id="f-333">838.11</ix:nonFraction> per share for the periods specified in the Series T Warrants, are not met. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty</ix:continuation>.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_43"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-334" continuedAt="f-334-1" escape="true">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-334-1" continuedAt="f-334-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-335" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2023 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2024, and the consolidated results of operations and consolidated stockholders&#8217; deficit for the three and six months ended June&#160;30, 2024 and 2023 and consolidated cash flows for the three and six months ended June&#160;30, 2024 and 2023. Consolidated results of operations for the three and six months ended June&#160;30, 2024 are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2024. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2023, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;28, 2024. </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-334-2" continuedAt="f-334-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-336" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-337" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-338" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the six months ended June&#160;30, 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DeferredChargesPolicyTextBlock" id="f-339" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-334-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-340" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the Company had a net loss in each of the three and six months ended June&#160;30, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-341" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.177%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.985%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-79" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-342">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-80" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-343">1,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-81" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-344">5,302,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-82" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-345">40,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-346">5,305,316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-347">41,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-348" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2024 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i442ee3de1de54639845a81d9f3db661d_49"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-349" continuedAt="f-349-1" escape="true">MERGER WITH VALLON</ix:nonNumeric></span></div><ix:continuation id="f-349-1" continuedAt="f-349-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into GRI Operations, with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of GRI Operations Common Stock outstanding immediately prior to the Effective Time, including any shares of GRI Operations Common Stock issued pursuant to the Equity SPA, automatically converted solely into the right to receive a number of shares of the Company&#8217;s Common Stock equal to <ix:nonFraction unitRef="number" contextRef="c-83" decimals="4" name="ck0001824293:CommonStockExchangeRatio" scale="0" id="f-350">0.0374</ix:nonFraction> (the Exchange Ratio).</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of GRI Operations Common Stock (each, a GRI Operations Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the GRI Operations Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s Common Stock, and the Company assumed the GRI Operations Plan and each such GRI Operations Option in accordance with the terms of the GRI Operations Plan (the Assumed Options). The number of shares of Common Stock subject to each Assumed Option was determined by multiplying (i) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per share exercise price for the Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of GRI Operations Common Stock (the GRI Operations Warrants) outstanding immediately prior to the Effective Time was assumed by the Company and converted into a warrant to purchase shares of Common Stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Common Stock; (ii) the number of shares of Common Stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-349-2" continuedAt="f-349-3"><div style="margin-bottom:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whole number of shares of Common Stock; and (iii) the per share exercise price for shares of Common Stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of GRI Operations Common Stock subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-84" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-351">4,632</ix:nonFraction> shares of the Company&#8217;s Common Stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-352">1,340.43</ix:nonFraction> per share.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to GRI Operations restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s Common Stock. The term, exercisability, vesting schedule and other provisions of the GRI Operations restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI Operations was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of GRI Operations immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately <ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-353">85</ix:nonFraction>% of the outstanding shares of the Company&#8217;s Common Stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately <ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="ck0001824293:CommonStockOwnershipPercentage" scale="-2" id="f-354">15</ix:nonFraction>% of the outstanding shares of the Company&#8217;s Common Stock (ii) GRI Operations holds the majority (4 out of 5) of board seats of the combined company, and (iii) GRI Operations&#8217; management holds the majority of key positions in the management of the combined company.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-355" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-356">941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="3" id="f-357">310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" format="ixt:num-dot-decimal" scale="3" id="f-358">4,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-359">2,939</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-360">2,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-361">5,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-349-3">In addition to the transaction costs noted above, at the Effective Time, <ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" format="ixt:num-dot-decimal" scale="0" id="f-362">4,363</ix:nonFraction> shares of Common Stock were issued to GRI Operations&#8217; financial advisor for services related to the Merger.</ix:continuation> </span></div><div id="i442ee3de1de54639845a81d9f3db661d_52"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-363" continuedAt="f-363-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-363-1" continuedAt="f-363-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-363-2"><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the six months ended June&#160;30, 2024.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-364" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.098%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-366">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="ck0001824293:WarrantLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-371" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.816%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.984%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-372">3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-373">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of June&#160;30, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-375" continuedAt="f-375-1" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the May 2022 Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.288%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.430%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-93" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-376">172.8</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-377">171.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-95" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-378">2.5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="1" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-379">2.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-380">0.0</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-381">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-99" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-382">4.62</ix:nonFraction>&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-383">4.12</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i442ee3de1de54639845a81d9f3db661d_55"></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-384" continuedAt="f-384-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-384-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-385" escape="true"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.511%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.512%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-386">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-387">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-388">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-389">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-390">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-391">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-392">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-393">26</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-394">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-395">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-396"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-397">2</ix:nonFraction></ix:nonFraction> for each of the six-month periods ended June&#160;30, 2024 and 2023.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_58"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-398" continuedAt="f-398-1" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-399" escape="true"><ix:continuation id="f-398-1"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-400">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedResearchAndDevelopmentCostsCurrent" scale="3" id="f-401">93</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-402">67</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent" scale="3" id="f-403">441</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-404">632</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="f-405">736</ix:nonFraction></span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="f-406">935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-407">1,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i442ee3de1de54639845a81d9f3db661d_61"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-408" continuedAt="f-408-1" escape="true">PROMISSORY NOTES</ix:nonNumeric></span></div><ix:continuation id="f-408-1"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, GRI Operations entered into a Securities Purchase Agreement, dated as of December 13, 2022 (the Bridge SPA), with Altium, pursuant to which GRI Operations issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-409">3,333</ix:nonFraction>, in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-410">2,500</ix:nonFraction>. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in <ix:nonFraction unitRef="closing" contextRef="c-106" decimals="INF" name="ck0001824293:DebtInstrumentNumberOfClosings" format="ixt-sec:numwordsen" scale="0" id="f-411">two</ix:nonFraction> closings: (i) the first closing for $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-412">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-413">1,250</ix:nonFraction>) closed on December 14, 2022; and (ii) the second closing for $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="3" id="f-414">1,667</ix:nonFraction> in aggregate principal amount (in exchange for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-415">1,250</ix:nonFraction>) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, Altium received warrants to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-416">13,763</ix:nonFraction> shares of Common Stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-417">121.03</ix:nonFraction> per share, were exercisable at any time on or after the applicable issuance date and had a term of <ix:nonNumeric contextRef="c-111" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-418">60</ix:nonNumeric> months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-419">1,250</ix:nonFraction> of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-420">679</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-421">571</ix:nonFraction>, respectively. The $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="ck0001824293:DebtInstrumentAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="3" id="f-422">1,250</ix:nonFraction> of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-423">718</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:ProceedsFromNotesPayable" scale="3" id="f-424">532</ix:nonFraction>, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered into the Equity SPA (Note 9) pursuant to which Altium agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-425">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-116" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-426">1,340.43</ix:nonFraction> per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-427">205</ix:nonFraction> of debt issuance costs related to its issuance of debt under the Bridge SPA, of which $<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" scale="3" id="f-428">90</ix:nonFraction> was incurred during the six months ended June&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Interest expense stemming from amortization of debt discounts and issuance costs was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-429">1,161</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-430">2,104</ix:nonFraction> for the three and six months ended June&#160;30, 2023, respectively.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_64"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-431" continuedAt="f-431-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-431-1" continuedAt="f-431-2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:InvestmentCompanyCommittedCapital" format="ixt:num-dot-decimal" scale="3" id="f-432">12,250</ix:nonFraction> in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and the Additional Shares into escrow with an escrow agent for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-433">11,704</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" scale="3" id="f-434">546</ix:nonFraction>.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="f-435">2,789</ix:nonFraction> shares of Common Stock and the Additional Shares converted into an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="INF" name="ck0001824293:ConversionOfStockAdditionalSharesConverted" format="ixt:num-dot-decimal" scale="0" id="f-436">11,157</ix:nonFraction> shares of Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Common Stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the February 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-55" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-437">25,419</ix:nonFraction> February 2024 Shares, (ii) <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-438">359,196</ix:nonFraction>  February 2024 Pre-Funded Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-439">359,196</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-440">384,615</ix:nonFraction> Series B-1 Common Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-441">384,615</ix:nonFraction> shares of Common Stock and (iv) <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-442">384,615</ix:nonFraction> Series B-2 Common Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-443">384,615</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-444">4,389</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-445">1,110</ix:nonFraction>. The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-59" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-446">one</ix:nonFraction> February 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-56" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-447">one</ix:nonFraction> February 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-57" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-448">one</ix:nonFraction> Series B-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-449">one</ix:nonFraction> Series B-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-450">14.30</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-451">0.0013</ix:nonFraction> for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for <ix:nonFraction unitRef="shares" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-452">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-60" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-453">0.0013</ix:nonFraction> and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-454">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-61" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-455">14.30</ix:nonFraction> for a <ix:nonNumeric contextRef="c-61" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-456">five-year</ix:nonNumeric> period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-457">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-62" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-458">14.30</ix:nonFraction> for an <ix:nonNumeric contextRef="c-62" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-459">18</ix:nonNumeric>-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-460">4,279</ix:nonFraction> is included in additional paid in capital. As of June&#160;30, 2024, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the February 2024 Pre-Funded Warrants approximates their fair value. <ix:continuation id="f-375-1" continuedAt="f-375-2">The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:</ix:continuation></span></div><ix:continuation id="f-375-2" continuedAt="f-375-3"><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-461">156.3</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-462">1.63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-123" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-463">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-464">4.65</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants issued in connection with the Merger was reduced to par, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-63" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-465">0.0001</ix:nonFraction>, per share pursuant to the terms of the Series A-1 Warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement,  shares up to $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="6" id="f-466">10.0</ix:nonFraction>&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of <ix:nonFraction unitRef="number" contextRef="c-64" decimals="3" name="ck0001824293:SaleOfStockAgentCompensationPercentage" scale="-2" id="f-467">3.0</ix:nonFraction>% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-431-2" continuedAt="f-431-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company has sold <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-468">293,892</ix:nonFraction> shares of Common Stock in the ATM Offering at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-469">3.27</ix:nonFraction> per share, raising $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-470">961</ix:nonFraction> of gross proceeds and net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="f-471">923</ix:nonFraction>, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, the Company filed a prospectus supplement to its registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="ck0001824293:SaleOfStockMaximumValueOfSharesOffered" format="ixt:num-dot-decimal" scale="3" id="f-472">2,644</ix:nonFraction>, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="f-473">961</ix:nonFraction> that have been sold under the ATM Offering.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the June 2024 Offering, (i) <ix:nonFraction unitRef="shares" contextRef="c-68" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-474">60,000</ix:nonFraction> June 2024 Shares, (ii) <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-475">2,125,793</ix:nonFraction> June 2024 Pre-Funded Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-476">2,125,793</ix:nonFraction> shares of Common Stock, (iii) <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-477">2,185,793</ix:nonFraction>  Series C-1 Common Warrants exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-478">2,185,793</ix:nonFraction> shares of Common Stock, and (iv) <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-479">2,185,793</ix:nonFraction> Series C-2 Common Warrants, exercisable for an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-480">2,185,793</ix:nonFraction> shares of Common Stock for net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-481">3,172</ix:nonFraction>, after deducting offering expenses of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="ck0001824293:StockIssuanceCostsOfferingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-482">1,057</ix:nonFraction>. The securities were offered in combinations of (a) <ix:nonFraction unitRef="shares" contextRef="c-72" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-483">one</ix:nonFraction> June 2024 Share or <ix:nonFraction unitRef="shares" contextRef="c-69" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-484">one</ix:nonFraction> June 2024 Pre-Funded Warrant, together with (b) <ix:nonFraction unitRef="shares" contextRef="c-70" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-485">one</ix:nonFraction> Series C-1 Common Warrant and <ix:nonFraction unitRef="shares" contextRef="c-71" decimals="INF" name="ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction" format="ixt-sec:numwordsen" scale="0" id="f-486">one</ix:nonFraction> Series C-2 Common Warrant, for a combined purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-72" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-487">1.83</ix:nonFraction> (less $<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-488">0.0001</ix:nonFraction> for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants are exercisable for <ix:nonFraction unitRef="shares" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-489">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-73" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-490">0.0001</ix:nonFraction>, are exercisable immediately and expire when exercised in full. Each Series C Common Warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-74" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" format="ixt-sec:numwordsen" scale="0" id="f-491">one</ix:nonFraction> share of Common Stock at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-75" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-492">1.83</ix:nonFraction> and are exercisable beginning on the effective date of the Warrant Stockholder Approval. The Series C-1 Common Warrants will expire on the <ix:nonNumeric contextRef="c-76" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-493">five-year</ix:nonNumeric> anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the <ix:nonNumeric contextRef="c-77" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-494">18</ix:nonNumeric>-month anniversary of the Warrant Stockholder Approval. The June 2024 Pre-Funded Warrants and the Series C Common Warrants were classified as equity and the allocated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-495">2,908</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an engagement agreement (the Engagement Agreement) with Wainwright, the Company, in connection with the June 2024 Offering, agreed to issue to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-496">153,006</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock (the Placement Agent Warrants). The Placement Agent Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-497">2.2875</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable following the Warrant Stockholder Approval. The Placement Agent Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" scale="3" id="f-498">229</ix:nonFraction> is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the June 2024 Pre-Funded Warrants approximates their fair value. <ix:continuation id="f-375-3" continuedAt="f-375-4">The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants and the Placement Agent Warrants with the following weighted-average assumptions:</ix:continuation></span></div><ix:continuation id="f-375-4"><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.012%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-499">159.1</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="2" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" id="f-500">1.65</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-131" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-501">0.0</ix:nonFraction>&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="f-502">4.92</ix:nonFraction>&#160;%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-431-3"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="f-503" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had the following warrants outstanding to purchase Common Stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.958%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-504">2,125,793</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-505">0.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Do not expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-506">384,615</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-134" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-507">14.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-508">8,950</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-509">1,117.48</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-510">42</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-511">27,300.00</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-512">271</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-513">2,561.65</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-514">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-138" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-515">0.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="f-516">26</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-139" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" scale="0" id="f-517">5,586.49</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-518">384,615</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-140" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-519">14.30</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-520">153,006</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-521">2.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-522">2,185,793</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-142" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-523">1.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-142" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-524">18</ix:nonNumeric> months after the Warrant Stockholder Approval</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-525">2,185,793</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-526">1.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-143" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durmonth" id="f-527">60</ix:nonNumeric> months after the Warrant Stockholder Approval</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_67"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-528" continuedAt="f-528-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-528-1" continuedAt="f-528-2"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Operations adopted the GRI Operations Plan, which provided GRI Operations with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Upon completion of the Merger, the Company assumed the GRI Operations Plan and <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="f-529">982</ix:nonFraction> outstanding and unexercised options issued thereunder, and ceased granting awards under the GRI Operations Plan. As of June&#160;30, 2024, <ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-530">no</ix:nonFraction> options remain outstanding under the GRI Operations Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving an amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by <ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-531">1,856</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-147" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-532">2,381</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s Common Stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to <ix:nonNumeric contextRef="c-148" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="f-533">10</ix:nonNumeric> years. As of June&#160;30, 2024, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-534">2,503</ix:nonFraction> shares of the Company's Common Stock were outstanding and <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-535">4,367</ix:nonFraction> shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" scale="-2" id="f-536">4</ix:nonFraction>% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-537" escape="true"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.261%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.264%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-538">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-540">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="3" id="f-541">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-542">37</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-543">13</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-544">74</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-545">25</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-546">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-547">13</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-548">74</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-549">25</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div></ix:continuation><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><ix:continuation id="f-528-2" continuedAt="f-528-3"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-550" escape="true"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-551">2,503</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-552">471.45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-158" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-553">9.55</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-554">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 4pt 0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-555">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:fixed-zero" scale="0" id="f-556">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 4pt 0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-557">2,503</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-558">471.45</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-559">9.06</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2024</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="f-560">456</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="f-561">1,655.14</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-562">8.56</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2024</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-563">2,503</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-564">471.45</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-565">9.06</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, all of the outstanding and exercisable stock options were out of the money and therefore had <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="f-566"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="0" id="f-567">no</ix:nonFraction></ix:nonFraction> intrinsic value. At June&#160;30, 2024, the unrecognized compensation cost related to unvested stock options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" id="f-568">313</ix:nonFraction>. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of <ix:nonNumeric contextRef="c-159" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-569">2.47</ix:nonNumeric> years </span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-528-3">No equity-based awards were granted during each of the three-month periods ended June&#160;30, 2024 and 2023.</ix:continuation> </span></div><div id="i442ee3de1de54639845a81d9f3db661d_76"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-570" continuedAt="f-570-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-570-1" continuedAt="f-570-2"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div></ix:continuation><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-570-2">In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for <ix:nonNumeric contextRef="c-160" name="ck0001824293:COBRABenefitsPaymentPeriod" format="ixt-sec:durmonth" id="f-571">18</ix:nonNumeric> months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to <ix:nonFraction unitRef="number" contextRef="c-160" decimals="INF" name="ck0001824293:PercentageOfTargetBonus" scale="-2" id="f-572">150</ix:nonFraction>% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</ix:continuation> </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_85"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the Company&#8217;s financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q, the audited financial statements and notes thereto, as well as management&#8217;s discussion and analysis of financial condition and results of operations included in the Company&#8217;s Annual Report on Form 10-K for the year ended  December&#160;31, 2023 filed with the Securities and Exchange Commission (the SEC) on March&#160;28, 2024 (the Annual Report). Some of the information contained in this discussion and analysis, including information with respect to the Company&#8217;s plans and strategy for its business and related financing, includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 12E of the Securities Exchange Act of 1934, as amended (the Exchange Act), that involve risks and uncertainties. As a result of many factors, including those factors set out under the section entitled &#8220;Risk Factors&#8221; included in the Annual Report, the Company&#8217;s actual results could differ materially from the results described in or implied by these forward-looking statements.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except as otherwise indicated, references herein to &#8220;GRI Bio,&#8221; or the &#8220;Company,&#8221; refer to GRI Bio, Inc. after the completion of the Merger (as defined below), and references to &#8220;GRI Operations&#8221; refer to the business of GRI Bio, Inc. prior to the completion of the Merger. References to &#8220;Vallon&#8221; refer to Vallon Pharmaceuticals, Inc. prior to the completion of the Merger.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_88"></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T (iNKT) cells. GRI-0621 is also an oral formulation of tazarotene, a synthetic retinoid acid receptor (RAR)-beta and gamma selective agonist, that is approved in the United States for topical treatment of psoriasis and acne. As of June 30, 2024, it has been evaluated in over 1,700 patients as an oral product for up to 52-weeks. We are developing GRI-0621 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung that affects approximately 140,000 people in the United States, with up to 40,000 new cases per year in the United States. Some estimate that IPF affects 3 million globally. While there are currently two approved therapies for the treatment of lung fibrosis, neither has been associated with improvements in overall survival, and both therapies have been associated with significant side effects leading to poor therapeutic adherence. In preliminary data from our trials to date with GRI-0621, and earlier trials with oral tazarotene, we have observed GRI-0621 to be well-tolerated and to inhibit iNKT cell activity in subjects. We and others have shown that activated iNKT are upregulated in IPF, primary sclerosing cholangitis (PSC), metabolic dysfunction-associated steatohepatitis (MASH), alcoholic liver disease (ALD), systemic lupus erythematosus  (SLE), multiple sclerosis (MS), ulcerative colitis (UC) patients as well as other indications. In these patients activated iNKT cells are correlated with more severe disease. The U.S. Food and Drug Administration has cleared our Investigative New Drug (IND) application for GRI-0621 for the treatment of IPF and we plan to evaluate GRI-0621 in a randomized, double-blind, multi-center Phase 2a biomarker study, for which we commenced enrollment in December 2023. Based on our current enrollment projections, we now expect interim data from this trial to be available in the fourth quarter of 2024 and topline results to be available in the first quarter of 2025. Additionally, on March 1, 2024, we received authorization of our clinical trial application from the United Kingdom Medicines and Healthcare Products Regulatory Agency to initiate the Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF in the United Kingdom.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T cells and would be developed for the treatment of autoimmune disorders, with much of our preclinical work in SLE or lupus and MS. In lupus, the immune system mistakenly attacks its own healthy tissues, especially joints and skin, but can affect almost every organ and tissue of the body. The condition can be fatal, and often causes debilitating bouts of fatigue and pain that prevent nearly half of adult patients from working. Lupus affects between 160,000 - 200,000 patients in the United States, with around 80,000 &#8211; 100,000 patients in the United States suffering from kidney nephritis, one of the most serious manifestations of SLE, typically within five years of diagnosis. There is no cure for lupus, but medical interventions and lifestyle changes can help control it. SLE treatment consists primarily of immunosuppressive drugs that inhibit the activity of the immune system. Only two drugs have been approved for lupus in the past 50 years, and new treatment options are sorely needed. In order to focus our resources on our GRI-0621 program, we have limited our development of GRI-0803 </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pending additional funding. Subject to obtaining the requisite additional funding and IND clearance, we intend to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE. We expect to file an IND with respect to this Phase 1a and 1b trial in 2025. We expect to continue to evaluate indications to select the best fit for further development of the program, but our initial focus would be on lupus.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">January 2024 and June 2024 Reverse Stock Split</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 19, 2024, our stockholders approved a reverse stock split of our Common Stock and our Board subsequently approved a reverse stock split of our Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 7, 2024, our stockholders approved a reverse stock split of our Common Stock and our Board subsequently approved a reverse stock split of our Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split). </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, we entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which we agreed to issue and sell, in a public offering (the June 2024 Offering), (i) 60,000 shares (the June 2024 Shares) of Common Stock, (ii) 2,125,793 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 2,125,793 shares of Common Stock, (iii) 2,185,793 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 2,185,793 shares of Common Stock, and (iv) 2,185,793 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of 2,185,793 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $1.83 (less $0.0001 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants were exercisable for one share of Common Stock at a price per share of $0.0001, were exercisable immediately and expired when exercised in full. Each Series C Common Warrant is exercisable into one share of Common Stock at a price per share of $1.83 and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series C Common Warrants (Warrant Stockholder Approval). The Series C-1 Common Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the 18-month anniversary of the Warrant Stockholder Approval. As of July 31, 2024, all of the June 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, we entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which we may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0 million of our Common Stock from time to time through Wainwright as our sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we have sold 293,892 shares of our Common Stock in the ATM Offering at a weighted-average price of $3.27 per share, raising $1.0 million of gross proceeds and net proceeds of $0.9 million, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, we filed a prospectus supplement to the Company&#8217;s registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $2.6 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $1.0 million that have been sold under the ATM Offering.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, we entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which we agreed to issue and sell, in a public offering, (i) 25,419 shares (the February 2024 Shares) of  Common Stock, (ii) 359,196 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 359,196 shares of Common Stock, (iii) 384,615 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 384,615 shares of Common Stock, and (iv) 384,615 Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 384,615 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $14.30 (less $0.0013 for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants became exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0013 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for an 18-month period after February 6, 2024 the date of issuance. In connection with the issuance of the February 2024 Shares and February 2024 Warrants pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants. As of June 30, 2024, all of the February 2024 Pre-Funded warrants and the Series A-1 Warrants have been exercised in full. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Compliance - Stockholders&#8217; Equity Deficiency </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2023, we received a letter (the Notice) from the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) notifying us that we were not in compliance with the minimum stockholders&#8217; equity requirement for continued listing on The Nasdaq Capital Market based on the information provided in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. Nasdaq Listing Rule 5550(b)(1) requires that companies listed on The Nasdaq Capital Market with a market value of listed securities of less than $35.0 million and annual net income of less than $0.5 million maintain stockholders&#8217; equity of at least $2.5 million (the Stockholders&#8217; Equity Requirement). In accordance with Nasdaq rules, we were provided until January 8, 2024, to submit a plan to regain compliance with the Stockholders&#8217; Equity Requirement (the Compliance Plan). On January 22, 2024, the Staff granted us an extension until May 20, 2024 to regain compliance with the Stockholders&#8217; Equity Requirement. Per the Staff&#8217;s January 22, 2024 letter, we must complete an equity offering to raise gross proceeds of at least $6.0 million and furnish to the Staff and Nasdaq evidence of compliance with the Stockholders&#8217; Equity Requirement by filing a publicly available report prior to May 24, 2024. We completed multiple equity offerings with gross proceeds of $10.5 million and have met the minimum Stockholders&#8217; Equity Requirement for each of the quarters ended March 31, 2024 and June 30, 2024. As such, on July 2, 2024, we received a letter from the Staff of Nasdaq notifying us that the stockholders&#8217; equity deficiency under Listing Rule 5550(b) had been cured and that we were then in compliance with all applicable continued listing standards. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nasdaq Compliance - Bid Price Deficiency</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules of The Nasdaq Capital Market also require that we maintain a closing price for shares of our Common Stock of at least $1.00 per share (the Minimum Bid Price Rule). On January 5, 2024, we received a letter (the Letter) from the Staff of Nasdaq indicating that we no longer met the Minimum Bid Price Rule set forth in Nasdaq Listing Rule 5550(a)(2) because the closing bid price for our Common Stock was less than $1.00 for the previous 30 consecutive business days. The Letter was in addition to the Notice described above. The Letter had no immediate effect on our continued listing on The Nasdaq Capital Market. Under Nasdaq Listing Rule 5810(c)(3)(A), we had a 180-calendar day period, or until July 3, 2024 (the Compliance Date), to regain compliance with the Minimum Bid Price Rule. The Minimum Bid Price Rule requires that a listed company maintain a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the 180-calendar day period, unless Nasdaq exercises its discretion to extend such 10&#8209;day period. On January 29, 2024, we filed an amendment to our Charter to implement the January 2024 Reverse Stock Split to attempt to regain compliance with the Minimum Bid Price Rule, but were not able to regain compliance following the January 2024 Reverse Stock Split. On June 7, 2024, we filed an amendment to our Amended and Restated Certificate of Incorporation to effect the June 2024 Reverse Stock Split to attempt to regain compliance with the Minimum Bid Price Rule. On July 2, 2024 and July 19, 2024, we received letters from the Staff of Nasdaq notifying us that we were again in compliance with the Minimum Bid Price Rule. If our closing price again remains below $1.00 for 30 trading days, we may again fail to comply with the Minimum Bid Price Rule, and we would receive an additional notification of our failure to comply with the Minimum Bid Price Rule and may be subject to delisting from Nasdaq. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Merger with Vallon Pharmaceuticals, Inc. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, the Company (formerly Vallon Pharmaceuticals, Inc. (Vallon)) consummated a merger with GRI Bio Operations, Inc. (formerly GRI Bio, Inc.) (GRI Operations) pursuant to an Agreement and Plan of Merger, as amended (the Merger Agreement), by and among the Company, GRI Operations and Vallon Merger Sub, Inc. (Merger Sub), a Delaware corporation and wholly-owned subsidiary of the Company. The Merger Agreement provided for the merger of Merger Sub with and into GRI Operations, with GRI Operations continuing as a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the Merger). In connection with the closing of the Merger, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div id="i442ee3de1de54639845a81d9f3db661d_91"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include personnel costs associated with research and development activities, including third party contractors to perform research, conduct clinical trials and manufacture drug supplies and materials. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses have consisted primarily of costs related to our development program for our lead product candidate GRI-0621. These expenses include:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">employee-related expenses, such as salaries, bonuses and benefits, consultant-related expenses such as consultant fees and bonuses, stock-based compensation, overhead-related expenses and travel-related expenses for our research and development personnel; and</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expenses incurred under agreements with contract research organizations (CROs), contract manufacturing organizations (CMOs) and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities as well as consultants that support the implementation of our clinical and non-clinical studies.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our direct research and development expenses are tracked by product candidate, we do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates as these costs are deployed across multiple programs. We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of compensation and consulting related expenses for executives and other administrative personnel, professional fees and other corporate expenses, including legal and accounting fees, travel expenses, facilities-related expenses, and consulting services relating to corporate matters.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our general and administrative expenses will continue to increase as we incur costs associated with being a public company, including expenses related to services associated with maintaining compliance with The Nasdaq Capital Market and SEC requirements, directors&#8217; and officers&#8217; insurance, legal and accounting costs and investor relations costs, as well as an increase in personnel expenses as we hire additional personnel.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrant Liability</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precludes the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were measured at fair value upon issuance using a Black-Scholes valuation model and are recorded as a liability on the consolidated balance sheet. The fair value of the May 2022 Warrants is measured at each reporting date and changes in fair value are recognized in the consolidated statements of operations in the period of change. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense)</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists of amortization of debt discounts, debt issuance costs and interest expense related to the Bridge Notes. Interest income consists of interest earned on our cash and cash equivalents held with institutional banks.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_94"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June&#160;30, 2024 and 2023 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,257</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,934</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,257)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,934)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(934)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,250)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,746)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $0.9 million in each of the three-month periods ended June&#160;30, 2024 and 2023. Research and development expenses in each of the three month periods ended June&#160;30, 2024 and 2023, were primarily comprised of expenses related to the development program of GRI-0621, consulting fees and personnel expenses.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $1.4 million and $5.1 million for the three months ended June&#160;30, 2024 and 2023, respectively. The $3.7 million decrease was primarily related to decreased costs for professional fees, including legal, accounting and </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment banking fees as a result of the completion of the Merger of $3.1 million and a decrease in personnel expenses of $0.5 million as a result of a decrease in bonus expense.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.1 million represents a decrease in the fair value of the May 2022 Warrants during the three months ended June&#160;30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net, was $6,000 for the three months ended June&#160;30, 2024.  Interest expense, net, was $0.9 million  for the three months ended June&#160;30, 2023 and related to senior secured promissory notes issued by GRI Operations prior to the Merger (the Bridge Notes).</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Six Months Ended June&#160;30, 2024 and 2023 </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the results of our operations for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,153</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,923</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,923)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,137)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,896)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $1.8 million and $1.0 million for the six months ended June&#160;30, 2024 and 2023, respectively. The $0.8 million increase was primarily due to increases in expenses related to the development program of GRI-0621. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $2.3 million and $5.9 million for the six months ended June&#160;30, 2024 and 2023, respectively. The $3.6 million decrease was primarily related to decreases in costs for professional fees, including legal, accounting and investment banking fees as a result of the completion of the Merger of $3.4 million, personnel expenses of $0.2 million and a $0.1 million decrease in consulting.This decrease were offset by an increase in administrative and insurance expenses of $0.1 million as a result of operating as a public company.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Liability</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of $0.1 million represents a decrease in the fair value of the May 2022 Warrants during the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income (Expense), net</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income (net) was $13,000 for the six months ended June&#160;30, 2024. Interest expense, net, was $2.1 million for the six months ended June&#160;30, 2023 and related to the Bridge Notes. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_97"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $4.1 million and $8.9 million for the six months ended June&#160;30, 2024 and 2023, respectively. As of June&#160;30, 2024, we had an accumulated deficit of $35.7 million.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our working capital requirements to date through the issuance of Common Stock, warrants, convertible notes and promissory notes. As of June&#160;30, 2024, we had $6.4 million in cash. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated (in thousands):</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.622%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.761%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,344)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June&#160;30, 2024 and 2023, $4.3 million and $2.1 million was used in operating activities, respectively. The $2.2 million increase was primarily due to a decrease in non-cash adjustments of $2.3&#160;million related to the amortization of debt discounts and debt issuance costs, the revaluation of the warrant liability and the carrying amount of right-of-use assets, as well as a $6.0&#160;million increase in cash used for accounts payable and  accrued expenses, offset by a $4.8&#160;million decrease in net loss and a $1.3&#160;million decrease in cash used for prepaid and other assets and operating lease liabilities. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $8,000 for the six months ended June&#160;30, 2023, which was related to the purchase of computer equipment.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $8.9 million for the six months ended June&#160;30, 2024 and was primarily related to $10.5 million of proceeds from the February 2024 Purchase Agreement, the ATM Offering and the June 2024 Purchase Agreement. The increase was offset by $1.6 million of stock issuance costs. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $6.9 million for the six months ended June&#160;30, 2023 and was primarily due to $12.3 million of proceeds from the Equity SPA and $1.3 million of proceeds from the funding of the second tranche of the Bridge Notes. The increase was offset by $2.9 million of net liabilities assumed in the connection with the Merger, $3.0 million in costs associated with the Merger, the payment of $0.5 million of debt issuance costs related to the Bridge Notes and $0.1 million of stock issuance costs related the Equity SPA. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, we entered into the June 2024 Purchase Agreement, pursuant to which we agreed to issue and sell, in the June 2024 Offering), (i) 60,000 June 2024 Shares, (ii) 2,125,793 June 2024 Pre-Funded Warrants exercisable for an aggregate of 2,125,793 shares of Common Stock, (iii) 2,185,793 Series C-1 Common Warrants exercisable for an aggregate of 2,185,793 shares of Common Stock, and (iv) 2,185,793 Series C-2 Common Warrants exercisable for an aggregate of 2,185,793 shares of Common Stock for net proceeds of $3.2&#160;million, after deducting offering expenses of $1.1&#160;million. </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, we have sold 293,892 shares of our Common Stock in the ATM Offering at a weighted-average price of $3.27 per share, raising $1.0 million of gross proceeds and net proceeds of $0.9 million, after deducting commissions to the sales agent and other ATM Offering related expenses. n July 26, 2024, we filed a prospectus supplement to the Company&#8217;s registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that we may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $2.6 million, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $1.0 million that have been sold under the ATM Offering.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, we entered into the February 2024 Purchase Agreement, pursuant to which we agreed to issue and sell, in a public offering, (i) 25,419 February 2024 Shares, (ii) 359,196  February 2024 Pre-Funded Warrants exercisable for an aggregate of 359,196 shares of Common Stock, (iii) 384,615 Series B-1 Common Warrants exercisable for an aggregate of 384,615 shares of Common Stock, and (iv) 384,615 Series B-2 Common Warrants exercisable for an aggregate of 384,615 shares of Common Stock for net proceeds of $4.4&#160;million, after deducting offering expenses of $1.1&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $12.3&#160;million in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and placed the Additional Shares into escrow with an escrow agent for net proceeds of $11.7&#160;million, after deducting offering expenses of $0.5&#160;million.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Funding Requirements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses were $4.1 million and $8.9 million for the six months ended June&#160;30, 2024 and 2023, respectively. As of June&#160;30, 2024, we had $6.4 million in cash and an accumulated deficit of $35.7 million. We expect to devote substantial financial resources to our planned activities, particularly as we prepare for, initiate, and conduct our planned clinical trials of GRI-0621 and GRI-0803, advance our discovery programs and continue our product development efforts. In addition, we expect to incur additional costs associated with operating as a public company. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our current operating plan, we believe that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the first quarter of 2025. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include, among other things, a requirement that shares of our Common Stock have a value weighted average price of at least $838.11 per share for the periods specified in the Series T Warrants, are not met. We intend to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if our research and development efforts are successful. If we are unable to secure adequate additional funding, we will need to reevaluate our operating plans and may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, delay, scale back or eliminate some or all of our development programs, or relinquish rights to our technology on less favorable terms than we would otherwise choose or cease operations entirely. These actions could materially impact our business, results of operations and future prospects and the value of shares of our Common Stock. In addition, attempting to secure additional financing may divert the time and attention of management from day-to-day activities and distract from our discovery and product development efforts. As a result, there is substantial doubt about our ability to continue as a going concern. We expect to continue to incur significant and increasing operating losses at least for the foreseeable future. We do not expect to generate product revenue unless and until we successfully complete development, obtain regulatory approval for and successfully commercialize our current, or any future, product candidates.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_100"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not party to any off-balance sheet transactions. We have no guarantees or obligations other than those which arise out of normal business operations.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_103"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of its financial condition and results of operations is based on its unaudited interim consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (GAAP). The preparation of these unaudited interim condensed consolidated financial statements requires us to make estimates and assumptions that affect the amounts reported in the unaudited interim consolidated financial statements and accompanying notes. Management evaluates these estimates and judgments on an ongoing basis. Management bases its estimates on historical experience and on various other factors that it believes are reasonable under the circumstances. Actual results could differ from those estimates.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in more detail in Note 3, &#8220;Summary of Significant Accounting Policies&#8221;, in the Company&#8217;s Annual Report.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_106"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) and may remain an emerging growth company for up to five years. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not applicable to emerging growth companies. These exemptions include:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure about our executive compensation arrangements;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no non-binding stockholder advisory votes on executive compensation or golden parachute arrangements; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken advantage of reduced reporting requirements in this report and may continue to do so until such time that we are no longer an emerging growth company. We will remain an &#8220;emerging growth company&#8221; until the earliest of (a) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more, (b) December 31, 2026, the last day of the fiscal year following the fifth anniversary of the completion of Vallon&#8217;s initial public offering, (c) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years or (d) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards. </span></div><div id="i442ee3de1de54639845a81d9f3db661d_109"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable to a smaller reporting company.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_112"></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Evaluation of our Disclosure Controls and Procedures</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of its disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e)) of the Exchange Act as of June&#160;30, 2024. We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls is based in part upon certain assumptions about the likelihood of future </span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2024, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the fiscal quarter covered by this report that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="margin-bottom:8pt"><span><br/></span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_115"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="i442ee3de1de54639845a81d9f3db661d_118"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition. </span></div><div id="i442ee3de1de54639845a81d9f3db661d_121"></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes from the risk factors previously disclosed in the Annual Report.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_124"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_127"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_130"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i442ee3de1de54639845a81d9f3db661d_133"></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June&#160;30, 2024, none of our directors or officers <ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-573"><ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-574">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-575"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-576">terminated</ix:nonNumeric></ix:nonNumeric> &#8220;Rule 10b5-1 trading arrangement&#8221; or &#8220;non-Rule 10b5-1 trading arrangement,&#8221; as each term is defined in Item 408 of Regulation S-K.</span></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_136"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits.</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:6.816%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.844%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.094%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.355%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference File No. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date Filed</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828024028928/gribio-20240618.htm">Amended and Restated Certificate of Incorporation, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-280323</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/20/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/ex32_amendedandrestatedbyl.htm">Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/26/2023</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828024030244/val-20240626.htm">Form of Pre-Funded Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/27/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828024030244/val-20240626.htm">Form of Series C-1 Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/27/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828024030244/val-20240626.htm">Form of Series C-2 Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/27/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828024030244/val-20240626.htm">Form of Placement Agent Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/27/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429324000052/val-20240520.htm">At The Market Offering Agreement, dated May 20, 2024, by and between GRI Bio, Inc. and H.C. Wainwright &amp; Co., LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/20/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000182429324000070/val-20240617.htm">Amendment No. 1 to Employment Agreement, dated June 17, 2024, by and between the GRI Bio, Inc. and Albert Agro, Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/18/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3&#9651;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001824293/000162828024030244/val-20240626.htm">Form of Securities Purchase Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-40034</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6/27/2024</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex311_ceo302cert63024.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex312_cfo302cert63024.htm">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex321_ceosection906cert630.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex322_cfosection906cert630.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">iXBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.722%"><tr><td style="width:0.1%"/><td style="width:2.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.774%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.933%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicates a management contract or any compensatory plan, contract or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, except to the extent specifically incorporated by reference into such filing.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9651;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company undertakes to furnish supplemental copies of any of the omitted schedules upon request by the U.S. Securities and Exchange Commission.</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="i442ee3de1de54639845a81d9f3db661d_139"></div><hr style="page-break-after:always"/><div style="min-height:68.99pt;width:100%"><div style="margin-bottom:8pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i442ee3de1de54639845a81d9f3db661d_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.352%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.815%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GRI BIO, INC.</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 13, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Leanne M. Kelly</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title: Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:98.99pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex311_ceo302cert63024.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic36ca54d96f74b39a767d308a2c3e19d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2024 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.726%"><tr><td style="width:1.0%"></td><td style="width:31.191%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;13, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex312_cfo302cert63024.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i1271d9fe2fb0466ebecb3a6a81ffa161_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 31.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:8pt"><font><br></font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly, certify that&#58;</font></div><div style="margin-top:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended June&#160;30, 2024 of GRI Bio, Inc.&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt">  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.299%"><tr><td style="width:1.0%"></td><td style="width:29.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;13, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex321_ceosection906cert630.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ife4a77abd7264eb48d2ad33e055d7e7f_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, W. Marc Hertz, President and Chief Executive Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2024 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.281%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;13, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; W. Marc Hertz</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">W. Marc Hertz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex322_cfosection906cert630.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia696faf4821647a2a59c13cf78392ef7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I, Leanne M. Kelly,  Chief Financial Officer of GRI Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the Quarterly Report on Form 10-Q of the Company for the quarter ended June&#160;30, 2024 (the &#8220;Quarterly Report&#8221;) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">the information contained in the Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.</font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.994%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date&#58; August&#160;13, 2024</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Leanne M. Kelly</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Leanne M. Kelly</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ck0001824293-20240630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4b2bd8b8-7391-472c-baa6-f4915a4212d0,g:cfdabf3d-48ec-4ec5-a4ba-2606592f7687-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ck0001824293="http://www.vallon-pharma.com/20240630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.vallon-pharma.com/20240630">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ck0001824293-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.vallon-pharma.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityDeficit" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952155 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESS" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS">
        <link:definition>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITY" roleURI="http://www.vallon-pharma.com/role/LIQUIDITY">
        <link:definition>9952157 - Disclosure - LIQUIDITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLON" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON">
        <link:definition>9952159 - Disclosure - MERGER WITH VALLON</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS">
        <link:definition>9952160 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENT" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT">
        <link:definition>9952161 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES">
        <link:definition>9952162 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTES" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES">
        <link:definition>9952163 - Disclosure - PROMISSORY NOTES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY">
        <link:definition>9952164 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>9952165 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>9952166 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONTables" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables">
        <link:definition>9954473 - Disclosure - MERGER WITH VALLON (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSTables" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables">
        <link:definition>9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTTables" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables">
        <link:definition>9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables">
        <link:definition>9954476 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>9954477 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954478 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails">
        <link:definition>9954479 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LIQUIDITYDetails" roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails">
        <link:definition>9954480 - Disclosure - LIQUIDITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails">
        <link:definition>9954481 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails">
        <link:definition>9954482 - Disclosure - MERGER WITH VALLON - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails">
        <link:definition>9954483 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1">
        <link:definition>9954483 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails">
        <link:definition>9954484 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails">
        <link:definition>9954485 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails">
        <link:definition>9954486 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>9954487 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails">
        <link:definition>9954488 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESDetails" roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails">
        <link:definition>9954489 - Disclosure - ACCRUED EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROMISSORYNOTESBridgeFinancingDetails" roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails">
        <link:definition>9954490 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails">
        <link:definition>9954491 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails">
        <link:definition>9954492 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails">
        <link:definition>9954493 - Disclosure - STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954494 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>9954495 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails">
        <link:definition>9954496 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954497 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ck0001824293_WarrantLiabilityCurrent" abstract="false" name="WarrantLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ChangeInFairValueOfWarrantLiability" abstract="false" name="ChangeInFairValueOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" abstract="false" name="StockIssuedDuringPeriodSharesFractionalShareAdjustment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" abstract="false" name="StockIssuedDuringPeriodSharesWarrantExercise" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" abstract="false" name="StockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodSharesPreClosingFinancing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" abstract="false" name="StockIssuedDuringPeriodValuePreClosingFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodSharesSettlementOfDebt" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" abstract="false" name="StockIssuedDuringPeriodValueSettlementOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodSharesReverseRecapitalization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" abstract="false" name="StockIssuedDuringPeriodValueReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ThroughFinancingMember" abstract="true" name="ThroughFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" abstract="false" name="OperatingLeaseRightOfUseAssetPeriodicAddition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ProceedsFromAdvancesFromEmployees" abstract="false" name="ProceedsFromAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_RepaymentOfAdvancesFromEmployees" abstract="false" name="RepaymentOfAdvancesFromEmployees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" abstract="false" name="NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PaymentOfReverseRecapitalizationCosts" abstract="false" name="PaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedForRepaymentOfNotesPayable" abstract="false" name="StockIssuedForRepaymentOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" abstract="false" name="DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" abstract="false" name="StockIssuedForPaymentOfReverseRecapitalizationCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantsIssued" abstract="false" name="WarrantsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" abstract="false" name="StockIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_NoncashMergerRelatedCostsFinancingActivities" abstract="false" name="NoncashMergerRelatedCostsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB1CommonWarrantsMember" abstract="true" name="SeriesB1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB2CommonWarrantsMember" abstract="true" name="SeriesB2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesA1WarrantsMember" abstract="true" name="SeriesA1WarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC1CommonWarrantsMember" abstract="true" name="SeriesC1CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC2CommonWarrantsMember" abstract="true" name="SeriesC2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesCCommonWarrantMember" abstract="true" name="SeriesCCommonWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesTWarrantsMember" abstract="true" name="SeriesTWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockHeldIntoEscrowAccount" abstract="false" name="CommonStockHeldIntoEscrowAccount" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_StockIssuanceCostsOfferingExpenses" abstract="false" name="StockIssuanceCostsOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_ConversionOfStockAdditionalSharesConverted" abstract="false" name="ConversionOfStockAdditionalSharesConverted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" abstract="false" name="SaleOfStockNumberOfSecuritiesIssuedPerTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ck0001824293_SaleOfStockMaximumValueOfSharesOffered" abstract="false" name="SaleOfStockMaximumValueOfSharesOffered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_SaleOfStockAgentCompensationPercentage" abstract="false" name="SaleOfStockAgentCompensationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_GRIOperationsMember" abstract="true" name="GRIOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_PrivateGRIMember" abstract="true" name="PrivateGRIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ExchangeWarrantsMember" abstract="true" name="ExchangeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ck0001824293_CommonStockOwnershipPercentage" abstract="false" name="CommonStockOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityFairValueDisclosure" abstract="false" name="WarrantLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_WarrantLiabilityMember" abstract="true" name="WarrantLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" abstract="false" name="AccruedResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_BridgeSecuritiesPurchaseAgreementMember" abstract="true" name="BridgeSecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_BridgeWarrantsMember" abstract="true" name="BridgeWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentAggregatePurchasePrice" abstract="false" name="DebtInstrumentAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ck0001824293_DebtInstrumentNumberOfClosings" abstract="false" name="DebtInstrumentNumberOfClosings" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ck0001824293_PreFundedAndSeriesCWarrantsMember" abstract="true" name="PreFundedAndSeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_ThePlacementAgentWarrantsMember" abstract="true" name="ThePlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" abstract="true" name="SeriesB1CommonAndSeriesB2CommonWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" abstract="true" name="SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsNotExpiringMember" abstract="true" name="WarrantsNotExpiringMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInAugust2025Member" abstract="true" name="WarrantsExpiringInAugust2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInDecember2025Member" abstract="true" name="WarrantsExpiringInDecember2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2026Member" abstract="true" name="WarrantsExpiringInFebruary2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInMay2027Member" abstract="true" name="WarrantsExpiringInMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJuly2027Member" abstract="true" name="WarrantsExpiringInJuly2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInApril2028Member" abstract="true" name="WarrantsExpiringInApril2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInFebruary2029Member" abstract="true" name="WarrantsExpiringInFebruary2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringInJune2029Member" abstract="true" name="WarrantsExpiringInJune2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" abstract="true" name="WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" abstract="true" name="WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_GRIOperationsPlanMember" abstract="true" name="GRIOperationsPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" abstract="true" name="AmendedAndRestated2018EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ck0001824293_FormerChiefExecutiveOfficerMember" abstract="true" name="FormerChiefExecutiveOfficerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ck0001824293_COBRABenefitsPaymentPeriod" abstract="false" name="COBRABenefitsPaymentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ck0001824293_PercentageOfTargetBonus" abstract="false" name="PercentageOfTargetBonus" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ck0001824293-20240630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4b2bd8b8-7391-472c-baa6-f4915a4212d0,g:cfdabf3d-48ec-4ec5-a4ba-2606592f7687-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_845a2537-ec24-4500-b3eb-bd99819da43b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7928fd1c-e747-4a7b-9b01-edc62f4bf8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_845a2537-ec24-4500-b3eb-bd99819da43b" xlink:to="loc_us-gaap_Liabilities_7928fd1c-e747-4a7b-9b01-edc62f4bf8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9abc2265-9193-4853-aafa-9caa9fdde6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_845a2537-ec24-4500-b3eb-bd99819da43b" xlink:to="loc_us-gaap_StockholdersEquity_9abc2265-9193-4853-aafa-9caa9fdde6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e562ad41-b99a-4d29-bea5-743cbdb3efc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_845a2537-ec24-4500-b3eb-bd99819da43b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e562ad41-b99a-4d29-bea5-743cbdb3efc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1ba74375-9507-48c3-b42e-7dbf6f2cdf7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00c03ff5-9a21-4c35-ba62-7981405361fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ba74375-9507-48c3-b42e-7dbf6f2cdf7a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00c03ff5-9a21-4c35-ba62-7981405361fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e7f67cd0-c885-4539-9324-03e1883b7549" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1ba74375-9507-48c3-b42e-7dbf6f2cdf7a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e7f67cd0-c885-4539-9324-03e1883b7549" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8e60d711-e2ec-4c81-8ed2-66dbf9693c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32180ab6-88d9-4cff-a1a8-b42014987f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e60d711-e2ec-4c81-8ed2-66dbf9693c20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32180ab6-88d9-4cff-a1a8-b42014987f88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3c5f39a2-c8e9-4a0c-bc66-147c2c7deaa9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8e60d711-e2ec-4c81-8ed2-66dbf9693c20" xlink:to="loc_us-gaap_LiabilitiesCurrent_3c5f39a2-c8e9-4a0c-bc66-147c2c7deaa9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_69963471-a1e4-44e1-91b0-f75364ae0ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c23e8ae6-0378-421b-960d-a5bb9bb6237d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69963471-a1e4-44e1-91b0-f75364ae0ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c23e8ae6-0378-421b-960d-a5bb9bb6237d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0df83429-13fb-4e9d-9f2e-37f7fff0fe53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69963471-a1e4-44e1-91b0-f75364ae0ba3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0df83429-13fb-4e9d-9f2e-37f7fff0fe53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4bb21b18-c4ad-451f-b18b-27086f958d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_69963471-a1e4-44e1-91b0-f75364ae0ba3" xlink:to="loc_us-gaap_AssetsCurrent_4bb21b18-c4ad-451f-b18b-27086f958d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0198da1b-d544-4166-b32b-d21777ee1283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d04e0df-e4da-44e6-bd3b-0396797663b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0198da1b-d544-4166-b32b-d21777ee1283" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8d04e0df-e4da-44e6-bd3b-0396797663b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_691d7bc1-a181-45c8-9b1d-d6f5f8302935" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0198da1b-d544-4166-b32b-d21777ee1283" xlink:to="loc_us-gaap_CommonStockValueOutstanding_691d7bc1-a181-45c8-9b1d-d6f5f8302935" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_37f6b675-95bc-4a83-b45b-21a488ec82dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0198da1b-d544-4166-b32b-d21777ee1283" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_37f6b675-95bc-4a83-b45b-21a488ec82dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_52078987-28a4-4054-8d69-8e649e23764e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7376f82d-cdbd-4882-b759-70cdd6d2d282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52078987-28a4-4054-8d69-8e649e23764e" xlink:to="loc_us-gaap_AccountsPayableCurrent_7376f82d-cdbd-4882-b759-70cdd6d2d282" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityCurrent_27c1606e-a87b-47e9-b246-255dcca8c470" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52078987-28a4-4054-8d69-8e649e23764e" xlink:to="loc_ck0001824293_WarrantLiabilityCurrent_27c1606e-a87b-47e9-b246-255dcca8c470" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_2f5e6218-fc9e-4d7b-b620-3529a789c4fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52078987-28a4-4054-8d69-8e649e23764e" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_2f5e6218-fc9e-4d7b-b620-3529a789c4fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c71b5e2-f790-41b4-83a2-79c51529cea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_52078987-28a4-4054-8d69-8e649e23764e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4c71b5e2-f790-41b4-83a2-79c51529cea4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_56107377-9f7f-4d92-83c9-9e3db62b9847" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_4fc4cbaa-011b-42cd-a2cb-d7b05b0454e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_56107377-9f7f-4d92-83c9-9e3db62b9847" xlink:to="loc_us-gaap_OperatingExpenses_4fc4cbaa-011b-42cd-a2cb-d7b05b0454e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_6efb3fe7-3529-4941-b09d-80a4c2aaa623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_9c2a3ade-151d-49f6-9a26-373cd27c37cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6efb3fe7-3529-4941-b09d-80a4c2aaa623" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_9c2a3ade-151d-49f6-9a26-373cd27c37cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2132ae28-0007-4e34-94da-864d4db6fb66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_6efb3fe7-3529-4941-b09d-80a4c2aaa623" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2132ae28-0007-4e34-94da-864d4db6fb66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1cb86b6-5b3b-4852-811e-9404e4d732fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e777a1b4-0443-4097-b89e-a8f432405ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f1cb86b6-5b3b-4852-811e-9404e4d732fb" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_e777a1b4-0443-4097-b89e-a8f432405ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_02bf772f-84ad-406e-817f-11ef59394b30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f1cb86b6-5b3b-4852-811e-9404e4d732fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_02bf772f-84ad-406e-817f-11ef59394b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_bfd50c49-f172-426f-9d9b-ea824a00687b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f1cb86b6-5b3b-4852-811e-9404e4d732fb" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_bfd50c49-f172-426f-9d9b-ea824a00687b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_2804a4c5-829d-4275-b73a-a40ea87cc053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_Depreciation_2804a4c5-829d-4275-b73a-a40ea87cc053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_5184b39b-f75b-4566-a609-8b0baf3be5a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_5184b39b-f75b-4566-a609-8b0baf3be5a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_30d29586-89ad-4173-8325-f6e87acd217f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_NetIncomeLoss_30d29586-89ad-4173-8325-f6e87acd217f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_85ea8247-16ef-4669-bd57-97ed6edb0f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_85ea8247-16ef-4669-bd57-97ed6edb0f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_6b29ed10-0016-4c6e-86d5-f16b2ebbc7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_ShareBasedCompensation_6b29ed10-0016-4c6e-86d5-f16b2ebbc7c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78546293-87ed-479b-bd73-d0f30df60964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_78546293-87ed-479b-bd73-d0f30df60964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_edc8d472-cc7f-4283-a681-b0f208ff38b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_edc8d472-cc7f-4283-a681-b0f208ff38b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c7ebb79f-d93a-44f4-bc56-c30338d069a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c7ebb79f-d93a-44f4-bc56-c30338d069a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d7373f77-a6c9-4ef9-a3f2-c722a3620407" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_d7373f77-a6c9-4ef9-a3f2-c722a3620407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_007b2be5-9cae-4099-bbda-fa98a58f39f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_007b2be5-9cae-4099-bbda-fa98a58f39f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_e2a6b73a-e9c5-4dbd-91b1-43c310f61cff" xlink:href="ck0001824293-20240630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4136b672-52f4-4d66-b07a-f3ca3e5036ae" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_e2a6b73a-e9c5-4dbd-91b1-43c310f61cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_166b029f-cb47-4346-9841-fb2bdbdcb8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_166b029f-cb47-4346-9841-fb2bdbdcb8f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4829230-4ee7-4919-a91c-87b181302d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b4829230-4ee7-4919-a91c-87b181302d4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_ec90b92f-dc19-40a0-9821-e55158e275de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_ec90b92f-dc19-40a0-9821-e55158e275de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_b0e900b0-44b3-4725-b034-44edae8650f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_b0e900b0-44b3-4725-b034-44edae8650f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_bd705439-4075-4b64-b9f0-387074cc5f6a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_bd705439-4075-4b64-b9f0-387074cc5f6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c1881a95-d1a9-40f3-ab34-3699bbfac2c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c1881a95-d1a9-40f3-ab34-3699bbfac2c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_4ae3cc31-b11e-4db1-bcc8-6dee7dcb9a8c" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_4ae3cc31-b11e-4db1-bcc8-6dee7dcb9a8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_88ab98a2-b8ab-4f44-a72d-296932581023" xlink:href="ck0001824293-20240630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_88ab98a2-b8ab-4f44-a72d-296932581023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_2af97696-6aca-416c-83f4-f5c06839a2aa" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c6054789-65fa-4202-a07d-87ac340070d7" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_2af97696-6aca-416c-83f4-f5c06839a2aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4167df49-a926-4aa6-a73a-8a0fdd5556d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27a79bfe-1bcb-47b2-9781-55fbebe09df4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4167df49-a926-4aa6-a73a-8a0fdd5556d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_27a79bfe-1bcb-47b2-9781-55fbebe09df4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0753fd12-6cbf-474d-81e0-c62ff8e3aaab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4167df49-a926-4aa6-a73a-8a0fdd5556d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0753fd12-6cbf-474d-81e0-c62ff8e3aaab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8780c065-6135-4456-a6b5-f4c39d71f763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_4167df49-a926-4aa6-a73a-8a0fdd5556d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8780c065-6135-4456-a6b5-f4c39d71f763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab0d4e14-472c-48c3-befd-6ba736e3a94b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ea548af-3185-493f-821f-9e6499434442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab0d4e14-472c-48c3-befd-6ba736e3a94b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1ea548af-3185-493f-821f-9e6499434442" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e28742dd-2c0e-4158-b86b-10a2bde8c35f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_b9e04a29-e3ad-4591-b470-3f1d78ec51f1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e28742dd-2c0e-4158-b86b-10a2bde8c35f" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_b9e04a29-e3ad-4591-b470-3f1d78ec51f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dedfee89-c50b-478e-b9f4-20ea5e4e57de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e28742dd-2c0e-4158-b86b-10a2bde8c35f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_dedfee89-c50b-478e-b9f4-20ea5e4e57de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d7077f14-0ed2-4f8e-96ec-dd5c4707d1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e28742dd-2c0e-4158-b86b-10a2bde8c35f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d7077f14-0ed2-4f8e-96ec-dd5c4707d1fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e9f3ddb-bd7b-40d1-bc14-a41d3ae7601b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_8ea0e6fe-df33-4122-8727-2408aa23b8f1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e9f3ddb-bd7b-40d1-bc14-a41d3ae7601b" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_8ea0e6fe-df33-4122-8727-2408aa23b8f1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_6e34212c-b462-4fd6-a5c1-61229524af36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2e9f3ddb-bd7b-40d1-bc14-a41d3ae7601b" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_6e34212c-b462-4fd6-a5c1-61229524af36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_8bb1552c-c554-4c11-8c61-b1366fbfe6a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_eb7e6ce2-199c-45cc-876e-712c66522a7f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_8bb1552c-c554-4c11-8c61-b1366fbfe6a7" xlink:to="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_eb7e6ce2-199c-45cc-876e-712c66522a7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_87de4f11-7b52-4804-a89b-69578f6570df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d99e31c7-3635-4332-af38-f0e39317e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_87de4f11-7b52-4804-a89b-69578f6570df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d99e31c7-3635-4332-af38-f0e39317e4fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02cb7d4c-f0f6-4e53-a375-aee75e8167ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_87de4f11-7b52-4804-a89b-69578f6570df" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_02cb7d4c-f0f6-4e53-a375-aee75e8167ef" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:calculationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5a66bb24-be06-4304-9c35-764f4f029619" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_fec852d9-a09c-42fc-9b7a-0116121bb0f4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5a66bb24-be06-4304-9c35-764f4f029619" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_fec852d9-a09c-42fc-9b7a-0116121bb0f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7e02688d-edc3-4d13-828e-c46df0bc4f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5a66bb24-be06-4304-9c35-764f4f029619" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7e02688d-edc3-4d13-828e-c46df0bc4f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_0570b1c2-99bf-45df-8ed8-bf1c750529fa" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_5a66bb24-be06-4304-9c35-764f4f029619" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_0570b1c2-99bf-45df-8ed8-bf1c750529fa" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ck0001824293-20240630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4b2bd8b8-7391-472c-baa6-f4915a4212d0,g:cfdabf3d-48ec-4ec5-a4ba-2606592f7687-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60ab91b0-841e-461f-8e3e-1580d12df2db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_60ab91b0-841e-461f-8e3e-1580d12df2db" xlink:to="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cd640b03-3eca-4aff-9da2-310dd84125a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:to="loc_us-gaap_EquityComponentDomain_cd640b03-3eca-4aff-9da2-310dd84125a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:to="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c517327-f25e-4f84-8d66-83bda4084ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:to="loc_us-gaap_CommonStockMember_6c517327-f25e-4f84-8d66-83bda4084ba2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ca33c444-e0ba-499a-9ece-a6f8ec297972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ca33c444-e0ba-499a-9ece-a6f8ec297972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f4cc15e9-96dd-42f4-8032-0a62c0ac3485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:to="loc_us-gaap_RetainedEarningsMember_f4cc15e9-96dd-42f4-8032-0a62c0ac3485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60ab91b0-841e-461f-8e3e-1580d12df2db" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd9de921-b309-4df4-9c2f-0a97b9403b93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd9de921-b309-4df4-9c2f-0a97b9403b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6322ce9a-a61d-49e5-ac5c-7e3e42244598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockholdersEquity_6322ce9a-a61d-49e5-ac5c-7e3e42244598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa2db891-4898-494f-b416-8305a3263b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa2db891-4898-494f-b416-8305a3263b43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_6397655c-0c9d-4eaa-88e9-7388c7fbb3b4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_6397655c-0c9d-4eaa-88e9-7388c7fbb3b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_35aa0d72-ea56-4b76-bbde-46c1824559f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_35aa0d72-ea56-4b76-bbde-46c1824559f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_833af6ee-da10-4db5-896d-3670ed426be2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_833af6ee-da10-4db5-896d-3670ed426be2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_704647ef-c229-482d-88e7-11e9120d4b59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_704647ef-c229-482d-88e7-11e9120d4b59" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ff196579-952b-4d17-a97a-1412cc2ed8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ff196579-952b-4d17-a97a-1412cc2ed8b9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_966ae9a3-9d0d-4a66-91f7-95e7fcf6d4a1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_966ae9a3-9d0d-4a66-91f7-95e7fcf6d4a1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_d8e18490-de4a-412f-8fd2-6282928dc7fd" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_d8e18490-de4a-412f-8fd2-6282928dc7fd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_707a54a0-1e43-427b-af6e-5ac183b6e246" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_707a54a0-1e43-427b-af6e-5ac183b6e246" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_a3c2df4a-7ee7-4393-8818-f7955e724d35" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_a3c2df4a-7ee7-4393-8818-f7955e724d35" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_507879bc-54ff-4c66-a08f-42a805d3ca45" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_507879bc-54ff-4c66-a08f-42a805d3ca45" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_2af51aa0-ca20-4e62-af95-5777ac5fe29d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_2af51aa0-ca20-4e62-af95-5777ac5fe29d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_28256644-669e-4fde-bb02-c165c7ba5a38" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_28256644-669e-4fde-bb02-c165c7ba5a38" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_8468e07f-4c6d-4f11-83cb-2ebbbab47e3f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_8468e07f-4c6d-4f11-83cb-2ebbbab47e3f" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_cb3960d4-3775-4468-aa34-069f88a92782" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_cb3960d4-3775-4468-aa34-069f88a92782" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_74e5293b-e6b3-450b-b408-1b559d8a3812" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_74e5293b-e6b3-450b-b408-1b559d8a3812" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0eab7e1-090a-4645-a0ad-1e535c59dcde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_NetIncomeLoss_e0eab7e1-090a-4645-a0ad-1e535c59dcde" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_be359863-4d43-43d6-9f5b-027f08a73d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_743fb0a9-2c1c-43f6-b9d0-4dad41b8b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_6239fd77-b42e-49a7-b06d-9a71d26fefb4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:to="loc_ck0001824293_ThroughFinancingMember_6239fd77-b42e-49a7-b06d-9a71d26fefb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_58adfd6d-c252-4f15-b72e-4f4fb5e1318a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_58adfd6d-c252-4f15-b72e-4f4fb5e1318a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d62c113-155e-4293-8c96-b543b7055c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:to="loc_us-gaap_NetIncomeLoss_8d62c113-155e-4293-8c96-b543b7055c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6dcdc344-d8b4-474a-b1fa-160ed9331b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_Depreciation_6dcdc344-d8b4-474a-b1fa-160ed9331b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0a87123-47c0-48cc-a68b-d02c1b1cacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0a87123-47c0-48cc-a68b-d02c1b1cacd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a973774e-d453-4f74-8cab-4a4cec28a552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_ShareBasedCompensation_a973774e-d453-4f74-8cab-4a4cec28a552" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a2be5adf-72a8-443e-8ed1-d43bb5307930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a2be5adf-72a8-443e-8ed1-d43bb5307930" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_315c289a-5458-4dea-8fde-1e1a5a78a79f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_315c289a-5458-4dea-8fde-1e1a5a78a79f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bc25eb16-aca0-4a9b-b6d5-92ecef9cfeba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bc25eb16-aca0-4a9b-b6d5-92ecef9cfeba" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f3258e0-4e90-4b6f-8751-7dd1e8f25523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f3258e0-4e90-4b6f-8751-7dd1e8f25523" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5335b674-666a-48fb-a983-997f5461f509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5335b674-666a-48fb-a983-997f5461f509" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c61310fb-1b8b-40a2-9805-8a4187fa8f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c61310fb-1b8b-40a2-9805-8a4187fa8f28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2b1dec9e-ca87-4a48-8db2-be8501ed952e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2b1dec9e-ca87-4a48-8db2-be8501ed952e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8e325ce-8078-4b72-a922-d78532ccd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8e325ce-8078-4b72-a922-d78532ccd1dd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d631fbf-04f3-4ea9-9004-f9c9d3d46ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d631fbf-04f3-4ea9-9004-f9c9d3d46ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c23a7a73-fe8d-48cc-8ea2-35e3d0f1cd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c23a7a73-fe8d-48cc-8ea2-35e3d0f1cd1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_5e56306f-5f75-4f03-a37c-e5d25a5cda97" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_5e56306f-5f75-4f03-a37c-e5d25a5cda97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_5ae15d2d-e6c2-4942-9991-3af29fb526e2" xlink:href="ck0001824293-20240630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_5ae15d2d-e6c2-4942-9991-3af29fb526e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9504ebc7-2973-438a-8e3c-4903c4277614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9504ebc7-2973-438a-8e3c-4903c4277614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_fadd96c2-6764-41e4-bccc-a91d9ff06b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_fadd96c2-6764-41e4-bccc-a91d9ff06b99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7980a8f1-a880-4728-8e67-a1991bd2dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7980a8f1-a880-4728-8e67-a1991bd2dee9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_f3bf4e63-1c61-4895-8f92-2cb8a36a2ecf" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_f3bf4e63-1c61-4895-8f92-2cb8a36a2ecf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_68d2658d-3f8d-4789-85f6-68178bc87042" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_68d2658d-3f8d-4789-85f6-68178bc87042" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3353f24d-4693-4c28-bc06-43f40769065d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3353f24d-4693-4c28-bc06-43f40769065d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4e7ed61f-7e00-4a7b-a992-4df129077f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4e7ed61f-7e00-4a7b-a992-4df129077f14" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfd4fcb5-1f4b-4045-b265-544c81444c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfd4fcb5-1f4b-4045-b265-544c81444c67" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a4d66e1-bedc-4eae-9fc5-7237d4d1a18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a4d66e1-bedc-4eae-9fc5-7237d4d1a18b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ca83045-e84a-4850-95d2-a24ff08441a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ca83045-e84a-4850-95d2-a24ff08441a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf2ad421-a8c1-4321-87cb-032c9fb579e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_63ecca1e-e505-4f1c-8898-1d6a131ec426" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_63ecca1e-e505-4f1c-8898-1d6a131ec426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_ac1301c2-8293-4da5-906e-7ea16e48d1c0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_ac1301c2-8293-4da5-906e-7ea16e48d1c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_1fba51eb-3115-4779-8553-912dbcf7a6b5" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_1fba51eb-3115-4779-8553-912dbcf7a6b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_cb9bdf42-8419-4a88-9cda-c0f7f1dca2a4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_WarrantsIssued_cb9bdf42-8419-4a88-9cda-c0f7f1dca2a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_543333b0-7caa-45d3-8bb9-7246cfb989ad" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_543333b0-7caa-45d3-8bb9-7246cfb989ad" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_5e566a58-dc37-486d-8c2c-1c8d57326e1f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_5e566a58-dc37-486d-8c2c-1c8d57326e1f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#LIQUIDITYDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d28dc6a6-ebcd-4d29-a000-0698573ab972_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:to="loc_us-gaap_RelatedPartyDomain_d28dc6a6-ebcd-4d29-a000-0698573ab972_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d547e9a0-131c-4eb0-94d7-8fc0af972270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:to="loc_us-gaap_RelatedPartyDomain_d547e9a0-131c-4eb0-94d7-8fc0af972270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_11d917dc-63e6-4ba7-9806-ed5d87ee7956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d547e9a0-131c-4eb0-94d7-8fc0af972270" xlink:to="loc_us-gaap_InvestorMember_11d917dc-63e6-4ba7-9806-ed5d87ee7956" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8d4798ef-d487-4a30-a1a2-91d9b9f41d76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:to="loc_us-gaap_EquityComponentDomain_8d4798ef-d487-4a30-a1a2-91d9b9f41d76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aaccf124-c694-43de-a56a-7b1ab271d3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:to="loc_us-gaap_EquityComponentDomain_aaccf124-c694-43de-a56a-7b1ab271d3b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e0c4f9e6-413a-4ad2-9a9d-58a95bbfb628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_aaccf124-c694-43de-a56a-7b1ab271d3b5" xlink:to="loc_us-gaap_CommonStockMember_e0c4f9e6-413a-4ad2-9a9d-58a95bbfb628" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_562f1154-3006-4dbd-b615-aa67513283c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_562f1154-3006-4dbd-b615-aa67513283c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_06e5d2e1-4c74-4a4f-af07-1abcc657987b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:to="loc_ck0001824293_PublicOfferingMember_06e5d2e1-4c74-4a4f-af07-1abcc657987b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_6c5ffba1-431c-4971-b7ff-75bb46b09017" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_6c5ffba1-431c-4971-b7ff-75bb46b09017" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a1b6702e-3541-4820-a13f-ba1d7034c228_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a1b6702e-3541-4820-a13f-ba1d7034c228_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_d0c795c9-24dd-4620-9a3c-a48bffa544d0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_d0c795c9-24dd-4620-9a3c-a48bffa544d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_30d2822e-8f0b-4c05-a1de-de62693ec247" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_30d2822e-8f0b-4c05-a1de-de62693ec247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_8627fb11-fb08-4118-8e45-ffd5f159cc37" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_8627fb11-fb08-4118-8e45-ffd5f159cc37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_fb4c2c3d-61f0-4c28-84b3-9d166f190ddc" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_fb4c2c3d-61f0-4c28-84b3-9d166f190ddc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_d59c04be-b630-4902-9bdb-2cdf5200a793" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_d59c04be-b630-4902-9bdb-2cdf5200a793" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_15301bea-1ada-498c-a3be-f596f3e6fd9d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_15301bea-1ada-498c-a3be-f596f3e6fd9d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesCCommonWarrantMember_a44db89c-191e-4e6f-ae21-bc4584283efc" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesCCommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesCCommonWarrantMember_a44db89c-191e-4e6f-ae21-bc4584283efc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_b162a1b1-5f78-4f5d-991e-ac077fa46fcc" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_b162a1b1-5f78-4f5d-991e-ac077fa46fcc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_bc3eac57-5064-46d1-9d39-7d1dbbc95427_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:to="loc_srt_RangeMember_bc3eac57-5064-46d1-9d39-7d1dbbc95427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8199a050-4796-407b-afa1-7d7149c86cfa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:to="loc_srt_RangeMember_8199a050-4796-407b-afa1-7d7149c86cfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_797b8ae4-a0be-4547-bb45-89c56201be64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8199a050-4796-407b-afa1-7d7149c86cfa" xlink:to="loc_srt_WeightedAverageMember_797b8ae4-a0be-4547-bb45-89c56201be64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9366c2a9-30ef-4d03-8ad8-3ee69573895b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9366c2a9-30ef-4d03-8ad8-3ee69573895b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0773f486-9634-4486-8dfe-6451892a664b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9366c2a9-30ef-4d03-8ad8-3ee69573895b" xlink:to="loc_us-gaap_SubsequentEventMember_0773f486-9634-4486-8dfe-6451892a664b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff2d3c86-8994-403b-90d5-c7500a2f54a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff2d3c86-8994-403b-90d5-c7500a2f54a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc535f39-547a-484d-bac3-f8b6a1b1ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc535f39-547a-484d-bac3-f8b6a1b1ac9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_466c6780-551f-4968-b749-bb093f87136f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_466c6780-551f-4968-b749-bb093f87136f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_41ecd5ab-99ee-4c5b-a480-3d90fde6a7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_CommonStockSharesIssued_41ecd5ab-99ee-4c5b-a480-3d90fde6a7e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67b91be9-aa1b-4f40-88f8-87072b7d21b0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67b91be9-aa1b-4f40-88f8-87072b7d21b0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_529d894b-7d20-4abf-b0ad-92e5df3e144d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_529d894b-7d20-4abf-b0ad-92e5df3e144d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_365fd1ab-663a-47c0-ad27-f87da846b351" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_365fd1ab-663a-47c0-ad27-f87da846b351" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_749c15ee-6cff-4ce7-825a-73567be1bacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_749c15ee-6cff-4ce7-825a-73567be1bacf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_31b640c6-ce79-4f29-b5b9-eddc3c8dc77e" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_31b640c6-ce79-4f29-b5b9-eddc3c8dc77e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d406b4c5-c810-49d2-b68d-b38e4b13a285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d406b4c5-c810-49d2-b68d-b38e4b13a285" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7044a8dc-3576-4550-8545-f9958103d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7044a8dc-3576-4550-8545-f9958103d86c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_22dffd4a-b9a2-4065-95e2-33142feba443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_22dffd4a-b9a2-4065-95e2-33142feba443" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b818f2a0-79b4-4a89-b06b-0765f7f55b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b818f2a0-79b4-4a89-b06b-0765f7f55b91" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_e9ecfd25-37bf-4983-8bbd-5759ff91850f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_e9ecfd25-37bf-4983-8bbd-5759ff91850f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_26442218-b6f8-4c14-baab-b449eef1771a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_26442218-b6f8-4c14-baab-b449eef1771a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3227f5ed-98bb-4ccf-ac2a-cbc096d35380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3227f5ed-98bb-4ccf-ac2a-cbc096d35380" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5d67ce72-c82b-4812-9825-35941dd96dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5d67ce72-c82b-4812-9825-35941dd96dbd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ba3369a-7b04-48c0-aded-00dbd749e543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ba3369a-7b04-48c0-aded-00dbd749e543" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_b397a943-464c-4750-b99f-800d35547263" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_b397a943-464c-4750-b99f-800d35547263" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8664d31a-d746-42c7-b05e-9b88b9dc04eb" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8664d31a-d746-42c7-b05e-9b88b9dc04eb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_17b84a1f-1cfe-4463-8140-af80daf5ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SharePrice_17b84a1f-1cfe-4463-8140-af80daf5ec4d" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ac2eeacd-b61b-4e1b-9a3f-0b7d0d13e2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ac2eeacd-b61b-4e1b-9a3f-0b7d0d13e2b5" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_954628c2-52f5-4ad5-986b-d6ca1b86c69c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_954628c2-52f5-4ad5-986b-d6ca1b86c69c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ee34d59a-e616-4428-9107-aa2ac1eae85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ee34d59a-e616-4428-9107-aa2ac1eae85c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6f1bfb50-b5ad-476e-8c47-b0d27e183ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:to="loc_us-gaap_WarrantMember_6f1bfb50-b5ad-476e-8c47-b0d27e183ebb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9b064534-c540-460b-ac64-05779c102cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ac2eeacd-b61b-4e1b-9a3f-0b7d0d13e2b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9b064534-c540-460b-ac64-05779c102cf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:to="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d343853a-1fef-4718-bfe2-9bdf15e1c883_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:to="loc_dei_EntityDomain_d343853a-1fef-4718-bfe2-9bdf15e1c883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:to="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember_e08b85d4-2efc-40bb-9a52-36fa4765a044" xlink:href="ck0001824293-20240630.xsd#ck0001824293_GRIOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:to="loc_ck0001824293_GRIOperationsMember_e08b85d4-2efc-40bb-9a52-36fa4765a044" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_a4d8bd8d-8fa8-4f41-9e81-8271fc4e6e23" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:to="loc_ck0001824293_PrivateGRIMember_a4d8bd8d-8fa8-4f41-9e81-8271fc4e6e23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ec6cef22-5fbc-4884-953d-cb9f570d1049_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ec6cef22-5fbc-4884-953d-cb9f570d1049_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_929e7932-b9f9-46bd-ab50-273732c2bf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_929e7932-b9f9-46bd-ab50-273732c2bf1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_0f16fb74-f7f8-4668-83a7-9910370afd8b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_929e7932-b9f9-46bd-ab50-273732c2bf1f" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_0f16fb74-f7f8-4668-83a7-9910370afd8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio_cf6d920a-5960-40d9-9d5c-f02b9f62d083" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_ck0001824293_CommonStockExchangeRatio_cf6d920a-5960-40d9-9d5c-f02b9f62d083" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b1fd45e3-ab09-4c5f-9582-5ee7ac0e9b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b1fd45e3-ab09-4c5f-9582-5ee7ac0e9b7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_51a4a204-c2ef-4974-9048-dab3345dcef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_51a4a204-c2ef-4974-9048-dab3345dcef9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_47fd465a-db62-4eae-8ee1-b150a8fd18e9" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_47fd465a-db62-4eae-8ee1-b150a8fd18e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_ab578df4-1871-4db2-b92f-7c23cfaa07a0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_ab578df4-1871-4db2-b92f-7c23cfaa07a0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee422688-d5a6-45ff-a847-e730e881c431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ee422688-d5a6-45ff-a847-e730e881c431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_12529e3a-eb2e-472a-8031-62d8d8a39cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_12529e3a-eb2e-472a-8031-62d8d8a39cd4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a8a7500-1676-4773-9fa8-7974a58ef945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a8a7500-1676-4773-9fa8-7974a58ef945" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2106bb68-0843-4b3a-a805-c2e258a25835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2106bb68-0843-4b3a-a805-c2e258a25835" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_04a3d8a3-74d5-4f9c-b4e4-c53651148ff5" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:to="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_04a3d8a3-74d5-4f9c-b4e4-c53651148ff5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4d9a82fd-7b84-4b68-874b-2aa95c4bc0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4d9a82fd-7b84-4b68-874b-2aa95c4bc0ce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c6551795-45af-47a9-aee1-996c869193d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_c6551795-45af-47a9-aee1-996c869193d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_599e50be-d105-4e4e-9aa0-cac11d68263e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_599e50be-d105-4e4e-9aa0-cac11d68263e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_25ede16a-48d3-4420-90b5-b1a12d6c012f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_599e50be-d105-4e4e-9aa0-cac11d68263e" xlink:to="loc_ck0001824293_WarrantLiabilityMember_25ede16a-48d3-4420-90b5-b1a12d6c012f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b7d1180-7cc4-401c-982d-806dd5f501ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b7d1180-7cc4-401c-982d-806dd5f501ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1a84411-693d-4721-9bcc-b4ac623a7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1a84411-693d-4721-9bcc-b4ac623a7bf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf462b9a-3850-470b-a712-141a48327acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c2e059af-0bf9-4fe0-acc5-e046801c6110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c2e059af-0bf9-4fe0-acc5-e046801c6110" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d79122f8-e4c8-4247-a017-7f849fa30a70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d79122f8-e4c8-4247-a017-7f849fa30a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_a795a905-a465-4566-8166-43db3218d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_a795a905-a465-4566-8166-43db3218d06e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_e179fbec-b9d0-4030-8c50-c62f8d131000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_e179fbec-b9d0-4030-8c50-c62f8d131000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_532ea3aa-23c2-46c3-89bf-9155bd964c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_532ea3aa-23c2-46c3-89bf-9155bd964c85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_229dadbd-b038-4bc1-8de4-de4a51501f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_229dadbd-b038-4bc1-8de4-de4a51501f73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:to="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_005f1170-64db-4446-b012-28527f5b86c8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:to="loc_srt_RangeMember_005f1170-64db-4446-b012-28527f5b86c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_061d8550-3e73-4e3e-8692-7607c2ab1a7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:to="loc_srt_RangeMember_061d8550-3e73-4e3e-8692-7607c2ab1a7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_2891a5cb-faf2-42b3-8848-4fcb39e941b1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_061d8550-3e73-4e3e-8692-7607c2ab1a7d" xlink:to="loc_srt_WeightedAverageMember_2891a5cb-faf2-42b3-8848-4fcb39e941b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7bd4d5d2-2e0b-42de-8570-b995f556ca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c2e059af-0bf9-4fe0-acc5-e046801c6110" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7bd4d5d2-2e0b-42de-8570-b995f556ca3a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d4c518d4-3457-4729-a3db-a62a79bbd4c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d4c518d4-3457-4729-a3db-a62a79bbd4c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_998f5495-5b60-4b64-89dd-2ca45938997c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:to="loc_us-gaap_ComputerEquipmentMember_998f5495-5b60-4b64-89dd-2ca45938997c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_51d271d5-8bdd-4610-affd-4447e93e60c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_51d271d5-8bdd-4610-affd-4447e93e60c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_19639179-1e50-4083-b599-6b7d3db806dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_19639179-1e50-4083-b599-6b7d3db806dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d605e1cf-efc9-45d7-9ab1-16b25f6a5d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d605e1cf-efc9-45d7-9ab1-16b25f6a5d07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dc00742e-7631-4cb4-9c9b-1e57d1b58882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dc00742e-7631-4cb4-9c9b-1e57d1b58882" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bc4ef201-5215-4466-be2f-6b5ad896705a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:to="loc_us-gaap_RelatedPartyDomain_bc4ef201-5215-4466-be2f-6b5ad896705a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b01d6a48-99cb-4062-99b7-1c91a9de7b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:to="loc_us-gaap_RelatedPartyDomain_b01d6a48-99cb-4062-99b7-1c91a9de7b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_16437541-d487-4c4c-8fb3-85cdd4af2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_b01d6a48-99cb-4062-99b7-1c91a9de7b60" xlink:to="loc_us-gaap_InvestorMember_16437541-d487-4c4c-8fb3-85cdd4af2fdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fb0ea414-f2d9-483e-8485-7c7f613aed61_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fb0ea414-f2d9-483e-8485-7c7f613aed61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b829331-9822-4dfc-8715-f5101f066919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b829331-9822-4dfc-8715-f5101f066919" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_41f21a83-4b5b-4143-bf10-73afb52e4765" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b829331-9822-4dfc-8715-f5101f066919" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_41f21a83-4b5b-4143-bf10-73afb52e4765" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_4001f4da-7bdc-4b94-9ff0-e010701d77c8" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:to="loc_ck0001824293_BridgeWarrantsMember_4001f4da-7bdc-4b94-9ff0-e010701d77c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_3149dff0-de9b-44a7-bc28-a13d76765e28" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_3149dff0-de9b-44a7-bc28-a13d76765e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_34a064e9-23e9-4c38-9194-5be2ec393d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_34a064e9-23e9-4c38-9194-5be2ec393d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_8e780e91-5c2f-4fd9-a1e3-192a5edf3c28" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_8e780e91-5c2f-4fd9-a1e3-192a5edf3c28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_9b0debde-28a9-4a7a-aed3-aed6d78c3281" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_9b0debde-28a9-4a7a-aed3-aed6d78c3281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_254756ec-e762-49aa-a758-404230398fef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_254756ec-e762-49aa-a758-404230398fef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97e82787-7764-4192-b4c9-9fcaa7e86c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97e82787-7764-4192-b4c9-9fcaa7e86c56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f3db8cb-bdd2-4bb3-a233-a1dc2b22ba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f3db8cb-bdd2-4bb3-a233-a1dc2b22ba2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_4cdaf53d-34a2-4cef-a27a-c06490ea3ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_4cdaf53d-34a2-4cef-a27a-c06490ea3ed7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_ad84d3e9-3f38-47f5-91ac-90b50398c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_ad84d3e9-3f38-47f5-91ac-90b50398c88c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_88ee56d3-83dd-4343-9eaa-81460eae11ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_88ee56d3-83dd-4343-9eaa-81460eae11ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_60d4074b-a7bb-44e3-8136-192a68831878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_60d4074b-a7bb-44e3-8136-192a68831878" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_fc267ebe-cd0d-4bd1-9619-ff19e78716f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:to="loc_us-gaap_RelatedPartyDomain_fc267ebe-cd0d-4bd1-9619-ff19e78716f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05ba9fc5-b5f4-4ef1-bfbe-49a9024df1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:to="loc_us-gaap_RelatedPartyDomain_05ba9fc5-b5f4-4ef1-bfbe-49a9024df1b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_a9963890-04a6-4d39-9cd2-1aac8cac81a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_05ba9fc5-b5f4-4ef1-bfbe-49a9024df1b7" xlink:to="loc_us-gaap_InvestorMember_a9963890-04a6-4d39-9cd2-1aac8cac81a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b4984c4-9914-4bac-b4fe-1778824eb157_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:to="loc_us-gaap_EquityComponentDomain_3b4984c4-9914-4bac-b4fe-1778824eb157_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:to="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1847f098-8d3f-4fc9-b8ea-1e14cc032755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:to="loc_us-gaap_CommonStockMember_1847f098-8d3f-4fc9-b8ea-1e14cc032755" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9d8b0c93-6607-4ea0-a4b1-c0153496d9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9d8b0c93-6607-4ea0-a4b1-c0153496d9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db243010-9111-42ae-aa6a-ce1c735e32fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_db243010-9111-42ae-aa6a-ce1c735e32fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_4c0d96d7-18e2-4438-be6c-54c7c4e2f4a9" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:to="loc_ck0001824293_PublicOfferingMember_4c0d96d7-18e2-4438-be6c-54c7c4e2f4a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_2357bcd3-f8d5-4634-95fc-e37a7acdf737" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_2357bcd3-f8d5-4634-95fc-e37a7acdf737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9dd265e0-ae12-4c5a-a55e-6046fc543f66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9dd265e0-ae12-4c5a-a55e-6046fc543f66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_4a22150a-37f9-4dd7-b4fd-4a2ee85becf8" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_4a22150a-37f9-4dd7-b4fd-4a2ee85becf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_d4ef6f57-b662-4033-a984-0d62ef69f130" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_d4ef6f57-b662-4033-a984-0d62ef69f130" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_306e875a-6bd6-4e83-8a94-9563424517ae" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_306e875a-6bd6-4e83-8a94-9563424517ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_62b14ca3-1119-46a2-9adf-ec773f8f15c1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_62b14ca3-1119-46a2-9adf-ec773f8f15c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_d9b453ee-6676-47c7-8210-2133073978f5" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_d9b453ee-6676-47c7-8210-2133073978f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_b6654b08-8c1e-4645-b13b-3ca65b50bc57" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_b6654b08-8c1e-4645-b13b-3ca65b50bc57" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesCCommonWarrantMember_5f4e550d-86de-4f5d-848c-d5221639605d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesCCommonWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesCCommonWarrantMember_5f4e550d-86de-4f5d-848c-d5221639605d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_fb2c1df4-28a7-422d-a09f-66e3a7fa1db1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_fb2c1df4-28a7-422d-a09f-66e3a7fa1db1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThePlacementAgentWarrantsMember_cea0a599-a4a6-4b9f-96a0-fdb4a445986a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ThePlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_ThePlacementAgentWarrantsMember_cea0a599-a4a6-4b9f-96a0-fdb4a445986a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a7764606-9d24-43b4-b7a6-ed36b3aeed26_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:to="loc_srt_RangeMember_a7764606-9d24-43b4-b7a6-ed36b3aeed26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f8eb23a-d137-4b66-a1c9-7c36ccd373de" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:to="loc_srt_RangeMember_7f8eb23a-d137-4b66-a1c9-7c36ccd373de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_aaaa8e69-70bd-4b12-835b-515eadc7d0c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7f8eb23a-d137-4b66-a1c9-7c36ccd373de" xlink:to="loc_srt_WeightedAverageMember_aaaa8e69-70bd-4b12-835b-515eadc7d0c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_55ee79be-f4e9-4f55-a705-aec0943b7936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_55ee79be-f4e9-4f55-a705-aec0943b7936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bfe471a5-4a1e-41b9-85b1-7a45228e962e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bfe471a5-4a1e-41b9-85b1-7a45228e962e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_802a29d8-71c9-47aa-8560-3d76b4ffa566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bfe471a5-4a1e-41b9-85b1-7a45228e962e" xlink:to="loc_us-gaap_SubsequentEventMember_802a29d8-71c9-47aa-8560-3d76b4ffa566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_c8ab13e9-b357-46d0-b987-ad19f410f107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_c8ab13e9-b357-46d0-b987-ad19f410f107" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_935aa7be-f996-48ff-bb1c-c252110420b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_935aa7be-f996-48ff-bb1c-c252110420b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3c2b6c4-f6e7-40ae-a64c-a37aeb026a95" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3c2b6c4-f6e7-40ae-a64c-a37aeb026a95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ebf5ec6b-5598-4cd3-93c0-ce0ff69cf5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ebf5ec6b-5598-4cd3-93c0-ce0ff69cf5ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_5d6a45be-0aa3-4679-b155-7ff1d7079711" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_5d6a45be-0aa3-4679-b155-7ff1d7079711" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8da0d16-ff8b-4e20-830f-0913f1100951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8da0d16-ff8b-4e20-830f-0913f1100951" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6fd08d81-3e3b-47a9-8821-f03300c6813b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6fd08d81-3e3b-47a9-8821-f03300c6813b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_657c0cd1-64d5-4fc7-a16e-4b12984f58a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_657c0cd1-64d5-4fc7-a16e-4b12984f58a6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ddbdcc81-cd41-4bd0-bb6c-a02d1bd3160d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ddbdcc81-cd41-4bd0-bb6c-a02d1bd3160d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_236344e6-718e-4684-9a4c-55ff85d1fe67" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_236344e6-718e-4684-9a4c-55ff85d1fe67" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_750f8dc6-0a3c-4990-9373-da31626c65db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_750f8dc6-0a3c-4990-9373-da31626c65db" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_557a99cd-7145-407f-ae75-38020f1c7d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_557a99cd-7145-407f-ae75-38020f1c7d81" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a516cdc5-ed5c-41b4-b3ab-b65768293041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a516cdc5-ed5c-41b4-b3ab-b65768293041" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15b0bb71-0482-42de-9fb9-b92ba2b48ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15b0bb71-0482-42de-9fb9-b92ba2b48ccc" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_0b529100-69b3-484f-9018-bdd402b31fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_0b529100-69b3-484f-9018-bdd402b31fae" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5fa4c1a1-8093-4b68-82fa-067918eb3b33" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5fa4c1a1-8093-4b68-82fa-067918eb3b33" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_4d83b9f0-a73d-4c77-a928-c20c65d2062a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_4d83b9f0-a73d-4c77-a928-c20c65d2062a" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a764e3bd-8ce8-4c5a-8e4b-6cacbf9093a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_a764e3bd-8ce8-4c5a-8e4b-6cacbf9093a5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7e8b8bae-d433-46af-9f48-9f6f21dac8f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7e8b8bae-d433-46af-9f48-9f6f21dac8f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_b3e8a53a-5a2e-46d5-ba4b-895f5d1ef35b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:to="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_b3e8a53a-5a2e-46d5-ba4b-895f5d1ef35b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_c4095899-69f7-44e8-8fa2-7fa4c2f2b159" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:to="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_c4095899-69f7-44e8-8fa2-7fa4c2f2b159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_b6eac1cb-f882-4221-bd03-b06fc8042ee1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_b6eac1cb-f882-4221-bd03-b06fc8042ee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f6636c7-97c8-4b38-825b-14d78d01e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f6636c7-97c8-4b38-825b-14d78d01e84f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d44aea75-3407-4870-8546-38cb948fb40d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d44aea75-3407-4870-8546-38cb948fb40d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5be9977f-adae-465f-997b-9effa39b5df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5be9977f-adae-465f-997b-9effa39b5df2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bb145c2e-fb6b-4b93-baa3-82ff7a633ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bb145c2e-fb6b-4b93-baa3-82ff7a633ba1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_98f8c2f4-d835-4a87-a387-0c1d5b213316_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:to="loc_srt_RangeMember_98f8c2f4-d835-4a87-a387-0c1d5b213316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_031435cb-3cca-4cb1-8a9c-b10a4e94acb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:to="loc_srt_RangeMember_031435cb-3cca-4cb1-8a9c-b10a4e94acb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0249c3d3-7359-4fe0-8631-65f98e43ed74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_031435cb-3cca-4cb1-8a9c-b10a4e94acb8" xlink:to="loc_srt_WeightedAverageMember_0249c3d3-7359-4fe0-8631-65f98e43ed74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cde84eed-fb2e-49ca-b5b5-782fce9d614f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_a764e3bd-8ce8-4c5a-8e4b-6cacbf9093a5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cde84eed-fb2e-49ca-b5b5-782fce9d614f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_759b7664-a6e1-4d88-98ea-f3393c77090e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_759b7664-a6e1-4d88-98ea-f3393c77090e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsNotExpiringMember_2201da69-3d1b-44f8-9bec-ccea52b98539" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsNotExpiringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsNotExpiringMember_2201da69-3d1b-44f8-9bec-ccea52b98539" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_5c51aaef-7e03-4301-9ce6-9648efe1bbc7" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_5c51aaef-7e03-4301-9ce6-9648efe1bbc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2025Member_296dac87-cef0-40ca-a879-c50f9b823e8d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInDecember2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInDecember2025Member_296dac87-cef0-40ca-a879-c50f9b823e8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_ed1f3431-bd63-452c-8f44-45eb62027d71" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_ed1f3431-bd63-452c-8f44-45eb62027d71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_e9952efc-ebb3-4a88-a187-13aed5a27966" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_e9952efc-ebb3-4a88-a187-13aed5a27966" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_375fae1f-bdc4-480c-a77f-6ba7d416e752" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_375fae1f-bdc4-480c-a77f-6ba7d416e752" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_d8866906-9945-40d1-bbf6-f7bd25ab7b00" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_d8866906-9945-40d1-bbf6-f7bd25ab7b00" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_70b84ec6-49bf-4f3e-8105-aee3156a2a16" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_70b84ec6-49bf-4f3e-8105-aee3156a2a16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_2759d5c1-b8f3-4b80-a50b-3276f994a1c0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_2759d5c1-b8f3-4b80-a50b-3276f994a1c0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_26b3bcc3-92a2-418e-96b9-5fe4771b6234" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_26b3bcc3-92a2-418e-96b9-5fe4771b6234" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_f6c68345-e8d4-493e-90ac-55e0127ffddf" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_f6c68345-e8d4-493e-90ac-55e0127ffddf" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_109fd6e3-83d3-4dc4-9414-b18d87ebadb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_109fd6e3-83d3-4dc4-9414-b18d87ebadb1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7d9baed7-4f6d-42b9-8f31-97b38bf1f882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7d9baed7-4f6d-42b9-8f31-97b38bf1f882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c89b850d-3de2-4fa0-a209-ddcf814dc1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c89b850d-3de2-4fa0-a209-ddcf814dc1f6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:to="loc_us-gaap_PlanNameDomain_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:to="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsPlanMember_9f7c6aae-0b69-4b10-887c-8b0751fd4302" xlink:href="ck0001824293-20240630.xsd#ck0001824293_GRIOperationsPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:to="loc_ck0001824293_GRIOperationsPlanMember_9f7c6aae-0b69-4b10-887c-8b0751fd4302" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_2f3389ef-5a32-4a6f-a92d-0fb478b46f8d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_2f3389ef-5a32-4a6f-a92d-0fb478b46f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46e07374-eeda-45a2-a76f-f73bb35568c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46e07374-eeda-45a2-a76f-f73bb35568c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d5d25d-b164-4526-bc97-07af2ae6101d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d5d25d-b164-4526-bc97-07af2ae6101d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8f67b0f2-7454-437d-9562-1a4dfaae1a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d5d25d-b164-4526-bc97-07af2ae6101d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8f67b0f2-7454-437d-9562-1a4dfaae1a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aec78aa0-7871-4bc9-bc1d-df11c133e0b5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:to="loc_srt_RangeMember_aec78aa0-7871-4bc9-bc1d-df11c133e0b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52da3fd8-0a33-442e-994f-a2e7898e1dcc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:to="loc_srt_RangeMember_52da3fd8-0a33-442e-994f-a2e7898e1dcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb292f62-5ac8-4927-ba5e-cf081cea97d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52da3fd8-0a33-442e-994f-a2e7898e1dcc" xlink:to="loc_srt_MaximumMember_cb292f62-5ac8-4927-ba5e-cf081cea97d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25721339-a300-4691-8183-3a762a214111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25721339-a300-4691-8183-3a762a214111" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e299c7f2-f9f6-42be-8cbd-a102762a13bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e299c7f2-f9f6-42be-8cbd-a102762a13bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6ea1a3c0-56c3-4a03-af40-90fba5944b18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6ea1a3c0-56c3-4a03-af40-90fba5944b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f824ecb-bc54-42a3-9466-0d3ccad05a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f824ecb-bc54-42a3-9466-0d3ccad05a26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd44408b-e285-46fa-b183-43138607dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd44408b-e285-46fa-b183-43138607dde8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_edfe4ec6-7a42-45b6-9be1-1a2e4f44a1cd" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_edfe4ec6-7a42-45b6-9be1-1a2e4f44a1cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bb98d731-b96e-4e66-9326-96118518d234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bb98d731-b96e-4e66-9326-96118518d234" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25c893a4-df90-4008-bf96-99f7f717c5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25c893a4-df90-4008-bf96-99f7f717c5a7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2e75623e-a660-45e4-a3bb-08ce4ef48978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2e75623e-a660-45e4-a3bb-08ce4ef48978" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f5505bf9-83b5-4166-900e-aa06be24cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f5505bf9-83b5-4166-900e-aa06be24cba1" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ecbf8fa4-4742-4d45-91be-949a5fcfc54d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ecbf8fa4-4742-4d45-91be-949a5fcfc54d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b87404b-961a-4cbc-b211-806a8202db0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b87404b-961a-4cbc-b211-806a8202db0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3f970815-f667-4b6a-aef4-322e254b9af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3f970815-f667-4b6a-aef4-322e254b9af5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89a72bd7-f9f3-4f7d-8453-178c337c52cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89a72bd7-f9f3-4f7d-8453-178c337c52cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00077ba2-5617-4d50-9e01-0985cd7f790e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ecbf8fa4-4742-4d45-91be-949a5fcfc54d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_00077ba2-5617-4d50-9e01-0985cd7f790e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:to="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:to="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a54a7d8f-bc67-4f32-badf-616babecc109_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_a54a7d8f-bc67-4f32-badf-616babecc109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af26c697-ef85-4a5d-ad4f-4627fa8eca94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af26c697-ef85-4a5d-ad4f-4627fa8eca94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_83498ea1-90d7-4104-b26b-f5866fe1805d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af26c697-ef85-4a5d-ad4f-4627fa8eca94" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_83498ea1-90d7-4104-b26b-f5866fe1805d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_30ace902-378e-452f-bacc-9116b1141d89" xlink:href="ck0001824293-20240630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_30ace902-378e-452f-bacc-9116b1141d89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_65125d49-3e3d-4498-babf-3d358b763cb3" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_65125d49-3e3d-4498-babf-3d358b763cb3" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ck0001824293-20240630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4b2bd8b8-7391-472c-baa6-f4915a4212d0,g:cfdabf3d-48ec-4ec5-a4ba-2606592f7687-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_d9a47999-a164-4017-b7a9-0620ba6b471e_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_317cd15a-8430-463d-ad2a-35a3b3d806b5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_cb1850dd-b28d-4c7b-8330-5b600516bf68_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9dcdbcae-f471-4e41-a866-355b604baf7a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_64a0d0d2-183d-40b2-b33c-3c80cf782b94_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_56d75081-e3cf-44c7-b3d6-828495bb8765_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_96db84ba-f73f-4c69-80b1-4ca3d608176b_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_62788fd7-f7df-4798-85a8-c21f20c915a7_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock placed into escrow (in shares)</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_label_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:label id="lab_ck0001824293_CommonStockHeldIntoEscrowAccount_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Held Into Escrow Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:to="lab_ck0001824293_CommonStockHeldIntoEscrowAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_0a580cbd-3f28-4f81-8b75-6da50a1db3e2_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_84642947-62cb-428f-842d-f279aa0e7a75_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for settlement of bridge note (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_1fed8aba-155c-44aa-b7dc-b2ab5a6de2d4_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, exchange ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_label_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:label id="lab_ck0001824293_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockExchangeRatio" xlink:to="lab_ck0001824293_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_57cbbff1-d64f-45e8-a122-af33804dd9b2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_df019dba-81ef-438b-a832-f19cdfb135c0_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock for repayment of bridge promissory note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Repayment Of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:to="lab_ck0001824293_StockIssuedForRepaymentOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_537cb168-ae42-4b44-afe9-8deea0067ac5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_dc4c6620-5b67-4bf0-9dde-e066c38d2ddc_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_8f7f1f67-88e9-4845-97c2-b120211768b7_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded warrant exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a65a10e8-9534-4c0d-bd83-ad19df3e2056_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7aed65f3-0d34-4e20-a7f8-44a02ef3cc13_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e50fbe58-8ffa-4bb7-a044-bec1297cab62_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_38be7c6c-0ee4-4df1-b571-2cce79f8249c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_9ec050a0-b643-4153-9523-0181517bd4b5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_527c6e40-5369-46e2-a5c4-ef9eb6de12b0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_abf6d526-1253-43a9-8c9f-dc5d596f40ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_295475ed-2814-410e-a5d7-bcffad642976_negatedLabel_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net liabilities assumed in connection with reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Liabilities Assumed In Connection With Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:to="lab_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2ff8e10f-449e-4bf2-96ba-81c808bf0e85_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and rights outstanding, term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f956112f-9722-4ff0-a234-d69d85809539_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_6366588f-7527-4315-928e-e8a146cf1486_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price per share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_5eb628af-e862-416c-ad3b-9574ec9afc82_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in pre-closing financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_49aaf228-c77f-4fc3-990b-dfc87d71307f_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_0d74065f-c570-46a6-8fe1-dd1afad32b84_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In 18 Months After The Warrant Stockholder Approval</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In 18 Months After The Warrant Stockholder Approval [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In 18 Months After The Warrant Stockholder Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_08086739-b2c4-42a7-80c6-cbaa4e6b2c68_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_70528762-034d-4635-8b36-83a27aa333a7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a44f897c-109d-42a7-b914-518dd020669b_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d24f94a5-4881-419b-b9d4-37e4407f9d9f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_75b77d90-1bd4-4700-b663-b3320d8dd7bf_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInApril2028Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In April 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInApril2028Member" xlink:to="lab_ck0001824293_WarrantsExpiringInApril2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_5ab11748-6b8c-412b-a535-b74351fb95f8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_e806480b-5066-4f23-bd53-b47be23277c7_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of advances from employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_RepaymentOfAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment Of Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:href="ck0001824293-20240630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:to="lab_ck0001824293_RepaymentOfAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7e613681-a462-4632-9442-3a1da0caa5a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_d21e36a2-82ea-4c5e-8117-f2bd58dac526_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_38e5e202-b7a8-4287-9ed9-2aa30aca990d_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge SPA</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:to="lab_ck0001824293_BridgeSecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_a6d7fa17-86dd-4cc0-8118-99c1383e8db7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8ffc694c-d143-49fe-aeb4-7278ea84e352_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b87c25b2-6942-4f36-a778-d2f48c37cca8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_84311dba-b681-4976-8c73-2a8aa225b1ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in-capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_dab732dd-b86a-456c-8bd6-2855c83879ed_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a976b71e-03ac-40e2-92d4-b612deb234ec_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_4609a9f3-fcc7-4925-80ef-fc868be4838d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_99e8e8f1-9436-48f1-ac0e-b4c563bb5ebc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ce3a30a6-7f7e-4374-aa2c-bcf4aa6a72ca_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_efb62508-124d-4b3a-9f67-078849913d17_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7d8b629b-4f09-48b4-b1ef-d6f6c6657495_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_ac29ec94-870a-47db-8ecc-1d3566b71401_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for reverse recapitalization expenses (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b51b8a83-1902-4ad8-a8e0-34bc353200eb_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b98929ab-1b72-455d-bae5-17caa02c0c12_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2838c63a-7564-41dc-b35f-8b1a03d1b7ed_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in usd per share)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_ec4d3f3a-2b42-41a7-96bd-936afb7885c0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_b28c945c-6144-4e5e-9680-cdd7f957d195_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityMember" xlink:to="lab_ck0001824293_WarrantLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b056582-9b50-4fed-9818-9809918b7871_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ac822186-8f35-4b60-8424-27b72816c4ee_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_94a97456-1b72-46ae-a4f3-73ecbca0d1e1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_255b98de-b43f-4766-99ff-d58c8308e91a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_c4f827c1-d3a8-4839-81f3-4965fc25f69c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsNotExpiringMember_8c9d69da-37f2-41cf-a670-76abaa609a93_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsNotExpiringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Not Expiring</link:label>
    <link:label id="lab_ck0001824293_WarrantsNotExpiringMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsNotExpiringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Expiring [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsNotExpiringMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsNotExpiringMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Not Expiring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsNotExpiringMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsNotExpiringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsNotExpiringMember" xlink:to="lab_ck0001824293_WarrantsNotExpiringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_156a4316-022e-402f-92a8-4c489f4cc014_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_9d9be8b7-9264-4233-ac21-8ff78effcb56_terseLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net liabilities assumed plus transaction costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_6e45b0f1-2833-442f-b5de-faccc14d577c_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7a4eb7b7-413d-4734-888a-ffd7deec5951_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_91b8c1ba-ff15-4c3a-996d-56f04d3c21ce_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_52a7ac68-2247-4c41-b9b7-21eac9cd9b90_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research and Development Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_e2ee3f0d-b9c5-4636-9c90-aedf037e3bdd_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fractional share adjustment (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Fractional Share Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_647dd8d2-0495-4c08-84dc-a41060e8a6fd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_6d207f8d-4e08-4fd2-bdb4-dcac7de29cd5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0e5ddb5f-a924-400f-9e28-c7011917e10b_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_fb2454a4-86f0-4025-9468-945562c89151_terseLabel_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merger costs included in accounts payable</link:label>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Merger Related Costs, Financing Activities</link:label>
    <link:label id="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_documentation_en-US" xlink:label="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:to="lab_ck0001824293_NoncashMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_46a89eba-903c-4cd3-a75e-990876322ea1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_556fa046-52be-42ad-8dc8-53cea2b5454e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_e89e2c82-6321-4964-ab84-e3cc725238ad_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2025Member_8b6a59cc-0260-439d-8e22-561811e7a426_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In December 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In December 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInDecember2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInDecember2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In December 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2025Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInDecember2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInDecember2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInDecember2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3cd13581-64e8-48a8-a19a-eaf2eac2e470_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_d16148a6-2b5a-479a-abe4-a8707a4070a7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares called by each warrant</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_399f969e-6f66-4918-8695-1ac9dc9e18ec_terseLabel_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of target bonus (as a percent)</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_label_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:label id="lab_ck0001824293_PercentageOfTargetBonus_documentation_en-US" xlink:label="lab_ck0001824293_PercentageOfTargetBonus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Target Bonus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PercentageOfTargetBonus" xlink:to="lab_ck0001824293_PercentageOfTargetBonus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_76bbe270-0258-4ff0-9b92-f911269b6a96_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1aa2bcbd-a1cc-438b-afd9-261d1ebce9bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_e99c0846-497e-47a4-935d-065c6e81df64_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_e746db74-0942-4a18-b1c3-ac8172e12750_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_b4e8fdc0-317c-412c-90f4-0397fe05b790_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in cash</link:label>
    <link:label id="lab_us-gaap_InvestmentCompanyCommittedCapital_label_en-US" xlink:label="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Company, Committed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentCompanyCommittedCapital" xlink:to="lab_us-gaap_InvestmentCompanyCommittedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_36ffe260-52ca-4535-8515-2da2cd748927_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_abf7ce27-d4a9-4f31-b177-f94312d8c59a_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Common, Series C-2 Common and Placement Agent Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:to="lab_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_1b5682f3-077e-4235-b279-413e158538f0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec87b9c1-5fe9-44de-b963-3bac28ecffed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_067c9148-3844-46a4-a4ec-db235ecd369e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d0ea3eb8-ea66-4091-9cea-0de6ba6f5406_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1a4b83fe-93a5-49b0-b654-522b4106da9c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_add7ee52-b286-4ec5-90dc-fa57cd00ab53_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_ce74776f-b5eb-4e2d-bddd-1e06f0cefdde_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Accounting</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_89123f04-f505-44f6-b92d-60c76221cab9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e5785f17-9b56-4915-abbc-64e615a67264_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_58a68929-f971-4212-bb5f-cc218bd7dd05_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_100578f1-1e25-4f0a-a171-ec3aa6bb8b48_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_be82ce87-a684-45a9-8a93-797e03464bef_terseLabel_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:label id="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_8b8658a6-6c5c-4da4-a911-8b48a7b72c58_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_ead1b268-75f4-4a32-a7d4-93a181d6d67c_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedWarrantsMember" xlink:to="lab_ck0001824293_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_49085418-3e9d-46d8-bd22-50d1dcfd2e5a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0731db91-ebf5-4a80-a70f-126ca9dbc09d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_GRIOperationsMember_180921de-9c79-4391-ae62-7d42cce4a153_terseLabel_en-US" xlink:label="lab_ck0001824293_GRIOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GRI Operations</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsMember_label_en-US" xlink:label="lab_ck0001824293_GRIOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GRI Operations [Member]</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsMember_documentation_en-US" xlink:label="lab_ck0001824293_GRIOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GRI Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_GRIOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_GRIOperationsMember" xlink:to="lab_ck0001824293_GRIOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_3ac83008-1f93-4040-bc2b-4e4adcca1561_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_ae7ccaf8-c013-4818-a891-9f994120ee7e_terseLabel_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage in common stock (as a percent)</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_label_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:label id="lab_ck0001824293_CommonStockOwnershipPercentage_documentation_en-US" xlink:label="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_CommonStockOwnershipPercentage" xlink:to="lab_ck0001824293_CommonStockOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2de2f323-05e5-47d9-a604-695b7953c413_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0b019104-ad59-4446-84b7-3eb2a6fb1943_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_4206f9ac-0f81-4bf9-b5b3-57770759a898_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_5cd83d9b-3c92-44e0-bd1d-df95858f14ff_verboseLabel_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Advances from employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_label_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:label id="lab_ck0001824293_ProceedsFromAdvancesFromEmployees_documentation_en-US" xlink:label="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Advances From Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:to="lab_ck0001824293_ProceedsFromAdvancesFromEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4dae4ef5-2243-40a0-aca7-5a484de0e887_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_60846f39-3aa4-4435-b24b-074df7ce9da6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_89c17659-81c8-408f-92c1-d00cd74d3286_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from warrant exercise</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f256ac0d-8101-4292-a1ef-6fe568a60091_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f8b103ff-64a1-4c5d-b4d7-20c39e96bebf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_00f084d5-dc98-4ea2-8388-62b26c0774ba_terseLabel_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_label_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:label id="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_documentation_en-US" xlink:label="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:to="lab_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_b9032403-8edd-4662-8b71-2cc361415b42_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_4582d4b2-73fc-449f-b7b2-e9d64e685f43_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prefunded warrant exercise (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrant Exercise</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_5f5db06c-4ed7-4e43-955e-2477f08f7db7_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0431da7e-0a03-4d30-a473-fe3a7bfadc1e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_1d534945-768f-455c-b1ce-ee6c0f9c0c87_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of stock for payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued For Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_34c8771c-bbcf-4f57-bbfd-e52fb3d5c961_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_51ce808f-f935-4d7b-9cb4-2c2bd3a915bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_6696224c-422e-49a6-9f5e-19dfb0f6874c_terseLabel_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares converted into common stock (in shares)</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_label_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:label id="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted_documentation_en-US" xlink:label="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Additional Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:to="lab_ck0001824293_ConversionOfStockAdditionalSharesConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1af5cf0f-8fc9-40c3-97d4-081bdceb3bc5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_15c45009-4040-4099-aec7-df87db3c8045_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MERGER WITH VALLON</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a752e941-a984-4aac-bdc7-5521b161f615_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_032a37ba-d76a-4706-975a-37c6df02eea4_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_38ba6782-aa20-4cba-b184-dbc3fcea4f64_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum value of shares offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Value Of Shares Offered</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:to="lab_ck0001824293_SaleOfStockMaximumValueOfSharesOffered" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_bec66f8e-01cf-4de2-ac5a-1f6ae67174b1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_5ecbdfdc-9229-44b7-b61b-fabd7de702a6_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_944dcf42-7069-4df1-86b7-085077fe9474_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_83695b6e-bdc4-416f-be12-48779e5a0b0f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_fc09b221-38b6-41f3-a730-5c588ab8be4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_862f7da1-3de2-45f1-9620-a757d61c40ef_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_af5fb076-8fc5-43ed-aea5-772457bd3688_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional&#160;Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_a642cc91-1e31-42e9-a555-3766a2b87ff8_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Aggregate Purchase Price</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:to="lab_ck0001824293_DebtInstrumentAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_f5e6787f-26a2-431c-b881-626b5a8b39b4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_9b889b03-4a83-4a7d-8677-d50a436e8581_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c9db665f-df84-458c-b5dd-1812ce613fc5_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1d46718c-a004-47fd-a81b-ddc2c5d148be_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_7d50f8d3-21e2-483a-b09e-7f458e0ef65d_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3e395c87-4d28-4e20-85c1-15312fd0b1d6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_c5d78953-b5f6-4e26-ba2a-43ed6e385151_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_e7bb39d5-a304-4f85-bf4e-05d6736117a2_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJuly2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In July 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJuly2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_9b92fa01-f13a-4683-bba0-525ea2407a35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Outstanding to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_0def43af-eadd-41be-911f-5796f4b4298a_terseLabel_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Warrants</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_BridgeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_BridgeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bridge Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BridgeWarrantsMember" xlink:to="lab_ck0001824293_BridgeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_7ff71dab-ea70-44ad-ab93-d16ddd8b99da_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_a6f6c0b9-0f51-4ea1-8d1e-eb73a88634eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_c4e994c5-a1cc-47e3-b4c9-f0131c280d6a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_44cdaa84-1459-40d1-98bb-da7c066199b8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant issuance</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e2011cca-2703-4aa0-ab25-196321dffb5c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash financing activities:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b710befc-ed6c-4111-9580-d0f45ae99268_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation, weighted average amortization period (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityFairValueDisclosure_f8d8ca0f-7b70-4956-94d3-8a81ecb7311a_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:to="lab_ck0001824293_WarrantLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_02c61ee3-aa0b-44a6-b264-a690065e3f5b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5f7de0b1-9f5b-48f7-a092-29412ba7381f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_fad5e5dc-a7a9-46cd-9a4e-064e8c7aa4f3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_87cceaa5-1dac-4f09-baac-c7536711bf21_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_45bcab37-6400-474f-b39e-81a2a9d2e633_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_a4641c5e-1552-48f5-824a-5c10f2223477_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payroll and related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_7475b3f3-5d35-4f2b-a46b-f80fb7998a45_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a918a0f9-a795-479a-8644-79eb6a942a88_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_4de43886-7e42-4a46-bc67-1b6a00468c65_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_53624e02-c158-42e7-9715-afe149f1fb52_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_f1ccaa4b-bfc8-4a49-b14d-cadebe05a86d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of bridge promissory note</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_f2eda6a2-d5e6-4f79-8f42-a3bc3d365893_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of notes</link:label>
    <link:label id="lab_us-gaap_ProceedsFromNotesPayable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_ca1950d5-fee5-4894-9155-ca71843bdc7f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_1dad6330-b64e-4669-8c1d-231f0ced2ce3_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_27dc4492-4cd4-427d-9794-17efed0a9805_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, 0.0001 par value; 250,000,000 shares authorized as of June&#160;30, 2024 and December&#160;31, 2023; 801,914 and 49,663 shares issued and outstanding as of June&#160;30, 2024 and December&#160;31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_546f7676-2587-43c4-a9cd-1508cbea2691_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_d8aedd1c-7a5d-45c5-b9e5-7a2910956cb2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_cd083fbc-a165-40c3-acc2-fd0a7d248259_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_7be1def0-692c-406f-b3f8-9634d5d36dd9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2a36c236-fe60-4b19-b5c2-a9ce60b01b02_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_b1f625ae-bc0f-429c-a324-222e40fa3e72_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_f219ef13-d1c6-4b17-94ee-b37274c0f051_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_04c6444e-40b0-48d1-9b59-4ecfa2d5b161_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_06e78341-964b-4734-85d2-daa5c185a6b7_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_fac2d3b0-d241-47e7-b10f-08e46f30e937_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a5c22f17-3dce-4464-94bb-7c0d24d598e4_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value as of December 31, 2023</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_bac1d3f8-1cff-414d-8535-447c19402b4b_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value as of June&#160;30, 2024</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_00ebaf0b-36a8-4004-8c6d-1459c376df38_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in pre-closing financing (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Pre-closing Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_a81c9bd5-f2a2-44e4-997d-4a1011b5f14f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_f008403a-0aed-4c87-a67d-71ef13883cd3_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants outstanding, measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02f4a642-3410-4944-a2ee-c3ceaddb0979_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100c58a7-4430-4be5-93f2-0801170c7359_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5a9967b-edf1-4c84-b98f-42f22838ac96_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending Balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a1951ae8-c61c-4389-9698-d0653a5b762d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_3c5d50bd-54e2-4425-960b-df02165869bc_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInMay2027Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In May 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInMay2027Member" xlink:to="lab_ck0001824293_WarrantsExpiringInMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_829c50f9-5125-4fe7-a13c-f51c0dcba3b0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_97b7d698-332f-4f3d-b0bd-253b88807210_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ae2856c-7bc2-47de-a28d-70cb998afaa3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_526084e2-45bc-4096-80ba-1b073ed50e57_terseLabel_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_label_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:label id="lab_ck0001824293_ChangeInFairValueOfWarrantLiability_documentation_en-US" xlink:label="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Of Warrant Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:to="lab_ck0001824293_ChangeInFairValueOfWarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_5993a1c1-0e9d-4a20-add1-c7f97509ba9d_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_label_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:label id="lab_ck0001824293_DebtInstrumentNumberOfClosings_documentation_en-US" xlink:label="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Closings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtInstrumentNumberOfClosings" xlink:to="lab_ck0001824293_DebtInstrumentNumberOfClosings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_a04fbfc2-9f79-4384-9579-41472a96e2a5_negatedTerseLabel_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of reverse recapitalization costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_label_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:label id="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts_documentation_en-US" xlink:label="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Of Reverse Recapitalization Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:to="lab_ck0001824293_PaymentOfReverseRecapitalizationCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_6e0591ee-5486-4825-9acf-b8ee17016509_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInAugust2025Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In August 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:to="lab_ck0001824293_WarrantsExpiringInAugust2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6fe5d90d-30db-41d9-ab01-1f0aabca3348_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bc948ad3-d7f3-4ebc-a57b-d783163ee9d5_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_50638480-eb16-422b-8c3f-70c5458ee7ee_terseLabel_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIQUIDITY</link:label>
    <link:label id="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_label_en-US" xlink:label="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="lab_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_2b19e522-13ba-4407-8961-0674ab6dd5fc_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_229337cb-4961-49c6-9bf7-11d0d4928007_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_000d6ba8-52a7-45ca-87ba-e32b22905e48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Plus: Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_db6736a6-568a-415b-9d63-098f31349dc1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_64ca9842-fd6b-48d4-a165-931c69f6e4b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_33b91be3-5869-4bf5-a109-4fa08efdd2ed_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_106616a9-4331-41a5-9d52-0a9dbb5e0bac_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_19fb6c8c-75b4-42a8-bb31-2db16b85b891_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_3c3e695a-ff28-445c-8217-9681ddab15ea_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_cba801d6-139a-4544-a875-027fa07d5c3b_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_1d85ea57-fb6e-48d1-8752-5da7f7d1c3ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_836485f4-6f92-49dc-89d3-d2ebd071f1b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term&#160;(years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_26e63534-6cab-4c6b-ba8b-20019973bb35_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6374ee03-fbb0-4215-b633-edb1f9bfc07f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_58c3a9de-8eca-4841-8032-45bedb3b08fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_64511d05-c2ff-4f72-a7d0-2947d1db9796_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_06428a7e-8606-4a4f-9c9a-da4a10d21988_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_8d762920-3f85-4d49-97d4-1e2fb1d9b836_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_2b5d53dc-0f1d-499c-a105-96f49420acf7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of deferred stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_02689707-a619-449f-bec3-ef5ed56e8423_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_e86f3678-5557-47fb-be18-123b3293e942_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_fd7af6e6-6ebc-410d-ab9a-01f97c933bb3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_d130cfb0-c27f-40ea-b510-10ef17f15467_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of option on grant date (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_GRIOperationsPlanMember_b15491b5-b9ca-4016-a0c2-6db2277d08c0_terseLabel_en-US" xlink:label="lab_ck0001824293_GRIOperationsPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GRI Operations Plan</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsPlanMember_label_en-US" xlink:label="lab_ck0001824293_GRIOperationsPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GRI Operations Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_GRIOperationsPlanMember_documentation_en-US" xlink:label="lab_ck0001824293_GRIOperationsPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GRI Operations Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsPlanMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_GRIOperationsPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_GRIOperationsPlanMember" xlink:to="lab_ck0001824293_GRIOperationsPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_2651cf3c-e736-4f94-a44d-58113388f36d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse stock split</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4dedfc86-1159-4f40-a108-10abdd415be9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_741c7409-94c3-4ffb-ad38-635c309d6ad4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Changes is the Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ceeb944d-4caf-4af2-8553-9d03c59bfb24_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2bccbbea-21e1-4418-8826-769d5f8d351d_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_52180730-cc49-4309-8f09-f51e63891a49_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_079dd002-d955-4af5-b44f-83ce26561f31_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_4ab1f569-c381-4e27-af22-ac14207101cf_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_a83deefd-3ca7-47c5-9b35-286df2fdc9fb_terseLabel_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COBRA benefits, payment period (in months)</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_label_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:label id="lab_ck0001824293_COBRABenefitsPaymentPeriod_documentation_en-US" xlink:label="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">COBRA Benefits, Payment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:href="ck0001824293-20240630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_COBRABenefitsPaymentPeriod" xlink:to="lab_ck0001824293_COBRABenefitsPaymentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_d22a975e-c0b0-45aa-812a-2f093d41c928_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_eb57437e-a520-40c2-836f-282db80275b6_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2026Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_266ac131-282b-4768-893a-6f9678504485_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_b451b833-fd12-4072-81e1-484bfae5c056_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 Common and Series B-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Common And Series B-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Common And Series B-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_3c148bae-fddd-4ef2-941b-ee928f92c53f_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInFebruary2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In February 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInFebruary2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_45ab1f15-1f8a-4423-818f-9ee286e2907a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1a1c0d2b-2eee-494b-b4bb-4eedf91f7629_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_99c6c14b-106c-4a28-a231-40807aa19e7d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_119f3354-6d51-4aaa-9a45-03334c0fcb0c_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_6d799ce6-fb7d-456e-b5bb-0845f4110f80_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_20504994-dc3a-49b7-a3bd-3cd10e92f007_negatedLabel_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_label_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:label id="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_documentation_en-US" xlink:label="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:to="lab_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_34db3c51-a027-4174-b273-0c88620ab6b6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d9fa881d-fa56-455a-949c-3bd7f0962cc9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d89513ec-4175-440a-bd78-30c6a1718859_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_14593bf9-08ac-4a91-83ac-3018d4df3b1b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_cc778f68-fb02-4933-a033-169cd2719176_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_6be70fd5-2672-4994-bd74-e84626d05fc7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_578927a5-5bdb-4c59-88c3-53fe1e03ae27_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In 60 Months After The Warrant Stockholder Approval</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In 60 Months After The Warrant Stockholder Approval [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In 60 Months After The Warrant Stockholder Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" xlink:to="lab_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a30d55b3-c076-4bb2-8c35-00f40a123609_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b74ba76f-6eac-4771-aabf-b569c51c9518_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_65eb3611-4e1c-40c2-8d27-4714b00ad5ee_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Fair Value of the Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9ef80336-1f4a-4d78-b5f4-30744bb697fe_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term in years</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_2821edbb-6cd4-4acf-bff6-7a8e00943470_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_7850fb12-b858-4e8f-82bb-d7a93dd24d3e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_8c39df2a-260a-419a-a8d8-4c00f341aae2_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsOfferingExpenses_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs, Offering Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:to="lab_ck0001824293_StockIssuanceCostsOfferingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8b9eb674-6e88-41eb-ae37-8b198c2e1c09_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_fd73f0f8-17b1-47c6-af2c-446631df6bf5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_85f1d2e0-a44a-4aee-a241-aca433d9c387_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_0c29e64d-4eba-4e92-80ff-efa934ba75ce_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesA1WarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesA1WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A-1 Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesA1WarrantsMember" xlink:to="lab_ck0001824293_SeriesA1WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8aa4b5b8-b5a3-40a5-a09d-4cceb3712524_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_fa687753-f1e5-47f1-a21f-18fa6b9df40b_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, agent compensation, percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockAgentCompensationPercentage_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Agent Compensation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:to="lab_ck0001824293_SaleOfStockAgentCompensationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_9343fba8-1b60-4b2a-82e1-2290ac8d9e6d_terseLabel_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_label_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:label id="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_documentation_en-US" xlink:label="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:to="lab_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_2fd32bc3-f9a2-45d4-aa93-9fa7fb169dfc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_664a1305-9ec5-4cbb-810f-3b10837595e8_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ead6254b-05ee-494c-ae82-b65864a4ce6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_14a91733-4bfc-4025-8dc0-0f20f21d804d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_b9b1915a-cce6-4f0f-825d-ca756497ec9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROMISSORY NOTES</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1d42bcda-88fb-4d14-8dba-e1c982c481a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_000e5825-683d-4f4f-ba21-d13e610f1d17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3064d6f3-0cb1-4f3c-a6e4-ff3a70347665_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock and prefunded warrants in financing</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_4e8a3472-686d-465a-a991-8e686e4aa0c8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0c9a54d7-e743-4911-ae3f-5c114556c2e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_c5025685-10be-4938-a905-c4564f01ae9b_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0cbcbe1b-cbac-493c-a6f4-b11debd42414_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_bde085a8-620b-491e-873c-73777439ab29_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesB1CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B-1 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesB1CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesB1CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fb588e2b-fc2f-419b-ace2-beb3802f82b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_7d7f6fee-6b9c-4dd2-b85c-895727ba94c8_terseLabel_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer [Member]</link:label>
    <link:label id="lab_ck0001824293_FormerChiefExecutiveOfficerMember_documentation_en-US" xlink:label="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former Chief Executive Officer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:to="lab_ck0001824293_FormerChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PublicOfferingMember_b91100b0-28d9-4cb2-a857-5b27e1717859_terseLabel_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_label_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_PublicOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PublicOfferingMember" xlink:to="lab_ck0001824293_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsIssued_0095aaf7-8998-41b1-b155-d496c7c820e3_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of warrants for payment of stock issuance costs</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_label_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued</link:label>
    <link:label id="lab_ck0001824293_WarrantsIssued_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsIssued" xlink:to="lab_ck0001824293_WarrantsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_ee3d48f3-01d8-4554-b291-79dcacb2ba1f_terseLabel_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">A&amp;R 2918 Plan</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_label_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended and Restated 2018 Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:to="lab_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantLiabilityCurrent_c6ffe3cb-1777-4bae-8b17-2cbba7932693_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityCurrent_label_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:label id="lab_ck0001824293_WarrantLiabilityCurrent_documentation_en-US" xlink:label="lab_ck0001824293_WarrantLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityCurrent" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantLiabilityCurrent" xlink:to="lab_ck0001824293_WarrantLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_8f1bc507-44c8-4f90-ba42-89e6dd81ccd5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6b4dd6a-45c9-4e3e-a8c7-432893e23c17_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e86b1cb0-fe78-488c-9b23-e0a9658ffa15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_221c5e68-6e55-445e-893e-3c2768df8a58_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b59d7a0b-fb24-47fd-8905-0f3df7687170_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_fe120968-c7f7-420b-9c54-8097774f0630_netLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock in financing / under ATM</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_611f79e4-a866-40f9-89cd-795978aff3bf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ThePlacementAgentWarrantsMember_81cc8879-4354-4642-b29a-9f0126784785_terseLabel_en-US" xlink:label="lab_ck0001824293_ThePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Placement Agent Warrants</link:label>
    <link:label id="lab_ck0001824293_ThePlacementAgentWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_ThePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Placement Agent Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_ThePlacementAgentWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_ThePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Placement Agent Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThePlacementAgentWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ThePlacementAgentWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ThePlacementAgentWarrantsMember" xlink:to="lab_ck0001824293_ThePlacementAgentWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_f90b5495-7a0a-4af7-9949-c39ec3feae06_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock awards, contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_38b65c7a-b51f-4e70-9b77-ebc7028190fd_terseLabel_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange Warrants</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exchange Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_ExchangeWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_ExchangeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exchange Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ExchangeWarrantsMember" xlink:to="lab_ck0001824293_ExchangeWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_72083f65-da5a-4719-9f32-d896343d0e07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_712738a0-75db-45d7-90d5-57f323d16d76_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f6ae0d9f-cc3f-48f5-8596-d935f65e817c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0370b41b-c17b-4414-b831-ddffc84cfdd4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fed7be85-08cd-4356-a9dd-16cb7454b045_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_3a0ba010-011b-442f-9e14-82aa19694c28_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_53f8e4c9-6065-4868-86a6-6849d8730a71_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series T Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series T Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesTWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesTWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series T Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesTWarrantsMember" xlink:to="lab_ck0001824293_SeriesTWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_a7974441-40ba-42a6-b208-7759abcabdd6_terseLabel_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_label_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Through Financing [Member]</link:label>
    <link:label id="lab_ck0001824293_ThroughFinancingMember_documentation_en-US" xlink:label="lab_ck0001824293_ThroughFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Through Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_ThroughFinancingMember" xlink:to="lab_ck0001824293_ThroughFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_308fe545-b454-41fd-98be-a3a3b959c117_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_4e9d9fc7-dc99-40f6-89ad-1b7aaf594faf_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_56e13804-bcca-45d6-913a-80eb13715c28_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock issuance costs in accounts payable and accrued expenses</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8bd09ad3-7122-4ebb-b69b-d1eafd25a255_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3b2ec99f-e8cb-4d9e-a773-b1b6d042b112_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price per Share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_aacbc07f-3249-4953-8ecd-a6a38dfb68c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_6967dc9d-e978-4574-a317-0c0adf847b65_terseLabel_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for settlement of bridge note</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_label_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:label id="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_documentation_en-US" xlink:label="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Settlement Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:to="lab_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_927648d6-fbb5-4d5e-be50-aea42a9702c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_893439fc-37b7-4a88-a320-1685f0c6deff_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_9c383212-7bce-40db-ba6d-6cec463f1cf6_terseLabel_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of securities issued (in shares)</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_label_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:label id="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_documentation_en-US" xlink:label="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Number Of Securities Issued Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:to="lab_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_d6a3803d-9e68-4dba-b461-c51c27eefe51_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, equity impact</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_40c7bb9d-7727-47fc-badf-634954fc12fd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_82a19fdb-3b3d-4201-9868-8aa688ed2e6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eccc6b9f-9848-41ae-814a-3c51b5797072_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Activity of Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8c3eba07-3439-4d89-8fe3-8374c6b6c033_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_4833d27d-564d-4d48-af9e-46913325ddeb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1a8e44fd-882a-4832-b1fc-33aaf6c5533b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb90584f-c577-4966-be7c-2349da240999_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_cb830d81-8e1c-44ae-8515-c6cafcb91939_negatedLabel_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in operating right of use assets</link:label>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_label_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Periodic Addition</link:label>
    <link:label id="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_documentation_en-US" xlink:label="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Periodic Addition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:href="ck0001824293-20240630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:to="lab_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_3bbce8e3-3b64-45e8-baa0-ee9118341b26_terseLabel_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded and Series C Warrants</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded And Series C Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:to="lab_ck0001824293_PreFundedAndSeriesCWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_dafc5d03-03de-42e8-ad6f-7de7fd5d6089_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_PrivateGRIMember_e7afbc7f-4d01-4a56-9d01-51df5b07f62e_terseLabel_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private GRI</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIMember_label_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private GRI [Member]</link:label>
    <link:label id="lab_ck0001824293_PrivateGRIMember_documentation_en-US" xlink:label="lab_ck0001824293_PrivateGRIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private GRI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_PrivateGRIMember" xlink:to="lab_ck0001824293_PrivateGRIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_875d874d-5c69-4531-8b28-769103b477fa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_fbc87283-62c1-40fc-85e2-e86ea8076b92_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_46b72797-510d-436f-84e1-5f6af716890f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_7e6ab1b5-81c3-45a4-b6ed-78d0b4808e95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_12c02a06-4523-445f-a593-ab996365ba8e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_502f2a7a-a892-43bb-9585-ed6f15bef3a0_terseLabel_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_ck0001824293_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ck0001824293_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_AtTheMarketOfferingMember" xlink:to="lab_ck0001824293_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_8e4327f4-0613-4064-a1b6-621743a1a2c3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c861abe6-aa07-461a-807a-769585bd17f5_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_9a791ef9-727c-460c-8d70-796e7c009afe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_90e26844-78b4-468d-b14d-947bb165c450_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_label_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesC2CommonWarrantsMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C-2 Common Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesC2CommonWarrantsMember" xlink:to="lab_ck0001824293_SeriesC2CommonWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_780d8eb6-0fd6-41ae-bf48-41efa28eb527_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Net Liabilities Assumed in the Merger</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d0fbc891-9898-4646-a7a8-c4a19b0bec28_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_99ebd104-c32a-4038-b6f1-d41da7e4e30b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_6eba6baa-8cd7-4fdd-8c54-4b97df8e1902_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_25e5f229-3d2a-4b45-875b-0e531ce4e8eb_terseLabel_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_label_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029 [Member]</link:label>
    <link:label id="lab_ck0001824293_WarrantsExpiringInJune2029Member_documentation_en-US" xlink:label="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants Expiring In June 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_WarrantsExpiringInJune2029Member" xlink:to="lab_ck0001824293_WarrantsExpiringInJune2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59693aba-860a-4a8d-9572-b2e23785fecc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_993af8d4-7c1f-4e71-83b3-f6b1753d1e1b_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_d3f48795-6b59-4425-917d-93e70c63117b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ck0001824293_SeriesCCommonWarrantMember_56d31a02-c105-4f22-8e29-83d068ac605c_terseLabel_en-US" xlink:label="lab_ck0001824293_SeriesCCommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C warrant</link:label>
    <link:label id="lab_ck0001824293_SeriesCCommonWarrantMember_label_en-US" xlink:label="lab_ck0001824293_SeriesCCommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Common Warrant [Member]</link:label>
    <link:label id="lab_ck0001824293_SeriesCCommonWarrantMember_documentation_en-US" xlink:label="lab_ck0001824293_SeriesCCommonWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C Common Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesCCommonWarrantMember" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesCCommonWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ck0001824293_SeriesCCommonWarrantMember" xlink:to="lab_ck0001824293_SeriesCCommonWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_30d334d2-3a9c-4f45-93d7-fb6bc428a1f8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_471b3e85-7cd9-4503-ace7-41e03eda3ada_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d6af154b-d58e-4365-ab36-e9b7e081ffb8_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f1c43e56-12e4-405d-8257-8ed2339bd2b3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_66c7a7ce-e16d-428b-a9d5-6e64bf2981af_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2a3d6d87-e2d7-4e51-84d9-20bd283d7c4a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited/Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4e823f4b-026f-4107-a5c9-abab4e379337_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_38275fe3-309b-451b-a8c7-3f9af3f5c24a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_fd5ff439-c052-4294-b4c8-caadac4213a2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ck0001824293-20240630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:4b2bd8b8-7391-472c-baa6-f4915a4212d0,g:cfdabf3d-48ec-4ec5-a4ba-2606592f7687-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/Cover" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9e573953-1005-4089-ab0e-5602d8fd26fc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_DocumentType_9e573953-1005-4089-ab0e-5602d8fd26fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_e655c037-25de-4a97-aef5-1edc4558d9af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_DocumentQuarterlyReport_e655c037-25de-4a97-aef5-1edc4558d9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_85f9600c-e3c2-404b-9ef9-1b9dc20dbd60" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_DocumentPeriodEndDate_85f9600c-e3c2-404b-9ef9-1b9dc20dbd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_a8c47954-ea49-4f65-89e6-d2645a02e910" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_DocumentTransitionReport_a8c47954-ea49-4f65-89e6-d2645a02e910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_f1596ca0-a5bc-4613-b00f-a4160a9f2c1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityFileNumber_f1596ca0-a5bc-4613-b00f-a4160a9f2c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_78a75830-ff66-4abb-af81-08ddf3a90453" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityRegistrantName_78a75830-ff66-4abb-af81-08ddf3a90453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4fea9122-a543-4fe8-aa00-2f6403122e1d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4fea9122-a543-4fe8-aa00-2f6403122e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d9d9e912-615c-49ac-9c7b-32df4e157878" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityTaxIdentificationNumber_d9d9e912-615c-49ac-9c7b-32df4e157878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f716660e-3f91-4838-a266-134f26bb3dbe" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityAddressAddressLine1_f716660e-3f91-4838-a266-134f26bb3dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_7be6a399-45f8-4642-bdd7-b6ec85882113" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityAddressAddressLine2_7be6a399-45f8-4642-bdd7-b6ec85882113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cd497ba2-b37c-4c95-94ca-6597b2655393" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityAddressCityOrTown_cd497ba2-b37c-4c95-94ca-6597b2655393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_c01fdef3-30d8-4be1-a5bf-099e7ec234c8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityAddressStateOrProvince_c01fdef3-30d8-4be1-a5bf-099e7ec234c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8079ab59-0f90-4ff4-9310-1c55aec9e422" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityAddressPostalZipCode_8079ab59-0f90-4ff4-9310-1c55aec9e422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_9baced43-6bb7-46f0-ad7c-4374a4ff118e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_CityAreaCode_9baced43-6bb7-46f0-ad7c-4374a4ff118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_2cce5a4c-87c9-4f32-8536-3d3c70ef8e9d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_LocalPhoneNumber_2cce5a4c-87c9-4f32-8536-3d3c70ef8e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_784ea2f5-d23a-4d17-b323-c5805599e2b2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_Security12bTitle_784ea2f5-d23a-4d17-b323-c5805599e2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e233749d-2f35-4ef7-b572-ba73de0b0a16" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_TradingSymbol_e233749d-2f35-4ef7-b572-ba73de0b0a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_065ae708-1a4c-494c-ad65-8bb4fd4daa70" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_SecurityExchangeName_065ae708-1a4c-494c-ad65-8bb4fd4daa70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_023df221-11c8-4927-9e21-ff8086efa021" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityCurrentReportingStatus_023df221-11c8-4927-9e21-ff8086efa021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_de551dd1-3859-4362-af7d-c3d0fc24f16c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityInteractiveDataCurrent_de551dd1-3859-4362-af7d-c3d0fc24f16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_262c354a-dddf-40db-92ab-c8aac33936f9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityFilerCategory_262c354a-dddf-40db-92ab-c8aac33936f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d39a7bf7-08eb-43c1-8411-e67ccb60e5ee" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntitySmallBusiness_d39a7bf7-08eb-43c1-8411-e67ccb60e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3409d41e-1c43-4c7f-98a6-e9869ca48b35" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityEmergingGrowthCompany_3409d41e-1c43-4c7f-98a6-e9869ca48b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_6dc31da2-1bb6-4e83-9762-6929111f928d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityExTransitionPeriod_6dc31da2-1bb6-4e83-9762-6929111f928d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_05c23d46-6bd8-427b-9324-7766443a5c9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityShellCompany_05c23d46-6bd8-427b-9324-7766443a5c9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4c7aec68-ca9e-4e6f-9e29-f2e33865afaf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4c7aec68-ca9e-4e6f-9e29-f2e33865afaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b00023cc-02cf-42d8-adc5-89c5ce5076d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_EntityCentralIndexKey_b00023cc-02cf-42d8-adc5-89c5ce5076d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4a584f93-9e68-4fea-b141-1fa84e53e563" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_CurrentFiscalYearEndDate_4a584f93-9e68-4fea-b141-1fa84e53e563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_02b0adf3-5026-4a36-a276-f428a11861e6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_DocumentFiscalYearFocus_02b0adf3-5026-4a36-a276-f428a11861e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_93948bb4-0569-403a-a1c6-9ba9d82fb856" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_DocumentFiscalPeriodFocus_93948bb4-0569-403a-a1c6-9ba9d82fb856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_be7bebb3-2d79-4214-bc6f-0375a8d3f080" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_20e930a0-bfd9-44c6-bcc0-5b91175749ca" xlink:to="loc_dei_AmendmentFlag_be7bebb3-2d79-4214-bc6f-0375a8d3f080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9344fd28-e59b-46ed-b4bc-72f68fce1f33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_41547d44-1298-49ec-8f5b-cccca07956cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9344fd28-e59b-46ed-b4bc-72f68fce1f33" xlink:to="loc_us-gaap_AssetsAbstract_41547d44-1298-49ec-8f5b-cccca07956cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ea4ff56b-1868-4e0a-b9aa-3098ae8e33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41547d44-1298-49ec-8f5b-cccca07956cd" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ea4ff56b-1868-4e0a-b9aa-3098ae8e33fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07af2c55-1947-4c29-a07f-92f77e0d12d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea4ff56b-1868-4e0a-b9aa-3098ae8e33fb" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07af2c55-1947-4c29-a07f-92f77e0d12d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07caa878-1f47-482e-b0c9-82da26eca1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea4ff56b-1868-4e0a-b9aa-3098ae8e33fb" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_07caa878-1f47-482e-b0c9-82da26eca1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3cb0530b-f7cc-4cba-b404-548427bf4d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ea4ff56b-1868-4e0a-b9aa-3098ae8e33fb" xlink:to="loc_us-gaap_AssetsCurrent_3cb0530b-f7cc-4cba-b404-548427bf4d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5230d74c-9cef-4390-84aa-65ac97cfc9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41547d44-1298-49ec-8f5b-cccca07956cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5230d74c-9cef-4390-84aa-65ac97cfc9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f356a96-7ece-4fad-b170-70cb209f9b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41547d44-1298-49ec-8f5b-cccca07956cd" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2f356a96-7ece-4fad-b170-70cb209f9b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0effa863-d800-460a-823b-6d9975544090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_41547d44-1298-49ec-8f5b-cccca07956cd" xlink:to="loc_us-gaap_Assets_0effa863-d800-460a-823b-6d9975544090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9344fd28-e59b-46ed-b4bc-72f68fce1f33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_20e4f23e-8d04-4507-b28e-e823dbffc864" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:to="loc_us-gaap_AccountsPayableCurrent_20e4f23e-8d04-4507-b28e-e823dbffc864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fd3ca0c7-7f2e-43f1-be5d-efdebc2104a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fd3ca0c7-7f2e-43f1-be5d-efdebc2104a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityCurrent_42eb6dd2-8544-4283-8b77-4eb21d26600d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:to="loc_ck0001824293_WarrantLiabilityCurrent_42eb6dd2-8544-4283-8b77-4eb21d26600d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_567666e3-b3b5-4d09-89ce-309d9177d60d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_567666e3-b3b5-4d09-89ce-309d9177d60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_30a09537-b944-4187-a315-bae8fd0d69de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_95474fc3-2d06-4027-b5eb-0d71639dba8f" xlink:to="loc_us-gaap_LiabilitiesCurrent_30a09537-b944-4187-a315-bae8fd0d69de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1a8a178f-5200-4d52-89a1-27088420d37e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1a8a178f-5200-4d52-89a1-27088420d37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_1a45b009-bb4c-447a-acc2-4e02a430e38d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:to="loc_us-gaap_Liabilities_1a45b009-bb4c-447a-acc2-4e02a430e38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3ef6c56b-442f-420a-8579-2bd1d002c628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3ef6c56b-442f-420a-8579-2bd1d002c628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4bd1ea15-1f98-40fb-967f-c573568df916" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4bd1ea15-1f98-40fb-967f-c573568df916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_fe2ecf4a-ef68-478b-9f46-eff993f3446c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4bd1ea15-1f98-40fb-967f-c573568df916" xlink:to="loc_us-gaap_CommonStockValueOutstanding_fe2ecf4a-ef68-478b-9f46-eff993f3446c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c6a18ba-2608-4d6c-a7e6-409d918aee35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4bd1ea15-1f98-40fb-967f-c573568df916" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3c6a18ba-2608-4d6c-a7e6-409d918aee35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b7edc46-75c0-40d0-bda2-33f658f59976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4bd1ea15-1f98-40fb-967f-c573568df916" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_0b7edc46-75c0-40d0-bda2-33f658f59976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_10d07a27-27c9-40d0-918c-aa0e4ef4da74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4bd1ea15-1f98-40fb-967f-c573568df916" xlink:to="loc_us-gaap_StockholdersEquity_10d07a27-27c9-40d0-918c-aa0e4ef4da74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_fba32b72-b3ef-418f-97ba-7f6a1bcd42e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c63e7e94-9c04-4c71-bd5c-b12a9b3a75ec" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_fba32b72-b3ef-418f-97ba-7f6a1bcd42e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_48aaddb0-58ee-424a-a717-ac8a7ab08689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_49eea8c0-2459-425b-8e06-c2ee210b471f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48aaddb0-58ee-424a-a717-ac8a7ab08689" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_49eea8c0-2459-425b-8e06-c2ee210b471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_9fa3ebe3-985f-45ca-9d78-ba5456b5b4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48aaddb0-58ee-424a-a717-ac8a7ab08689" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_9fa3ebe3-985f-45ca-9d78-ba5456b5b4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_0b46bace-6c52-4da6-affe-363d42f68f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48aaddb0-58ee-424a-a717-ac8a7ab08689" xlink:to="loc_us-gaap_CommonStockSharesIssued_0b46bace-6c52-4da6-affe-363d42f68f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3b2461e0-7cc9-4844-86eb-ad533d344d8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_48aaddb0-58ee-424a-a717-ac8a7ab08689" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3b2461e0-7cc9-4844-86eb-ad533d344d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_0cca2662-e68e-4006-8f63-762508c5ee0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_0cca2662-e68e-4006-8f63-762508c5ee0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1a12b5bf-aba4-479a-9bc8-a5d57942c1ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0cca2662-e68e-4006-8f63-762508c5ee0f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1a12b5bf-aba4-479a-9bc8-a5d57942c1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_46f9dc8f-440c-4324-bc1e-74dcbc416d09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0cca2662-e68e-4006-8f63-762508c5ee0f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_46f9dc8f-440c-4324-bc1e-74dcbc416d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bd4a09ae-b848-4eca-a7b2-192ec2a403a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_0cca2662-e68e-4006-8f63-762508c5ee0f" xlink:to="loc_us-gaap_OperatingExpenses_bd4a09ae-b848-4eca-a7b2-192ec2a403a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2e083f42-074b-4c08-91a8-eca8ece038bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_OperatingIncomeLoss_2e083f42-074b-4c08-91a8-eca8ece038bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_1dc35964-64f8-43aa-a813-7cbf376e6b9e" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ChangeInFairValueOfWarrantLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_ck0001824293_ChangeInFairValueOfWarrantLiability_1dc35964-64f8-43aa-a813-7cbf376e6b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fedea2db-27b2-4615-bda5-e61fd46653a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_fedea2db-27b2-4615-bda5-e61fd46653a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f4a9e03d-6a6c-4554-a91e-8415aa726fea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_NetIncomeLoss_f4a9e03d-6a6c-4554-a91e-8415aa726fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_bd575652-7c6b-496f-8ab1-b7787a60369f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_EarningsPerShareBasic_bd575652-7c6b-496f-8ab1-b7787a60369f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d76f9239-917d-4022-b137-13fa2c417368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d76f9239-917d-4022-b137-13fa2c417368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31e11a9b-d2c1-43d5-b02c-93d37023544a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_31e11a9b-d2c1-43d5-b02c-93d37023544a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f8a0e73-a1b4-4c9c-81c3-400400818894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_c672b15f-bad3-4d6e-9101-6590439e6fe7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8f8a0e73-a1b4-4c9c-81c3-400400818894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofChangesinStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_f68f1efd-9c72-4288-aa1b-ed78fc43382e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_f68f1efd-9c72-4288-aa1b-ed78fc43382e" xlink:to="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cd640b03-3eca-4aff-9da2-310dd84125a4" xlink:to="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c517327-f25e-4f84-8d66-83bda4084ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:to="loc_us-gaap_CommonStockMember_6c517327-f25e-4f84-8d66-83bda4084ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_ca33c444-e0ba-499a-9ece-a6f8ec297972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_ca33c444-e0ba-499a-9ece-a6f8ec297972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f4cc15e9-96dd-42f4-8032-0a62c0ac3485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76074f10-aa57-495d-8e74-59776e575092" xlink:to="loc_us-gaap_RetainedEarningsMember_f4cc15e9-96dd-42f4-8032-0a62c0ac3485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_60ab91b0-841e-461f-8e3e-1580d12df2db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_fd3505ab-0f76-4ef0-9269-6bf604d16c53" xlink:to="loc_us-gaap_StatementLineItems_60ab91b0-841e-461f-8e3e-1580d12df2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60ab91b0-841e-461f-8e3e-1580d12df2db" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dd9de921-b309-4df4-9c2f-0a97b9403b93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dd9de921-b309-4df4-9c2f-0a97b9403b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6322ce9a-a61d-49e5-ac5c-7e3e42244598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockholdersEquity_6322ce9a-a61d-49e5-ac5c-7e3e42244598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa2db891-4898-494f-b416-8305a3263b43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_fa2db891-4898-494f-b416-8305a3263b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_6397655c-0c9d-4eaa-88e9-7388c7fbb3b4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment_6397655c-0c9d-4eaa-88e9-7388c7fbb3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_35aa0d72-ea56-4b76-bbde-46c1824559f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_35aa0d72-ea56-4b76-bbde-46c1824559f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_833af6ee-da10-4db5-896d-3670ed426be2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_833af6ee-da10-4db5-896d-3670ed426be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_704647ef-c229-482d-88e7-11e9120d4b59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_704647ef-c229-482d-88e7-11e9120d4b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ff196579-952b-4d17-a97a-1412cc2ed8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ff196579-952b-4d17-a97a-1412cc2ed8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_966ae9a3-9d0d-4a66-91f7-95e7fcf6d4a1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise_966ae9a3-9d0d-4a66-91f7-95e7fcf6d4a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_d8e18490-de4a-412f-8fd2-6282928dc7fd" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueWarrantExercises"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises_d8e18490-de4a-412f-8fd2-6282928dc7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_707a54a0-1e43-427b-af6e-5ac183b6e246" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing_707a54a0-1e43-427b-af6e-5ac183b6e246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_a3c2df4a-7ee7-4393-8818-f7955e724d35" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing_a3c2df4a-7ee7-4393-8818-f7955e724d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_507879bc-54ff-4c66-a08f-42a805d3ca45" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt_507879bc-54ff-4c66-a08f-42a805d3ca45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_2af51aa0-ca20-4e62-af95-5777ac5fe29d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt_2af51aa0-ca20-4e62-af95-5777ac5fe29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_28256644-669e-4fde-bb02-c165c7ba5a38" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_28256644-669e-4fde-bb02-c165c7ba5a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_8468e07f-4c6d-4f11-83cb-2ebbbab47e3f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses_8468e07f-4c6d-4f11-83cb-2ebbbab47e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_cb3960d4-3775-4468-aa34-069f88a92782" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization_cb3960d4-3775-4468-aa34-069f88a92782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_74e5293b-e6b3-450b-b408-1b559d8a3812" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization_74e5293b-e6b3-450b-b408-1b559d8a3812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e0eab7e1-090a-4645-a0ad-1e535c59dcde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_NetIncomeLoss_e0eab7e1-090a-4645-a0ad-1e535c59dcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_be359863-4d43-43d6-9f5b-027f08a73d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_be359863-4d43-43d6-9f5b-027f08a73d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_743fb0a9-2c1c-43f6-b9d0-4dad41b8b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3adcb3ae-2fc5-4820-b2c7-5b2074124a43" xlink:to="loc_us-gaap_StockholdersEquity_743fb0a9-2c1c-43f6-b9d0-4dad41b8b7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b905d35b-dd01-455a-b4bd-ca4b8795a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b905d35b-dd01-455a-b4bd-ca4b8795a8b0" xlink:to="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b2e2efbf-7f2e-4ffb-8674-69ce00fae8db" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThroughFinancingMember_6239fd77-b42e-49a7-b06d-9a71d26fefb4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ThroughFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:to="loc_ck0001824293_ThroughFinancingMember_6239fd77-b42e-49a7-b06d-9a71d26fefb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_58adfd6d-c252-4f15-b72e-4f4fb5e1318a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_fc7a90a8-0432-4a7b-97c2-33a0985a55cc" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_58adfd6d-c252-4f15-b72e-4f4fb5e1318a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e383a321-06bc-48bb-8554-76bc59babc1f" xlink:to="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d62c113-155e-4293-8c96-b543b7055c66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:to="loc_us-gaap_NetIncomeLoss_8d62c113-155e-4293-8c96-b543b7055c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e3162504-130b-4773-add7-b8694e88fadc" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6dcdc344-d8b4-474a-b1fa-160ed9331b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_Depreciation_6dcdc344-d8b4-474a-b1fa-160ed9331b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0a87123-47c0-48cc-a68b-d02c1b1cacd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f0a87123-47c0-48cc-a68b-d02c1b1cacd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a973774e-d453-4f74-8cab-4a4cec28a552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_ShareBasedCompensation_a973774e-d453-4f74-8cab-4a4cec28a552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a2be5adf-72a8-443e-8ed1-d43bb5307930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a2be5adf-72a8-443e-8ed1-d43bb5307930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_315c289a-5458-4dea-8fde-1e1a5a78a79f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition_315c289a-5458-4dea-8fde-1e1a5a78a79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bc25eb16-aca0-4a9b-b6d5-92ecef9cfeba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_bc25eb16-aca0-4a9b-b6d5-92ecef9cfeba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f3258e0-4e90-4b6f-8751-7dd1e8f25523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4f3258e0-4e90-4b6f-8751-7dd1e8f25523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5335b674-666a-48fb-a983-997f5461f509" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5335b674-666a-48fb-a983-997f5461f509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c61310fb-1b8b-40a2-9805-8a4187fa8f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c61310fb-1b8b-40a2-9805-8a4187fa8f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2b1dec9e-ca87-4a48-8db2-be8501ed952e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c43ad832-c073-4426-b463-8d76171ff202" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_2b1dec9e-ca87-4a48-8db2-be8501ed952e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8e325ce-8078-4b72-a922-d78532ccd1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2f98434-2388-468c-afcd-81a940378530" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e8e325ce-8078-4b72-a922-d78532ccd1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d631fbf-04f3-4ea9-9004-f9c9d3d46ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7d631fbf-04f3-4ea9-9004-f9c9d3d46ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c23a7a73-fe8d-48cc-8ea2-35e3d0f1cd1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2b79daa6-a627-4685-8400-a7dd7bb36aa6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c23a7a73-fe8d-48cc-8ea2-35e3d0f1cd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_5e56306f-5f75-4f03-a37c-e5d25a5cda97" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ProceedsFromAdvancesFromEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_ProceedsFromAdvancesFromEmployees_5e56306f-5f75-4f03-a37c-e5d25a5cda97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_5ae15d2d-e6c2-4942-9991-3af29fb526e2" xlink:href="ck0001824293-20240630.xsd#ck0001824293_RepaymentOfAdvancesFromEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_RepaymentOfAdvancesFromEmployees_5ae15d2d-e6c2-4942-9991-3af29fb526e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9504ebc7-2973-438a-8e3c-4903c4277614" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9504ebc7-2973-438a-8e3c-4903c4277614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_fadd96c2-6764-41e4-bccc-a91d9ff06b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_fadd96c2-6764-41e4-bccc-a91d9ff06b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7980a8f1-a880-4728-8e67-a1991bd2dee9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7980a8f1-a880-4728-8e67-a1991bd2dee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_f3bf4e63-1c61-4895-8f92-2cb8a36a2ecf" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization_f3bf4e63-1c61-4895-8f92-2cb8a36a2ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_68d2658d-3f8d-4789-85f6-68178bc87042" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_ck0001824293_PaymentOfReverseRecapitalizationCosts_68d2658d-3f8d-4789-85f6-68178bc87042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_3353f24d-4693-4c28-bc06-43f40769065d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_3353f24d-4693-4c28-bc06-43f40769065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4e7ed61f-7e00-4a7b-a992-4df129077f14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4e7ed61f-7e00-4a7b-a992-4df129077f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfd4fcb5-1f4b-4045-b265-544c81444c67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_797c8434-78de-4af0-b289-2a6c00e4ed37" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dfd4fcb5-1f4b-4045-b265-544c81444c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a4d66e1-bedc-4eae-9fc5-7237d4d1a18b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9a4d66e1-bedc-4eae-9fc5-7237d4d1a18b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ca83045-e84a-4850-95d2-a24ff08441a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8ca83045-e84a-4850-95d2-a24ff08441a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf2ad421-a8c1-4321-87cb-032c9fb579e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cf2ad421-a8c1-4321-87cb-032c9fb579e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d68745d3-0cff-4c61-a482-43877a287b8c" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_63ecca1e-e505-4f1c-8898-1d6a131ec426" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedForRepaymentOfNotesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_StockIssuedForRepaymentOfNotesPayable_63ecca1e-e505-4f1c-8898-1d6a131ec426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_ac1301c2-8293-4da5-906e-7ea16e48d1c0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants_ac1301c2-8293-4da5-906e-7ea16e48d1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_1fba51eb-3115-4779-8553-912dbcf7a6b5" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts_1fba51eb-3115-4779-8553-912dbcf7a6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsIssued_cb9bdf42-8419-4a88-9cda-c0f7f1dca2a4" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_WarrantsIssued_cb9bdf42-8419-4a88-9cda-c0f7f1dca2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_543333b0-7caa-45d3-8bb9-7246cfb989ad" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid_543333b0-7caa-45d3-8bb9-7246cfb989ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_5e566a58-dc37-486d-8c2c-1c8d57326e1f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_NoncashMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_ac7dcc99-7e34-49de-80c5-e71e1e8aae41" xlink:to="loc_ck0001824293_NoncashMergerRelatedCostsFinancingActivities_5e566a58-dc37-486d-8c2c-1c8d57326e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3af11f70-4261-4389-8f0e-2cfef7a96d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_1538db84-b7ff-44e4-9279-dece8626be49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3af11f70-4261-4389-8f0e-2cfef7a96d40" xlink:to="loc_us-gaap_NatureOfOperations_1538db84-b7ff-44e4-9279-dece8626be49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#LIQUIDITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34137911-9bb0-4c53-aabd-511ae6c1c370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_409906b8-afc6-4c60-9a53-72db77b84c12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34137911-9bb0-4c53-aabd-511ae6c1c370" xlink:to="loc_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_409906b8-afc6-4c60-9a53-72db77b84c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_dd91a2f6-a5d4-45a1-b478-829708776b20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0936b317-8fb5-4090-95e7-fc7c654bcd12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_dd91a2f6-a5d4-45a1-b478-829708776b20" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_0936b317-8fb5-4090-95e7-fc7c654bcd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLON"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLON" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_23a0fd9d-a671-454c-99ab-bd0bf7a61699" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_17c0a667-09b7-4691-b49e-6ae085c3fc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_23a0fd9d-a671-454c-99ab-bd0bf7a61699" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_17c0a667-09b7-4691-b49e-6ae085c3fc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2a03e827-23a9-41c5-9405-52f1c7855b31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_3a4f6367-fa42-4a15-89ea-a54032597d63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2a03e827-23a9-41c5-9405-52f1c7855b31" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_3a4f6367-fa42-4a15-89ea-a54032597d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROPERTYANDEQUIPMENT"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4e4f870a-3200-4bb2-8ed6-ac1921bc3456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_96a1786a-a0c7-45b1-bd27-e07be9b31d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4e4f870a-3200-4bb2-8ed6-ac1921bc3456" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_96a1786a-a0c7-45b1-bd27-e07be9b31d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_bb813476-0c00-4e72-b795-0154cc170995" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ce7d83e4-080f-4d52-a54e-a3c4d5ae3acf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_bb813476-0c00-4e72-b795-0154cc170995" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_ce7d83e4-080f-4d52-a54e-a3c4d5ae3acf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROMISSORYNOTES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4f671a1f-2a8f-42d4-8f65-0f168fe2a75f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_7e4f9fbf-0678-4929-9294-2f32255245b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4f671a1f-2a8f-42d4-8f65-0f168fe2a75f" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_7e4f9fbf-0678-4929-9294-2f32255245b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f08791b1-07cc-450e-94ef-7fdbb20b30c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a31ed651-ed14-483d-8fae-605459141b99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f08791b1-07cc-450e-94ef-7fdbb20b30c7" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a31ed651-ed14-483d-8fae-605459141b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afb61857-13c8-473b-9422-889784d51ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_15fe2239-c2d5-4857-b7cf-883f0d60823f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_afb61857-13c8-473b-9422-889784d51ec1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_15fe2239-c2d5-4857-b7cf-883f0d60823f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e8cf44a-7930-462e-9209-d7012a72d6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1915428a-9899-4a58-bd98-f77591ea5276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e8cf44a-7930-462e-9209-d7012a72d6b1" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1915428a-9899-4a58-bd98-f77591ea5276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a9a8d6f-2444-4fb4-98e1-83ea044e22e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2a9a8d6f-2444-4fb4-98e1-83ea044e22e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_9e8ee3cb-20e0-4d69-9b36-070b26f555c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_9e8ee3cb-20e0-4d69-9b36-070b26f555c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_36672d17-d341-408e-9268-dcb254b9699d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_UseOfEstimates_36672d17-d341-408e-9268-dcb254b9699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d689a90c-5bb9-4465-931b-6930c736a103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_d689a90c-5bb9-4465-931b-6930c736a103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_a240da44-1bc4-4e81-80be-346763d44791" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_a240da44-1bc4-4e81-80be-346763d44791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_9ae28281-1a35-449e-8fa0-ec257be3e161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_9ae28281-1a35-449e-8fa0-ec257be3e161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5c380853-e8cd-45f0-a787-7fde38f45a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d63d1718-6b00-4524-9fde-71ede0a7446a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5c380853-e8cd-45f0-a787-7fde38f45a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9c4789f-61cc-42b8-8969-70fb974d3f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40c0bd97-fa11-4a37-a232-723790bc5d19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9c4789f-61cc-42b8-8969-70fb974d3f79" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_40c0bd97-fa11-4a37-a232-723790bc5d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b0d5ed7-61a0-4b46-90ea-e1768efb6cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_689fc7dc-5a50-415a-84db-ac4fb1b6b29c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b0d5ed7-61a0-4b46-90ea-e1768efb6cbb" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_689fc7dc-5a50-415a-84db-ac4fb1b6b29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3a8354b8-1bb4-4998-baa4-a9b6cc916251" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d84f17b3-0bab-4a5e-a33b-925666e42a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a8354b8-1bb4-4998-baa4-a9b6cc916251" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d84f17b3-0bab-4a5e-a33b-925666e42a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a431fb60-9473-4711-a4f1-bb9cef8c3067" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a8354b8-1bb4-4998-baa4-a9b6cc916251" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a431fb60-9473-4711-a4f1-bb9cef8c3067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2f60d1a7-e568-479c-b887-30401e588304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3a8354b8-1bb4-4998-baa4-a9b6cc916251" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_2f60d1a7-e568-479c-b887-30401e588304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROPERTYANDEQUIPMENTTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_803083eb-15d4-4129-85f6-f7f150bb5a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_08eb4a50-09ae-47c2-bf72-355d9c4189e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_803083eb-15d4-4129-85f6-f7f150bb5a2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_08eb4a50-09ae-47c2-bf72-355d9c4189e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_39069581-9164-49bf-90bd-59f6bd20b479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0a277118-6d5a-4e0c-afd2-1a0fcfb5415d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_39069581-9164-49bf-90bd-59f6bd20b479" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0a277118-6d5a-4e0c-afd2-1a0fcfb5415d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3d8495d4-52f1-43ba-b198-9cbb206a8a46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_85c5e6e3-c321-4969-90b1-02b84a5f1819" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d8495d4-52f1-43ba-b198-9cbb206a8a46" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_85c5e6e3-c321-4969-90b1-02b84a5f1819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f9d1a79e-0280-4e46-9b5a-cf6167d6634d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3d8495d4-52f1-43ba-b198-9cbb206a8a46" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f9d1a79e-0280-4e46-9b5a-cf6167d6634d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5acc9d5-dfe2-4173-ace0-558068b0955f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_17907cbb-726b-4b07-ac2a-b0129d5a070b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5acc9d5-dfe2-4173-ace0-558068b0955f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_17907cbb-726b-4b07-ac2a-b0129d5a070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f8961c3c-ec96-426a-84c6-d241435c51b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b5acc9d5-dfe2-4173-ace0-558068b0955f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f8961c3c-ec96-426a-84c6-d241435c51b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5b0cd11f-b1ed-4e58-bf66-7aa71401f26c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_977979d9-ea6c-4d75-b0bb-c3866d64b78c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5b0cd11f-b1ed-4e58-bf66-7aa71401f26c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_977979d9-ea6c-4d75-b0bb-c3866d64b78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6ebfd39d-610f-482f-b7a5-1152c2cfa213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5b0cd11f-b1ed-4e58-bf66-7aa71401f26c" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_6ebfd39d-610f-482f-b7a5-1152c2cfa213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#LIQUIDITYDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/LIQUIDITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9b30deb-a7b0-4855-aa00-49edfb2a46e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b9b30deb-a7b0-4855-aa00-49edfb2a46e0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d547e9a0-131c-4eb0-94d7-8fc0af972270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d28dc6a6-ebcd-4d29-a000-0698573ab972" xlink:to="loc_us-gaap_RelatedPartyDomain_d547e9a0-131c-4eb0-94d7-8fc0af972270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_11d917dc-63e6-4ba7-9806-ed5d87ee7956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d547e9a0-131c-4eb0-94d7-8fc0af972270" xlink:to="loc_us-gaap_InvestorMember_11d917dc-63e6-4ba7-9806-ed5d87ee7956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_aaccf124-c694-43de-a56a-7b1ab271d3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8d4798ef-d487-4a30-a1a2-91d9b9f41d76" xlink:to="loc_us-gaap_EquityComponentDomain_aaccf124-c694-43de-a56a-7b1ab271d3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e0c4f9e6-413a-4ad2-9a9d-58a95bbfb628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_aaccf124-c694-43de-a56a-7b1ab271d3b5" xlink:to="loc_us-gaap_CommonStockMember_e0c4f9e6-413a-4ad2-9a9d-58a95bbfb628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_562f1154-3006-4dbd-b615-aa67513283c3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_06e5d2e1-4c74-4a4f-af07-1abcc657987b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:to="loc_ck0001824293_PublicOfferingMember_06e5d2e1-4c74-4a4f-af07-1abcc657987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_6c5ffba1-431c-4971-b7ff-75bb46b09017" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_41e6310f-29c9-43c5-b810-848b6d4b5de6" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_6c5ffba1-431c-4971-b7ff-75bb46b09017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a1b6702e-3541-4820-a13f-ba1d7034c228" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_d0c795c9-24dd-4620-9a3c-a48bffa544d0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_d0c795c9-24dd-4620-9a3c-a48bffa544d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_30d2822e-8f0b-4c05-a1de-de62693ec247" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_30d2822e-8f0b-4c05-a1de-de62693ec247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_8627fb11-fb08-4118-8e45-ffd5f159cc37" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_8627fb11-fb08-4118-8e45-ffd5f159cc37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_fb4c2c3d-61f0-4c28-84b3-9d166f190ddc" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_fb4c2c3d-61f0-4c28-84b3-9d166f190ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_d59c04be-b630-4902-9bdb-2cdf5200a793" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_d59c04be-b630-4902-9bdb-2cdf5200a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_15301bea-1ada-498c-a3be-f596f3e6fd9d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_15301bea-1ada-498c-a3be-f596f3e6fd9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesCCommonWarrantMember_a44db89c-191e-4e6f-ae21-bc4584283efc" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesCCommonWarrantMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesCCommonWarrantMember_a44db89c-191e-4e6f-ae21-bc4584283efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesTWarrantsMember_b162a1b1-5f78-4f5d-991e-ac077fa46fcc" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesTWarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1e11163-6cd0-4f71-b55b-33a0753e7c01" xlink:to="loc_ck0001824293_SeriesTWarrantsMember_b162a1b1-5f78-4f5d-991e-ac077fa46fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8199a050-4796-407b-afa1-7d7149c86cfa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_bc3eac57-5064-46d1-9d39-7d1dbbc95427" xlink:to="loc_srt_RangeMember_8199a050-4796-407b-afa1-7d7149c86cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_797b8ae4-a0be-4547-bb45-89c56201be64" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8199a050-4796-407b-afa1-7d7149c86cfa" xlink:to="loc_srt_WeightedAverageMember_797b8ae4-a0be-4547-bb45-89c56201be64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9366c2a9-30ef-4d03-8ad8-3ee69573895b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_25f253ad-9579-4ed0-b6b7-b6c1ab7e53a8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9366c2a9-30ef-4d03-8ad8-3ee69573895b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0773f486-9634-4486-8dfe-6451892a664b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9366c2a9-30ef-4d03-8ad8-3ee69573895b" xlink:to="loc_us-gaap_SubsequentEventMember_0773f486-9634-4486-8dfe-6451892a664b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_58fdd23b-b214-434f-a2db-ff2ec9b8e9fd" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff2d3c86-8994-403b-90d5-c7500a2f54a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ff2d3c86-8994-403b-90d5-c7500a2f54a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc535f39-547a-484d-bac3-f8b6a1b1ac9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bc535f39-547a-484d-bac3-f8b6a1b1ac9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_466c6780-551f-4968-b749-bb093f87136f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_466c6780-551f-4968-b749-bb093f87136f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_41ecd5ab-99ee-4c5b-a480-3d90fde6a7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_CommonStockSharesIssued_41ecd5ab-99ee-4c5b-a480-3d90fde6a7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67b91be9-aa1b-4f40-88f8-87072b7d21b0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockHeldIntoEscrowAccount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_CommonStockHeldIntoEscrowAccount_67b91be9-aa1b-4f40-88f8-87072b7d21b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_529d894b-7d20-4abf-b0ad-92e5df3e144d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_529d894b-7d20-4abf-b0ad-92e5df3e144d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_365fd1ab-663a-47c0-ad27-f87da846b351" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_365fd1ab-663a-47c0-ad27-f87da846b351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_749c15ee-6cff-4ce7-825a-73567be1bacf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_749c15ee-6cff-4ce7-825a-73567be1bacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_31b640c6-ce79-4f29-b5b9-eddc3c8dc77e" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_31b640c6-ce79-4f29-b5b9-eddc3c8dc77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d406b4c5-c810-49d2-b68d-b38e4b13a285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d406b4c5-c810-49d2-b68d-b38e4b13a285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7044a8dc-3576-4550-8545-f9958103d86c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7044a8dc-3576-4550-8545-f9958103d86c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_22dffd4a-b9a2-4065-95e2-33142feba443" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_22dffd4a-b9a2-4065-95e2-33142feba443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b818f2a0-79b4-4a89-b06b-0765f7f55b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_b818f2a0-79b4-4a89-b06b-0765f7f55b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_e9ecfd25-37bf-4983-8bbd-5759ff91850f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_e9ecfd25-37bf-4983-8bbd-5759ff91850f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_26442218-b6f8-4c14-baab-b449eef1771a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_26442218-b6f8-4c14-baab-b449eef1771a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3227f5ed-98bb-4ccf-ac2a-cbc096d35380" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3227f5ed-98bb-4ccf-ac2a-cbc096d35380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5d67ce72-c82b-4812-9825-35941dd96dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_5d67ce72-c82b-4812-9825-35941dd96dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ba3369a-7b04-48c0-aded-00dbd749e543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_7ba3369a-7b04-48c0-aded-00dbd749e543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_b397a943-464c-4750-b99f-800d35547263" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_b397a943-464c-4750-b99f-800d35547263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8664d31a-d746-42c7-b05e-9b88b9dc04eb" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_8664d31a-d746-42c7-b05e-9b88b9dc04eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_17b84a1f-1cfe-4463-8140-af80daf5ec4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7e86f9f5-4215-4094-88e0-f49a5f323d99" xlink:to="loc_us-gaap_SharePrice_17b84a1f-1cfe-4463-8140-af80daf5ec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aab6922a-85b0-46f8-81be-3b135b05eb9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aab6922a-85b0-46f8-81be-3b135b05eb9f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_954628c2-52f5-4ad5-986b-d6ca1b86c69c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ee34d59a-e616-4428-9107-aa2ac1eae85c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ee34d59a-e616-4428-9107-aa2ac1eae85c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_6f1bfb50-b5ad-476e-8c47-b0d27e183ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_902950ab-3889-419c-a9e5-0ccbefb6064a" xlink:to="loc_us-gaap_WarrantMember_6f1bfb50-b5ad-476e-8c47-b0d27e183ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ac2eeacd-b61b-4e1b-9a3f-0b7d0d13e2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6cd0ae71-f2ee-4682-848d-034612781aa6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ac2eeacd-b61b-4e1b-9a3f-0b7d0d13e2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9b064534-c540-460b-ac64-05779c102cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_ac2eeacd-b61b-4e1b-9a3f-0b7d0d13e2b5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9b064534-c540-460b-ac64-05779c102cf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ead8ec11-8e78-4646-b49a-975477ef4f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_ead8ec11-8e78-4646-b49a-975477ef4f56" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:to="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d343853a-1fef-4718-bfe2-9bdf15e1c883" xlink:to="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsMember_e08b85d4-2efc-40bb-9a52-36fa4765a044" xlink:href="ck0001824293-20240630.xsd#ck0001824293_GRIOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:to="loc_ck0001824293_GRIOperationsMember_e08b85d4-2efc-40bb-9a52-36fa4765a044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PrivateGRIMember_a4d8bd8d-8fa8-4f41-9e81-8271fc4e6e23" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PrivateGRIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_baae6c89-b9b8-463b-954e-3c7ae1d8405e" xlink:to="loc_ck0001824293_PrivateGRIMember_a4d8bd8d-8fa8-4f41-9e81-8271fc4e6e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_929e7932-b9f9-46bd-ab50-273732c2bf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ec6cef22-5fbc-4884-953d-cb9f570d1049" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_929e7932-b9f9-46bd-ab50-273732c2bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_0f16fb74-f7f8-4668-83a7-9910370afd8b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_929e7932-b9f9-46bd-ab50-273732c2bf1f" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_0f16fb74-f7f8-4668-83a7-9910370afd8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_563c4c78-226f-4ca9-bb65-f77ea693a3d1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockExchangeRatio_cf6d920a-5960-40d9-9d5c-f02b9f62d083" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockExchangeRatio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_ck0001824293_CommonStockExchangeRatio_cf6d920a-5960-40d9-9d5c-f02b9f62d083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b1fd45e3-ab09-4c5f-9582-5ee7ac0e9b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_b1fd45e3-ab09-4c5f-9582-5ee7ac0e9b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_51a4a204-c2ef-4974-9048-dab3345dcef9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_51a4a204-c2ef-4974-9048-dab3345dcef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_CommonStockOwnershipPercentage_47fd465a-db62-4eae-8ee1-b150a8fd18e9" xlink:href="ck0001824293-20240630.xsd#ck0001824293_CommonStockOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_ck0001824293_CommonStockOwnershipPercentage_47fd465a-db62-4eae-8ee1-b150a8fd18e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_ab578df4-1871-4db2-b92f-7c23cfaa07a0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_35db8456-5b93-4f63-a7b2-c5e5636ca231" xlink:to="loc_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses_ab578df4-1871-4db2-b92f-7c23cfaa07a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_eb907093-df22-425d-9872-f634bb6d3334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_eb907093-df22-425d-9872-f634bb6d3334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_de06dee9-3cf9-4a64-88e2-7ee5f16d258e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_de06dee9-3cf9-4a64-88e2-7ee5f16d258e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_49e7e95b-6bfb-4afe-88ce-47a6ecd2b405" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses_49e7e95b-6bfb-4afe-88ce-47a6ecd2b405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_37a59db0-42cc-4643-ab34-1d2ff6c50694" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_37a59db0-42cc-4643-ab34-1d2ff6c50694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_e6514a9a-2795-4e81-87e7-ba3acde9146d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_e6514a9a-2795-4e81-87e7-ba3acde9146d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_1bc813c9-d33e-4a25-a189-5156d125bf78" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b9c72b1-bcd3-48ab-8949-e6e408b36fd1" xlink:to="loc_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts_1bc813c9-d33e-4a25-a189-5156d125bf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_71255a7c-d52d-49da-8474-1ab85d4572a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_71255a7c-d52d-49da-8474-1ab85d4572a0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ee422688-d5a6-45ff-a847-e730e881c431" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_12529e3a-eb2e-472a-8031-62d8d8a39cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_12529e3a-eb2e-472a-8031-62d8d8a39cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9a8a7500-1676-4773-9fa8-7974a58ef945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9a8a7500-1676-4773-9fa8-7974a58ef945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_2106bb68-0843-4b3a-a805-c2e258a25835" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0e2f3f17-401e-4de5-bb87-cfd27d3a85a1" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_2106bb68-0843-4b3a-a805-c2e258a25835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e620ec3f-0bd2-4a95-854d-bfba4b845af4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_04a3d8a3-74d5-4f9c-b4e4-c53651148ff5" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:to="loc_ck0001824293_WarrantLiabilityFairValueDisclosure_04a3d8a3-74d5-4f9c-b4e4-c53651148ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_4d9a82fd-7b84-4b68-874b-2aa95c4bc0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e09f3ebd-8bf0-4a8b-b817-57addb765843" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_4d9a82fd-7b84-4b68-874b-2aa95c4bc0ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42dddb75-f580-4884-b034-5570c9a43590" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42dddb75-f580-4884-b034-5570c9a43590" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_599e50be-d105-4e4e-9aa0-cac11d68263e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_c6551795-45af-47a9-aee1-996c869193d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_599e50be-d105-4e4e-9aa0-cac11d68263e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantLiabilityMember_25ede16a-48d3-4420-90b5-b1a12d6c012f" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_599e50be-d105-4e4e-9aa0-cac11d68263e" xlink:to="loc_ck0001824293_WarrantLiabilityMember_25ede16a-48d3-4420-90b5-b1a12d6c012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_4f7ac64b-969f-4796-8e0a-5e34d573f6da" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b7d1180-7cc4-401c-982d-806dd5f501ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2b7d1180-7cc4-401c-982d-806dd5f501ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1a84411-693d-4721-9bcc-b4ac623a7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1a84411-693d-4721-9bcc-b4ac623a7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf462b9a-3850-470b-a712-141a48327acc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dce0c50b-2935-4eb5-a651-46da329fa500" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cf462b9a-3850-470b-a712-141a48327acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a54ea889-dc9e-469c-b3da-8c8f37a47672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a54ea889-dc9e-469c-b3da-8c8f37a47672" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d79122f8-e4c8-4247-a017-7f849fa30a70" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_a795a905-a465-4566-8166-43db3218d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_a795a905-a465-4566-8166-43db3218d06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_e179fbec-b9d0-4030-8c50-c62f8d131000" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_e179fbec-b9d0-4030-8c50-c62f8d131000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_532ea3aa-23c2-46c3-89bf-9155bd964c85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_532ea3aa-23c2-46c3-89bf-9155bd964c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_229dadbd-b038-4bc1-8de4-de4a51501f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_04be782d-689d-413a-8be5-74531ea9f90c" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_229dadbd-b038-4bc1-8de4-de4a51501f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:to="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_061d8550-3e73-4e3e-8692-7607c2ab1a7d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_005f1170-64db-4446-b012-28527f5b86c8" xlink:to="loc_srt_RangeMember_061d8550-3e73-4e3e-8692-7607c2ab1a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_2891a5cb-faf2-42b3-8848-4fcb39e941b1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_061d8550-3e73-4e3e-8692-7607c2ab1a7d" xlink:to="loc_srt_WeightedAverageMember_2891a5cb-faf2-42b3-8848-4fcb39e941b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c2e059af-0bf9-4fe0-acc5-e046801c6110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_0cf4c389-b82b-467f-974d-6a3c87ff30db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c2e059af-0bf9-4fe0-acc5-e046801c6110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7bd4d5d2-2e0b-42de-8570-b995f556ca3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_c2e059af-0bf9-4fe0-acc5-e046801c6110" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_7bd4d5d2-2e0b-42de-8570-b995f556ca3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ebf965c-4c67-448d-b328-5b1b53512b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9ebf965c-4c67-448d-b328-5b1b53512b2c" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d4c518d4-3457-4729-a3db-a62a79bbd4c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerEquipmentMember_998f5495-5b60-4b64-89dd-2ca45938997c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:to="loc_us-gaap_ComputerEquipmentMember_998f5495-5b60-4b64-89dd-2ca45938997c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_51d271d5-8bdd-4610-affd-4447e93e60c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf115df6-12df-4e54-a45a-8722f7159b53" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_51d271d5-8bdd-4610-affd-4447e93e60c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_3e9ac798-f1dc-4981-9c34-bd1098398be3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_19639179-1e50-4083-b599-6b7d3db806dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_19639179-1e50-4083-b599-6b7d3db806dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d605e1cf-efc9-45d7-9ab1-16b25f6a5d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d605e1cf-efc9-45d7-9ab1-16b25f6a5d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dc00742e-7631-4cb4-9c9b-1e57d1b58882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_897ff567-75d8-4b67-ac97-1fd5fda5ddf6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dc00742e-7631-4cb4-9c9b-1e57d1b58882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROPERTYANDEQUIPMENTNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7010d787-be67-4673-b5d1-236049fac1cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fc7c578b-bcf3-4b07-9d55-4114591d2763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7010d787-be67-4673-b5d1-236049fac1cc" xlink:to="loc_us-gaap_Depreciation_fc7c578b-bcf3-4b07-9d55-4114591d2763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#ACCRUEDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_060dd894-23b1-4fff-8cea-fc6ec41c78c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_cdf888d3-bcf8-496f-9ce0-89a083a29e0a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AccruedResearchAndDevelopmentCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_060dd894-23b1-4fff-8cea-fc6ec41c78c3" xlink:to="loc_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent_cdf888d3-bcf8-496f-9ce0-89a083a29e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_e1091bf9-077d-4f30-87f9-273710a075c9" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_060dd894-23b1-4fff-8cea-fc6ec41c78c3" xlink:to="loc_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent_e1091bf9-077d-4f30-87f9-273710a075c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d4491ee0-253e-4181-ab40-1279fa59ee8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_060dd894-23b1-4fff-8cea-fc6ec41c78c3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d4491ee0-253e-4181-ab40-1279fa59ee8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d4cc06c4-5ff5-4d94-8751-7dcc2efac960" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_060dd894-23b1-4fff-8cea-fc6ec41c78c3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d4cc06c4-5ff5-4d94-8751-7dcc2efac960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#PROMISSORYNOTESBridgeFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a1b111bc-6321-4183-a250-4fed99f4d6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a1b111bc-6321-4183-a250-4fed99f4d6c3" xlink:to="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_b01d6a48-99cb-4062-99b7-1c91a9de7b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc4ef201-5215-4466-be2f-6b5ad896705a" xlink:to="loc_us-gaap_RelatedPartyDomain_b01d6a48-99cb-4062-99b7-1c91a9de7b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_16437541-d487-4c4c-8fb3-85cdd4af2fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_b01d6a48-99cb-4062-99b7-1c91a9de7b60" xlink:to="loc_us-gaap_InvestorMember_16437541-d487-4c4c-8fb3-85cdd4af2fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b829331-9822-4dfc-8715-f5101f066919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fb0ea414-f2d9-483e-8485-7c7f613aed61" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b829331-9822-4dfc-8715-f5101f066919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_41f21a83-4b5b-4143-bf10-73afb52e4765" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BridgeSecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b829331-9822-4dfc-8715-f5101f066919" xlink:to="loc_ck0001824293_BridgeSecuritiesPurchaseAgreementMember_41f21a83-4b5b-4143-bf10-73afb52e4765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7028ef9b-7d6d-4f89-abfa-a2f4b14c0467" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_BridgeWarrantsMember_4001f4da-7bdc-4b94-9ff0-e010701d77c8" xlink:href="ck0001824293-20240630.xsd#ck0001824293_BridgeWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:to="loc_ck0001824293_BridgeWarrantsMember_4001f4da-7bdc-4b94-9ff0-e010701d77c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ExchangeWarrantsMember_3149dff0-de9b-44a7-bc28-a13d76765e28" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ExchangeWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1643a155-17e1-487a-a0c8-80561abebc49" xlink:to="loc_ck0001824293_ExchangeWarrantsMember_3149dff0-de9b-44a7-bc28-a13d76765e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_4f2523fe-6005-4286-836c-775c0ef15cb4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_34a064e9-23e9-4c38-9194-5be2ec393d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_34a064e9-23e9-4c38-9194-5be2ec393d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_8e780e91-5c2f-4fd9-a1e3-192a5edf3c28" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtInstrumentAggregatePurchasePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_ck0001824293_DebtInstrumentAggregatePurchasePrice_8e780e91-5c2f-4fd9-a1e3-192a5edf3c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_DebtInstrumentNumberOfClosings_9b0debde-28a9-4a7a-aed3-aed6d78c3281" xlink:href="ck0001824293-20240630.xsd#ck0001824293_DebtInstrumentNumberOfClosings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_ck0001824293_DebtInstrumentNumberOfClosings_9b0debde-28a9-4a7a-aed3-aed6d78c3281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_254756ec-e762-49aa-a758-404230398fef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_254756ec-e762-49aa-a758-404230398fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97e82787-7764-4192-b4c9-9fcaa7e86c56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_97e82787-7764-4192-b4c9-9fcaa7e86c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f3db8cb-bdd2-4bb3-a233-a1dc2b22ba2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_4f3db8cb-bdd2-4bb3-a233-a1dc2b22ba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_4cdaf53d-34a2-4cef-a27a-c06490ea3ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_4cdaf53d-34a2-4cef-a27a-c06490ea3ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_ad84d3e9-3f38-47f5-91ac-90b50398c88c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_ad84d3e9-3f38-47f5-91ac-90b50398c88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_88ee56d3-83dd-4343-9eaa-81460eae11ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_88ee56d3-83dd-4343-9eaa-81460eae11ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_60d4074b-a7bb-44e3-8136-192a68831878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_61972df5-a9f3-4040-9bba-f33a53bc7c42" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_60d4074b-a7bb-44e3-8136-192a68831878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2dc924b4-a4ee-40ec-806a-5d39427ae99f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2dc924b4-a4ee-40ec-806a-5d39427ae99f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_05ba9fc5-b5f4-4ef1-bfbe-49a9024df1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_fc267ebe-cd0d-4bd1-9619-ff19e78716f7" xlink:to="loc_us-gaap_RelatedPartyDomain_05ba9fc5-b5f4-4ef1-bfbe-49a9024df1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_a9963890-04a6-4d39-9cd2-1aac8cac81a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_05ba9fc5-b5f4-4ef1-bfbe-49a9024df1b7" xlink:to="loc_us-gaap_InvestorMember_a9963890-04a6-4d39-9cd2-1aac8cac81a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3b4984c4-9914-4bac-b4fe-1778824eb157" xlink:to="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1847f098-8d3f-4fc9-b8ea-1e14cc032755" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:to="loc_us-gaap_CommonStockMember_1847f098-8d3f-4fc9-b8ea-1e14cc032755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9d8b0c93-6607-4ea0-a4b1-c0153496d9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f74e661b-3f98-49aa-90c1-13208b91bd9b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9d8b0c93-6607-4ea0-a4b1-c0153496d9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_db243010-9111-42ae-aa6a-ce1c735e32fc" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PublicOfferingMember_4c0d96d7-18e2-4438-be6c-54c7c4e2f4a9" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:to="loc_ck0001824293_PublicOfferingMember_4c0d96d7-18e2-4438-be6c-54c7c4e2f4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AtTheMarketOfferingMember_2357bcd3-f8d5-4634-95fc-e37a7acdf737" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_63978799-6cc6-4f45-9ffd-a7e8a7b3a469" xlink:to="loc_ck0001824293_AtTheMarketOfferingMember_2357bcd3-f8d5-4634-95fc-e37a7acdf737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9dd265e0-ae12-4c5a-a55e-6046fc543f66" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedWarrantsMember_4a22150a-37f9-4dd7-b4fd-4a2ee85becf8" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_PreFundedWarrantsMember_4a22150a-37f9-4dd7-b4fd-4a2ee85becf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonWarrantsMember_d4ef6f57-b662-4033-a984-0d62ef69f130" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesB1CommonWarrantsMember_d4ef6f57-b662-4033-a984-0d62ef69f130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB2CommonWarrantsMember_306e875a-6bd6-4e83-8a94-9563424517ae" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesB2CommonWarrantsMember_306e875a-6bd6-4e83-8a94-9563424517ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesA1WarrantsMember_62b14ca3-1119-46a2-9adf-ec773f8f15c1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesA1WarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesA1WarrantsMember_62b14ca3-1119-46a2-9adf-ec773f8f15c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonWarrantsMember_d9b453ee-6676-47c7-8210-2133073978f5" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesC1CommonWarrantsMember_d9b453ee-6676-47c7-8210-2133073978f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC2CommonWarrantsMember_b6654b08-8c1e-4645-b13b-3ca65b50bc57" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC2CommonWarrantsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesC2CommonWarrantsMember_b6654b08-8c1e-4645-b13b-3ca65b50bc57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesCCommonWarrantMember_5f4e550d-86de-4f5d-848c-d5221639605d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesCCommonWarrantMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_SeriesCCommonWarrantMember_5f4e550d-86de-4f5d-848c-d5221639605d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_fb2c1df4-28a7-422d-a09f-66e3a7fa1db1" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PreFundedAndSeriesCWarrantsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_PreFundedAndSeriesCWarrantsMember_fb2c1df4-28a7-422d-a09f-66e3a7fa1db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ThePlacementAgentWarrantsMember_cea0a599-a4a6-4b9f-96a0-fdb4a445986a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ThePlacementAgentWarrantsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_92ffe8c4-cf0f-4b0a-a4a5-8cd40fa2fb5a" xlink:to="loc_ck0001824293_ThePlacementAgentWarrantsMember_cea0a599-a4a6-4b9f-96a0-fdb4a445986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f8eb23a-d137-4b66-a1c9-7c36ccd373de" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a7764606-9d24-43b4-b7a6-ed36b3aeed26" xlink:to="loc_srt_RangeMember_7f8eb23a-d137-4b66-a1c9-7c36ccd373de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_aaaa8e69-70bd-4b12-835b-515eadc7d0c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7f8eb23a-d137-4b66-a1c9-7c36ccd373de" xlink:to="loc_srt_WeightedAverageMember_aaaa8e69-70bd-4b12-835b-515eadc7d0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_bfe471a5-4a1e-41b9-85b1-7a45228e962e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_55ee79be-f4e9-4f55-a705-aec0943b7936" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_bfe471a5-4a1e-41b9-85b1-7a45228e962e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_802a29d8-71c9-47aa-8560-3d76b4ffa566" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_bfe471a5-4a1e-41b9-85b1-7a45228e962e" xlink:to="loc_us-gaap_SubsequentEventMember_802a29d8-71c9-47aa-8560-3d76b4ffa566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_77e841ef-1514-442d-835f-fc4af528c30f" xlink:to="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentCompanyCommittedCapital_c8ab13e9-b357-46d0-b987-ad19f410f107" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentCompanyCommittedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_InvestmentCompanyCommittedCapital_c8ab13e9-b357-46d0-b987-ad19f410f107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_935aa7be-f996-48ff-bb1c-c252110420b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_935aa7be-f996-48ff-bb1c-c252110420b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3c2b6c4-f6e7-40ae-a64c-a37aeb026a95" xlink:href="ck0001824293-20240630.xsd#ck0001824293_StockIssuanceCostsOfferingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_StockIssuanceCostsOfferingExpenses_c3c2b6c4-f6e7-40ae-a64c-a37aeb026a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_ebf5ec6b-5598-4cd3-93c0-ce0ff69cf5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_ebf5ec6b-5598-4cd3-93c0-ce0ff69cf5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_5d6a45be-0aa3-4679-b155-7ff1d7079711" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ConversionOfStockAdditionalSharesConverted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_ConversionOfStockAdditionalSharesConverted_5d6a45be-0aa3-4679-b155-7ff1d7079711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8da0d16-ff8b-4e20-830f-0913f1100951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a8da0d16-ff8b-4e20-830f-0913f1100951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6fd08d81-3e3b-47a9-8821-f03300c6813b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_6fd08d81-3e3b-47a9-8821-f03300c6813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_657c0cd1-64d5-4fc7-a16e-4b12984f58a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_657c0cd1-64d5-4fc7-a16e-4b12984f58a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ddbdcc81-cd41-4bd0-bb6c-a02d1bd3160d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ddbdcc81-cd41-4bd0-bb6c-a02d1bd3160d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_236344e6-718e-4684-9a4c-55ff85d1fe67" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction_236344e6-718e-4684-9a4c-55ff85d1fe67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_750f8dc6-0a3c-4990-9373-da31626c65db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_750f8dc6-0a3c-4990-9373-da31626c65db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_557a99cd-7145-407f-ae75-38020f1c7d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_557a99cd-7145-407f-ae75-38020f1c7d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a516cdc5-ed5c-41b4-b3ab-b65768293041" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_a516cdc5-ed5c-41b4-b3ab-b65768293041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15b0bb71-0482-42de-9fb9-b92ba2b48ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_15b0bb71-0482-42de-9fb9-b92ba2b48ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_0b529100-69b3-484f-9018-bdd402b31fae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_0b529100-69b3-484f-9018-bdd402b31fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5fa4c1a1-8093-4b68-82fa-067918eb3b33" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockMaximumValueOfSharesOffered"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_SaleOfStockMaximumValueOfSharesOffered_5fa4c1a1-8093-4b68-82fa-067918eb3b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_4d83b9f0-a73d-4c77-a928-c20c65d2062a" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SaleOfStockAgentCompensationPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_dae87b45-90ba-42eb-a21c-c2161963a1a5" xlink:to="loc_ck0001824293_SaleOfStockAgentCompensationPercentage_4d83b9f0-a73d-4c77-a928-c20c65d2062a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bfa2ed9c-bd9f-4074-bcb4-312363b9b84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bfa2ed9c-bd9f-4074-bcb4-312363b9b84f" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_7e8b8bae-d433-46af-9f48-9f6f21dac8f4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_b3e8a53a-5a2e-46d5-ba4b-895f5d1ef35b" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:to="loc_ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember_b3e8a53a-5a2e-46d5-ba4b-895f5d1ef35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_c4095899-69f7-44e8-8fa2-7fa4c2f2b159" xlink:href="ck0001824293-20240630.xsd#ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_113c68ee-15f0-4cb2-a091-433517149a4a" xlink:to="loc_ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember_c4095899-69f7-44e8-8fa2-7fa4c2f2b159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_b6eac1cb-f882-4221-bd03-b06fc8042ee1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f6636c7-97c8-4b38-825b-14d78d01e84f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_8f6636c7-97c8-4b38-825b-14d78d01e84f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_d44aea75-3407-4870-8546-38cb948fb40d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_d44aea75-3407-4870-8546-38cb948fb40d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5be9977f-adae-465f-997b-9effa39b5df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_5be9977f-adae-465f-997b-9effa39b5df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bb145c2e-fb6b-4b93-baa3-82ff7a633ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c6f4af4e-41b0-424c-a146-4e5b5e4c6c44" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_bb145c2e-fb6b-4b93-baa3-82ff7a633ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_031435cb-3cca-4cb1-8a9c-b10a4e94acb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_98f8c2f4-d835-4a87-a387-0c1d5b213316" xlink:to="loc_srt_RangeMember_031435cb-3cca-4cb1-8a9c-b10a4e94acb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_0249c3d3-7359-4fe0-8631-65f98e43ed74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_031435cb-3cca-4cb1-8a9c-b10a4e94acb8" xlink:to="loc_srt_WeightedAverageMember_0249c3d3-7359-4fe0-8631-65f98e43ed74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_a764e3bd-8ce8-4c5a-8e4b-6cacbf9093a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d6c57ce3-69b6-40f1-84af-02d6a89abcd7" xlink:to="loc_us-gaap_ClassOfStockLineItems_a764e3bd-8ce8-4c5a-8e4b-6cacbf9093a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cde84eed-fb2e-49ca-b5b5-782fce9d614f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_a764e3bd-8ce8-4c5a-8e4b-6cacbf9093a5" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_cde84eed-fb2e-49ca-b5b5-782fce9d614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_47530dc1-8d45-4f6d-ad97-42247bffb62b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_47530dc1-8d45-4f6d-ad97-42247bffb62b" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_759b7664-a6e1-4d88-98ea-f3393c77090e" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsNotExpiringMember_2201da69-3d1b-44f8-9bec-ccea52b98539" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsNotExpiringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsNotExpiringMember_2201da69-3d1b-44f8-9bec-ccea52b98539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInAugust2025Member_5c51aaef-7e03-4301-9ce6-9648efe1bbc7" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInAugust2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInAugust2025Member_5c51aaef-7e03-4301-9ce6-9648efe1bbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInDecember2025Member_296dac87-cef0-40ca-a879-c50f9b823e8d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInDecember2025Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInDecember2025Member_296dac87-cef0-40ca-a879-c50f9b823e8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_ed1f3431-bd63-452c-8f44-45eb62027d71" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInFebruary2026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2026Member_ed1f3431-bd63-452c-8f44-45eb62027d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInMay2027Member_e9952efc-ebb3-4a88-a187-13aed5a27966" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInMay2027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInMay2027Member_e9952efc-ebb3-4a88-a187-13aed5a27966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJuly2027Member_375fae1f-bdc4-480c-a77f-6ba7d416e752" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInJuly2027Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInJuly2027Member_375fae1f-bdc4-480c-a77f-6ba7d416e752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInApril2028Member_d8866906-9945-40d1-bbf6-f7bd25ab7b00" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInApril2028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInApril2028Member_d8866906-9945-40d1-bbf6-f7bd25ab7b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_70b84ec6-49bf-4f3e-8105-aee3156a2a16" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInFebruary2029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInFebruary2029Member_70b84ec6-49bf-4f3e-8105-aee3156a2a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringInJune2029Member_2759d5c1-b8f3-4b80-a50b-3276f994a1c0" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringInJune2029Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringInJune2029Member_2759d5c1-b8f3-4b80-a50b-3276f994a1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_26b3bcc3-92a2-418e-96b9-5fe4771b6234" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember_26b3bcc3-92a2-418e-96b9-5fe4771b6234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_f6c68345-e8d4-493e-90ac-55e0127ffddf" xlink:href="ck0001824293-20240630.xsd#ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_d1b529ce-4c27-4cba-a0c6-3c4a4c79b63a" xlink:to="loc_ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember_f6c68345-e8d4-493e-90ac-55e0127ffddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_4b2952a7-265b-44af-9830-fdd718c31d6b" xlink:to="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_109fd6e3-83d3-4dc4-9414-b18d87ebadb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_109fd6e3-83d3-4dc4-9414-b18d87ebadb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7d9baed7-4f6d-42b9-8f31-97b38bf1f882" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7d9baed7-4f6d-42b9-8f31-97b38bf1f882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c89b850d-3de2-4fa0-a209-ddcf814dc1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_11db96db-8eea-4ebc-b097-c7de04534903" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_c89b850d-3de2-4fa0-a209-ddcf814dc1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4763647-fd13-4391-b977-572074115038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a4763647-fd13-4391-b977-572074115038" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d4a6e73d-9089-4c4c-b8b0-4d9147a88edd" xlink:to="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_GRIOperationsPlanMember_9f7c6aae-0b69-4b10-887c-8b0751fd4302" xlink:href="ck0001824293-20240630.xsd#ck0001824293_GRIOperationsPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:to="loc_ck0001824293_GRIOperationsPlanMember_9f7c6aae-0b69-4b10-887c-8b0751fd4302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_2f3389ef-5a32-4a6f-a92d-0fb478b46f8d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_586ae1df-8378-448f-9f40-a18c4b9de437" xlink:to="loc_ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember_2f3389ef-5a32-4a6f-a92d-0fb478b46f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d5d25d-b164-4526-bc97-07af2ae6101d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_46e07374-eeda-45a2-a76f-f73bb35568c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d5d25d-b164-4526-bc97-07af2ae6101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8f67b0f2-7454-437d-9562-1a4dfaae1a81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50d5d25d-b164-4526-bc97-07af2ae6101d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8f67b0f2-7454-437d-9562-1a4dfaae1a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52da3fd8-0a33-442e-994f-a2e7898e1dcc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aec78aa0-7871-4bc9-bc1d-df11c133e0b5" xlink:to="loc_srt_RangeMember_52da3fd8-0a33-442e-994f-a2e7898e1dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb292f62-5ac8-4927-ba5e-cf081cea97d6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52da3fd8-0a33-442e-994f-a2e7898e1dcc" xlink:to="loc_srt_MaximumMember_cb292f62-5ac8-4927-ba5e-cf081cea97d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_b109cc16-e19e-4a1d-b6b1-584eac5673fa" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25721339-a300-4691-8183-3a762a214111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_25721339-a300-4691-8183-3a762a214111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e299c7f2-f9f6-42be-8cbd-a102762a13bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_e299c7f2-f9f6-42be-8cbd-a102762a13bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6ea1a3c0-56c3-4a03-af40-90fba5944b18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6ea1a3c0-56c3-4a03-af40-90fba5944b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f824ecb-bc54-42a3-9466-0d3ccad05a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_6f824ecb-bc54-42a3-9466-0d3ccad05a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd44408b-e285-46fa-b183-43138607dde8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_dd44408b-e285-46fa-b183-43138607dde8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_edfe4ec6-7a42-45b6-9be1-1a2e4f44a1cd" xlink:href="ck0001824293-20240630.xsd#ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum_edfe4ec6-7a42-45b6-9be1-1a2e4f44a1cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bb98d731-b96e-4e66-9326-96118518d234" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_bb98d731-b96e-4e66-9326-96118518d234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25c893a4-df90-4008-bf96-99f7f717c5a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_25c893a4-df90-4008-bf96-99f7f717c5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2e75623e-a660-45e4-a3bb-08ce4ef48978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2e75623e-a660-45e4-a3bb-08ce4ef48978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f5505bf9-83b5-4166-900e-aa06be24cba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_4a2bf5e6-c8ac-4100-ace1-1e74d4c504ec" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f5505bf9-83b5-4166-900e-aa06be24cba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5bc3d572-b70b-46df-91a2-3be4eb6c7f47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5bc3d572-b70b-46df-91a2-3be4eb6c7f47" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9b87404b-961a-4cbc-b211-806a8202db0a" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3f970815-f667-4b6a-aef4-322e254b9af5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3f970815-f667-4b6a-aef4-322e254b9af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89a72bd7-f9f3-4f7d-8453-178c337c52cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8037162f-20df-4d98-b0b4-87f7238d489c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_89a72bd7-f9f3-4f7d-8453-178c337c52cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ecbf8fa4-4742-4d45-91be-949a5fcfc54d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9ac6657c-327b-44cf-9775-ba910587f9a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ecbf8fa4-4742-4d45-91be-949a5fcfc54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_00077ba2-5617-4d50-9e01-0985cd7f790e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ecbf8fa4-4742-4d45-91be-949a5fcfc54d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_00077ba2-5617-4d50-9e01-0985cd7f790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d589b608-186d-48aa-9e3d-a24e021d984d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d589b608-186d-48aa-9e3d-a24e021d984d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b93a8b7d-f655-494f-b756-f514c1a3b5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b93a8b7d-f655-494f-b756-f514c1a3b5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63790556-51a2-4761-a933-9146a7635741" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_63790556-51a2-4761-a933-9146a7635741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_68ff595d-0b4b-41d9-8de4-5c328de7ab63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_68ff595d-0b4b-41d9-8de4-5c328de7ab63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a61d7f60-2fe1-44d0-a3b4-9d528e637d86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e5742835-68f4-46d8-9781-87d29824130d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a61d7f60-2fe1-44d0-a3b4-9d528e637d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fbd49763-c296-40c0-af3f-cc5f15612f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_fbd49763-c296-40c0-af3f-cc5f15612f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ae8afb1a-7791-4f37-bcff-05aa391c98b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ae8afb1a-7791-4f37-bcff-05aa391c98b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_94c3f22b-0315-42f6-bcc2-60c01a37729d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_94c3f22b-0315-42f6-bcc2-60c01a37729d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a90fc22d-82ce-438d-adab-94c739fcd402" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_94c3f22b-0315-42f6-bcc2-60c01a37729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a90fc22d-82ce-438d-adab-94c739fcd402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7040ccaf-2c8a-4fbd-8006-6cfd791e4358" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_94c3f22b-0315-42f6-bcc2-60c01a37729d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7040ccaf-2c8a-4fbd-8006-6cfd791e4358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_df13c71e-d604-4294-a3ca-f05cf97878bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_df13c71e-d604-4294-a3ca-f05cf97878bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0ff6f9cd-4219-4195-89f6-99c0461a7b83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0ff6f9cd-4219-4195-89f6-99c0461a7b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b46d8eca-c3fb-4f2d-a12d-d7dea42de50c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c2c5d741-893a-4332-82cd-6b06bf984506" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b46d8eca-c3fb-4f2d-a12d-d7dea42de50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6b77d9d6-bf45-4113-8a80-5c94fc08c16c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b46d8eca-c3fb-4f2d-a12d-d7dea42de50c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6b77d9d6-bf45-4113-8a80-5c94fc08c16c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_86ceb621-904b-484c-a41c-ec54bb69d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b46d8eca-c3fb-4f2d-a12d-d7dea42de50c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_86ceb621-904b-484c-a41c-ec54bb69d56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_e86cfadd-2e5e-4f28-9990-8bdf78278f49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b46d8eca-c3fb-4f2d-a12d-d7dea42de50c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_e86cfadd-2e5e-4f28-9990-8bdf78278f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ck0001824293-20240630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a32923c-aa07-4b07-9f4f-6582a6d83b94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a32923c-aa07-4b07-9f4f-6582a6d83b94" xlink:to="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:to="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af26c697-ef85-4a5d-ad4f-4627fa8eca94" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_a54a7d8f-bc67-4f32-badf-616babecc109" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af26c697-ef85-4a5d-ad4f-4627fa8eca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_FormerChiefExecutiveOfficerMember_83498ea1-90d7-4104-b26b-f5866fe1805d" xlink:href="ck0001824293-20240630.xsd#ck0001824293_FormerChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af26c697-ef85-4a5d-ad4f-4627fa8eca94" xlink:to="loc_ck0001824293_FormerChiefExecutiveOfficerMember_83498ea1-90d7-4104-b26b-f5866fe1805d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_56eee675-df46-4361-81d3-4ad48b11db4c" xlink:to="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_COBRABenefitsPaymentPeriod_30ace902-378e-452f-bacc-9116b1141d89" xlink:href="ck0001824293-20240630.xsd#ck0001824293_COBRABenefitsPaymentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:to="loc_ck0001824293_COBRABenefitsPaymentPeriod_30ace902-378e-452f-bacc-9116b1141d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ck0001824293_PercentageOfTargetBonus_65125d49-3e3d-4498-babf-3d358b763cb3" xlink:href="ck0001824293-20240630.xsd#ck0001824293_PercentageOfTargetBonus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_7b92a19e-6143-455a-8a58-cb2237560674" xlink:to="loc_ck0001824293_PercentageOfTargetBonus_65125d49-3e3d-4498-babf-3d358b763cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ck0001824293-20240630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ck0001824293-20240630_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
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M.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"-
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M)*75\.*CY6;"@T2D)?%D_]H # ,!  (1 Q$ /P"_P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MF8X8IKIG#BJARY?5<Q=OT6ZJ:.355$<$3T?#7Q$8:X
M
M
M
M
M                      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M
M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#7YY8UB'?]\R>
MU/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M     "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M               $CW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>
M*V!T R\@
M
M
M
M                                               %8KTM'ZK;7OE6
M<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O
M!_\ K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M                              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP
M'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L
M:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M
M
M
M
M             !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)
M9IZ8E;                 "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*I
MVLG[;M^CCQ6P.@&7D
M
M
M
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M      !(]X/_ -:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
M                                        5BO2T?JMM>^59Q+^9O*K
M<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"
M^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M
M
M
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M      %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M                )'O!_P#K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ
M./%; Z 9>0
M
M
M
M                                                 "L5Z6C]5MKW
MRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $
MCW@__6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M
M
M
M
M                               %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?
M@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY
M8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M
M
M
M
M              "L5Z6C]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B
M2S3TQ*V                 $CW@_P#UI/0%\JSAK\\L:Q#O^^9/:GX#S?L5
M3M9/VW;]''BM@= ,O(
M
M
M
M                                                         !6*
M]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M       "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7
MD
M
M
M
M                                         K%>EH_5;:]\JSB7\S>5
M6YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_ -:3
MT!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
M
M
M
M
M                        0G>/AT+\^>(5T.8G@7IQQ^L9/D&SYVT'?ZUM
MMNR6VJXJ&NZ]KN]XW)5)<G=4:]*:[ENL_;PDI=WMGEC-'M^];'<UW>9LMNHW
ME7-J-KZ[U&E5:9?L1-JW-VKLERY9JI\K$Q.&%%6,]#@Z;HZAE[F9L=CM8<KE
M1/BJ8WV5SQ:?^#^#??JPOL<D._?=W$_A&I^\Z_5*)W)SG2IZY]E<\6G_ (/X
M-]^K"^QQ^^[N)_"-3]YU^J.Y.<Z5/7/LKGBT_P#!_!OOU87V./WW=Q/X1J?O
M.OU1W)SG2IZY]E<\6G_@_@WWZL+[''[[NXG\(U/WG7ZH[DYSI4]<^RN>+3_P
M?P;[]6%]CC]]W<3^$:G[SK]4=R<YTJ>N?97/%I_X/X-]^K"^QQ^^[N)_"-3]
MYU^J.Y.<Z5/7/LKGBT_\'\&^_5A?8X_?=W$_A&I^\Z_5'<G.=*GKGV5SQ:?^
M#^#??JPOL<?ON[B?PC4_>=?JCN3G.E3US[*YXM/_  ?P;[]6%]CC]]W<3^$:
MG[SK]4=R<YTJ>N?97/%I_P"#^#??JPOL<?ON[B?PC4_>=?JCN3G.E3US[*YX
MM/\ P?P;[]6%]CC]]W<3^$:G[SK]4=R<YTJ>N?97/%I_X/X-]^K"^QQ^^[N)
M_"-3]YU^J.Y.<Z5/7/LKGBT_\'\&^_5A?8X_?=W$_A&I^\Z_5'<G.=*GKGV5
MSQ:?^#^#??JPOL<?ON[B?PC4_>=?JCN3G.E3US[*YXM/_!_!OOU87V./WW=Q
M/X1J?O.OU1W)SG2IZY]E<\6G_@_@WWZL+[''[[NXG\(U/WG7ZH[DYSI4]<^R
MN>+3_P '\&^_5A?8X_?=W$_A&I^\Z_5'<G.=*GKGV5SQ:?\ @_@WWZL+[''[
M[NXG\(U/WG7ZH[DYSI4]=[%\/?T<7Q,.G'KCZ4>>N3-7X?M>/N(N=N.M_P!R
MN</RSB<ME:&NZUL5EDLI4Q^,I6-.K?W<EK0FC)2EFA&>;U.UC_>MSNMS>UV[
M77=E]&OZA5JN?TS,6+45Y6JFF;ERW--/*JFK"F,9X9Z#FR^F9JW?HN513R::
MHF>%H2HHUQ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M0]:TR)G4LGFLO$1$_7;5RWP3.$>;ICCG@CIRY(KHJ\S,3X;GJEOH
M
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M/%)\_P!ZK/?EW+V2/D!W)_%;0_>EKU)VYF_7*^O)],!XI/G^]5GOR[E[)'R
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MY[^,D].>2,81A&$81A'LB_:='TBFJ*J<KEHJB<8F+5&,3Z4Y573EPE4GR
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MF*J:HFFJF8XXJIG"8F.C$QB[<3$QC'$^@XGZ
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MQ,3$\3L92]>G-6XFNJ8FN.C/3:NR#5=P
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M:JIGJNC<OWKOV2NJKP9EY@7HX0
M
M &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M           I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*
M&:3Y;X
M                      #T[T[=:?5ITE9/\*]-?45R[PU-4NZ=[>XK2-VS
M6-U7-7-+M\G-L>F37-;4=FIR=O;"GD+&YI]OJ]WM67M;NZV$V[L]@VPTC(:C
M$4X15>LT57:(GUN]A%VWX-NNF>JYK=^]9G&U553X$^-Q++'2%Z77U4<>3XC7
M.L?AK1NHG6Z7DK:_Y X_\AQ%RO"6I7DC<9;(8NRM,AQALE>WH=Z%*RL\9K<E
M2;L[US+V1C'3O;[F%[$:M%S-[OM0S.D9R<9IL7\<UEN+@IIJF:<S;B9XZZ[F
M8F.A1*IV=8NT\%ZF*HZ<<$^1XBV9T2>-IX=77E-A\#Q/SGB],Y3S$U.A;\)\
MSRVG&W)E?(58R0DQ>!L\G?W&M;WD)X3=Z%+7LGEIX22S330E[LW=T5WD<W#>
MWNPBYFM=TRO,:);X9SF4QS&7BF/IJYIIBY9IZM^W:C'"(QQC&KV,]ELQP458
M5]*>"?Z?"Q2R,%.X                          K%>EH_5;:]\JSB7\S>
M56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:
M3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M.,N/NV_
M                                              &A]Z'E\1_J<^57
M7^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F
M6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@
M
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MR9>>+&:X[%RIBFB]7*OY;/V,SP4SR;G2GQNGXO43)->W=
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M7*O*]*."/_'@XHT68W5
M
M :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M          "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAF
MD^6^
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MPKHF,:;ENK#&BY1-5%<<--4QPKBMW+=VB*[<Q-$NZ%NOL
M      !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M'$<C&[R9FFN]7"W,UG[^:X)GDVNE'C]/Q.HAD;#NB
M
M                         T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF
M%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*4C/>]?
MRQM1[FR/U>94/6_,V_!GQE#-)\M\
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M=FN>5&$U437;PKFZ,KG+6;HQHX*XXXZ,>3'52A,+.V
M   K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MJJF9JGHRXH[SY
M                                                          :'
MWH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M       "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6
M^
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M +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M\51'+O1]-F)B)C'DVHIIY55RV<[J->8F;=O&FQ]&?!ZG4ZZMHW!4L
M
M                                       !H?>AY?$?ZG/E5U_@BXV1
M-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03
M[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M
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M9NS$133F+43$5Q$1%=,TW*(B*IIHNW)9RC-V\>*Y'''CQU)2[L".X
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M.*/'GJ^(AK;".B
M
M  T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M              4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?
M&4,TGRWP
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MSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M2
M                                                  :'WH>7Q'^I
MSY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K                 "
ME-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M
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MJVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M   "1[P?_K2>@+Y5G#7YY8UB'?\ ?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M                                    ^7F\WA]:PN7V/8LKC\%K^OXN
M_P WG<WEKRAC\5A\/BK2K?Y/*Y._NJE*UL<?C[*A/6K5JDTM.E3DC--&$(1B
MYLMELQG,Q;R>4HKNYJ[731113$U55UU3%----,8S-54S$1$<,S.$/R9B(QGB
MAF >/3XS.?\ $CYEJ\1\/9C*8KHPX=V*M'0\9-)5Q]7E_<\?2O,7=\Q[-8SP
MDN9+.I1N[BWUNQN/Y2RQ=6:XJTZ-W>W%"C-'S7^;SE=T&ST:]M!;HKWB:A9C
ML]7FHRMFJ8JC*6ZN+'&*:LQ73P5W(BBF:K=NBJJUM0SLYJOD4?8*9X.K/3\A
M7M;7*:
M                                                        T/O0
M\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M     %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M
M                          !H!^BM>*36Y3X]O_#FYIV.:YWWB/"76R=-
MN7RUUW[K9>)K*;RFP\9PN+NO&M=Y3C.M7A=8NC)WYHZ_6J4I):=#%0[T5_/>
MW)TZ)JU.]S9VSAI>?N1;U"FF."WFI^QYC"(PBG,1')N3.'U^(JF9JO\ !<6D
MYOET]K5SY:/,^!TO"\3P%R)'PK0                "L5Z6C]5MKWRK.)?S
M-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@_\
MUI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                         !1%])]\8N?/Y//>&CTU[7V8+"W<E'JXW; W
M<)OPQG;*XH75EP+C<A;S?R=CK]W0EN-K\E-&:M?0I8N>:G"VR5O7DXYE_-^C
M*V;6^/;"Q_S5RG'2[-<>8HF)B<[53/TUR)Y.6QXJ.5?B)Y=FNF@:KG<9[5M3
MP?33XWD];IJ2B1]0@
M
M       &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P
M                 I3>F6_V:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFW
MX,^,H9I/EO@
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M >;]BJ=K)^V[?HX\5L#H!EY
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M1$1$80M.9F9QGC?@<K\
M
M          :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H
M8K                 "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?
MF;?@SXRAFD^6^
M                                          NJ^B+==\VO[WR[X>^\
MYJ?\%;_0ON<."*-]=TH4;;<=>QUM9\JZABZ=:::YJU]BU*RM,W1MZ791H28+
M(UHR]^O/-&.?GZ;L8S>EY#>MIEN.SY6:<GG9IB<9M7*IG+7:L."(MW9JLS5/
M#,WK5..%,0KFCYC"JK+5<4\,>#T8ZW#X4KZ",!<                "L5Z6
MC]5MKWRK.)?S-Y5;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V
M     $CW@_\ UI/0%\JSAK\\L:Q#O^^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MW3V3,WHC"<QFJXCLMV>CAC$46XGAIM46Z)F>3BLW-9BK,WINU<70CI1T(_\
M'1>#&4'7
M
M:'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M         "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9
MI/EO@
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M^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
MD>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                              *.'I9GB33R2ZEX:G%6=[):TF Y6ZH+
MO'7$(]Z2%23*<4\3WLU.O&,.RI2I[3E+>I2A'U,)/3J?_P 1325<Q7<_$]GW
MQ:Y:X8FO+:=%4?Z.9S4<'5G+6ZHG\)B8\Q*@ZOFN+*T>#5XT>/UE&E):H(
M
M                                                  #0^]#R^(_U
M.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M
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MRLNY75=KFY7YJ9Q=3JZ^
M
M             &A]Z'E\1_J<^577^"+C9$WWP#YR=%^ X_&LPN31OL%?H_&A
M;G:&*P                 I3>F6_P!FO03[>>H#\0<4I&>]Z_EC:CW-D?J\
MRH>M^9M^#/C*&:3Y;X
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ME6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
M                 *(OI=/7E5RFT<0^'GH><J0QVL4+'G+GVC9S3227&PY6
MVN;+B33;ZK)4ISS?@C!5[W.75K/+/0J1R6+K0CY6AV22<<PO=A38R6?WL:I:
MCLUZ:LGD9GH6Z9B<U=IC^O7%%FFJ)BJ.QWJ>*KAH&L9C&:<M3Q1PSXT>/UE)
M1(^H0
M                                                          #0
M^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M        4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGR
MWP
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ME1_R.G92W9B<,)KJICZY<JC&<*KMR:KE7#YJJ<%E7KE5Z[5=JXZIQ>?%UN(
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MA>&I_EY=#7S2^ _< ?+1OB^-FTO^*9W[^=JY7UNWZ6/(/HPO#4_R\NAKYI?
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MH?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL
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M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MJY<KJZ=5=<S55/5F9E58B*8Y-,1$0Y ZC]
M                                            9&/CA_6T==O[<\M^
M)L*GGYMGS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\
M4Y\JNO\ !%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M  4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
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M%VC&.53C,3$TUT556ZJ*ZK6O6;F7N3;N1A5'T>K'4>7%ZN$
M     !KY^#/N,^]>%7T#YN>M+6FL>F?C;3H3RUJ%Q"63CO$2\?TZ/?MY*=.6
M:WIZQ"G&2,._3C+W)XS3RS1C 9SA=/C3-]^U.6B,.5K.8N\4Q]GJ[/CP]/LF
M./%/'&$3"\LE5RLI;G^K$=;@29,-NT              K%>EH_5;:]\JSB7\
MS>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/\
M]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQT(=K*&^P
M                    &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/\
MMRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?
MC687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,]
M[U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_>
M)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
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M5%VU<HG&FNW<IBJBNF>C353,3$]*5HU1-,S35P51+C;N/D
M   !JZ^CI9FKG?!FZ*KVM1IT)Z&&YGPT)*<TTTLU+7>H_F'7Z%:,9O5\I<T<
M9+4GA]R$TT80]3L0;<[;+TY;G#;1VZ9F8FYE*_#N:?E+DQX4U81U(7=ILXY*
MCP_JI38-<7>              5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+E
ME*UCVI'HX\26:>F)6P                 D>\'_ .M)Z OE6<-?GEC6(=_W
MS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MG&9GAF9GCF9Z,RN%_5\@
M                                #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9
MCX,I^KK6?G_;EST2*AG!TP                &A]Z'E\1_J<^577^"+C9$W
MWP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_V:]!/M
MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO@                )R
MO1M?KINC'^\3_A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y=H
M                                          #/$]+-Z#L?PYU(<<=;
M?'^"DQVG]35I<:CRK+C[2%''V7.&D8ZA-99RX\C3I6MM=\CZ'3IU/)RPC4N+
MW W]W5FFJ5YXI8^8KO/N[0;(9S=OJMV:]0T:J+N6Y4XU3D[U4XT1CC,QE[^,
M8\5-%^U13$13"W-7R_(NQ?ICRM?'X,>3'B2J*M]%&                  :
MKGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
M     %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
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MKU55=ZNJ:JJJIF:JJIG&9F9X9F9X9F>&9X973Q<$<3];C
M                                                           &
M1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M     -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M              !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9
M\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_8/TG
MDG?TSV]1X?U,M5M!\NT
M          !"]Z01TW6/4KX475'C?P?+>;)PUK5#J-TVYC#O5,5DN&YZNQ;3
M>4)/^W5N^,)L_8]GW>[>1C#MC"$&Q'-5VPN;';\M$O<ODY/4;TY"['GJ<WA;
MMQ/4C,]@K_T'1U&UV7*5QT:8Y4>%_1BR>TYZT0                 &JYZ-
MK]2ST8_WB?\ %?SJ@^YX'\16T7]@_1F27;IGM&CP_JI3DM:7?
M   5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F)6P
M             D>\'_ZTGH"^59PU^>6-8AW_ 'S)[4_ >;]BJ=K)^V[?HX\5
ML#H!EY                                  ,]7TP7GR;;>K;IIZ<["_
MEN,7PQPEEN1,O;T*L>Y:;AS/M=:PKV%]2AW>]>6FJ<88JZIQC":$E')?>QA&
M>I!*[S MEHR&P>L[77:<+^HZE38IF8X[64M15%5,]*;N9NTSTYM\/%"W-9N8
MWJ;70IIQ\.?_ /%01OTHP                  #T_T9=)_)G6_U,\2=,'$M
MM+-MW*>S4L5/EJ]&-?&ZGK5C0KY;;]VS4D*UO&;$:AK%C=9"M3EJ2U;B%"%&
MEWJU2G+-9>\/;G1MVVQN?VTUV?\ D,C9FKDQ.%5VY5,4VK-'!/E[MRJFB)PF
M*>5RJL*8F8YK%FJ_=IM4>:F?_P#9\)L =*/3%Q5T;=/?%O37PMAI<-Q_Q9K-
MM@L=-4EI?A//9.>>I?;'M^P5Z,E*G>;-N&P75SDLA6EEDDGN[F?N2R4X222P
M$;<[9ZYO"VKSNV&T5SLFJYZ]-=7'R:*>*W:MQ/%;M413;MQPS%-,8S,XS-Y6
M;5%BW%JCS,1_XGPWH9:;D
M                                    9&/CA_6T==O[<\M^)L*GGYMG
MS$[,?!E/U=:S\_[<N>B14,X.F                 T/O0\OB/\ 4Y\JNO\
M!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?
M[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M    $Y7HVOUTW1C_ 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M                                                  <&Y/T?'\G<
M:<A\;9:G0JXKD+1MMT?)TKJG"M;5,?MF R&!O:=Q2FEGEJT)[:_FA/+&6,)I
M>V'9%4]%U*[HNLY36+$S%_*9FU>IF.">5:KIKC">A.-/ ^:Z8KHFF>*8F&(W
M=6MS8W-Q97MO7L[RSKUK6[M+JC4M[FUN;>I-2KV]Q0JRR5:%>A5DC+/)-"$T
MLT(PC"$8/2#171<HBY;F*K=41,3$XQ,3PQ,3'!,3'%*QGYWV_
M      &JYZ-K]2ST8_WB?\5_.J#[G@?Q%;1?V#]&9)=NF>T:/#^JE.2UI=\
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MG'@PNW;U%48T1*Y-(RW(MSF*O-5<7@?TSXD+<C0U6
M                                                         &1C
MXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M   -#[T/+XC_ %.?*KK_  1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M               %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!
MGQE#-)\M\                !.5Z-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2
M>2=_3/;U'A_4RU6T'R[0
M            &(GR?_:5R'[>=M_'^0>D31?R/E/<UKZBE8M7FI\%P94WR
M              U7/1M?J6>C'^\3_BOYU0?<\#^(K:+^P?HS)+MTSVC1X?U4
MIR6M+O@             *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[
M4CT<>)+-/3$K8                 2/>#_]:3T!?*LX:_/+&L0[_OF3VI^
M\W[%4[63]MV_1QXK8'0#+R                                 <0Y!W
M3#\;Z%N_(FPU/(X#0M0V7=,Y5[TLGDL/JV&O<YDZG?F^]D[EE8SQ[8^I#L=_
M2M.S&L:IEM)RD8YK-9BW9HCIUW*XHI^C5#YJJBFF:IXHC%B7[IMN:W[<=LWO
M9+B6[V+==ESNVY^ZEA/++<YK8\I=9C*W$LM2>K4A+6OKRI-"$TTT?5]6,?NO
M1WIV0RVEZ?8TS)QR<IEK-%JB.E1;IBBF.AQ4Q"QZIFJJ:IXYEQEW7R
M            ]8]"W2OLG6UU=\ ]+6KU+RTNN8.0L3@,UF,?;0N[K6=(LI:^
M=Y"VZE;3RS4J\VI:+B<CDNY/V23QM>[-&$(]JQ=YFV^3W<;!:KMMG8IJHT_*
M55T453A%R].%%BU,\<=EO56[>,<,<K&'-8M3?O4VH^FGZ'1GPH;(^@Z+J?%^
MC:;QKH6$LM:T?C[5L!I6G:[CI(T[#!:QJ^*M<)@<19R1C--+;8[%V5*E)VQC
M'NR0[8QCZKSXZIJ>?UK4\QK&J7*KVI9N_7>NW*O-5W+E4UUUSU:JIF9\%>M-
M,44Q33P4Q&$.6N@_0
M                                &1CXX?UM'7;^W/+?B;"IY^;9\Q.S
M'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_U.?*KK_!%QLB
M;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@G
MV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $
MY7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                            !B)\G_VE<A^WG;?Q
M_D'I$T7\CY3W-:^HI6+5YJ?!<&5-\@                -5ST;7ZEGHQ_O$
M_P"*_G5!]SP/XBMHO[!^C,DNW3/:-'A_52G):TN^              K%>EH_
M5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M   !(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M+@
M                   9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W
M+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-
M9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO
M7\L;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/]XG
M_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M                               &(GR?_:5R'[>=M_'^0>D31?R/E/<U
MKZBE8M7FI\%P94WR                 U7/1M?J6>C'^\3_ (K^=4'W/ _B
M*VB_L'Z,R2[=,]HT>']5*<EK2[X             "L5Z6C]5MKWRK.)?S-Y5
M;G<Q/Y[+OP'FO9<LI6L>U(]''B2S3TQ*V                 $CW@__ %I/
M0%\JSAK\\L:Q#O\ OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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M,.">7CU5WZ=:[%E*(Z,QC/A_T8)E&O;N@
M                                                 ,C'QP_K:.NW
M]N>6_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>
M7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M    "E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M               G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^I
MEJMH/EV@
M,1/D_P#M*Y#]O.V_C_(/2)HOY'RGN:U]12L6KS4^"X,J;Y
M   :KGHVOU+/1C_>)_Q7\ZH/N>!_$5M%_8/T9DEVZ9[1H\/ZJ4Y+6EWP
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MF[]RJY75/'5775-554]69F97Q$13&$<4/MNL_0
M                                                      &1CXX?
MUM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M         !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2
M?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;
MU'A_4RU6T'R[0
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M/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MQ1PQWM-HY><HCH1,SUH\EJ](-%W
M                                             ,C'QP_K:.NW]N>6
M_$V%3S\VSYB=F/@RGZNM9^?]N7/1(J&<'3                 :'WH>7Q'^
MISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M"E-Z9;_9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M           G*]&U^NFZ,?[Q/^%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH
M/EV@
M                               *Q7I:/U6VO?*LXE_,WE5N=S$_GLN_
M >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D] 7RK.&OSR
MQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MCF:JNE1XLPT9T1RY0
M                                  &1CXX?UM'7;^W/+?B;"IY^;9\Q
M.S'P93]76L_/^W+GHD5#.#I@                -#[T/+XC_4Y\JNO\$7&R
M)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@                !2F],M_LUZ"
M?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
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M57J%VJ.'Z6,G11/2X>5<ZL8=")X:]HE/#<J]#'BKT:,Y7@
M
M   &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76L_/^W+GHD5#.#I@
M         -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,
M5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS
M-OP9\90S2?+?                 3E>C:_73=&/]XG_  H<ZM:>>!_#KM%_
M8/TGDG?TSV]1X?U,M5M!\NT
M                                                  !6*]+1^JVU
M[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M"1[P?_K2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MG^M'B+DR/=6@
M                             &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P9
M3]76L_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^
M^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O
M/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5
MZ-K]=-T8_P!XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4RU6T'R[0
M
M                   %8KTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J
M1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G#7YY8UB'?]\R>U/P
M'F_8JG:R?MNWZ./%; Z 9>0                                #+<])
MV^N(Y_\ :-P+\#6FIKN9C_#_ *5[ISOXW=6IJGMVKP(\2%?UM2IP
M         #0^]#R^(_U.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#
M%8
M                    9&/CA_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_[<
MN>B14,X.F                 T/O0\OB/\ 4Y\JNO\ !%QLB;[X!\Y.B_ <
M?C687)HWV"OT?C0MSM#%8                 4IO3+?[->@GV\]0'X@XI2,
M][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP                $Y7HVOUTW1C_
M 'B?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M          5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U[+EE*UCVI'HX\26:>F
M)6P                 D>\'_P"M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^
MV[?HX\5L#H!EY                                 ,MSTG;ZXCG_P!H
MW OP-::FNYF/\/\ I7NG._C=U:FJ>W:O CQ(5_6U*G
M-#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M
M          !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8
M*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>Y
MLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM
M:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M!6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M          "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.
M@&7D                                 RZ_2@L;>V/C <UW5U1\E0S/
M''!.2QL_E*4_KFRI<6Z]AZE;NTZD\]'NY'%7%/NU(23Q\GWH0[LTLT9JN9;>
MMW=P.FT43C5;SF=IJX^"9S-RO#J^5JIG@QCAPXXF%J:K&&=J\"/$5[FUJG
M                - 7T.+.>N.FKK)UKU_Y3\$\Y:'G/P9V__P '_2'0:]AZ
M_P"[W?4_"7]&/)]O;'M]:_<AV>K%=WP7+<C;'9[.<G#LFF7Z.5T^QWXJY/\
MH]DQ_P!)<6BS]:KC^M'B+D"/E6@
M                                            &1CXX?UM'7;^W/+?
MB;"IY^;9\Q.S'P93]76L_/\ MRYZ)%0S@Z8                #0^]#R^(_
MU.?*KK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8
M 4IO3+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M           $Y7HVOUTW1C_>)_PH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M
M!\NT
M                               !6*]+1^JVU[Y5G$OYF\JMSN8G\]EW
MX#S7LN64K6/:D>CCQ)9IZ8E;                 "1[P?\ ZTGH"^59PU^>
M6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M        S+_2M\-5Q?BMWM]4K4ZLFQ].G#F9H222S0FMJ5"OM^O1HU8S>I/4
MFK8&>I",/4[M2$/NPBF3YCF8IO;C:;<1,39U?-T3U9F+5S&/"KB/!A:^KQAF
M_!IA6J;B*6                  O&^AF[;W:_B"Z+7JS1C4H]-.VXNA"E1A
M++Y&?G'#YVK4K]Z%Q--/ZXQT)).R:2$)9H]LL8_?1J]\,R&-.RFITQQ3J%JJ
M<9Z/:==$8<70N8SQ\7'T*]HD_9*?0^.O,(TE>
M                                                       9&/CA
M_6T==O[<\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@
M  -#[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M           !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90
MS2?+?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3
M/;U'A_4RU6T'R[0
M                                          %8KTM'ZK;7OE6<2_F;
MRJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K
M2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M3/#P81RL:QHU6&8JIZ='B3#1;1)+D
M                                               9&/CA_6T==O[<
M\M^)L*GGYMGS$[,?!E/U=:S\_P"W+GHD5#.#I@                -#[T/+
MXC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M   !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M              3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_4R
MU6T'R[0
M                                  %8KTM'ZK;7OE6<2_F;RJW.YB?S
MV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_P#K2>@+Y5G#
M7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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MD9RCI3C'7CR6K0@Z7:
M                                    R,?'#^MHZ[?VYY;\385//S;/
MF)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5U_@BX
MV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO
M03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X
M "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M
M                      K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K
M'M2/1QXDLT],2M@                !(]X/_P!:3T!?*LX:_/+&L0[_ +YD
M]J?@/-^Q5.UD_;=OT<>*V!T R\@                                %
M,WTR+1I,AP#T4<E1HTYI]2Y@Y1T:6O&%#RM.3D/2]?S\]&2,T?7,*=>/&$L9
MH20[D8TY>_ZL).V0SO?.IS:VIVCT?&<+^GY:]AP_["]71CTN#MGH\/#.'143
M6J?K=NKI3,=>/Z% Q*6MX                 !W1TX\NY#I_P"H3@OG;%23
MU<CPQS!QKRI9T*<T99KFOH&Y8;:I+2/9&'>DN_P5Y.:6/J32SQA'U(Q6[M?H
M%K:K934]F+^$6=1T_,9:9Z47[5=K'PN5C'@.2U7-NY3<CCIJB>M+:KPV8QFP
MXC%9_"7M#)8;.8VQS&(R-K-W[;(8S)VM*]L+VWG[(=^A=6M>2I)'L]66:#SH
M9C+WLIF*\KF:9HS%JNJBJF>.FJF9BJ)ZL3$Q*]XF)C&.)])POT
M
M      !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M            #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^
M-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7
MF5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_PH<ZM:>>!
M_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M                                                        !6*]
M+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
M      "1[P?_ *TGH"^59PU^>6-8AW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
M                                 K5>E;\>S;IX4EYLD)._#B/J+X<Y
M"FF[9X>2ER5#;^*._P#>75O+'MFY.A+]])7E^^_U(1[*E/</F-ZM&G;\:<GC
M[?TC-V/2S:S/2G\&Z<>#T)I>KT\K*8]*J)\6/'9EZ91:X
M   #6Q\"?J1I=3_A7=).Y7%[Z[V30^/Z/!>Y25*TMQ>T,]PE<5>/+.ODJLL9
MHS7V?U7"8W+31FC&I-)D)9I_OHQ01<YO9"K8O?=KVGTT\G)YK-SG;7!A$T9R
M.SS%,>=HNUW+7!P8VYB.!>&0N]ERE%71B,)\+@\3A2Z,"NX
M
M    R,?'#^MHZ[?VYY;\385//S;/F)V8^#*?JZUGY_VY<]$BH9P=,
M         !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVA
MBL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^
M9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M// _AUVB_L
M'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                  K%>EH_5;:]
M\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !
M(]X/_P!:3T!?*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
M                           $5OC>\71Y@\)OKLU&6WFNIL9P7F.3)*,D
MTLDT:G"F6PW,U.I+WJ=7OS4)]"A/"2$.]/W>[+&6:,)H9OYMNM]P-^NS&?QY
M,5ZG1E\?=E->4ZG'V?#'H<<X\3J9^CEY.Y']7'K</C,BQ/0LX
M       !=R]#UZLY,?L74_T2;#E>Y2V&TQ/49QACZUQ&G1_"V(EQ^A<L6]M2
MJ=M.O?9+$U=8N))*<99X4,;<3QA/++&-.-[G_P"PDW<IHN\C*48U6JJLAF:H
MCAY-?*OY69GH4TU1F*9F>#&Y3'!,\-=T:]A-=B>CY:/$GQE[-&2KX
M
M         #(Q\</ZVCKM_;GEOQ-A4\_-L^8G9CX,I^KK6?G_ &Y<]$BH9P=,
M                !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z
M/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:CW-D?
MJ\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6M//
M_AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:
M                                                         K%>
MEH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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MT[.7M/S]NJUGK%VJW<HJC"JBNBJ::Z*HZ%5-43$QT)A>D3%4153PQ+[KK/T
M
M              !D8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0
MS@Z8                #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<
MFC?8*_1^-"W.T,5@                !2F],M_LUZ"?;SU ?B#BE(SWO7\L
M;4>YLC]7F5#UOS-OP9\90S2?+?                 3E>C:_73=&/\ >)_P
MH<ZM:>>!_#KM%_8/TGDG?TSV]1X?U,M5M!\NT
M
M    !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S7LN64K6/:D>CCQ)9IZ8E;
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M.9[)9[!5YNCB\#^CBZRUBT=5<
M                                        !D8^.'];1UV_MSRWXFPJ
M>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8                #0^]#R^(_U.?*K
MK_!%QLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3
M+?[->@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M      $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M
M                            5BO2T?JMM>^59Q+^9O*K<[F)_/9=^ \U
M[+EE*UCVI'HX\26:>F)6P                 D>\'_ZTGH"^59PU^>6-8AW
M_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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MRB[;BY1.-,P[F6\^P
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M77,4Q%,355.$1$<40CT_BOZI?.4Y^]^/D3W1KP[@:#^!93[C;]2VI^1#<O\
M%#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/X
MK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY
M$]T9W T'\"RGW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RG
MW&WZD^1#<O\ %#9?_"LC]X/XK^J7SE.?O?CY$]T9W T'\"RGW&WZD^1#<O\
M%#9?_"LC]X6B?1X.4N3>3M.ZI:_)/(V]\A5\/LW%5+$UMXV[8-LJXNE>8O>I
M[RECJF>R%_/94[J>WIQJ2THRPGC3EC-V]V'9@K?#D,CD<SD(R5FU9BJB[CR*
M*:,<)HPQY,1CAT,4,O?6-B]CMCM?V+M[(Z3IFE6\QD]2F[&3RMC+1<FBYDXI
MFY%FBB*YIBJJ*9JQPY4X88RL>L,HE
M                                           %8KTM'ZK;7OE6<2_F
M;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\
MK2>@+Y5G#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
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M&,)I9H1[81A]U$!,3$X3QKF?Z?@
M                                         R,?'#^MHZ[?VYY;\385
M//S;/F)V8^#*?JZUGY_VY<]$BH9P=,                !H?>AY?$?ZG/E5
MU_@BXV1-]\ ^<G1?@./QK,+DT;[!7Z/QH6YVABL                 *4WI
MEO\ 9KT$^WGJ _$'%*1GO>OY8VH]S9'ZO,J'K?F;?@SXRAFD^6^
M        G*]&U^NFZ,?[Q/\ A0YU:T\\#^'7:+^P?I/)._IGMZCP_J9:K:#Y
M=H    #/B\7[ZR#JC]M6J?!KI3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L
M+T;=@    +9GHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN1
M6>&#D-X
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MCA5T
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M\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M                                                         %8K
MTM'ZK;7OE6<2_F;RJW.YB?SV7?@/->RY92M8]J1Z./$EFGIB5L
M       )'O!_^M)Z OE6<-?GEC6(=_WS)[4_ >;]BJ=K)^V[?HX\5L#H!EY
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MJ9B:9<B=1^@
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MV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
M  K%>EH_5;:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
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M?@
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MZ_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                                                  *Q7I:/U6VO
M?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M_1PXS3%=,3-%6'T]NK&BN."::Z:HF(F,%E7;=5JY5;J\U3.#I1<;C
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M;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\
M        !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+
MM     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A
M>C;L    !;,]&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<
MBL\,'(;P
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MQ;ICBPM7JJ;D=&>V*^A0M[6,OR:XS%/%5P3X,<77CQ%,A(<H@
M
M                                          #0^]#R^(_U.?*KK_!%
MQLB;[X!\Y.B_ <?C687)HWV"OT?C0MSM#%8                 4IO3+?[-
M>@GV\]0'X@XI2,][U_+&U'N;(_5YE0];\S;\&?&4,TGRWP
M  $Y7HVOUTW1C_>)_P *'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M
M 9\7B_?60=4?MJU3X-=*;>[N_P!2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[
M     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_P"UWO%MH.N^]_K%L+[BU3V7(K/#
M!R&\
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M%43A+KY57R
M
M   T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HOP''XUF%R:-]@K]'XT+<[0Q6
M            %*;TRW^S7H)]O/4!^(.*4C/>]?RQM1[FR/U>94/6_,V_!GQE
M#-)\M\                !.5Z-K]=-T8_WB?\*'.K6GG@?PZ[1?V#])Y)W]
M,]O4>']3+5;0?+M     9\7B_?60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_
M  D;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_?7[:T_[7>\6V@Z
M[[W^L6PON+5/9<BL\,'(;P
M                                   %8KTM'ZK;7OE6<2_F;RJW.YB?
MSV7?@/->RY92M8]J1Z./$EFGIB5L                 )'O!_\ K2>@+Y5G
M#7YY8UB'?]\R>U/P'F_8JG:R?MNWZ./%; Z 9>0
M               "AOZ63X;,^N[7JGB3<5X'LP>XSX+B_J8ML=;PA)CMNM+6
M3&<8\G7=.A0FFEH;)B+277LC<U)Y*-*ZL<5)+":M>U)HR>\Q;?!&;R-_<_K=
MW_F<O%>9TZ:I\U:F>5F<O&,\=NJ>SVZ8B9FFN_,X4VXA;^KY7"8S5'%/!5X/
M0GQNLI1)&E#
M
M    :'WH>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M             "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,
M^,H9I/EO@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3
MR3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-
M<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBV
MT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                      K%>EH_5;:]\JSB7\S>56YW
M,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@                !(]X/_P!:3T!?
M*LX:_/+&L0[_ +YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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M75HJ\S,Q'+MS1<B,*X6;F+%67O3:KZ'T8Z$O&;(;@
M
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M)ZMO;5Q#^*.0&O\ OK]M:?\ :[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M
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MF.&)B>*8GHQ*U7\7T_
M
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MVN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M                                           *Q7I:/U6VO?*LXE_,
MWE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\
M6D] 7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
M                          !GY^DX^#K5X=W/->(OTXZSV<3\BYVE-U*Z
M;AK6;R7'7).=NI*-OREC[:WIQDHZ;R-DJT*>5A&$L+#8*LM2$T]/)0DM)4^9
MGS@:=H-.M[I-KKW_ /=REJ>Y]VN>',9>B,9RU4SQW<O3&-KS]B)C")LXW+=U
M3)<BKMFU'E)GRT=*>GX$^+X*G,D$44
M
M                    !H?>AY?$?ZG/E5U_@BXV1-]\ ^<G1?@./QK,+DT;
M[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\0<4I&>]Z_EC:C
MW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7ZZ;HQ_O$_X4.=6
MM// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W
M=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY
M:_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
M                                                    K%>EH_5;
M:]\JSB7\S>56YW,3^>R[\!YKV7+*5K'M2/1QXDLT],2M@
M !(]X/\ ]:3T!?*LX:_/+&L0[_OF3VI^ \W[%4[63]MV_1QXK8'0#+R
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MH,&S#H
M                                                        -#[T
M/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M     !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+?
M                3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'A_
M4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N
M+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L
M+[BU3V7(K/#!R&\
M                            !6*]+1^JVU[Y5G$OYF\JMSN8G\]EWX#S
M7LN64K6/:D>CCQ)9IZ8E;                 "1[P?_ *TGH"^59PU^>6-8
MAW_?,GM3\!YOV*IVLG[;M^CCQ6P.@&7D
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M:[%SAFU<PC'"JBK"NBNF+2S>4KRESDU<-$\4]/\ IZ:+AFMU
M
M                                     &A]Z'E\1_J<^577^"+C9$WW
MP#YR=%^ X_&LPN31OL%?H_&A;G:&*P                 I3>F6_P!FO03[
M>>H#\0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<
MKT;7ZZ;HQ_O$_P"%#G5K3SP/X==HO[!^D\D[^F>WJ/#^IEJMH/EV@    ,^+
MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
M
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M9NV*Y\Q=BF(Q\I7%-<32M/-Y2YE*^35PT3Q3T_Z>HBM9O=0
M
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MHU']2>K;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
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M?@/-^Q5.UD_;=OT<>*V!T R\@
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MFJNS,S=M1$S]<MTS<6QG<A<RL\NGRUGI]+P?)XD"#:)3@
M
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MK;VU<0_BCD!K_OK]M:?]KO>+;0==][_6+87W%JGLN16>&#D-X
M                                  "GYZ0)\<GC3Y,NF_"GS.V"W4?J
M[>]VU^Q64XW>S_F(U;]K<U^C]+08,GI$     $Y_H_?QR>2_DR[E\*?##&&]
M?]7;/NVCV*\CO[YA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/
MU6VO?*LXE_,WE5N=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8
M    2/>#_P#6D] 7RK.&OSRQK$._[YD]J?@/-^Q5.UD_;=OT<>*V!T R\@
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MJIJB8F*HF8F)QB5#F)B<)X)A\ESOP
M
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MG_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
M                  *?GI GQR>-/DRZ;\*?,[8+=1^KM[W;7[%93C=[/^8C
M5OVMS7Z/TM!@R>D0     3G^C]_')Y+^3+N7PI\,,8;U_P!7;/NVCV*\CO[Y
MA\Q&D_M;E?T?JBX&U]0<@                  *Q7I:/U6VO?*LXE_,WE5N
M=S$_GLN_ >:]ERRE:Q[4CT<>)+-/3$K8                 2/>#_\ 6D]
M7RK.&OSRQK$._P"^9/:GX#S?L53M9/VW;]''BM@= ,O(
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MT=..+^CPT73-;J
M                                                          -#
M[T/+XC_4Y\JNO\$7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M       !2F],M_LUZ"?;SU ?B#BE(SWO7\L;4>YLC]7F5#UOS-OP9\90S2?+
M?                 3E>C:_73=&/]XG_"ASJUIYX'\.NT7]@_2>2=_3/;U'
MA_4RU6T'R[0    &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_PD;%^
MXLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^VM/^UWO%MH.N^]_K
M%L+[BU3V7(K/#!R&\
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M,\C,VOMMBO"Y3&/!%?)FW5/F*ZHX5"OY:]EYPNTS'5Z$^&\3LCN
M
M                                 !H?>AY?$?ZG/E5U_@BXV1-]\ ^<
MG1?@./QK,+DT;[!7Z/QH6YVABL                 *4WIEO]FO03[>>H#\
M0<4I&>]Z_EC:CW-D?J\RH>M^9M^#/C*&:3Y;X                "<KT;7Z
MZ;HQ_O$_X4.=6M// _AUVB_L'Z3R3OZ9[>H\/ZF6JV@^7:     SXO%^^L@Z
MH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_
M4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_P!8MA?<6J>RY%9X8.0W@
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M1.,3''$CPOS7X87AX]1'KZMS!T9=.^UY7)=OKW:*'&6N:ON]QV]G^MO>H6>
MW*'9V>IV7T.S_1]V+)FSF^C>QLER:= VBU:Q8HXK<YBY<LQ_]F[-=G_4=>O*
MY:YYNBF9\#AZ\<*%OJ"]$O\ #EY+EO[_ (1VSG'IJS5:::..Q^&VRERGH-C"
M:$_WMQ@N2:&3WB^EDFC+W>S:*,>[",(QFC'O0V*V5Y]F]S1IIM;26--UC+QY
MJJNU.6OU>!7EYILT^]I\)TKFCY:KAMS53/7CZ/#]% IU,>B3=?7%DF2RW3QR
M+P]U1X*T\I&QP]*_J\+\FY&62-2,DT-;WB]O^/;;OTI9?O8[?--"I'NPA-"'
M>CM!L;S[]UNMS18VLRFH:)FJO-5S3&;R]/\ ]RS%-^>'_P#Y8C#AZBGW='S%
M'#;FFN.M/T>#Z*O-U"='G51TGYG\!=2/3YRWPO=U+F:TL;O?M'SN$P&;JR0G
M[TVM;37M(ZSM%MVTYH>6QUW=48S230A-VRS0AMALIO V(VYR_;.Q^JY#4;<1
MC5%B]1771'^\MQ/9+<\7!<IIGAC@X84VY9NV9PNTS3X,/1O@_P#UI/0%\JSA
MK\\L:M'?]\R>U/P'F_8JG+D_;=OT<>*V!T R\@
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M8X8F."8='BX)?F?;\
M                                                        :'WH
M>7Q'^ISY5=?X(N-D3?? /G)T7X#C\:S"Y-&^P5^C\:%N=H8K
M     "E-Z9;_ &:]!/MYZ@/Q!Q2D9[WK^6-J/<V1^KS*AZWYFWX,^,H9I/EO
M@                )RO1M?KINC'^\3_ (4.=6M// _AUVB_L'Z3R3OZ9[>H
M\/ZF6JV@^7:     SXO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8O
MW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UB
MV%]Q:I[+D5GA@Y#>
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M<]PX5YB]7=F,>A3RZIBBGI4TQ%,1$1$1$/JBW;M1R;=,4QU(P=S+>?8
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MJ(Y-=,Q/!Q<'4XNM@F8:\NZ
M              \/=4WAK]"?6G;W?\2G3%Q;R+G+RA"WFWO\"1U;DZA2D_[J
ME:<H:;7U_?[>A2G[)H49<CY",8??230[81R5L3OAWF[NJZ?\GZUG<IEJ9Q[#
MR^RY:9Z,SEKL7+$S/3['CTIAP7<KE[_V6B)GI]'KQPJWW4[Z'UT_;5-DLWTE
M=3'(7$60J2UKFUT?F#!8WE34)[F,?Y+&X_9\'4TG;==Q<LO9_*W=+8;F$81[
M>]",.[M[L9S_ ':K(Q1EMN]&RF?M1A$WLK75EKN'1JJMU]FM7*NI3-BGP.C3
M+NC6YX;-<Q/2GA\CQU?GJ+]&>\5[@.:]O<!P_JW43K%G-7FCL' >\8S8+N-"
M2/;0C#1]OIZ3R)=W-Q3^[3LL3>0DFA&6,\>V2,VU.R//'W&;4Q3;S6H7])SM
M6'UO/6:K<8]'Z]:[-8B(Z==VC&.'#CPIUW2\W;XJ8JCJ3XTX2A4Y3X.YJX,S
M<^M<U\0\G<0;%)/-3FP7)^A;3H>7[\G>[T(8[:<5B[N;L[L?5A)&$80[6QFB
M;2[.[39;MS9S/Y+/Y28\WEK]N_1Z:W55'T71KMUVYPKIFF>K&#JU6WP
M
M                               T/O0\OB/]3GRJZ_P1<;(F^^ ?.3HO
MP''XUF%R:-]@K]'XT+<[0Q6                 %*;TRW^S7H)]O/4!^(.*
M4C/>]?RQM1[FR/U>94/6_,V_!GQE#-)\M\                !.5Z-K]=-T
M8_WB?\*'.K6GG@?PZ[1?V#])Y)W],]O4>']3+5;0?+M     9\7B_?60=4?M
MJU3X-=*;>[N_U+R'VNOV2MZFN8;_  D;%^XLS^D,VC87HV[     6S/1J/ZD
M]6WMJXA_%'(#7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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MT5U3%,353$S,88S$8XS"VFP*A6
M
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M0C&G7MKB2G6HU(0C]R:6$7?M7;=ZW%VS537:JC&)IF)B8ZDQP2_.+C?D<C\
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M7_?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
M
M
M
M                         &1CXX?UM'7;^W/+?B;"IY^;9\Q.S'P93]76
ML_/^W+GHD5#.#I@                -#[T/+XC_ %.?*KK_  1<;(F^^ ?.
M3HOP''XUF%R:-]@K]'XT+<[0Q6
M         &?%XOWUD'5'[:M4^#72FWN[O]2\A]KK]DK>IKF&_P )&Q?N+,_I
M#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U_WU^VM/^UWO%MH.N^]_K%L+[BU
M3V7(K/#!R&\
M
M
M                                                          !D
M8^.'];1UV_MSRWXFPJ>?FV?,3LQ\&4_5UK/S_MRYZ)%0S@Z8
M    #0^]#R^(_P!3GRJZ_P $7&R)OO@'SDZ+\!Q^-9A<FC?8*_1^-"W.T,5@
M                                          !GQ>+]]9!U1^VK5/@U
MTIM[N[_4O(?:Z_9*WJ:YAO\ "1L7[BS/Z0S:-A>C;L    !;,]&H_J3U;>VK
MB'\4<@-?]]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
M
M
M
M                                8_'C 9C\.>*3U^WOX0_"?D.JSF7#
M^N?+>7\G_1[<LE@/P?W^V/=_!/X,]:]S_P#Q^1[GJ=U/SN"R_:VY/9:WR.1C
MH>4KPPP^R6J:^5_I<KE8]'''HK-SDXYNYZ.?%1PLO.J
MT6?0^<--0\/SJ'V&-Q+-)E.L;9\-+:PIQA-1FP/"G"-]/<1J]^,)Y;F&QRRP
ME[L.[Y*,>V/>]2)+G^YB*MZNDY3#AHV?MUX]/EYS.1AAU.Q_1ZBY=&C_ )>J
M?Z_C0MF-%57                                           9\7B_?
M60=4?MJU3X-=*;>[N_U+R'VNOV2MZFN8;_"1L7[BS/Z0S:-A>C;L    !;,]
M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M0
M
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MQ?OK(.J/VU:I\&NE-O=W?ZEY#[77[)6]37,-_A(V+]Q9G](9M&PO1MV
MMF>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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MFJM MX_\_D\,YDN3&'EJ[MCE3EXF9PB,U18JF8X*9C"9]TK5:U@
M
M
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M]2>K;VU<0_BCD!K_ +Z_;6G_ &N]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M^J11FKU-7!PV+,T4Y;+83CR*[5F+\4SR:KU?#,QF+V;A
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MI%CAH/,33/)JX)A_T?@
M
M                           "'+Q^.=;?@/PENL#-0N_(9?D?0[;@K VT
MM2%*MD[CFG-8_0,_:49H^I-ZWTC,Y6[J2_\ :H6T\(>K&#8+FM;,U[4[]M R
MW)QR^3S4YVN>.*8RE%5^B9\&]1:ICI550Z6H7.QY.N>C,8=?@\1DSIU5H
M               -:SP$]%CQWX0G0W@(T9J'X0XOS6]=R;RW;-#E#D;=N2X5
MH>7KW$_=N8;;Y2'9-"3LF^\EDE[))8(^=#J?=;?YM+FL<>1G:+/0_P#QLO9R
M^'!$<78L.GP<,S/#-X:?3R<G;CJ8]>9E+RP([@
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M.#9?<U^K%_W?7[%8>A7O37\.FM?MKG/T9HZ 5EI*      L1^C?_ !IN<_V
M5OA%TEAW?/\ D+*^Z_\ AUHI>^V?,MLW^U$?B&<7(6N" 0
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MW+U,<I(0M!JP
M
M                    H\^F&=6%K+C^EWHDP&2FGO:MYE>I/DNQHUX2RVUK
M;T,OQWQ/0N):?>FJS7M6ZVFO4I5(R0IPH6]3NS]^2:22?F ;"US=UO>1FJ,+
M<4TZ?EZICCF9HOYJ8Z6$1EHB8QQY5<8QA,30M9O>8L1Z*?$CQU&!)@H
M             #:/Z+^-YN'.CWI3XDJ4?6];C'IPX1T&YI1A2[\+O4>--9P-
MY-5C1J5J4]>I=6$\U2>$\_?GC&;O3=O;'SL[Q-8C:#;_ %S7HG&G.ZOG+\3P
M\5W,7*XPQPG#"J,(PC".#"%[V*>19HHZ5,1]!Z66<Y0
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MTW.?[ *WPBZ2P[OG_(65]U_\.M%+WVSYEMF_VHC\0SBY"UP0"
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M\=%RW7%-5%4=&*HB7WG$I@
M
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M<Q<F;E^[PQ$X57:JN1%7#3;Y%'%3"S,S>G,7JKL]&>#J1T/H/%S(K@
M           >B^D#B*?G_JOZ:.#I;?UU)RYSSQ+QU=THTX5:<N.V_>\%@\I7
MN))I9I/6EICKVK5K1FA&66E)-&/J0BM';[7HV6V&UG:69Y,Y#2\UF(GB\M:L
MUUTQ'5FJ(B.K,.6S1V2]3;\]5$=>6TT\ZR]P
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M&*,Q.
M
M        _E7KT+6A6NKJM2MK:VI5*]Q<5ZDE&A0H49(U*U:M6J1EITJ5*G+&
M::::,(2PAVQ]1]4TU5U111$S7,X1$<,S,\41'1F1GB>DA^-GB>J?-9#H1Z5-
MJI97IYTC8J%SS9R;@,A"OA^;]YUZ[M[K%ZIK=S;PEI9'C+0<W;1KSW<)ZMMG
M<S1HW%O#UK8VMS>2Q<T+FXW]B,O1O.VXL31M9F;,QD\O73A7D[-R)BJ[<B>&
MG,7Z)Y,4X159LS517Y>[71;MS4\]%V>U[,_6XGAGISY$?1E4:;YJ,
M           GR]&AX.FYG\6_@S*7%E+?8/@W5N2^<<_2F[>RE+K^JW.GZK>P
MFA_JS6'(F]86M#_\QD[/]+5SGC;2QL[N'U.Q15R<SJ=_+Y.B>GR[L7;L?Z5B
MS>CPU1TNWR\Y3/0IB9\;Q9AJ9H2UU@
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M.6:6>66:6:$TLT(32S2QA&6:6,.V$TL8=L(PC"/J18 0?S$TSR:N"8?]'X
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M:V*W?92+.6C"K,9BO"K,YR_$83?S-W")KKGAY-,13:M4SR+5%%$12\S*VS"
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MEFJW=K]R+6:W@
M
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M<<,38IKB*KMVF>&+]RFF:9B)MV[=4<J;=SFIW,Q$V[6--GZ,^#Y"M W'4L
M                !>D]#CZ>)Z6(ZQNK#)V';3OLCH_3QI64[D(=V?%VT>2>
M3[#RD>V:/?ES&H5.R'9"'=[8]O;#NQG=\%VLBJ_L_L+9KX::+V?O4^BGM?+5
M?ZF:C_QPU_1;?!7>GJ1'BSXR\"C95T
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M73+5,1&;B(FJ[G<I1'!&:B,:\Q8IC#-1C=MQVSRJ<S;<:^(+P
M%+7TC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
M    6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+7! (
M            \0=>'77Q5T(<1U-^WJ>&=W/8(9#'<7<:V5U);YK>]ALZ-&>M
M#RL9*T<5K.%C>4*F4R4].>2UI59))):MS6MZ%6Z-E-E<_M7J/:F5\IEJ,)NW
M)CRMNF?%JJPGDT]&8F9PIB9C8WFT<VK;;G+[=1LQLU':VS^5Y%S4=0KIFJSD
M[%4S$<&,=DS%[DUTY:Q%43<JIJJJJHLV[MVW02ZD>I'EGJMY9V+F3F38JF>V
MK/5(4;6UHPJV^"U?!6]6M/B]5U7%SUJTF(U[$25IH4J4)IZE2I//7KSU;BK6
MK5-M-%T73] T^C3=-HY&7HXY^FJJZ-=<]&J>C/0X(B(IB(CT^;H]T>P^Y'8?
M*; ; 92,MHN6C&JJ<*KV9O51$7,SF;D1$W;]V8CE581333%-NW31:HMVZ>AU
M59,          ?KL;&^R=Y;8_&V=UD+^\JR4+2QL;>M=WEU7J1[)*-M;6\E2
MM7JSQ]2$LLL8Q?E5=-%,UUS$41QS/!$>#+@S.9RV3L5YK.7*+65MTS55775%
M--,1QS555,1$1T9F<'MGC'PTNO/E^G2KZ3TM<K1L[B$)K;([?AK?C3%75.;M
M[*MIEN2;W4L;=4(QEC#OTZLTG;ZG:MC/;;;)Z=,QFL_E^5''%$]DF/!BW%<Q
MUFNVV7.^YLNP==5K:+;31.ST<%5O*W:M0N4STJK60HS-RF>I53$]1[NTCT>[
MKLV:%*KLV6X.XYHQ[(UZ.Q;WF<QD:<O=I31EHT-*U+9L=6JPFJ1AV37=.7MI
MS??=G<[UJ9K>_LK8X+%.:O3_ %:*8C_7KIGZ$M:-H^^G\VK1YJHT>QM)JU?0
MFQD[5JW/#/'.;S67N1'!CP6JI\M'!YKD^F==]&LY)N9:$=LZJ]'PD\T\D+F7
M7>,<]M$M*2-*6-2:A-DMMU"-Q/)6C&666:%*$TL(31C+&/=A1+V^O)4X]KY"
M[5'0Y5VFGQ**_'8?U7OO.R-F:NX>Q.I9BF(GD]GU"SE\9QX,8MY;-<F)C"9F
M)JPG@PF(QGLW&>C18*E+6_#'6+EK^::,GD(XS@JSQ,M.6$)O*0K2W7+>:C7C
M-&,.R,L:?=[(]L(]OJ=&O?9=G#L>FTQX-^9\2U2L[.=]_P!2KFGM#8&Q:CAY
M79-9KNX]+#DZ9:PZ../*QZG1_GDO1H</5GI1P_61DK&E"2,*TF2X%M<K/4G[
M?O9J52UY@PTM*2$OJ1EC+/&,?5[8?<*-]ER(^N:;3,]2_,>+9J?64[[_ )^B
MF8S^P%FY7CP3;UJJW$1U8JTN[C/5B8\!U=L?HUW*=K+6CJ/5+H&<GEGN86\N
MQ\=;%JTM6G)'_P '-6GQFQ;C&A/7A_WLLLM2%&/^K&H[]G?5D*L.V,A>IC@\
MS<IJ\'CIH\+BQZB]-)[[OL7>JI[N[%ZIEJ9BGE=@S]C,S$SYO"+EC*\J*?I9
MF:>5T8H>7MZ]'XZ]]4IUZVN3\+<FRR=LU"VU#D.[Q5]7DC4C+)+-)R#K6DV%
M&X\GV332^N9J<OW(3S1^[7<KO=V3S$Q%[MFQZ.W$Q_Z=5<_0\)F79OOI'-CU
MNNFWJT;0Z/,^:JS61IN41.&,SCD<QFZYIQX(GL<53QS3#PAREX='7+PU+=5M
M^Z7^6K.QLIYI;S,:YKLV_8"UA+&,L:MQL.@5MGP=&WC&'9+5FN(4YHQAV31[
M8=MUY#;+9;4L(RF>R\USQ155V.J?]&YR:O"P;,;%\['FW;P)HM[,;9Z'<S-R
M,:+5^_&2OU=2FQG8R]Z:NG3%'*CHQP2\8UZ%>UKUK:YHU;>YMZM2A<6]>G/1
MKT*]&>-.K1K4JD):E*K2J2QEFEFA",L8=D?57)$Q5$54SC3+8*U=MWK=-ZS5
M379KIBJFJF8F*HF,8F)C@F)CAB8X)A_)^OL         !W/P!S_RITQ\J:US
M%P[LMQK.YZS<=M.I#O5L7FL76FI_A+6]DQOE*=',:[F*-.%.YMJD8=O9+4IS
M4ZU.G4DINKZ1D-<R%>FZE1%>6KCPZ9Z%5,]"J.A/A3C$S$X^WH;K]BM\>Q6<
MV!V^R=&<V?SE'#'!%RS<B)['F,O<PF;5^U,XV[D=6FJ*K=5=%5_+H$Z[^,NN
M[AVTWC5JME@>0\!2M,?RKQE-?>N<KI6?JRU(4Z]#RU.WN,EJN=];SUL;?RR>
M3JR0GHSQEN:%>G)J5M;LIGME-2G*W\:\G7C-J[AA%=/C5T\55/0X)CRLQ,^7
M_G/\VC;'FT;?7-F]:IN9K97-555Z;J'(Y-O-V(PQIG":J;>9L\J*<Q9F>53/
M)N4Q-JY;KJ]UK5:U@                              *MWB=^DJ?1P]8
MF_\ 2=_!=^F3^@N#T+-?T^_B,_1Y^%/Z;Z;AMN];?T5_01O/K+\&?A?UOW_P
ME6\MY/RG=I][N2[K[F.9Y\KN[_*[=?YB[G]LW;]'8.T.S\GL-ZNUCV7MVSCR
MN3RL.QQACAC.&*DYK5.UKTV>1RL,.'E8<<8]*4?WVSS_ .MS_G"_^+3*G\O#
M_P"8?]*_]R=?NW_NO];_ ,I]L\_^MS_G"_\ BT?R\/\ YA_TK_W([M_[K_6_
M\I]L\_\ K<_YPO\ XM'\O#_YA_TK_P!R.[?^Z_UO_*?;//\ ZW/^<+_XM'\O
M#_YA_P!*_P#<CNW_ +K_ %O_ "GVSS_ZW/\ G"_^+1_+P_\ F'_2O_<CNW_N
MO];_ ,I]L\_^MS_G"_\ BT?R\/\ YA_TK_W([M_[K_6_\KZ.*],XQ%:[EDS?
MAU9+'V'<GC-<XKJNM<S=PJPA_)R2V5WTY8*C-)/'_6F]<0C+_HEF<5_O>-^F
MWCEMK:*[N/%5IDT1UXS]<_ZOAP_8UN.C:_UO_*Y1]LMXU\PG>?G 8#]U+I?R
M]=8^-&6]XU_WE^]VZ?6YZ_\ 0?;+>-?,)WGYP& _=2?R]=8^-&6]XU_WD[MT
M^MSU_P"@^V6\:^83O/S@,!^ZD_EZZQ\:,M[QK_O)W;I];GK_ -!]LMXU\PG>
M?G 8#]U)_+UUCXT9;WC7_>3NW3ZW/7_H/MEO&OF$[S\X# ?NI/Y>NL?&C+>\
M:_[R=VZ?6YZ_]!]LMXU\PG>?G 8#]U)_+UUCXT9;WC7_ 'D[MT^MSU_Z#[9;
MQKYA.\_. P'[J3^7KK'QHRWO&O\ O)W;I];GK_T'VRWC7S"=Y^<!@/W4G\O7
M6/C1EO>-?]Y.[=/K<]?^@^V6\:^83O/S@,!^ZD_EZZQ\:,M[QK_O)W;I];GK
M_P!!]LMXU\PG>?G 8#]U)_+UUCXT9;WC7_>3NW3ZW/7_ *#[9;QKYA.\_. P
M'[J3^7KK'QHRWO&O^\G=NGUN>O\ T'VRWC7S"=Y^<!@/W4G\O76/C1EO>-?]
MY.[=/K<]?^@^V6\:^83O/S@,!^ZD_EZZQ\:,M[QK_O)W;I];GK_T'VRWC7S"
M=Y^<!@/W4G\O76/C1EO>-?\ >3NW3ZW/7_H/MEO&OF$[S\X# ?NI/Y>NL?&C
M+>\:_P"\G=NGUN>O_0?;+>-?,)WGYP& _=2?R]=8^-&6]XU_WD[MT^MSU_Z#
M[9;QKYA.\_. P'[J3^7KK'QHRWO&O^\G=NGUN>O_ $'VRWC7S"=Y^<!@/W4G
M\O76/C1EO>-?]Y.[=/K<]?\ H/MEO&OF$[S\X# ?NI/Y>NL?&C+>\:_[R=VZ
M?6YZ_P#0?;+>-?,)WGYP& _=2?R]=8^-&6]XU_WD[MT^MSU_Z#[9;QKYA.\_
M. P'[J3^7KK'QHRWO&O^\G=NGUN>O_0?;+>-?,)WGYP& _=2?R]=8^-&6]XU
M_P!Y.[=/K<]?^A^BS],JXIGNK>3(="'(5M9359(75Q9\ZZW?75&A&:'E*EO9
MUN-<=1N:LLOJRR35Z4)H^I&:'W7Q<[WMKD43-K:?*57,.")R5RF)GJS&8JF(
MZO)GP#NU1T;<X>#_ $.8_;'>FKS-N<OR]T'_ '"G_P OK;'XPZ9]PO\ DOKN
MU:\Y5UX/MCO35YFW.7Y>Z#_N#^7UMC\8=,^X7_).[5KSE77@^V.]-7F;<Y?E
M[H/^X/Y?6V/QATS[A?\ ).[5KSE77@^V.]-7F;<Y?E[H/^X/Y?6V/QATS[A?
M\D[M6O.5=>#[8[TU>9MSE^7N@_[@_E];8_&'3/N%_P D[M6O.5=>#[8[TU>9
MMSE^7N@_[@_E];8_&'3/N%_R3NU:\Y5UX/MCO35YFW.7Y>Z#_N#^7UMC\8=,
M^X7_ "3NU:\Y5UX/MCO35YFW.7Y>Z#_N#^7UMC\8=,^X7_).[5KSE77@^V.]
M-7F;<Y?E[H/^X/Y?6V/QATS[A?\ ).[5KSE77@^V.]-7F;<Y?E[H/^X/Y?6V
M/QATS[A?\D[M6O.5=>#[8[TU>9MSE^7N@_[@_E];8_&'3/N%_P D[M6O.5=>
M#[8[TU>9MSE^7N@_[@_E];8_&'3/N%_R3NU:\Y5UX/MCO35YFW.7Y>Z#_N#^
M7UMC\8=,^X7_ "3NU:\Y5UX/MCO35YFW.7Y>Z#_N#^7UMC\8=,^X7_).[5KS
ME77@^V.]-7F;<Y?E[H/^X/Y?6V/QATS[A?\ ).[5KSE77@^V.]-7F;<Y?E[H
M/^X/Y?6V/QATS[A?\D[M6O.5=>#[8[TU>9MSE^7N@_[@_E];8_&'3/N%_P D
M[M6O.5=>#[8[TU>9MSE^7N@_[@_E];8_&'3/N%_R3NU:\Y5UX/MCO35YFW.7
MY>Z#_N#^7UMC\8=,^X7_ "3NU:\Y5UX/MCO35YFW.7Y>Z#_N#^7UMC\8=,^X
M7_).[5KSE77@^V.]-7F;<Y?E[H/^X/Y?6V/QATS[A?\ ).[5KSE77@^V.]-7
MF;<Y?E[H/^X/Y?6V/QATS[A?\D[M6O.5=>#[8[TU>9MSE^7N@_[@_E];8_&'
M3/N%_P D[M6O.5=>'-Y/3#NB&,LL9^F'JJEGC+",\LE+B.>66;LAWH2SQY&I
MQGEA'[D8RP[?_P 04V>]_P"\G'@UK0\/!S7]W?7=JQYROZ'DO]?;#>A_S8^J
MO_8<1?O)?G\O_>3^>M#Z^:_NYW9L><K^AY)]L-Z'_-CZJ_\ 8<1?O)/Y?^\G
M\]:'U\U_=SNS8\Y7]#R3[8;T/^;'U5_[#B+]Y)_+_P!Y/YZT/KYK^[G=FQYR
MOZ'DGVPWH?\ -CZJ_P#8<1?O)/Y?^\G\]:'U\U_=SNS8\Y7]#R3[8;T/^;'U
M5_[#B+]Y)_+_ -Y/YZT/KYK^[G=FQYROZ'DGVPWH?\V/JK_V'$7[R3^7_O)_
M/6A]?-?W<[LV/.5_0\D^V&]#_FQ]5?\ L.(OWDG\O_>3^>M#Z^:_NYW9L><K
M^AY)]L-Z'_-CZJ_]AQ%^\D_E_P"\G\]:'U\U_=SNS8\Y7]#R3[8;T/\ FQ]5
M?^PXB_>2?R_]Y/YZT/KYK^[G=FQYROZ'DGVPWH?\V/JK_P!AQ%^\D_E_[R?S
MUH?7S7]W.[-CSE?T/)/MAO0_YL?57_L.(OWDG\O_ 'D_GK0^OFO[N=V;'G*_
MH>2?;#>A_P V/JK_ -AQ%^\D_E_[R?SUH?7S7]W.[-CSE?T/)/MAO0_YL?57
M_L.(OWDG\O\ WD_GK0^OFO[N=V;'G*_H>2?;#>A_S8^JO_8<1?O)/Y?^\G\]
M:'U\U_=SNS8\Y7]#R3[8;T/^;'U5_P"PXB_>2?R_]Y/YZT/KYK^[G=FQYROZ
M'DGVPWH?\V/JK_V'$7[R3^7_ +R?SUH?7S7]W.[-CSE?T/)/MAO0_P";'U5_
M[#B+]Y)_+_WD_GK0^OFO[N=V;'G*_H>2?;#>A_S8^JO_ &'$7[R3^7_O)_/6
MA]?-?W<[LV/.5_0\D^V&]#_FQ]5?^PXB_>2?R_\ >3^>M#Z^:_NYW9L><K^A
MY)]L-Z'_ #8^JO\ V'$7[R3^7_O)_/6A]?-?W<[LV/.5_0\D^V&]#_FQ]5?^
MPXB_>2?R_P#>3^>M#Z^:_NYW9L><K^AY)]L-Z'_-CZJ_]AQ%^\D_E_[R?SUH
M?7S7]W.[-CSE?T/)<OL?3 /#BJ6E"?)<#];5I?S4X1NK:QT'@G(VE&KVQ[9*
M%[<=1.+K7-.$.S[Z:WI1_P#[70N\P3>[%R8LZILW5:QX)JOYVF9CJQ&0JB/3
M3X+]C6<MT:;F/@1Y+]7VOWPU/U(=<OO:\!_]3#C_ '!-\7YRV:]\9W_MS][L
MY7SMSK1ZH^U^^&I^I#KE][7@/_J8/W!-\7YRV:]\9W_MQW9ROG;G6CU1]K]\
M-3]2'7+[VO ?_4P?N";XOSELU[XSO_;CNSE?.W.M'JC[7[X:GZD.N7WM> _^
MI@_<$WQ?G+9KWQG?^W'=G*^=N=:/5'VOWPU/U(=<OO:\!_\ 4P?N";XOSELU
M[XSO_;CNSE?.W.M'JC[7[X:GZD.N7WM> _\ J8/W!-\7YRV:]\9W_MQW9ROG
M;G6CU1]K]\-3]2'7+[VO ?\ U,'[@F^+\Y;->^,[_P!N.[.5\[<ZT>J/M?OA
MJ?J0ZY?>UX#_ .I@_<$WQ?G+9KWQG?\ MQW9ROG;G6CU3K_8_3#^BFU]<_T1
MZ7>J3.=VO)+9_P!(X\3:KY>VC_KUKG\&;_N/K6O+_HIR^6EF_P#ZX*MD^]_[
MQJ\.W];T2UP</8^VKN$]*.58M8QU9P\!\3K5CH45_0\F7C7E'TRC<KJA6M>%
M>A;6<%<RRS^M\YRCS9E=LH59II*7DXUM5U/C_2ZE"6C4A/":$N9J>5A&6,(T
MXPC".0M$[WMI]%45[1[37KM'1HRV3IM3''Q7;M^]CCP?[*,.'C<->M5?26XC
MP9Q\:/%0\=1WI)GBP]1%M>8FTYOP?3[KE]W_ "^#Z<=1H:#<R=ZG/2E]9[UF
M[_<.5,;Y.6I-V>ML_2[9NR:/;-+)&78#9#F?[C-DZZ;]S3;NJYNGBKU"[-^/
M#LT4VLM5_I6)Z7%,X]*[J><N<'*Y,?U8P^CPS]%!QM&U;1N^?RFV;ILF>V_:
M<Y<QO,ULNT9C(9_/YB\C))2C=Y3,Y:XN\CD+F-.G++Y2K4GF[LL(=O9"#97)
M9'):;E:,CIUFUE\E:C"BW;HIHHHCI4T4Q%-,=2(B'0F9JG&J<9? =I^
M               -:KP(NE^KTH>%MTMZ3E<?^#]QW_4:G.N]R3RS27<=@YDN
M9MTQMID:,\E.:WR6OZ5?XG%5Z<8=LE2PC+&,8PC&,$G.<VTC;G?9K>I6*^7I
M^5S':5GI<C*1V&J:9Z--=ZF[=IGHQ7BO#3[78<I13/FIC&?#X?$2]L!NX
M                                         SXO%^^L@ZH_;5JGP:Z4
MV]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4GJV]M7$/X
MHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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M4PT"[7-S6<E:IX,M<KJ\MJ-BBG_\>Y5,=MVZ8^L7)G,1]9KN]@LT,(H>0
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MP]GD9.Q'*OWZHI[/G,Q5$1<S.8JIB.5<KPB(CS-NW31:MQ3;HIB/-JM,N
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M:[F8_P /^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       ]T>&CTHWO6WUU]-'393LJ]Y@=^Y+P]QR#-0[\
MDUEQ9J<*NX<GWL*\)8R6]>GHV"OY+:,\999[N>E3[>]/+".,]\>W-O=ONRUG
M;":HIS65R=<6,>CF;N%K+1AT8[-71-6'%3%4\42[&5L]GS%-KH3/#X''/T&Q
MQ0H4+6A1M;6C2MK:VI4Z%O;T*<E&A0H49(4Z-&C1IPEITJ5*G+"6666$(2PA
MV0]1Y]JJJJZIKKF9KF<9F>&9F>.9GHS*]']7R
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MBS.\#4J;=[5<W3'!7>B)Y&6LU3'*[5RO*JHM8X3<KJNYB::)N]CHCH7DVP
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M:TU-=S,?X?\ 2O=.=_&[JU-4]NU>!'B0K^MJ5.
M
M                          7F?1!>BB>G1Y]Z^]NQ522%QW^G;AFM=T(2
MRU*-.?#[;RWLEE+7AWZDD:TN#Q5K=T80D[U/)6_>C&%266-'G\[QHFK2]UN0
MKC@_Y_-Q$]'R]K*VYPZG9KE5,\/#9KPXIFO:-8\UF)]#'BSXWT5XQ&LKP
M                                         #/B\7[ZR#JC]M6J?!KI
M3;W=W^I>0^UU^R5O4US#?X2-B_<69_2&;1L+T;=@    +9GHU']2>K;VU<0_
MBCD!K_OK]M:?]KO>+;0==][_ %BV%]Q:I[+D5GA@Y#>
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MCM+I=B*=7M6Z>',Y*B,*,[A3PU7LE3Y6]5,535E,*JJJ:,I$56_&NR!P
M                        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?Q
MNZM35/;M7@1XD*_K:E3@
M
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M-JGBIC__ &?#EZD62Y0
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MB:H[/DIJG'&O)7*XHIQFJJK+UY>Y75RZZHB3I8[3D
M        !EN>D[?7$<_^T;@7X&M-37<S'^'_ $KW3G?QNZM35/;M7@1XD*_K
M:E3@
M                                                  %S;T37PY:^
M\<F[CXC')F%__P"2XHJ9CC'I[M[^VDFIYODS,XOUKR!O=K"K/+/ZTT74\I#%
M6M2%.I1N+[,W,9)Y*^-FA&/+GU;W*=-T;+[H]&N?\_GHHS.>FF?,9>BK&Q9G
M#HWKM/9:HQB::+5&,33>A6](RW*KG,U>9C@CP>C/A>/U%^]%JN$
M                                    !GQ>+]]9!U1^VK5/@UTIM[N[
M_4O(?:Z_9*WJ:YAO\)&Q?N+,_I#-HV%Z-NP    %LST:C^I/5M[:N(?Q1R U
M_P!]?MK3_M=[Q;:#KOO?ZQ;"^XM4]ER*SPP<AO
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MUQ'/_M&X%^!K34UW,Q_A_P!*]TYW\;NK4U3V[5X$>)"OZVI4X
M
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M&H_J3U;>VKB'\4<@-?\ ?7[:T_[7>\6V@Z[[W^L6PON+5/9<BL\,'(;P
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M_5R8\I:U*WAVY1.'%VQRJ,W3-4XUW+F8BF.3:3H,6(V@
M          &6YZ3M]<1S_P"T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU>!'B0K
M^MJ5.
M                                                  ?ZEEFGFEDD
MEFGGGFA+))+",TTTTT>R6666';&:::,>R$(?=?DS$1C/$-.+T=+PE*W0'T\5
M^>.;=9EQ_5CU&X3'7N>QN3LH4\SP]Q5/4I936N+YO+QFN,?L68JRT<MLM/NT
M)Y+V%M85:<9\9"K4AFYVV_>G>EM9&R^S=[E["Z1<JBBJF?*9O,\--S,\'!5;
MHC&UEYX8FCEW:9PO<F+ITW)]KV^R7(^O5?0CI>3_ $+(+4)4P
M                                   &?%XOWUD'5'[:M4^#72FWN[O]
M2\A]KK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_
M 'U^VM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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M .E=MU>5SNHVY^P3,>:L9"K&F:<>37G(KJFF>U[%Q8A8=13
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MP-::FNYF/\/^E>Z<[^-W5J:I[=J\"/$A7];4J<
M
M                       N/>C0^"]<\N[;K/B)]3^I5:?$VBY>7*=,^AY^
MQEEH\F[WAKN:6CRQE+.ZEC-6T?0LI;QCAY8R0ER>;HPK][UM8QDO(^N>-SB*
M- R%[=+L7?B==S5ODZC>HJX<O9KCARM,QQ7K],_79Q^MV9Y.'+NXVZUI>1Y<
MQF;L>4CS,=.>GX$=#JM =%:N(
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M%%-.;JKG,VJ>#DTQ:SE.8IHMT\%%F;7!3$Q"458K3$
M       !EN>D[?7$<_\ M&X%^!K34UW,Q_A_TKW3G?QNZM35/;M7@1XD*_K:
ME3@
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MJIF9F9F9G%=$1%,81P1#[+KOT
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M975-A=K]4V*UNGDZOI.H9C)WHC'#LF6NUV:YIQ^EFJB9IGHTS$QP2YVZBV@
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MBU5-54<,Q1FZ,I%$3P4]FN3$Q-4Q5<T:V//P
M  RW/2=OKB.?_:-P+\#6FIKN9C_#_I7NG._C=U:FJ>W:O CQ(5_6U*G
M
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M>C4?U)ZMO;5Q#^*.0&O^^OVUI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M<AJEV;NU.S-<:7F9JG&NNU:HIJR5Z>&9F*\K-%J:ZIY5=ZQ>JGIS$@R"WH
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MZZYFJJNNJJ9JJJJJF9JJF9F9G&5Q1$4QA'!$/MNL_0
M                               &?%XOWUD'5'[:M4^#72FWN[O]2\A]
MKK]DK>IKF&_PD;%^XLS^D,VC87HV[     6S/1J/ZD]6WMJXA_%'(#7_ 'U^
MVM/^UWO%MH.N^]_K%L+[BU3V7(K/#!R&\
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MD[G*T39/(TV,(G&F<[FZ;>9S5<<.&,6^U;%7!$Q78JB9GH3HL6(V0
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M5MW+]=J(C@B;<TQP0D%6@U:                         9;GI.WUQ'/\
M[1N!?@:TU-=S,?X?]*]TYW\;NK4U3V[5X$>)"OZVI4X
M
M                      !W;T]].'.759RCK_#'3QQEM/*W).RU>YCM;U:P
MC<SV]K+/3DN<QF\C6GH8G6]=QT*L)KO)9"O;6-I3CWJU627U5M[5[7[-;#Z+
M=VBVLSMC(Z/9CRURY5AC/0HHIC&JY<JP\K;MTU5U3P4TS+DMVKEVN*+<3-4M
M"_P@_1MN&>BROK7/O5U'5NH'J@L9K7,:YKDMK-E>&.%<K1GA7L[S7;#+V=O4
MWW>\;4A+4DS.0MJ=MC[F$LV/M:=>A3OZD4&_SG@;0[Q:;VRVP79]*V+JQHN7
M,>3F\Y3/!,7*J9GL%FKBFS;JFJY3C%VN::IM1<>3TRBQA<O857?H1Y,]7K=-
M:):5JJ                                                    SX
MO%^^L@ZH_;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8
M"V9Z-1_4GJV]M7$/XHY :_[Z_;6G_:[WBVT'7?>_UBV%]Q:I[+D5GA@Y#>
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MTU_#IK7[:YS]&:.@%9:2@     +$?HW_ ,:;G/\ 8!6^$726'=\_Y"RONO\
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MNG._C=U:FJ>W:O CQ(5_6U*G
M
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MO:R]'(M1A'T9\&7KQ8+F
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MIMN.+E1G[]O+WX]Z59BKJ\G#@B<8T#VHKRW
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MK::>5=T_:*K+8X3,TT9W*7KE4XQ&$4S7DK=,S,QY::(C&97%VN* H
M                 !EN>D[?7$<_^T;@7X&M-37<S'^'_2O=.=_&[JU-4]NU
M>!'B0K^MJ5.
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MHBF.!6\OD<OEN&B,:^G/#/\ 1X25Y@QW
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M7NG._C=U:FJ>W:O CQ(5_6U*G
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M$XTTW+D]BHF>/L5BGDV;6/1[';IB>BJMJQ9L1A:IBGQ>OQO4RR'*
M                                                 SXO%^^L@ZH_
M;5JGP:Z4V]W=_J7D/M=?LE;U-<PW^$C8OW%F?TAFT;"]&W8    "V9Z-1_4G
MJV]M7$/XHY :_P"^OVUI_P!KO>+;0==][_6+87W%JGLN16>&#D-X
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MGO\ \I3^8?\ _#_^J_\ MIW$_P![_J_^8^QA_P#V1_\ )[_\I3^8?_\ #_\
MJO\ [:=Q/][_ *O_ )C[&'_]D?\ R>__ "E/YA__ ,/_ .J_^VG<3_>_ZO\
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MOKSZD^R!>)7^N_H:]\KGS_IG/W^]SOYMVE][Y+_N)W&S7GK?7GU)]D"\2O\
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MI\.7:IIIIC"F(B.HY:Z#Z
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M\AR>&ULC9N<K'C[+J.HTX8=3L4SCCP\KJ<-A!B!%B
M            K]^D;V-K4Z,>)<E/2[;VTZGM5L;>MWZD/)VN0XJYAKWE+R<)
MX4I_+5<90CWII8S2]SLEC"$9NW+FYFJJ-I<Q1]+.1KGPXNV</%E*/WIC,WJ>
M<'KN4IG_ )>O8W,UU1A'#51J6E4TSCAC&$7*XPB<)QX8G",*7[95Z#@    '
MM+PY/CY](G[?^-/SEL5M;9_JGJ/N2Y]3+7KG9_PS;=_LOJ'XO6T<FF;R7@
M
M
M                                                           ,
M_#QC\=<8OQ*.I^VN8TXU*N<T#(R^2FC-+ZWR_$7'^6M(1C&66,*D+6]D[\.S
MLA/VPA&,(=L=NMV]<5[%9&JGBY-R.M>N1/T8>I'F!9JUG.:'L;>LX\B,MG:.
M'@\M:U3/6JO"Y5$X=.,)X.)&4O=N(     MF>C4?U)ZMO;5Q#^*.0&O^^OVU
MI_VN]XMM!UWWO]8MA?<6J>RY%9X8.0W@
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M-%X!][76_P#T1_G/:S\XYO[I5Y)^]GSFOCWM1_B&8]6?1Q]!GFB\ ^]KK?\
MZ(_SGM9^<<W]TJ\D_>SYS7Q[VH_Q#,>K/HX^@SS1> ?>UUO_ -$?YSVL_..;
M^Z5>2?O9\YKX][4?XAF/5O0G$_"O$G!&NWNH\,\<ZAQCJ^1S5SL=_@=*P=E@
M,5=YZ\L<;C+K+W%G84J5&ID+C'X>UHSU8P[T:=O)+V]DL%'U#4]0U6]&8U*]
M<OWZ:8IBJNJ:IBF)F8C&>AC,SATYEBS;C>'MUO+U:WKN\#5L_K.LVLO38HO9
MN]7?N4V::[ERFU377,S%%-=VY7%/%%5=4\<R[/=%9H
M            " ;TC3XD?%ORJ-(^"3G!EO<U^L]_W!7[+82@=Z:_B+UK]BLY
M^D]'4M&RST*@    /:7AR?'SZ1/V_P#&GYRV*VML_P!4]1]R7/J9:]<[/^&;
M;O\ 9?4/Q>MHY-,WDO
M
M
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M)Y4S7&FUVXQPPPCL=V<)F)QJX(G&J8M7,"(30
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M]YMGR67GN\K0U3CKCK7)[7^EO)6[WMK<WMK@,/&\GDM,=86=C9UKO(Y&X_\
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MGB:*S3AY00
M
M
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ME;69RF;IJGI?9;=BGACZ;@F.*;G[6IY\0
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MV3'H<6/'"JZ1RNVIPXN1./T/':5*'A<X
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M3Y[#C7]&I3R_
M
M
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M9HY>;R61MZA1.$S-$:??M9N]5&'_ /S6K],S/!%-4SP<<:#[4)Y9
M                       $'_I /)M+2^@VKI,E;_QG,/*^AZE&VEGFEGGQ
M>N5K[D>]NYI8?>U+>VR.FV5.:$?N5*\D>SU/4RANCR,YG:OMK#RN6R]RO'JU
M86XCPXKJZTI&^]=['5[0\YFG:*JG_E] T/.YKE8<$7+\49"BG'H556\W>JC^
MK15"CVVA>CH    !]7!8:_V/-X;7L52\OE,]E<?AL;0^^_EK_*7=&QLZ7WDL
M\_\ *7%>6'J2QCZOJ0B^+MVBS:JO7."W13-4^!$8RZ6I:AE=)T[,:KG:N3DL
MM8KNW)Z5%NF:ZYX<(X*8F>&8:B^O82RUK 8/7,;+W,=K^'QF$L).[))W++%6
M5"PM9>Y2EDIR=VA0EAV2PA+#_1"$&BMZ[5?O5WJ_-UU35/@S.,O&-JNHYC6-
M4S.K9N<<WFLQ<O5SPSC7<KFNKAG&9X:IXYF>F^PXW0     4M?2-/CN<6_)7
MTCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24     !8C]&_^--S
MG^P"M\(NDL.[Y_R%E?=?_#K12]]L^9;9O]J(_$,XN0M<$ @         #P5X
MC'AW<$^)?T\Y'@+F^EE,5&TRE+:^.>1-:A:2[=QKO5G9W=E9;!A_7M*M:9''
MW5I>U;7)8VXAY"_LZLTL)J-Q);W5OE#='O9VGW.;64;4[-S1<BJCL68L7,>Q
M9BS,Q,VZ\)B::HF(JMW*?+45Q$X543717U\SEK>:M]CN>%/2E2_S?H=_6K0W
MJ./USJCZ7,KQGZ]GDEV[-R<L8#>HXZ%6O"G=1X[L="V7 2WLU"6E--0_I1&2
M6>>:6%:,)(33R(Y;O@&[FK3.RYO1-;HUGD_8J.U:[/*PC@[/5?MUX8X^6[6Q
MPB)Y/#A%$G1K_*PBNCD^'CUL/'6T_"=\)#@[PI^),[JNC9J^Y+Y>Y'J8F]Y?
MYGSN)M,-?[/7PM*XDQ.OZS@;>XR$=3T;"U+VXJV]C->7UQ4N;BI5N+FK'R4M
M'1+?IOXVEWXZ]:SVIVZ<GH&3BJ,KE**IKIMQ7,<JY<KF*>RWJ\*8JKBBBF*:
M8IIHI\M-57R>3MY2C"GAKGCG_P =!W;X@GB1]+_AH<3XKECJ6V#/4J.TY>YU
M_0M"T;$6VQ\B\@YJQLX9#)V>KX2]RF#Q<MMB;*:2>[OLC?V&-M9J]"E5N):U
MS;TZMM[JMT&VN^/7;FA;'6K4U6+<5W[]ZN;>7L453R:9N5Q375C5.,446Z*[
ME6%4TT3317-/)F<U:RM'+NS/#Q1''+S_ .&KXUG1KXHF6VS2N$*O(6B\KZ5A
M([1F.*N7<#A<'M%]J5*\QV,O-MUF\U?9-NUS/8''Y;+6UK<=V]I7UO4KTYJM
MM3IU*<\]U;X>;GO"W*V+&H[21E,UH>9N=CHS.5KKKMTW9BJJ+5R+ENU<HKJI
MIJJI\I-%44S%-<S$Q''E<]8S<S3;QBN.A/\ XE+JP*[@
M             "BEX\?)DN_^(1M^ HUZ=>UXBX\X[XVH3T9H34_*U<7<<BY&
MGWI8QEFKVV3Y K4*G^F6>E&2/JRMJ=U.1[4V0MWIC"K,7KESZ/8XZ\6XF/!>
ME3O9VQ\[+\UC(:I<IFF_KNJY[/S$\>$7*<C1/@56\C173TXJBJ."4-#)"0$
M   !/1Z/!ID^?ZV]QVFI3CZTT/@7;[^G7[)XRRY;/;5I&O6=O'N5Z4(1KXR^
MOIX1FEJR_P E&'=A-&6>7%&^',]BV8MV(\U=S=$>%3175/T8IZ7&C*[ZQM!3
MIG-UT_1:)^OZGM/E:)C@^Q6<MG+]=7#$\5RBS'!-,^6X\(FF;KC65YWP
M
M
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M5=)U',Y.]&&'UW+7J[-S@X>#E43APSP=&7-W56X
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M%<VW;7:#E]CNT[/9NQ;JX,:;V<MSD[$QCP8Q>S%$QCCP]">*='5IF\EH
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M)M6-0SUVG'C[+7E\OEZII_J]AS,1/#CRIB,,)QM&,%(8P
M
M
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M0B*[M41$<$1A$1$<"\<C7->4MU5<?)PZW!XR4MA-VP
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MJ?\ 0S.;OT3Q>6IGP9E]8[:'
M
M
M                          /GY;%8[.XK)X3+VE*_Q.9Q]YBLI8UX1C0O
M<=D+:I:7MI6A+&6:-*YMJTTDW9&$>R9]V[E=JY3=MSA<IF)B>E,3C$^%+M9'
M.YO3<[9U'(5U6L]E[M%RW73QT7**HJHJCJTU1$QU89D7.W%F3X/YIY7X=S$:
MM3(<8\A;;I%:XK2RR3WU/7,Y>XRUR4L)/O(TLI:6].XIQE^]FDJPC#U(P;OZ
M5GZ-4TS+ZE;\Q?LT5X=+E4Q,QX4\'A/8INTVUR>\?=YHFWV0Y,976=*RN<BF
M)QBB;]FBY5;X>'&W55-%43PQ-,Q/"ZH=]>X    ":7P+.IZGP-UEV''6?R$E
MGH_4?BJ/&]]&O5IT;2UWNSKU<GQKD:LTT835+BYRM2YPM"2$>R-3-]L8?>PC
M#&F]30YU;9N<Y9C'-9*KLD=.;<\%R/"C"N?0(]>^4;FZ]YG-_N[5Z7:FYM'L
ME?G/T<F)FJK)UTQ;U"W&'%33;BWFZY\[E,(X^&\^U9>;0
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M1'!$1$1P1#LETEH@
M
M
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M9N-IVUUFQV/:S:ZNWG*N5&%=&0HIF-/MSTHKHKN9O@XZ<U135PT81">R:D1
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M7C<KM7+<533%RJNNBJW5RKE454Q35=-SU>9B;=W[)3&./3CR5FIIJJ@
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M3$\GM&UF:<8X.551$\$X3?I:F/,,
M
M
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M<C&BJ:Z8HJGDU2K&EY.Y8Y5Z[&%5481'1PZJW T.5@
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MM,V9R79,Q$3P=OY^*+M5-41P53:RE&6FF<9FFJ_>HPIGE<JPBQ BP
M
M
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MPQPBN_<JN333CQ44<KD41]+1333'!#L-TUJ
M
M
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M3R]>&,3V?,4U9BJF<*J>U;%7#3=X;;;7Q!B
M
M
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M(X8GCIKHJC&FY:N4S%=J[1-5NY;JIKHJFF8EV2Z2T0
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M^7L[LS<FYG9HJQHNZG<HPY$X8Q/:-FJ;7'$TW[V9MUQC;C"PPP^BL
M 4M?2-/CN<6_)7TCX6^<&R^YK]6+_N^OV*P]"O>FOX=-:_;7.?HS1T K+24
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MZ)GA['E[%%NS1,\,TT1-6-4S+O-2F-@
M
M
M                                     %?SQY.AJ?FWANRZH^/L1&ZY
M,X'Q-Q0W6TL+:2>]VKAZ:YJ7^0KU)I98UJ]SQQ?5ZV2I2]L)9<?<Y":/>GEI
M2LN;J-J8TS4IT+.589'-U>4F9X*+V&$>%<C"F?ZT4=5*-WLWG(T[NMO[FYC:
MJ_R-C]IK]-64JKJF*,MJG)BBB(QG"FG/T4T9>J<)F;]O*Q&%,URI?-E7H/
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M_P#C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_ &HC\0SBY"UP0"
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MNQ7"SDP>AS
M
M
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M4SO.T*FWE]2IX(JS%,Q,9?/TQ'!AF::*HO<G"*,S1=B**+=5GE14+];L@
M   /8?1MUP\Z]$'(<N[<19[RF%RE6TI[SQSFJEQ<:5O>-MJD8RV^8QU.K)&U
MRMK3GGA9Y*WC3O+.,\T)9YJ52K2J6[M)LOI6U&3[5U&CZ[3CR+E/!7;F>E/1
MB>C3/E9\&(F,";_^;ANUYQNRD[.[=Y7#4;--4Y//V8IIS>3N51YJU<F)Y5NJ
M8CLN7N<JU=PB9IBNFBNB\1T.>(OP!UU:G)>:!E8:MR9C+"2YW/AS9+VVAMVO
M3R>3IW-]BZDLEO1VW5H7%2$*62M*<(0EGDA<T;6M-Y&&KNU.QNK[*YCDYNGL
MF1JG"B]3$\BKI1/G*NG3/5Y,U1PO.'SC^:?O1YM>N38VHL=N['7KLTY35<O1
M5VK?B<9IHN1C5.5S/)B9JR]VJ9QBJ;-R];CLD^^5I-80
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M.KN4[OM*Y>5TJU/*C&S%7US.5T3AR;V<KB+DXTTU46:;%FO&JS-54DRRFHH
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MC/9W-Q$9N]=NQ3Q<NNJK#'CPQF<'Y%,1Q1$/O.J_0
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MLT5\FK,YJYA7F\Y=IC#LN9O81-4QC5R+=,46;7*JBU;HBJK'RXKK,X
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MHS,ON.)30
M
M
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M^5MY'(6K=C)6:*:+=NW3%%%%%,84T444Q%---,1$4TTQ$1$81&#\3Z=@
M  !SKC+C7=N8M_U+B_CC 7NT;QO&:M,!KF#Q]/OU[V_NYH_?5)X]E.ULK.A+
M/7N;BI&6C;6U*>K4FEIR330ZN>SN5TW*7,]G:XMY6U3-554]"(\69XHB.&9F
M(CAE;6V.U^SNP.R^>VSVMS5O);.:;EZK]^]7.%-%%/2CCJKJF8HMT4Q-=RY5
M311$U51$Z%?A_P#17IO0ST_X+BW!QL\MNN5C1V3E;=:-"$E;;-WN;2E2N_6]
M6I))<R:W@J<OK3%V\W=A3MY(U9I85Z]>:?4#:[:;,[4ZO7G[N-.5I\K:H\Y1
M$\'4Y57'5/3X.*(P\KG.BYPVT'.1WHYG;34>R6-GK&.7TW*35C&6R=-4S3RH
MB>3.8O3]=S%<8\JN8HB>Q6K44^WUKM<@
M
M
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MW/Y^[<OYZ_<JN7+ERJJNY<N5U3577775,U5UUU3-5554S555,S,S,OVOEUP
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M9S-4<JJU3:G#8N1Q
M
M
M                             *^7C$^%%3ZAL7FNI_IXP="CSGKV)JWG
M(.CXNS[L_,F$Q-KWI<ABJ%K)VUN2\18V_DZ4G<FGS-O));PCZXI4):N7MW.W
M\Z/<IT+6*IG2JZL+=<S]AJF>*<?]G,\?G)QGBF<)3>8-SW:]U6=R^YK>KF:J
MMVV;OQ1D<Y<JX-*O7:O,7*JIX-/NUU<JJ<8C*7)JNX=BKNS13,JTJM"K5H5Z
M52C7HU)Z5:C5DFIU:56G-&2I2JTYX0GIU*<\(PFEC"$81AV1;)Q,3&,<,2]
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MS>-Q^ZJJB[L!LOH^G9VWAR<Q38INYJ,.+_F[_9<S/AW9Z?&\OJXS*
M   _[++---"66$9IIHPEEEEA&,TTT8]D(0A#U8QC$?DS%,8SP1"WGX-WA+U>
M+9,#U9=3^KPI\E5Z=EF.&.,\W;S0K\<V]22>M0WK;\;7EA"GO=W3J4Y\9959
M>]A*?\M6EAD)Y)+#7C>1O C/\O9_0[G_ "48Q>NT_P"T_J43ZW'TU4>;XH\I
MC-<$//\ N?)1MI5FMQ^YO.X[(4S7:U;4+-7!GZHF(JR>5N1QY*F8F,Q>IG#.
M3];MSVK355FK*#"J(D
M
M
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MBNBJ(JIKHJIF::J:J9B::HF8F)B8G!^1^N<
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ME!A5$2
M
M
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M:+E7#;S6J1'!CF,)QM92>&:,I$_7(F*\SC5R;5F<5BY'
M
M
M
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MFWYIHSN5G@BJJ;<3]>L<J8BC,VN5:JQBFJ;=WE6Z?$JYVQ0
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M*\WFZZ[N:NUU5UUUU357775,S5555,S-554S,U53,S,S,S.+]+Y<(
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MM?9G+W)JR>F6)FG*9:)QB*IC@G,9CDS,59F]C7.-5-N+5J8MT^Y5K-;@
M
M
M
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M+U++W**OIN3>F<O<HCJ53<HJF.#AMTSCP835-(KFG-<CH54S]#A:7:'-=
M  #JKG;^Q#F3]E7(?YHY=W]*_*F6]T6_JX7KNU^<;0/AO(_C5IF(-XGL@
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MU3/!$1Q0Y X5+
M
M
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MKJKKKKJFJNNNJ9JJKKJJF:JJJJIF:JIF9F9F9G%^M\N
M!2U](T^.YQ;\E?2/A;YP;+[FOU8O^[Z_8K#T*]Z:_ATUK]M<Y^C-'0"LM)0
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M[';IFO")KFJKA>@%(8N
M
M
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M&I7KN8S]ZN:[EV[75<N7*ZIQJKKKJF:JJJIX9JJF9F>&9?0?#J@
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MJGD6;>/%;M4T6XZ%,.U'064
M
M
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MC3X[G%OR5](^%OG!LON:_5B_[OK]BL/0KWIK^'36OVUSGZ,T= *RTE
M6(_1O_C3<Y_L K?"+I+#N^?\A97W7_PZT4O?;/F6V;_:B/Q#.+D+7! (
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MFI3&P
M
M
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MU3/17RN5VQF[][E<KS6/9+E6/*^FQX^B[!=-:P
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M35551PX\G&(F/9"VV
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                             '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562588000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Aug. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GRI BIO, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4369909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2223 Avenida de la Playa<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">#208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">La Jolla<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-1170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GRI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,927,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001824293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558987776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 6,353<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">531<span></span>
</td>
<td class="nump">1,126<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">6,884<span></span>
</td>
<td class="nump">2,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">7,031<span></span>
</td>
<td class="nump">2,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,236<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">935<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityCurrent', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,312<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, 0.0001 par value; 250,000,000 shares authorized as of June&#160;30, 2024 and December&#160;31, 2023; 801,914 and 49,663 shares issued and outstanding as of June&#160;30, 2024 and December&#160;31, 2023, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">40,389<span></span>
</td>
<td class="nump">31,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(35,670)<span></span>
</td>
<td class="num">(31,533)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,719<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 7,031<span></span>
</td>
<td class="nump">$ 2,956<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562479168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">801,914<span></span>
</td>
<td class="nump">49,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">801,914<span></span>
</td>
<td class="nump">49,663<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562530112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 880<span></span>
</td>
<td class="nump">$ 1,811<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">5,054<span></span>
</td>
<td class="nump">2,342<span></span>
</td>
<td class="nump">5,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,257<span></span>
</td>
<td class="nump">5,934<span></span>
</td>
<td class="nump">4,153<span></span>
</td>
<td class="nump">6,923<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(2,257)<span></span>
</td>
<td class="num">(5,934)<span></span>
</td>
<td class="num">(4,153)<span></span>
</td>
<td class="num">(6,923)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(934)<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="num">(2,095)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,250)<span></span>
</td>
<td class="num">$ (6,746)<span></span>
</td>
<td class="num">$ (4,137)<span></span>
</td>
<td class="num">$ (8,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in usd per share)</a></td>
<td class="num">$ (4.92)<span></span>
</td>
<td class="num">$ (239.37)<span></span>
</td>
<td class="num">$ (8.82)<span></span>
</td>
<td class="num">$ (433.14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in usd per share)</a></td>
<td class="num">$ (4.92)<span></span>
</td>
<td class="num">$ (239.37)<span></span>
</td>
<td class="num">$ (8.82)<span></span>
</td>
<td class="num">$ (433.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">457,742<span></span>
</td>
<td class="nump">28,181<span></span>
</td>
<td class="nump">469,100<span></span>
</td>
<td class="nump">20,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">457,742<span></span>
</td>
<td class="nump">28,181<span></span>
</td>
<td class="nump">469,100<span></span>
</td>
<td class="nump">20,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571557255120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional&#160;Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">$ (1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 16,871<span></span>
</td>
<td class="num">$ (18,496)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant issuance</a></td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">(3,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
<td class="num">(20,646)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(1,625)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,871<span></span>
</td>
<td class="num">(18,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,430<span></span>
</td>
<td class="num">(27,392)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">(3,230)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,416<span></span>
</td>
<td class="num">(20,646)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Prefunded warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises', window );">Prefunded warrant exercise</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing', window );">Issuance of common stock in pre-closing financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing', window );">Issuance of common stock in pre-closing financing</a></td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt', window );">Issuance of common stock for settlement of bridge note</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses</a></td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization', window );">Issuance of common stock to Vallon stockholders in reverse recapitalization</a></td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(6,746)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 4,038<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,430<span></span>
</td>
<td class="num">(27,392)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">49,663<span></span>
</td>
<td class="nump">49,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,792<span></span>
</td>
<td class="num">(31,533)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and prefunded warrants in financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and prefunded warrants in financing</a></td>
<td class="nump">4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Prefunded warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 2,798<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,218<span></span>
</td>
<td class="num">(33,420)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">49,663<span></span>
</td>
<td class="nump">49,663<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">$ 259<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">31,792<span></span>
</td>
<td class="num">(31,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,137)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">801,914<span></span>
</td>
<td class="nump">801,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 4,719<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">40,389<span></span>
</td>
<td class="num">(35,670)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2024</a></td>
<td class="nump">2,798<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,218<span></span>
</td>
<td class="num">(33,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment', window );">Fractional share adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and prefunded warrants in financing (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and prefunded warrants in financing</a></td>
<td class="nump">4,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise', window );">Prefunded warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">801,914<span></span>
</td>
<td class="nump">801,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2024</a></td>
<td class="nump">$ 4,719<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,389<span></span>
</td>
<td class="num">$ (35,670)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Fractional Share Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Warrant Exercise</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Pre-closing Financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Settlement Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558283584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (4,137)<span></span>
</td>
<td class="num">$ (8,896)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition', window );">Change in operating right of use assets</a></td>
<td class="num">(127)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Change in operating right of use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">370<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(400)<span></span>
</td>
<td class="nump">4,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(250)<span></span>
</td>
<td class="nump">1,157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">127<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(4,344)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ProceedsFromAdvancesFromEmployees', window );">Advances from employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_RepaymentOfAdvancesFromEmployees', window );">Repayment of advances from employees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(195)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of bridge promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercise</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization', window );">Net liabilities assumed in connection with reverse recapitalization</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PaymentOfReverseRecapitalizationCosts', window );">Payment of reverse recapitalization costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of deferred stock issuance costs</a></td>
<td class="num">(1,571)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(150)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">8,889<span></span>
</td>
<td class="nump">6,917<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">4,545<span></span>
</td>
<td class="nump">4,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">1,808<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">6,353<span></span>
</td>
<td class="nump">4,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable', window );">Issuance of stock for repayment of bridge promissory note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants', window );">Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts', window );">Issuance of stock for payment of reverse recapitalization costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantsIssued', window );">Issuance of warrants for payment of stock issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid', window );">Stock issuance costs in accounts payable and accrued expenses</a></td>
<td class="nump">367<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_NoncashMergerRelatedCostsFinancingActivities', window );">Merger costs included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember', window );">Through Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing / under ATM</a></td>
<td class="nump">9,499<span></span>
</td>
<td class="nump">12,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in financing / under ATM</a></td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Liabilities Assumed In Connection With Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_NoncashMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Merger Related Costs, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_NoncashMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Periodic Addition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ProceedsFromAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ProceedsFromAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_RepaymentOfAdvancesFromEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Advances From Employees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_RepaymentOfAdvancesFromEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Payment Of Reverse Recapitalization Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedForRepaymentOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued For Repayment Of Notes Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedForRepaymentOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_ThroughFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571565065472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text">ORGANIZATION AND DESCRIPTION OF BUSINESS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#8217;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#8217;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#8217;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reverse Merger with Vallon Pharmaceuticals, Inc.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to an Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among the Company, GRI Bio Operations, Inc., formerly known as GRI Bio, Inc. (GRI Operations), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI Operations (the Merger), with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company (Note 4). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and amended its bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recapitalization                              </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, and immediately prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of its common stock, par value $0.0001 (Common Stock), at a ratio of  one-for-thirty (the April 2023 Reverse Stock Split). On January 29, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split and together with the April 2023 Reverse Stock Split and the January 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, GRI Operations. All Common Stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio (as defined below) and the Reverse Stock Splits for all periods presented, to the extent applicable.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562967760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text">LIQUIDITY<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and, as a result, has incurred $35,670 in accumulated deficit through June&#160;30, 2024. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2024, the Company had cash of approximately $6,353. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium Growth Fund, LP (Altium) entered into a Securities Purchase Agreement, dated December 13, 2022 (the Equity SPA), pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes (as defined below) in return for the issuance of shares of GRI Operations common stock (GRI Operations Common Stock) immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued 74,584 shares of GRI Operations Common Stock (the Initial Shares) to Altium and 298,339 shares of GRI Operations Common Stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 2,789 shares of the Company&#8217;s Common Stock and the Additional Shares converted into an aggregate of 11,157 shares of the Company&#8217;s Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Company&#8217;s Common Stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering, (i) 25,419 shares (the February 2024 Shares) of  Common Stock, (ii) 359,196 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 359,196 shares of Common Stock, (iii) 384,615 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 384,615 shares of Common Stock, and (iv) 384,615 Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 384,615 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#8220;February 2024 Warrants.&#8221; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $14.30 (less $0.0013 for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants became exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0013 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for an 18-month period after February 6, 2024 the date of issuance. As of June&#160;30, 2024, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the February 2024 Shares and February 2024 Warrants pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company has sold 293,892 shares of Common Stock in the ATM Offering at a weighted-average price of $3.27 per share, raising $961 of gross proceeds and net proceeds of $923, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, the Company filed a prospectus supplement to its registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $2,644, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $961 that have been sold under the ATM Offering.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering (the June 2024 Offering), (i) 60,000 shares (the June 2024 Shares) of  Common Stock, (ii) 2,125,793 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 2,125,793 shares of Common Stock, (iii) 2,185,793 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 2,185,793 shares of Common Stock, and (iv) 2,185,793 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of 2,185,793 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#8220;June 2024 Warrants.&#8221; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $1.83 (less $0.0001 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants are exercisable for one share of Common Stock at a price per share of $0.0001, are exercisable immediately and will expire when exercised in full. Each Series C Common Warrant is exercisable into one share of Common Stock at a price per share of $1.83 and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series C Common Warrants (Warrant Stockholder Approval). The Series C-1 Common Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the 18-month anniversary of the Warrant Stockholder Approval. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025. </span></div>The Company&#8217;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of Common Stock have a value weighted average price of at least $838.11 per share for the periods specified in the Series T Warrants, are not met. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#8217;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571565299552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2023 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#8217;s financial position as of June&#160;30, 2024, and the consolidated results of operations and consolidated stockholders&#8217; deficit for the three and six months ended June&#160;30, 2024 and 2023 and consolidated cash flows for the three and six months ended June&#160;30, 2024 and 2023. Consolidated results of operations for the three and six months ended June&#160;30, 2024 are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2024. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2023, included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March&#160;28, 2024. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the Company had a net loss in each of the three and six months ended June&#160;30, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2024 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562967760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">MERGER WITH VALLON</a></td>
<td class="text">MERGER WITH VALLON<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into GRI Operations, with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#8220;Vallon Pharmaceuticals, Inc.&#8221; to &#8220;GRI Bio, Inc.&#8221;</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Effective Time:</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each share of GRI Operations Common Stock outstanding immediately prior to the Effective Time, including any shares of GRI Operations Common Stock issued pursuant to the Equity SPA, automatically converted solely into the right to receive a number of shares of the Company&#8217;s Common Stock equal to 0.0374 (the Exchange Ratio).</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Each option to purchase shares of GRI Operations Common Stock (each, a GRI Operations Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the GRI Operations Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#8217;s Common Stock, and the Company assumed the GRI Operations Plan and each such GRI Operations Option in accordance with the terms of the GRI Operations Plan (the Assumed Options). The number of shares of Common Stock subject to each Assumed Option was determined by multiplying (i) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per share exercise price for the Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Each warrant to purchase shares of GRI Operations Common Stock (the GRI Operations Warrants) outstanding immediately prior to the Effective Time was assumed by the Company and converted into a warrant to purchase shares of Common Stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Common Stock; (ii) the number of shares of Common Stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest </span></div><div style="margin-bottom:8pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">whole number of shares of Common Stock; and (iii) the per share exercise price for shares of Common Stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of GRI Operations Common Stock subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. </span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 4,632 shares of the Company&#8217;s Common Stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $1,340.43 per share.</span></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All rights with respect to GRI Operations restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#8217;s Common Stock. The term, exercisability, vesting schedule and other provisions of the GRI Operations restricted stock awards otherwise remained unchanged.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI Operations was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of GRI Operations immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#8217;s Common Stock and the Company&#8217;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#8217;s Common Stock (ii) GRI Operations holds the majority (4 out of 5) of board seats of the combined company, and (iii) GRI Operations&#8217; management holds the majority of key positions in the management of the combined company.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>In addition to the transaction costs noted above, at the Effective Time, 4,363 shares of Common Stock were issued to GRI Operations&#8217; financial advisor for services related to the Merger.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562028448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the six months ended June&#160;30, 2024.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of June&#160;30, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the May 2022 Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.8&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562869360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense related to property and equipment was $2 for each of the six-month periods ended June&#160;30, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562035136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562891808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">PROMISSORY NOTES</a></td>
<td class="text">PROMISSORY NOTES<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bridge Financing</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, GRI Operations entered into a Securities Purchase Agreement, dated as of December 13, 2022 (the Bridge SPA), with Altium, pursuant to which GRI Operations issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#8217;s assets. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, upon the funding of each tranche, Altium received warrants to purchase an aggregate of 13,763 shares of Common Stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $121.03 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered into the Equity SPA (Note 9) pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $1,340.43 per share subject to adjustments for splits and recapitalization events.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred $205 of debt issuance costs related to its issuance of debt under the Bridge SPA, of which $90 was incurred during the six months ended June&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Interest expense stemming from amortization of debt discounts and issuance costs was $1,161 and $2,104 for the three and six months ended June&#160;30, 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562033664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Securities Purchase Agreement</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#8217; Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and the Additional Shares into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 2,789 shares of Common Stock and the Additional Shares converted into an aggregate of 11,157 shares of Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Common Stock issued in exchange for the Additional Shares. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">February 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the February 2024 Offering, (i) 25,419 February 2024 Shares, (ii) 359,196  February 2024 Pre-Funded Warrants exercisable for an aggregate of 359,196 shares of Common Stock, (iii) 384,615 Series B-1 Common Warrants exercisable for an aggregate of 384,615 shares of Common Stock and (iv) 384,615 Series B-2 Common Warrants exercisable for an aggregate of 384,615 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $14.30 (less $0.0013 for each February 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0013 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for an 18-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid in capital. As of June&#160;30, 2024, all of the February 2024 Pre-Funded Warrants have been exercised.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the February 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants issued in connection with the Merger was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">May 2024 At The Market Offering</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement,  shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company has sold 293,892 shares of Common Stock in the ATM Offering at a weighted-average price of $3.27 per share, raising $961 of gross proceeds and net proceeds of $923, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, the Company filed a prospectus supplement to its registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $2,644, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $961 that have been sold under the ATM Offering.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">June 2024 Securities Purchase Agreement</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the June 2024 Offering, (i) 60,000 June 2024 Shares, (ii) 2,125,793 June 2024 Pre-Funded Warrants exercisable for an aggregate of 2,125,793 shares of Common Stock, (iii) 2,185,793  Series C-1 Common Warrants exercisable for an aggregate of 2,185,793 shares of Common Stock, and (iv) 2,185,793 Series C-2 Common Warrants, exercisable for an aggregate of 2,185,793 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $1.83 (less $0.0001 for each June 2024 Pre-Funded Warrant).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The June 2024 Pre-Funded Warrants are exercisable for one share of Common Stock at a price per share of $0.0001, are exercisable immediately and expire when exercised in full. Each Series C Common Warrant is exercisable into one share of Common Stock at a price per share of $1.83 and are exercisable beginning on the effective date of the Warrant Stockholder Approval. The Series C-1 Common Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the 18-month anniversary of the Warrant Stockholder Approval. The June 2024 Pre-Funded Warrants and the Series C Common Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an engagement agreement (the Engagement Agreement) with Wainwright, the Company, in connection with the June 2024 Offering, agreed to issue to Wainwright, or its designees, warrants to purchase up to an aggregate of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153,006</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of Common Stock (the Placement Agent Warrants). The Placement Agent Warrants have an exercise price of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2875</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, will expire on June 26, 2029 and are exercisable following the Warrant Stockholder Approval. The Placement Agent Warrants were classified as equity and the fair value of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$229 is included in additional paid in capital.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the amount paid for the June 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants and the Placement Agent Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.1&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;%</span></td></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had the following warrants outstanding to purchase Common Stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,125,793</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Do not expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,615</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,950</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,117.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$27,300.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2,561.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,586.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,615</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,185,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 months after the Warrant Stockholder Approval</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,185,793</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after the Warrant Stockholder Approval</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562973280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2015 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRI Operations adopted the GRI Operations Plan, which provided GRI Operations with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Upon completion of the Merger, the Company assumed the GRI Operations Plan and 982 outstanding and unexercised options issued thereunder, and ceased granting awards under the GRI Operations Plan. As of June&#160;30, 2024, no options remain outstanding under the GRI Operations Plan. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended and Restated 2018 Equity Incentive Plan</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;R 2018 Plan). The A&amp;R 2018 Plan had previously been approved by the Company&#8217;s board of directors, subject to stockholder approval. The A&amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving an amendment to the A&amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by 1,856</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,381</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company&#8217;s Common Stock </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for issuance as awards under the A&amp;R 2018 Plan, (ii) to extend the term of the A&amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#8220;repricing&#8221; of an award without further approval by the stockholders of Company and (iv) to revise the limits on awards to non-employee directors.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The A&amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;R 2018 Plan generally have a contractual life of up to 10 years. As of June&#160;30, 2024, awards granted under the A&amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 2,503 shares of the Company's Common Stock were outstanding and 4,367 shares of the Company&#8217;s Common Stock were reserved for issuance under the A&amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;R 2018 Plan may be increased pursuant to the A&amp;R 2018 Plan&#8217;s &#8220;evergreen&#8221; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#8217;s Common Stock outstanding on the final day of the immediately preceding calendar year.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 4pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 4pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2024</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.56</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2024</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06</span></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. At June&#160;30, 2024, the unrecognized compensation cost related to unvested stock options expected to vest was $313. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.47 years </span></div>No equity-based awards were granted during each of the three-month periods ended June&#160;30, 2024 and 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563561504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Separation and Release Agreement</span></div>In connection with the resignation of David Baker, the Company&#8217;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#8217;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562887008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,250)<span></span>
</td>
<td class="num">$ (1,887)<span></span>
</td>
<td class="num">$ (6,746)<span></span>
</td>
<td class="num">$ (2,150)<span></span>
</td>
<td class="num">$ (4,137)<span></span>
</td>
<td class="num">$ (8,896)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563469664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562513744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#8220;authoritative guidance&#8221; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2023 balance sheet was derived from the Company&#8217;s audited consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#8217;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#8217;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></div><div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company&#8217;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging &#8212; Contracts in Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. </span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the six months ended June&#160;30, 2024.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Stock Issuance Costs</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred Stock Issuance Costs</span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Common Share</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As the Company had a net loss in each of the three and six months ended June&#160;30, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2024 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563203136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.177%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.985%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,302,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,305,316&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,347&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563562976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MERGER WITH VALLON (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of the Net Liabilities Assumed in the Merger</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the net liabilities assumed in the Merger:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">April 21, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid and other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,939)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Transaction costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,984)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net liabilities assumed plus transaction costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,923)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571565341888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#8217;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of the Changes is the Fair Value</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the fair value of the Level 3 liability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.816%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.984%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrant Liability </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of June&#160;30, 2024</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the May 2022 Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.8&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants and the Placement Agent Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.1&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562872160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.512%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571650252480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:8pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll and related</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">632</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562927280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of the Fair Value of the Warrants</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes valuation model was used to estimate the fair value of the May 2022 Warrants with the following weighted-average assumptions:</span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.8&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.3&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.65&#160;%</span></td></tr></table></div>The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants and the Placement Agent Warrants with the following weighted-average assumptions:<div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159.1&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term in years</span></td><td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92&#160;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants Outstanding to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2024, the Company had the following warrants outstanding to purchase Common Stock. </span></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.958%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,125,793</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Do not expire</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,615</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,950</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,117.48</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$27,300.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2,561.65</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5,586.49</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,615</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.30</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,006</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,185,793</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 months after the Warrant Stockholder Approval</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,185,793</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60 months after the Warrant Stockholder Approval</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563304624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2024 and 2023:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity of Stock Options</a></td>
<td class="text"><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2024:</span></div><div style="margin-bottom:8pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.816%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted average remaining contractual term&#160;(years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 4pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited/Cancelled</span></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 4pt 0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2024</span></td><td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,655.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.56</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at June 30, 2024</span></td><td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471.45</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562328288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th"><div>Jun. 17, 2024</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split</a></td>
<td class="nump">0.07690<span></span>
</td>
<td class="nump">0.14290<span></span>
</td>
<td class="nump">0.0333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571554414288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35,670)<span></span>
</td>
<td class="num">$ (35,670)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (31,533)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,353<span></span>
</td>
<td class="nump">$ 6,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">801,914<span></span>
</td>
<td class="nump">801,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockHeldIntoEscrowAccount', window );">Common stock placed into escrow (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember', window );">Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesCCommonWarrantMember', window );">Series C warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember', window );">Series T Warrants | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of option on grant date (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 838.11<span></span>
</td>
<td class="nump">$ 838.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 2,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockHeldIntoEscrowAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Held Into Escrow Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockHeldIntoEscrowAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesCCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesCCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesTWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562532768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">5,305,316<span></span>
</td>
<td class="nump">41,347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">1,094<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in usd per share)</a></td>
<td class="nump">5,302,813<span></span>
</td>
<td class="nump">40,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571565830336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses', window );">Issuance of common stock for reverse recapitalization expenses (in shares)</a></td>
<td class="nump">4,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">4,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1,340.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_GRIOperationsMember', window );">GRI Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockExchangeRatio', window );">Common stock, exchange ratio</a></td>
<td class="nump">0.0374<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember', window );">Private GRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_CommonStockOwnershipPercentage', window );">Ownership percentage in common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Exchange Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_CommonStockOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_CommonStockOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Reverse Recapitalization Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_GRIOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_GRIOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ck0001824293_PrivateGRIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ck0001824293_PrivateGRIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562286640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(4,190)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total net liabilities assumed</a></td>
<td class="num">(2,939)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Plus: Transaction costs</a></td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts', window );">Total net liabilities assumed plus transaction costs</a></td>
<td class="num">$ (5,923)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571553456720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Other Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_WarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_WarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563198288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details) - Warrant Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of December 31, 2023</a></td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in valuation</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value as of June&#160;30, 2024</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=ck0001824293_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571553452064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.728<span></span>
</td>
<td class="nump">1.710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0462<span></span>
</td>
<td class="nump">0.0412<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571564012896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571553272544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571563207712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent', window );">Research and development</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent', window );">General and administrative</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related</a></td>
<td class="nump">632<span></span>
</td>
<td class="nump">736<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">$ 1,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research and Development Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558512320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROMISSORY NOTES - Bridge Financing (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 21, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 14, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 13, 2022 </div>
<div>USD ($) </div>
<div>closing</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discounts and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,161<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember', window );">Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 532<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember', window );">Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) | shares</a></td>
<td class="nump">4,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1,340.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember', window );">Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 205<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Exchange Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1,340.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Bridge SPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,667<span></span>
</td>
<td class="nump">1,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentAggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_DebtInstrumentNumberOfClosings', window );">Number of closings | closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_DebtInstrumentNumberOfClosings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Closings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_DebtInstrumentNumberOfClosings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_BridgeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ExchangeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ck0001824293_BridgeSecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571556097536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Jun. 26, 2024</div></th>
<th class="th"><div>May 20, 2024</div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember', window );">Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember', window );">Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember', window );">Series A-1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember', window );">Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember', window );">Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesCCommonWarrantMember', window );">Series C warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of shares called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ThePlacementAgentWarrantsMember', window );">Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_StockIssuanceCostsOfferingExpenses', window );">Offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,125,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series B-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-1 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember', window );">Public Offering | Series C-2 Common Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,185,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction', window );">Number of securities issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">293,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockAgentCompensationPercentage', window );">Sale of stock, agent compensation, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered', window );">Sale of stock, maximum value of shares offered</a></td>
<td class="nump">$ 2,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember', window );">ATM | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ConversionOfStockAdditionalSharesConverted', window );">Additional shares converted into common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional&#160;Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional&#160;Paid-in Capital | Pre-Funded and Series C Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional&#160;Paid-in Capital | Placement Agent Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Warrants, equity impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember', window );">Investor | Common&#160;Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentCompanyCommittedCapital', window );">Investment in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ConversionOfStockAdditionalSharesConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Additional Shares Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ConversionOfStockAdditionalSharesConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockAgentCompensationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Agent Compensation, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockAgentCompensationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockMaximumValueOfSharesOffered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Value Of Shares Offered</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockMaximumValueOfSharesOffered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Securities Issued Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_StockIssuanceCostsOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs, Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_StockIssuanceCostsOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyCommittedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funds committed to investment company from investors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478494/946-205-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyCommittedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesA1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesCCommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesCCommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ThePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_ThePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ck0001824293_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_PreFundedAndSeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558145152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.728<span></span>
</td>
<td class="nump">1.710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0462<span></span>
</td>
<td class="nump">0.0412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember', window );">Series B-1 Common and Series B-2 Common Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember', window );">Series B-1 Common and Series B-2 Common Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember', window );">Series B-1 Common and Series B-2 Common Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember', window );">Series B-1 Common and Series B-2 Common Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember', window );">Series C-1 Common, Series C-2 Common and Placement Agent Warrants | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember', window );">Series C-1 Common, Series C-2 Common and Placement Agent Warrants | Expected term in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember', window );">Series C-1 Common, Series C-2 Common and Placement Agent Warrants | Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember', window );">Series C-1 Common, Series C-2 Common and Placement Agent Warrants | Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants outstanding, measurement input</a></td>
<td class="nump">0.0492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571562547344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsNotExpiringMember', window );">Warrants Not Expiring</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">2,125,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member', window );">Warrants Expiring In August 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">384,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2025Member', window );">Warrants Expiring In December 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">8,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1,117.48<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member', window );">Warrants Expiring In February 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 27,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member', window );">Warrants Expiring In May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2,561.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member', window );">Warrants Expiring In July 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member', window );">Warrants Expiring In April 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 5,586.49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member', window );">Warrants Expiring In February 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">384,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 14.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member', window );">Warrants Expiring In June 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">153,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 2.29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember', window );">Warrants Expiring In 18 Months After The Warrant Stockholder Approval</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">2,185,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember', window );">Warrants Expiring In 60 Months After The Warrant Stockholder Approval</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares (in shares) | shares</a></td>
<td class="nump">2,185,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price per Share (in usd per share) | $ / shares</a></td>
<td class="nump">$ 1.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, term</a></td>
<td class="text">60 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsNotExpiringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsNotExpiringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInAugust2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInDecember2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJuly2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInApril2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInFebruary2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringInJune2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558496576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 21, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation, weighted average amortization period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_GRIOperationsPlanMember', window );">GRI Operations Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares outstanding</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized</a></td>
<td class="nump">2,381<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common shares reserved for future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum', window );">Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember', window );">A&amp;R 2918 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock awards, contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_GRIOperationsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_GRIOperationsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558677744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571553282112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Activity of Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited/Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">2,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable, Ending Balance (in shares)</a></td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning Balance (in usd per share)</a></td>
<td class="nump">$ 471.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending Balance (in usd per share)</a></td>
<td class="nump">471.45<span></span>
</td>
<td class="nump">$ 471.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, Ending Balance (in usd per share)</a></td>
<td class="nump">1,655.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in usd per share)</a></td>
<td class="nump">$ 471.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term&#160;(years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (years)</a></td>
<td class="text">9 years 21 days<span></span>
</td>
<td class="text">9 years 6 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable (years)</a></td>
<td class="text">8 years 6 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (years)</a></td>
<td class="text">9 years 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140571558925296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - Former Chief Executive Officer<br></strong></div></th>
<th class="th"><div>Apr. 21, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_COBRABenefitsPaymentPeriod', window );">COBRA benefits, payment period (in months)</a></td>
<td class="text">18 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ck0001824293_PercentageOfTargetBonus', window );">Percentage of target bonus (as a percent)</a></td>
<td class="nump">150.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_COBRABenefitsPaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>COBRA Benefits, Payment Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_COBRABenefitsPaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ck0001824293_PercentageOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Target Bonus</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ck0001824293_PercentageOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ck0001824293_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ck0001824293_FormerChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>59
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MT3$2J*Z6=QTC&U<.%])@<77-"J\_4#8 YY=2FON.K;#]A9K_ U!+ P04
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M*SAYUY=K1E,F- #>+SE7AQN=H/V@,_D74$L#!!0    ( +:@#5FKY]"$/@H
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MCTG;A$O\BO>9LY^U+GJWCN<60-LJCE8;#T##_%&0-#5 7A$SLTZ "QL@7%@
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M=F2T,TKF/!:+SMFE%4YH'S?,G)U*S74FN6)3; I4IG?L]_',>8O:^F-3A"*
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M)KV*C7X<B;-HO:VU(1NA=B4-^A6]SOC5_8A\4ZR8-\YH*%R(!6(-#R,[RZ9
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M"FDG/8:6.BK'-2KG<Q1GJ@R*(KP@J\YG6*]2)I5:SG3)_;\'U;Z(:#75&8J
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MT: .ME\,^!*Y-2+33BS 8DZZ:^GAO'#E0TAE+K/GJ7HI+UYG-_H/:P=I$'M
M\GC@DB_"+:GP+"-*7.*Q5R.)+*SZW8%):U2[;#,S00G V[)8%0_X=%?1;20>
MY>=/3!+QP/ VS; "1D (%(G5]$FDN%E0>?)$E=!6'0:UR\MSU>9BZ<02L/77
MW.\GALL R0&NI\,U -&V50EQLV=\_HPN?$5SQX*ER/!;&4V$^EQ9SH#"<JS<
M+Y/JJ<<H2GVK6H708F)GVE2ELZD]<HK&BQR?U3/0\F%IB7"IX5C:@0]XKWN"
M76R9_"L<7^VB^#F&]V(K\MV,DRCT1(!]1@]Q*+- [1O#!EG4B@VN4 70:<$J
M(&9%DE "0O =Z:.MFID([5;VY%0E*$E=EA-"3<>)J$C %P]YTJPZN=$+9;E>
M=W/KQRT)H@$Z9@ )J"<K0O4.2_5>2F/*=>>U\KU#&KYX:[;S/0LH5UBE:9CC
M#:G#Z)O2^@+V;; 50RN491+P7#;#/+"V;)1^.;*2\#I+6![EZDN-M:7AM=^S
ME1A\MRI6&%Z0Q>!OEL42QO^]9_]>63QCZY@$]8)";>;Q>V1R?YZV=++A>P7J
MA63]$U/T*C5M1QU>IZZ,BM!ZU8BB_9O&<\-QQU<BE-XCSLJR'K2!;-7$Z^U/
MNYXYGJOFY3EDTGT['KUBD^67T2TG+.@HHGQR0EDCUI!.JU*52%/NELJXF[$1
M=[%<,#:5X9$9-]<-TNH=]YMA=SP9]";C54T@:= 1 2XAO+^W?H^&X>1E)32*
MH%JLZ(# 12.1P,AZ9@]7U^K57G/53G&K YLZMMM")5YJA>;PM?R[9.&PU!^V
M'#.X72OQCC5Q'X//+] /J_,[+XNX1R\R5[8$G^@-8+YX=BASY62B_NM/V_[,
M\R$(;GG=*G ,2Y]1=(%(-0".P9:';:Z,4%I_U\ ?L"#50B;8L[9'ESF5?]Y(
M%7BPMX"'\D:@#>'#Q$R]Y[7)DNZ-#/@[P<@KZM9YH[JWJ#F>R=!I8U<'[-/Z
M& #^#(=9QZ!WK79[Y:_TPC<B73K&Q9!$59/1_L)#I6.]CZ+6%9ECTA^1339Z
M?/2O"OCZIN<5!^[&N:X>Q.521790' UHP[\,C;<O#48)D>6IJ?Q3&Z*_/2$'
M9/&H0W^GFEK<@G2UFY O$8&$AOUUUU;F30<E$K2>R3E?D.URB6:_ E*A_2VD
MK=*T-FN/9]]<,XW%OV1M\?NY6"]M*25.),KWOH+5EK1TX/D^;=SRB??[&DB\
M$2>3H;@UD$L5K55UV8CCX4 $OD.LR.43H^'=?A@:.D+ 8PX9-ARRW!V>#' %
MU=CM>V&V1]V3\4D'C^F%/14/N A9&9:G$DO+*+X_GKQD)<?9PFU-?B/:1]V3
MT;BSZP*VOW:ASE>8]+,!K9T8FK];KY_6OTP$_D)^-=S_K/%1FKG"I"8PPZF#
MWKNCEF_-ZHO3.5_/3[5S.N6/,4CL%!J [V<:=Q3E%W)0_UYS^3]02P,$%
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MW;2@1HG*!M!Y+J4Y+.P%7>M-_@!02P,$%     @ MJ -68=N3'AT!@  KQ
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MY),%L#\W:/]VP0[6_T=Q_B=02P,$%     @ MJ -67DQDB"A"@  %B0  !D
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M"5V#(A%;PE;'GHQZ1)JO4,Q-)E+]Y<="9)F(]67(*$B("^#]4HBLO$$&U:=
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MJT_4ZU<DWA7+1$>)**QYU.B.US)+[1->*V<Z)6O>B 4JXP4 $'T74$YR7=
M2J0C,A7>R*6T,>SGL3!08(5B=_=G7.;J+;2IK$C-LU+0$6L+2C 6E[0L@F)
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MT4W^5A=E!ZW^E;*UZ]Z$F:/AJS#I@<XPVFB8 #0*:CN67HD]U+%&&62,C6N
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M3)3$K$ ">#\WQM<W9*#YJGW^7U!+ P04    " "VH U95[:8Z?$"  "%!@
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MWPG4SH'LF5+VN'$!VB_/Z"]02P,$%     @ MJ -68UW1VJN @  ? D  !D
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MU95-C=6]OIX(NM2MYHD*V;CT,)/7(V#*0+Z?4RHV$^6@O7#%_P!02P,$%
M  @ MJ -61#"[$!$ @  B@8  !D   !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&ULG95=;YLP%$#_BL6D/;6!0#ZV#)"2;M-2J5.4=MNS@R]@U=C,-DG[[V<;
MPK(IH5)>P#;W'I]KQ"4^"/FL2@"-7BK&5>*56M<+WU=9"156(U$#-T]R(2NL
MS506OJHE8.*2*N:'03#S*TRYE\9N;2/36#2:40X;B51355B^KH")0^*-O>/"
MEA:EM@M^&M>X@$?0/^J--#._IQ!: 5=4<"0A3[SE>+&:VW@7\)/"09V,D:UD
M)\2SG:Q)X@56"!ADVA*PN>WA#ABS(*/QNV-Z_98V\71\I']UM9M:=EC!G6"_
M*-%EXGWP$($<-TQOQ>$;=/5,+2\33+DK.K2QT4</98W2HNJ2C4%%>7O'+]TY
MG"08SOF$L$L(G7>[D;/\C#5.8RD.2-IH0[,#5ZK+-G*4VY?RJ*5Y2DV>3M?F
M> E(]"0QH;Q 2RDQ+\ <NU:QK\T.-L[/.MJJI847:!%Z$%R7"GWA!,B_^;XQ
MZ_7"H]XJ' 3>-WR$HN &A4$X&>!%?;F1XT47>.?*O$&[5[3FA.XI:3 [5W4+
MG9R'VN]FH6J<0>*9#T.!W(.7OG\WG@6?!I0GO?)DB)YN&P9H'.RFM^-3;;0D
MHM;_'W*K.PS,,5,P(#;MQ::#G.^"WUXA-PQ]2V[6R\VN.K4GD.8KPA?<AIEO
MN<U[M_G5!S?L-\R]Z.>?](<*9.&ZH$*9:+AN6T6_VC?:9=M?_H:W7?H!RX)R
MA1CD)C48S<WKE&WG:R=:U*[;[(0VO<L-2_.S &D#S/-<"'V<V WZWT_Z!U!+
M P04    " "VH U9Z^_G 6@+   3(   &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6S-6OMOVS@2_E<(+[!( #</IZ_M(X#CIET?MFFN;G9Q.-P/M$3;
MO$JD2E)Q?'_]?3.D'FD5[U[W#KA?&DNBAO/XYIL9JJ^VUGWV&Z6"N"L+XU^/
M-B%4+XZ/?;91I?1'ME(&3U;6E3+@TJV/?>64S/FELCB>G)P\/2ZE-J/S5WSO
MVIV_LG4HM%'73OBZ+*7;7:C";E^/3D?-C8]ZO0ETX_C\5277:J'"377M<'7<
M2LEUJ8S7U@BG5J]'T],7%Z<G] *O^%6KK>_]%F3*TMK/=#'/7X].2"-5J"R0
M"(D_MVJFBH(D08\O2>BHW9->[/]NI+]EXV',4GHUL\5O.@^;UZ/G(Y&KE:R+
M\-%N?U;)H"<D+[.%YW_%-JT]&8FL]L&6Z65H4&H3_\J[Y(@_\L(DO3!AO>-&
MK.4;&>3Y*V>WPM%J2*,?;"J_#>6TH:@L@L-3C??"^<5T,5^(#V_%]<?+Q>75
MI^FG^8<K,;UZ(Q8W[]]//_Z-GBWF[Z[F;^>SZ=4G,9W-/MQ<?9I?O1/7'WZ9
MS^:7"W%P;0N=:>4/7QT'*$6BC[.DP$548/*  D_%>VO"QHM+DZO\_OO',*:U
M:-)8=#'9*_ OM3D29R=C,3F9/-XC[ZSUT!G+.WM WC3+;&V"-FO1F"G^/EWZ
MX("H?PP9'.4]'I9':?;"5S)3KT?((Z_<K1J=__C#Z=.3EWNT?=QJ^WB?]/,+
MZ;47=B4ZM8=4W"_DTT8A73);5M+LR/#:R#K70>5"FZ"<+L5*&VDR+0OA@PP*
M>1J\V,A;)99*&0'+*NEX/4MR.58K8#ML^#HYM'(:0JH"+ETKHYPLBAT]5U7<
M2P1H<F-XYP7MX\7!N^GT^E" CP9TJ7!M<R^DR455.U]+$T2P+,;5M T\0Q<+
ME=5.!XHEK;V\RS;2K)68V;+4GBGG@-==S@Z/Q-3LB(&44V1$4NM[' 15?OSA
M^61R\E+686.A@212$NM:LX/XX>E+@1"6*NG.&],/,EQ(#]-KTSJGATXXR.32
MP?R9S?5*9Y)Y[V"ZF!VRE8-K;ZH\^G6ZN#ELW/.V57[PG0N+/^+@[71Q >\0
M6MZH3)5+Z'EVRHEW!JHL..2QMFRA=PZ_W,)#*V=+WF46_4=&GSY[B4@D%V;6
M>&0:Z94/^O%H3Z(\:1/ER5Z,7W?0@]&S=DNX;"AAOEL8N^=;>/RNC5B9%76N
M6JS5=!/2WWV<BPMMQV)NLB..J\:#[<8B=Q[9K8$\7R^]SC6J[+A9+CX@-U@A
MG]Z<%D74)L&XB5C,"+";\9(K9S^O5:%1A$CI?3%XVL;@Z5ZWW7A%%EWZH$L"
MX9#C_S,)[.U(/M'[>/B =RD$U-7HL(N\Q/GEU)=:@Y918PVZ$EI,N5?*STJH
M=A?RD/3H9*KHH+"10<C5"JU&Y!I564>1E64;-ZQ7(;Y::+G4!=//.'H;[^3:
M9X7UM6.+H!PE'6T__**0<2M"4).V@Y8V\H=T4G?H[CR$Y6!#I'BWCMF9V?2H
MY]VO[0;%$X>CG],@[E+FS(Y.%='YB7EO95&WT? ;>LE6"8I;Z1P1'4BW9KZ@
M+0B_B ,9[U3[-E9WDE I[#;"-6Y'VEOJQY2CNA/D77+<F++'U;C76DM[I& F
MK4A-))QCG\%_2^N 91+JR+]4;6B)C4F$VX5"*W@DYBOJ*VN\ <R@$80G]8KX
M^D&2:T$T%M8U'E)W@8&V03_0AQD\)?-_H@N,U7!5!X)'JG+C0?GWB*51"A;:
M-O^QI"[@ & >BBY1=U<ZL,*LTI+VO%4.G?,N81J2ECM"Z@ZAR38B%4MHU.BZ
MCPV>M6SP;&\NOY7:B5\1827>P[MU#,8@*7R7(,'W;_F^IG*$=*%T\.Q'P#A3
M,9&W[)\EI4*FNI(%AQ04>FDBLLA9E=0Y!Y'HDN(NVQS=<>\#=#D4/KBRQZB0
M';9$ITB<SQ $M@IH+!''T.9UV6G..8XZ:R-$ 3R.L@8L3+9C-#.'N][&J\[6
MLN\#6LP) ZLZQ@&6T"6(YQ.TS</>XS:"%AR.*>AR66A4=LCK[[31P)C+-B#4
MC09.X%/J<?2_E$\95M6Q"^H2.:AL8S22W8O:*W9F4K@O&86*,L4IU"%G)9A0
MW:K"Q^8CWH]WF/"'-&K"O=PUIG)ZY<IG3B_I 4VH+\0O)$:<BA?H.]O<^U);
M^L,8\;&GY;XMQJ_A?\>%6J%]7!;JH3C&SC7')1JT8HS6 .X/$,S4'*D>*WI,
M?Y1TFD"GOWZMR#<:&!N2=IS-R>4Q'LR\2QHY$#\\3Q20H^!E 1#E]<W5F#4E
M*D;?%S2WYEQD:C0.:!O*AC?;9!C0^0PZ7T=EK1N..FN>RFZ+D,::I45A]GIM
MN)_MFOEA>#.Z:].9* [TD3H:PXHJ%3^$'QH&/((^QC89R!Y#ZE"SSQC"%*G:
M*7*8:;MJJPTB6-]KVY"2TF_&_*\@XZ L/1_'[D1_58TL!P(SB>LJ_KAK^RJY
MBQ$;+&69<D$""QWS9 5$P&58F0IL2I4,5SRP-$U VQ6D>>)>V^X9 O\#0V(C
M\8TM5>7L'=<3T@41[H69CEX@/FKI,3N%1PQ"K*9);I?0Z%4_&M'H%#BB<PLD
M,1LEOO8M%7?T\16^.@I)F_<[+KQD&/M=2<RTR^J2DB9KT)W)2&W$56ECX"P,
M@ R0WRK.XAZ\!EFAP7U.1--3EWHCLA01H#@OXWD 1P6Z1 M^!RAS(][+'2DU
M&5,E*"#S&FU;*3-5,VTU,\1!?'K([5M/1AR>&R'BMW3[,+7=)AW)Q>, %-9V
M&,?0#D\BB'(-3J<8'C4:I$8P^?$;V4,G#4STIT\>/8:+W]#TR=-V!.K/*E^3
M@SB=)R]I:.,3'19T"<(+7:9_V.(6H ^''70R#\>I]#89'UD+>6%O-1\AI)SZ
M5M>F C='$RJOLWXKJNXPEFG?="7DM93C]]&%%&SW'MJ'^Y:EXH2/*4C-#( D
M/;<,UJAF$F#SF/UD:AO'#PAE@%(NN3RV3_V>QP[02!O"]J6O4BQ9_>U6=45>
M;$:#VK,AXJ*0V>='BPPC+WS0%972YJJXG_+:-Z4ECV<I<</AW1 ])5$FNPF(
M4SVB%,)BCONOVJO6*-RF2;P=O>YWW5&O>Z/0 SB./3Q:!%*Z-OC;%M-][)23
M71%/1D5S:Z_NC6L)C[TR_%^JLZFXM!PX'-_&BF;FZW7*%*95$4>-]/X#?FQG
M,:_O$'$^.E9T='R?3?<-),_;@>3YWCGB33-,+H+-/HMY@\.9]<-CR9\0)]JG
MGI^VH,_X*2!)9\4T*/>FU/@,=^HX\S;1;!LZ&=!9+NO -1<A!355ENLH#:E
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M V3<^*;=[)U:?JDEQACW8& 9$?$K!(T-?!00L9F&8)Z;T]YQ.J2Y)$M=&I^
MXRT,)T6KD$D#QQ_^1''<^TY;*C K?8WF\S@3XB?;]F[[Q7L:O_-VR^/G\O<@
M9E RQI857CTY>O9D)%S\ ATO@JWXJR\J>[ E_]PH"3_3 CQ?6: M7= &[?\#
M./\W4$L#!!0    ( +:@#5G)GT=CU0(  .D%   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;(U486_:,!#]*Z=,FC8)-2$)M&. %"ATF5I #5TU3?M@
MDH-$=>+4=DKW[V<[(6421?N0Q'>^>_>>X[OAGO$GD2)*>,UI(496*F4YL&T1
MIY@3<<%*+-3.EO&<2&7RG2U*CB0Q23FU7<?IVSG)"FL\-+X5'P]9)6E6X(J#
MJ/*<\#\3I&P_LKK6P7&?[5*I'?9X6)(=1B@?RA57EMVB)%F.A<A8 1RW(ROH
M#B:^CC<!/S+<BZ,U:"4;QIZT$28CR]&$D&(L-0)1GQ><(J4:2-%X;C"MMJ1.
M/%X?T.=&N]*R(0*GC#YFB4Q'UI4%"6Y)1>4]VW_#1D]/X\6,"O.&?1/K6!!7
M0K*\258,\JRHO^2U.8?_27";!-?PK@L9EM=$DO&0LSUP':W0],)(-=F*7%;H
MGQ))KG8SE2?'DR *(UC.874_BV:+=; .EPL(%M<0/=S=!?<_]5X4WBS">3@-
M%FL(IM/EPV(=+FY@M;P-I^$L@D]KLJ$H/@]MJ2AI8#MNRD_J\NX[Y?MPQPJ9
M"I@5"2;_YMM*2JO'/>B9N&<!OU?%!7A.!US']<_@>>WY> ;/>P<OB&-6%3(K
M=K!B-(LS%/ KV C)U7WZ?4IPC>>?QM,]-A EB7%DJ282R%_0&G_\T.T[7\^P
M]5NV_CGT<:1Z-JDH MO"E.6YNO:19/$3S)ZK[(50+*0ZZM>85NJT8<Y9#M<9
MK:0R%FH W#(A8(4<HI1PA"FA<46)[IY30L]2.2VTX20,)SSBA =.6\U)I@A)
MPZM0O*CF52I><9-OZ,5O] 1H!Q&P952-&3$ =0^PO0?ZY34GP<HZP>WT' ^Z
M'>>+#X^$<Z)I]#J>XW:NNA[X3L?M><:AGFX?_&['\R_AU$^RC]HO1[XS0T:
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M2MG>WNU"B]K>F$NAZ?ZUKSE]\* T!J1?":&?%R9 ]PDU_0=02P,$%     @
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MG_\,WP(_XC4%@90;-$E37F,JT*_)6DBNKM7O(8,-8S#,J$OM6E0XA;&E:DD
MWX&5O'SA1L[[(;O_B>S O-^9]\^Q)TO%B'F:&_,9[%0=5ZHJY9#IABDR3+H=
M[!+/CV)[U_=R&O/.[T(.% :=PN"LPH]0 L?4",29NO-$?Q==[4,:&ZZPES\:
M'4D\#0D"=UACV&D,SVI45X@SVFCD0+&$;$A<>"K.]X[4G<:,>H=\H"[JU$5G
MU=TRJ<]/WVS($#RHEB]@L&ZC@:\7'@D\C7&]D7.DT.ZU(-W^OV*^):5 %#8*
MYER-E$'>M-1F(EEENM*:2=7CS#!7?R'@.D#M;QB33Q/=Z+K_6O(74$L#!!0
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M5'.AF@?5?*@60+40JC&4IL>W+539(^S4&%JG@FHN5/.@F@_5 J@60C6&TO1
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MH30WM[:4B_RE7+.>.#_L2!\_UCFH: ^':@+5)*HI5-.H9BC-C;.M[*(ANJQ
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MMNV>!B/R':0!VC.A6HQJ M4DJBE4TZAF*,W-LVVC!OXVRJYB+[9=ZKZE*UI
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M39L#01?9"T*/5 B:9#_G!$\(4PWD]2FEXO5 O7-4O&,V^!]02P,$%     @
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M'EU&:MD!'@W5@H32W=RC7-3!T>H="Z=W\-VTX/YD,>2P@J=?X.EK\<P%]9X
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M=V]R:W-H965T<R]S:&5E=#0T+GAM;,586V_3,!3^*U9 "*1M29->MM%&:IL
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M=U ZU)-\ 4F8^D2;4M8R4+!BG*0E6%B0QEGQC>_*0.P !$\SP"X!]D- ]Q&
M4P*<IVKHEH#N4S7T2H!RW2Q\5X'S,,?ND)(-HE):L,F%BKY"BWC%F2R4.:?B
M:2QPW)U?7TX_'$[&<]]#T\OSF7\Q'U^?75Z@0S0711FN$D!D@>:<!+>',B,A
MFI)4E"G#*M'^G5P#>ND!QW'"7@G@I[F'7CY_A9ZC.$/7$5DQG(5L:')AK]1J
M!J5MD\(V^Q';''1.,AXQY&<AA UXKQW?;\&;(DY5L.QML"9V*^'[57:$'.L
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M #Q@2!29]^#>^RC8O*>"[6^QXT=02P,$%     @ MJ -69>*NQS     $P(
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MVQ+>WH^Z0%3U]R85E!8I?D75"1Y5'9Y)E$:PFE;JZA6ZQC5N2H*Z$ H-T $
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M9[&IZT#U)<V$X6JW0[O;7?[\&U!+ P04    " "VH U9_2S5I:X!  #!&P
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M*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMGLX1
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M E!+ 0(4 Q0    ( +:@#5D'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ MJ -6:?[=#+O    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ MJ -69E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " "VH U9@@:67_0%  "0(   &
M        @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ MJ -6;_C0)0'!0  WQ,  !@              ("!. X  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +:@#5E5EEEZH (  %P'   8
M              " @743  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " "VH U9#=D;_WP$  #<$0  &               @(%+%@  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ MJ -6:OGT(0^"@
MJ5<  !@              ("!_1H  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( +:@#5EVKS"CP0<  -0F   8              " @7$E
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "VH U9R##V
M(V\'  !_$@  &               @(%H+0  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ MJ -62-?Y+ 2"P  UR,  !@
M ("!#34  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( +:@
M#5F\*'M*< P  ( B   8              " @55   !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " "VH U93GX./@@(  "[&0  &0
M        @('[3   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( +:@#5D&I65%\P4  'D.   9              " @3I5  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ MJ -6?@40?"< @  P04
M !D              ("!9%L  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " "VH U9@A*W0X$"  "&!0  &0              @($W7@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( +:@#5F';DQX
M= 8  *\0   9              " @>]@  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ MJ -67DQDB"A"@  %B0  !D
M ("!FF<  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "V
MH U9'-'A^DD(  #A%@  &0              @(%R<@  >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +:@#5E7MICI\0(  (4&   9
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M970R,2YX;6Q02P$"% ,4    " "VH U9-MUN@-\"   P!@  &0
M    @($ED@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M +:@#5G96<8U(00  )D*   9              " @3N5  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ MJ -68)3DU1V @  5P4  !D
M             ("!DYD  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " "VH U9;8U.:Y "  "*!0  &0              @(% G   >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +:@#5G<^W![!00
M $X)   9              " @0>?  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ MJ -6:62Y<8*!   8@D  !D              ("!
M0Z,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "VH U9
M5B$%[.@"  #%"0  &0              @(&$IP  >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( +:@#5EDLY*-21(  *PC 0 9
M      " @:.J  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ MJ -60^V$*M2 P  [ L  !D              ("!([T  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "VH U9SY/:LJ8#  "L#P
M&0              @(&LP   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( +:@#5EX ;X;[@(  #<'   9              " @8G$  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ MJ -60/[#O +
M P   0L  !D              ("!KL<  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " "VH U994MGV[@"   ]!@  &0
M@('PR@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( +:@
M#5F+ID5U3P,  *<.   9              " @=_-  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ MJ -6:N&*M ' P  P@L  !D
M         ("!9=$  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " "VH U9ZA7#!6X"  "V!0  &0              @(&CU   >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +:@#5D.Q#%NH (  .,&
M   9              " @4C7  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ MJ -60%O4$[[!P  ]%<  !D              ("!']H
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "VH U90$.H
M&'L1  "!%0$ &0              @(%1X@  >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( +:@#5G",G58*P4  &\F   9
M  " @0/T  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MMJ -6>^H/LI"!0  #"$  !D              ("!9?D  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " "VH U9C"8!!DP%  "X'0  &0
M            @('>_@  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( +:@#5E#_)H6B@,  )H0   9              " @6$$ 0!X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ MJ -63N=TS08!
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M96QS+RYR96QS4$L! A0#%     @ MJ -63E?W%<O!   X1X   \
M     ( !8A,! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( +:@#5G]+-6E
MK@$  ,$;   :              "  ;X7 0!X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( +:@#5DF^H>GM0$  -P;   3
M  "  :09 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     V #8 L0X  (H;
$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>160</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>56</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITY</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - MERGER WITH VALLON</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLON</Role>
      <ShortName>MERGER WITH VALLON</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - PROMISSORY NOTES</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTES</Role>
      <ShortName>PROMISSORY NOTES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - MERGER WITH VALLON (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONTables</Role>
      <ShortName>MERGER WITH VALLON (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/MERGERWITHVALLON</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - LIQUIDITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/LIQUIDITYDetails</Role>
      <ShortName>LIQUIDITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/LIQUIDITY</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails</Role>
      <ShortName>BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - MERGER WITH VALLON - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails</Role>
      <ShortName>MERGER WITH VALLON - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails</Role>
      <ShortName>MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - ACCRUED EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails</Role>
      <ShortName>ACCRUED EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails</Role>
      <ShortName>PROMISSORY NOTES - Bridge Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - STOCKHOLDERS??? EQUITY - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - STOCKHOLDERS??? EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS??? EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Activity of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ck0001824293-20240630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ck0001824293-20240630.htm">ck0001824293-20240630.htm</File>
    <File>ck0001824293-20240630.xsd</File>
    <File>ck0001824293-20240630_cal.xml</File>
    <File>ck0001824293-20240630_def.xml</File>
    <File>ck0001824293-20240630_lab.xml</File>
    <File>ck0001824293-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ck0001824293-20240630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="440">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="33">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ck0001824293-20240630.htm": {
   "nsprefix": "ck0001824293",
   "nsuri": "http://www.vallon-pharma.com/20240630",
   "dts": {
    "inline": {
     "local": [
      "ck0001824293-20240630.htm"
     ]
    },
    "schema": {
     "local": [
      "ck0001824293-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ck0001824293-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ck0001824293-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ck0001824293-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ck0001824293-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 168,
   "keyCustom": 42,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 20,
   "memberCustom": 35,
   "hidden": {
    "total": 8,
    "http://fasb.org/us-gaap/2024": 3,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 160,
   "entityCount": 1,
   "segmentCount": 56,
   "elementCount": 455,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 440,
    "http://xbrl.sec.gov/dei/2024": 33,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.vallon-pharma.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "dei:DocumentType",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
     "longName": "9952153 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "shortName": "Consolidated Statements of Changes in Stockholders\u2019 Equity (Deficit)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952155 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS",
     "longName": "9952156 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITY",
     "longName": "9952157 - Disclosure - LIQUIDITY",
     "shortName": "LIQUIDITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "9952158 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLON",
     "longName": "9952159 - Disclosure - MERGER WITH VALLON",
     "shortName": "MERGER WITH VALLON",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS",
     "longName": "9952160 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT",
     "longName": "9952161 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES",
     "longName": "9952162 - Disclosure - ACCRUED EXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTES",
     "longName": "9952163 - Disclosure - PROMISSORY NOTES",
     "shortName": "PROMISSORY NOTES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY",
     "longName": "9952164 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION",
     "longName": "9952165 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "9952166 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables",
     "longName": "9954473 - Disclosure - MERGER WITH VALLON (Tables)",
     "shortName": "MERGER WITH VALLON (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
     "longName": "9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)",
     "shortName": "FAIR VALUE MEASUREMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "9954475 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables",
     "longName": "9954476 - Disclosure - ACCRUED EXPENSES (Tables)",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "9954477 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954478 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails",
     "longName": "9954479 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
     "longName": "9954480 - Disclosure - LIQUIDITY (Details)",
     "shortName": "LIQUIDITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "ck0001824293:CommonStockHeldIntoEscrowAccount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
     "longName": "9954481 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Diluted Net Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
     "longName": "9954482 - Disclosure - MERGER WITH VALLON - Narrative (Details)",
     "shortName": "MERGER WITH VALLON - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-86",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-86",
      "name": "ck0001824293:CommonStockOwnershipPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails",
     "longName": "9954483 - Disclosure - MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "shortName": "MERGER WITH VALLON - Schedule of the Net Liabilities Assumed in the Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails",
     "longName": "9954484 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Liabilities Measured on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-87",
      "name": "ck0001824293:WarrantLiabilityFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "ck0001824293:WarrantLiabilityFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails",
     "longName": "9954485 - Disclosure - FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Liability Measured at Estimated Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-90",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-90",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
     "longName": "9954486 - Disclosure - FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS - Derivative Liability Measurement Inputs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R36": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "longName": "9954487 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails",
     "longName": "9954488 - Disclosure - PROPERTY AND EQUIPMENT - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:Depreciation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R38": {
     "role": "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
     "longName": "9954489 - Disclosure - ACCRUED EXPENSES (Details)",
     "shortName": "ACCRUED EXPENSES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ck0001824293:AccruedResearchAndDevelopmentCostsCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
     "longName": "9954490 - Disclosure - PROMISSORY NOTES - Bridge Financing (Details)",
     "shortName": "PROMISSORY NOTES - Bridge Financing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-115",
      "name": "us-gaap:ProceedsFromNotesPayable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
     "longName": "9954491 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-49",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
     "longName": "9954492 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Estimate of the Fair Value of the Warrants and Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails",
     "longName": "9954493 - Disclosure - STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "shortName": "STOCKHOLDERS\u2019 EQUITY - Schedule of Warrants Outstanding to Purchase Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-133",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9954494 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails",
     "longName": "9954495 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
     "longName": "9954496 - Disclosure - STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Activity of Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9954497 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-160",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "ck0001824293:COBRABenefitsPaymentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ck0001824293-20240630.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r50",
      "r637"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r478"
     ]
    },
    "ck0001824293_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Accrued General and Administrative Expenses, Current",
        "documentation": "Accrued General and Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails",
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ck0001824293_AccruedResearchAndDevelopmentCostsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "AccruedResearchAndDevelopmentCostsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Accrued Research and Development Costs, Current",
        "documentation": "Accrued Research and Development Costs, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r104",
      "r358"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r527"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in-capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional\u00a0Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r588",
      "r589",
      "r590",
      "r591",
      "r638",
      "r664"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r240"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant issuance",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r24",
      "r76"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r573"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r509",
      "r519",
      "r551"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r502",
      "r512",
      "r522",
      "r554"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r547",
      "r555",
      "r559",
      "r567"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r273"
     ]
    },
    "ck0001824293_AmendedAndRestated2018EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "AmendedAndRestated2018EquityIncentivePlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "A&amp;R 2918 Plan",
        "label": "Amended and Restated 2018 Equity Incentive Plan [Member]",
        "documentation": "Amended and Restated 2018 Equity Incentive Plan"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discounts and issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r461",
      "r462",
      "r584",
      "r647"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities (in usd per share)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r88",
      "r106",
      "r121",
      "r147",
      "r150",
      "r151",
      "r152",
      "r154",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r287",
      "r289",
      "r323",
      "r352",
      "r404",
      "r454",
      "r455",
      "r478",
      "r490",
      "r607",
      "r608",
      "r653"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r110",
      "r121",
      "r154",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r287",
      "r289",
      "r323",
      "r478",
      "r607",
      "r608",
      "r653"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM",
        "label": "At The Market Offering [Member]",
        "documentation": "At The Market Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Accounting",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ck0001824293_BridgeSecuritiesPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "BridgeSecuritiesPurchaseAgreementMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge SPA",
        "label": "Bridge Securities Purchase Agreement [Member]",
        "documentation": "Bridge Securities Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_BridgeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "BridgeWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Warrants",
        "label": "Bridge Warrants [Member]",
        "documentation": "Bridge Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Plus: Transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLON"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MERGER WITH VALLON",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r284"
     ]
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts payable and accrued expenses",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accounts Payable And Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total net liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39"
     ]
    },
    "ck0001824293_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails_1": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONScheduleoftheNetLiabilitiesAssumedintheMergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net liabilities assumed plus transaction costs",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net, Including Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_COBRABenefitsPaymentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "COBRABenefitsPaymentPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COBRA benefits, payment period (in months)",
        "label": "COBRA Benefits, Payment Period",
        "documentation": "COBRA Benefits, Payment Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r102",
      "r449"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r63"
     ]
    },
    "ck0001824293_ChangeInFairValueOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ChangeInFairValueOfWarrantLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant liability",
        "label": "Change In Fair Value Of Warrant Liability",
        "documentation": "Change In Fair Value Of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r535"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r533"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r149",
      "r213",
      "r214",
      "r215",
      "r217",
      "r220",
      "r225",
      "r227",
      "r374",
      "r375",
      "r376",
      "r377",
      "r463",
      "r578",
      "r585"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "verboseLabel": "Exercise Price per Share (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by each warrant",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares called by warrants (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "verboseLabel": "Number of Shares (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r84",
      "r354",
      "r391"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r166",
      "r167",
      "r445",
      "r599",
      "r604"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for future awards (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ck0001824293_CommonStockExchangeRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "CommonStockExchangeRatio",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, exchange ratio",
        "label": "Common Stock Exchange Ratio",
        "documentation": "Common Stock Exchange Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_CommonStockHeldIntoEscrowAccount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "CommonStockHeldIntoEscrowAccount",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock placed into escrow (in shares)",
        "label": "Common Stock Held Into Escrow Account",
        "documentation": "Common Stock Held Into Escrow Account"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common\u00a0Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r588",
      "r589",
      "r591",
      "r638",
      "r663",
      "r664"
     ]
    },
    "ck0001824293_CommonStockOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "CommonStockOwnershipPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership percentage in common stock (as a percent)",
        "label": "Common Stock, Ownership Percentage",
        "documentation": "Common Stock, Ownership Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in usd per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r392"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r392",
      "r410",
      "r664",
      "r665"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, 0.0001 par value; 250,000,000 shares authorized as of June\u00a030, 2024 and December\u00a031, 2023; 801,914 and 49,663 shares issued and outstanding as of June\u00a030, 2024 and December\u00a031, 2023, respectively",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r392"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r450"
     ]
    },
    "ck0001824293_ConversionOfStockAdditionalSharesConverted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ConversionOfStockAdditionalSharesConverted",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares converted into common stock (in shares)",
        "label": "Conversion of Stock, Additional Shares Converted",
        "documentation": "Conversion of Stock, Additional Shares Converted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of stock (in shares)",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROMISSORY NOTES",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r119",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r174",
      "r175",
      "r185",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r201",
      "r208",
      "r209",
      "r211",
      "r331"
     ]
    },
    "ck0001824293_DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognition of debt discount and additional paid-in-capital for issuance of warrants in connection with the issuance of promissory notes",
        "label": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants",
        "documentation": "Debt Discount And Additional Paid-In-Capital Recognized From Issuance Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_DebtInstrumentAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "DebtInstrumentAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price",
        "label": "Debt Instrument Aggregate Purchase Price",
        "documentation": "Debt Instrument Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r82",
      "r83",
      "r122",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r477",
      "r586",
      "r600",
      "r601",
      "r602",
      "r646",
      "r648"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r331",
      "r332",
      "r459",
      "r460",
      "r477"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r477",
      "r586",
      "r646",
      "r648"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r122",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r477",
      "r586",
      "r600",
      "r601",
      "r602",
      "r646",
      "r648"
     ]
    },
    "ck0001824293_DebtInstrumentNumberOfClosings": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "DebtInstrumentNumberOfClosings",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of closings",
        "label": "Debt Instrument, Number Of Closings",
        "documentation": "Debt Instrument, Number Of Closings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r27",
      "r30",
      "r43",
      "r74",
      "r75",
      "r122",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r210",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r477",
      "r586",
      "r646",
      "r648"
     ]
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Stock Issuance Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r648"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r22"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r241",
      "r269",
      "r270",
      "r272",
      "r468"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r137",
      "r139",
      "r141",
      "r142",
      "r143",
      "r146",
      "r281",
      "r286",
      "r299",
      "r300",
      "r350",
      "r362",
      "r451"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share of common stock, diluted (in usd per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r139",
      "r141",
      "r142",
      "r143",
      "r146",
      "r281",
      "r286",
      "r299",
      "r300",
      "r350",
      "r362",
      "r451"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r145"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payroll and related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation, weighted average amortization period (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r271"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r572"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r98",
      "r113",
      "r114",
      "r115",
      "r123",
      "r124",
      "r125",
      "r127",
      "r132",
      "r134",
      "r136",
      "r148",
      "r155",
      "r156",
      "r157",
      "r229",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r333",
      "r334",
      "r338",
      "r361",
      "r367",
      "r368",
      "r369",
      "r379",
      "r432"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r499",
      "r509",
      "r519",
      "r551"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r496",
      "r506",
      "r516",
      "r548"
     ]
    },
    "ck0001824293_ExchangeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ExchangeWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Warrants",
        "label": "Exchange Warrants [Member]",
        "documentation": "Exchange Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in fair value of warrant liability",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r316",
      "r471"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r303",
      "r316",
      "r471"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r473"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r473"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Fair Value of the Warrants",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r473"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r316",
      "r318",
      "r342",
      "r343",
      "r344",
      "r459",
      "r460",
      "r464",
      "r465",
      "r466",
      "r471",
      "r473"
     ]
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByLiabilityClassAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Class [Axis]",
        "label": "Liability Class [Axis]",
        "documentation": "Information by class of liability."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r317"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r349",
      "r471",
      "r474"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r231",
      "r236",
      "r303",
      "r316",
      "r342",
      "r464",
      "r465",
      "r466",
      "r471"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r231",
      "r236",
      "r303",
      "r304",
      "r316",
      "r343",
      "r459",
      "r460",
      "r464",
      "r465",
      "r466",
      "r471"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Unobservable Inputs (Level 3)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r303",
      "r304",
      "r305",
      "r306",
      "r316",
      "r344",
      "r459",
      "r460",
      "r464",
      "r465",
      "r466",
      "r471",
      "r473"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value by Liability Class [Domain]",
        "label": "Fair Value by Liability Class [Domain]",
        "documentation": "Represents classes of liabilities measured and disclosed at fair value."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r317"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument liability measured at fair value on recurring basis using unobservable input."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r317"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Changes is the Fair Value",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r312",
      "r317"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r317"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value as of December 31, 2023",
        "periodEndLabel": "Fair value as of June\u00a030, 2024",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r317"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r301",
      "r303",
      "r304",
      "r305",
      "r306",
      "r315",
      "r316",
      "r318",
      "r342",
      "r343",
      "r344",
      "r459",
      "r460",
      "r464",
      "r465",
      "r466",
      "r471",
      "r473"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r555"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r555"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r555"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r555"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r555"
     ]
    },
    "ck0001824293_FormerChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "FormerChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Former Chief Executive Officer",
        "label": "Former Chief Executive Officer [Member]",
        "documentation": "Former Chief Executive Officer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_GRIOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "GRIOperationsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GRI Operations",
        "label": "GRI Operations [Member]",
        "documentation": "GRI Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_GRIOperationsPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "GRIOperationsPlanMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GRI Operations Plan",
        "label": "GRI Operations Plan [Member]",
        "documentation": "GRI Operations Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r414"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r164",
      "r165",
      "r308",
      "r312",
      "r317",
      "r364",
      "r366",
      "r417",
      "r448",
      "r472",
      "r662"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r308",
      "r312",
      "r317",
      "r364",
      "r366",
      "r417",
      "r448",
      "r472",
      "r662"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r579",
      "r583"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r547",
      "r555",
      "r559",
      "r567"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r495",
      "r571"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r495",
      "r571"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r495",
      "r571"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r581",
      "r593"
     ]
    },
    "us-gaap_InvestmentCompanyCommittedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentCompanyCommittedCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in cash",
        "label": "Investment Company, Committed Capital",
        "documentation": "Amount of funds committed to investment company from investors."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r52",
      "r121",
      "r154",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r288",
      "r289",
      "r290",
      "r323",
      "r390",
      "r452",
      "r490",
      "r607",
      "r653",
      "r654"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r85",
      "r356",
      "r478",
      "r587",
      "r598",
      "r645"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r101",
      "r121",
      "r154",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r288",
      "r289",
      "r290",
      "r323",
      "r478",
      "r607",
      "r653",
      "r654"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r639"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r173",
      "r274",
      "r457",
      "r605",
      "r606"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r173",
      "r274",
      "r457",
      "r605",
      "r606"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r238",
      "r274",
      "r306",
      "r347",
      "r363",
      "r365",
      "r372",
      "r382",
      "r383",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r446",
      "r447",
      "r456",
      "r463",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r609",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend rate",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term in years",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r473"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r473"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r97"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r65"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r65",
      "r86",
      "r99",
      "r111",
      "r112",
      "r115",
      "r121",
      "r126",
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r135",
      "r136",
      "r140",
      "r154",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r281",
      "r286",
      "r300",
      "r323",
      "r360",
      "r412",
      "r430",
      "r431",
      "r488",
      "r607"
     ]
    },
    "ck0001824293_NetLiabilitiesAssumedInConnectionWithReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "NetLiabilitiesAssumedInConnectionWithReverseRecapitalization",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net liabilities assumed in connection with reverse recapitalization",
        "label": "Net Liabilities Assumed In Connection With Reverse Recapitalization",
        "documentation": "Net Liabilities Assumed In Connection With Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r503",
      "r513",
      "r523",
      "r547",
      "r555"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ck0001824293_NoncashMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "NoncashMergerRelatedCostsFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger costs included in accounts payable",
        "label": "Noncash Merger Related Costs, Financing Activities",
        "documentation": "Noncash Merger Related Costs, Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r453",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating right of use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "ck0001824293_OperatingLeaseRightOfUseAssetPeriodicAddition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "OperatingLeaseRightOfUseAssetPeriodicAddition",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in operating right of use assets",
        "label": "Operating Lease, Right-Of-Use Asset, Periodic Addition",
        "documentation": "Operating Lease, Right-Of-Use Asset, Periodic Addition"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r501",
      "r511",
      "r521",
      "r553"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r504",
      "r514",
      "r524",
      "r556"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r504",
      "r514",
      "r524",
      "r556"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PaymentOfReverseRecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "PaymentOfReverseRecapitalizationCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of reverse recapitalization costs",
        "label": "Payment Of Reverse Recapitalization Costs",
        "documentation": "Payment Of Reverse Recapitalization Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of deferred stock issuance costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r529"
     ]
    },
    "ck0001824293_PercentageOfTargetBonus": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "PercentageOfTargetBonus",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of target bonus (as a percent)",
        "label": "Percentage Of Target Bonus",
        "documentation": "Percentage Of Target Bonus"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r531"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r530"
     ]
    },
    "ck0001824293_PreFundedAndSeriesCWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "PreFundedAndSeriesCWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded and Series C Warrants",
        "label": "Pre-Funded And Series C Warrants [Member]",
        "documentation": "Pre-Funded And Series C Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "documentation": "Pre-Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "ck0001824293_PrivateGRIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "PrivateGRIMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private GRI",
        "label": "Private GRI [Member]",
        "documentation": "Private GRI"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ProceedsFromAdvancesFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ProceedsFromAdvancesFromEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Advances from employees",
        "label": "Proceeds From Advances From Employees",
        "documentation": "Proceeds From Advances From Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Proceeds from issuance of common stock in financing / under ATM",
        "terseLabel": "Net proceeds from sale of stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of bridge promissory note",
        "verboseLabel": "Proceeds from issuance of notes",
        "label": "Proceeds from Notes Payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from warrant exercise",
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r582"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r337"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r92",
      "r95",
      "r96"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r103",
      "r359"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r337",
      "r351",
      "r359",
      "r478"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r337"
     ]
    },
    "ck0001824293_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r528"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r230",
      "r238",
      "r264",
      "r265",
      "r266",
      "r274",
      "r306",
      "r345",
      "r346",
      "r347",
      "r363",
      "r365",
      "r372",
      "r382",
      "r383",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r446",
      "r447",
      "r456",
      "r463",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r482",
      "r603",
      "r609",
      "r642",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r172",
      "r230",
      "r238",
      "r264",
      "r265",
      "r266",
      "r274",
      "r306",
      "r345",
      "r346",
      "r347",
      "r363",
      "r365",
      "r372",
      "r382",
      "r383",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r446",
      "r447",
      "r456",
      "r463",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479",
      "r482",
      "r603",
      "r609",
      "r642",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r496",
      "r506",
      "r516",
      "r548"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r237",
      "r339",
      "r340",
      "r353",
      "r357",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r409",
      "r411",
      "r437"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r237",
      "r339",
      "r340",
      "r353",
      "r357",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r409",
      "r411",
      "r437",
      "r652"
     ]
    },
    "ck0001824293_RepaymentOfAdvancesFromEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "RepaymentOfAdvancesFromEmployees",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of advances from employees",
        "label": "Repayment Of Advances From Employees",
        "documentation": "Repayment Of Advances From Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r448",
      "r454",
      "r661"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r497",
      "r507",
      "r517",
      "r549"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r498",
      "r508",
      "r518",
      "r550"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r505",
      "r515",
      "r525",
      "r557"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r76",
      "r355",
      "r370",
      "r371",
      "r378",
      "r393",
      "r478"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r123",
      "r124",
      "r125",
      "r127",
      "r132",
      "r134",
      "r136",
      "r155",
      "r156",
      "r157",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r285",
      "r286",
      "r291",
      "r293",
      "r294",
      "r296",
      "r298",
      "r333",
      "r334",
      "r367",
      "r369",
      "r379",
      "r664"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "ck0001824293_SaleOfStockAgentCompensationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SaleOfStockAgentCompensationPercentage",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, agent compensation, percentage",
        "label": "Sale Of Stock, Agent Compensation, Percentage",
        "documentation": "Sale Of Stock, Agent Compensation, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gross proceeds from sale of stock",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockMaximumValueOfSharesOffered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SaleOfStockMaximumValueOfSharesOffered",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum value of shares offered",
        "label": "Sale Of Stock, Maximum Value Of Shares Offered",
        "documentation": "Sale Of Stock, Maximum Value Of Shares Offered"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SaleOfStockNumberOfSecuritiesIssuedPerTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SaleOfStockNumberOfSecuritiesIssuedPerTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of securities issued (in shares)",
        "label": "Sale Of Stock, Number Of Securities Issued Per Transaction",
        "documentation": "Sale Of Stock, Number Of Securities Issued Per Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price per share (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/ACCRUEDEXPENSESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Equivalents Excluded From Diluted Net Loss Per Share Calculation",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r283"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Net Liabilities Assumed in the Merger",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONScheduleofStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r337"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Activity of Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r8",
      "r78"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r72",
      "r74",
      "r75",
      "r76",
      "r107",
      "r108",
      "r109",
      "r149",
      "r213",
      "r214",
      "r215",
      "r217",
      "r220",
      "r225",
      "r227",
      "r374",
      "r375",
      "r376",
      "r377",
      "r463",
      "r578",
      "r585"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants Outstanding to Purchase Common Stock",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "ck0001824293_SeriesA1WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesA1WarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A-1 Warrants",
        "label": "Series A-1 Warrants [Member]",
        "documentation": "Series A-1 Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB1CommonAndSeriesB2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesB1CommonAndSeriesB2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 Common and Series B-2 Common Warrants",
        "label": "Series B-1 Common And Series B-2 Common Warrants [Member]",
        "documentation": "Series B-1 Common And Series B-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesB1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-1 Common Warrants",
        "label": "Series B-1 Common Warrants [Member]",
        "documentation": "Series B-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesB2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesB2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B-2 Common Warrants",
        "label": "Series B-2 Common Warrants [Member]",
        "documentation": "Series B-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1 Common, Series C-2 Common and Placement Agent Warrants",
        "label": "Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants [Member]",
        "documentation": "Series C-1 Common, Series C-2 Common Warrants And Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC1CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesC1CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-1 Common Warrants",
        "label": "Series C-1 Common Warrants [Member]",
        "documentation": "Series C-1 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesC2CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesC2CommonWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C-2 Common Warrants",
        "label": "Series C-2 Common Warrants [Member]",
        "documentation": "Series C-2 Common Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesCCommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesCCommonWarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C warrant",
        "label": "Series C Common Warrant [Member]",
        "documentation": "Series C Common Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_SeriesTWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "SeriesTWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series T Warrants",
        "label": "Series T Warrants [Member]",
        "documentation": "Series T Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ck0001824293_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum increase in shares reserved for issuance as a percentage of aggregate common stock outstanding",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Increase In Shares Reserved For Issuance As Percentage Of Aggregate Common Stock Outstanding, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual term\u00a0(years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Exercisable, Ending Balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited/Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares outstanding",
        "periodStartLabel": "Outstanding, Beginning Balance (in shares)",
        "periodEndLabel": "Outstanding, Ending Balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, Beginning Balance (in usd per share)",
        "periodEndLabel": "Outstanding, Ending Balance (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of option on grant date (in usd per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock awards, contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable, intrinsic value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r261"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r54",
      "r57",
      "r58",
      "r98",
      "r113",
      "r114",
      "r115",
      "r123",
      "r124",
      "r125",
      "r127",
      "r132",
      "r134",
      "r136",
      "r148",
      "r155",
      "r156",
      "r157",
      "r229",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r282",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r333",
      "r334",
      "r338",
      "r361",
      "r367",
      "r368",
      "r369",
      "r379",
      "r432"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r148",
      "r334",
      "r348",
      "r373",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r413",
      "r414",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r483"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r148",
      "r153",
      "r334",
      "r348",
      "r373",
      "r381",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r392",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r411",
      "r413",
      "r414",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r432",
      "r483"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r500",
      "r510",
      "r520",
      "r552"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuanceCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuanceCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock issuance costs in accounts payable and accrued expenses",
        "label": "Stock Issuance Costs Incurred But Not Yet Paid",
        "documentation": "Stock Issuance Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuanceCostsOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuanceCostsOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering expenses",
        "label": "Stock Issuance Costs, Offering Expenses",
        "documentation": "Stock Issuance Costs, Offering Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesFractionalShareAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesFractionalShareAdjustment",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fractional share adjustment (in shares)",
        "label": "Stock Issued During Period, Shares, Fractional Share Adjustment",
        "documentation": "Stock Issued During Period, Shares, Fractional Share Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r374",
      "r432",
      "r443"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesPreClosingFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesPreClosingFinancing",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in pre-closing financing (in shares)",
        "label": "Stock Issued During Period, Shares, Pre-closing Financing",
        "documentation": "Stock Issued During Period, Shares, Pre-closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit",
      "http://www.vallon-pharma.com/role/MERGERWITHVALLONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses (in shares)",
        "label": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses",
        "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodSharesSettlementOfDebt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesSettlementOfDebt",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for settlement of bridge note (in shares)",
        "label": "Stock Issued During Period, Shares, Settlement Of Debt",
        "documentation": "Stock Issued During Period, Shares, Settlement Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKBASEDCOMPENSATIONActivityofStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r250"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodSharesWarrantExercise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodSharesWarrantExercise",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded warrant exercise (in shares)",
        "label": "Stock Issued During Period, Shares, Warrant Exercise",
        "documentation": "Stock Issued During Period, Shares, Warrant Exercise"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and prefunded warrants in financing",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r53",
      "r54",
      "r76",
      "r379",
      "r432",
      "r443",
      "r489"
     ]
    },
    "ck0001824293_StockIssuedDuringPeriodValuePreClosingFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValuePreClosingFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in pre-closing financing",
        "label": "Stock Issued During Period, Value, Pre-closing Financing",
        "documentation": "Stock Issued During Period, Value, Pre-closing Financing"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock to Vallon stockholders in reverse recapitalization",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueReverseRecapitalizationExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueReverseRecapitalizationExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for reverse recapitalization expenses",
        "label": "Stock Issued During Period, Value, Reverse Recapitalization Expenses",
        "documentation": "Stock Issued During Period, Value, Reverse Recapitalization Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueSettlementOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueSettlementOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for settlement of bridge note",
        "label": "Stock Issued During Period, Value, Settlement Of Debt",
        "documentation": "Stock Issued During Period, Value, Settlement Of Debt"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedDuringPeriodValueWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedDuringPeriodValueWarrantExercises",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prefunded warrant exercise",
        "label": "Stock Issued During Period, Value, Warrant Exercises",
        "documentation": "Stock Issued During Period, Value, Warrant Exercises"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedForPaymentOfReverseRecapitalizationCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedForPaymentOfReverseRecapitalizationCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for payment of reverse recapitalization costs",
        "label": "Stock Issued For Payment Of Reverse Recapitalization Costs",
        "documentation": "Stock Issued For Payment Of Reverse Recapitalization Costs"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_StockIssuedForRepaymentOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "StockIssuedForRepaymentOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of stock for repayment of bridge promissory note",
        "label": "Stock Issued For Repayment Of Notes Payable",
        "documentation": "Stock Issued For Repayment Of Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets",
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofChangesinStockholdersEquityDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r57",
      "r58",
      "r67",
      "r394",
      "r410",
      "r433",
      "r434",
      "r478",
      "r490",
      "r587",
      "r598",
      "r645",
      "r664"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity (deficit):",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r120",
      "r212",
      "r214",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r226",
      "r229",
      "r297",
      "r435",
      "r436",
      "r444"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.vallon-pharma.com/role/ORGANIZATIONANDDESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r341"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r341"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r341"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIQUIDITY",
        "label": "Substantial Doubt about Going Concern [Text Block]",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of non-cash financing activities:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "ck0001824293_ThePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ThePlacementAgentWarrantsMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants",
        "label": "The Placement Agent Warrants [Member]",
        "documentation": "The Placement Agent Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_ThroughFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "ThroughFinancingMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Through Financing",
        "label": "Through Financing [Member]",
        "documentation": "Through Financing"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r651"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.vallon-pharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r538"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.vallon-pharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r569"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r567"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r570"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r568"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r90",
      "r91",
      "r93",
      "r94"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "ck0001824293_WarrantLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant Liability, Current",
        "documentation": "Warrant Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantLiabilityFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueLiabilitiesMeasuredonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant Liability, Fair Value Disclosure",
        "documentation": "Warrant Liability, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantLiabilityMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSLiabilityMeasuredatEstimatedFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Liability",
        "label": "Warrant Liability [Member]",
        "documentation": "Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/BASISOFPRESENTATIONANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofDilutedNetLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r484",
      "r485",
      "r486",
      "r487"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding, measurement input",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/PROMISSORYNOTESBridgeFinancingDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants and rights outstanding, term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r642",
      "r643"
     ]
    },
    "ck0001824293_WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In 18 Months After The Warrant Stockholder Approval",
        "label": "Warrants Expiring In 18 Months After The Warrant Stockholder Approval [Member]",
        "documentation": "Warrants Expiring In 18 Months After The Warrant Stockholder Approval"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In 60 Months After The Warrant Stockholder Approval",
        "label": "Warrants Expiring In 60 Months After The Warrant Stockholder Approval [Member]",
        "documentation": "Warrants Expiring In 60 Months After The Warrant Stockholder Approval"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInApril2028Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInApril2028Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In April 2028",
        "label": "Warrants Expiring In April 2028 [Member]",
        "documentation": "Warrants Expiring In April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInAugust2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInAugust2025Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In August 2025",
        "label": "Warrants Expiring In August 2025 [Member]",
        "documentation": "Warrants Expiring In August 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInDecember2025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInDecember2025Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In December 2025",
        "label": "Warrants Expiring In December 2025 [Member]",
        "documentation": "Warrants Expiring In December 2025"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2026Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInFebruary2026Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2026",
        "label": "Warrants Expiring In February 2026 [Member]",
        "documentation": "Warrants Expiring In February 2026"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInFebruary2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInFebruary2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In February 2029",
        "label": "Warrants Expiring In February 2029 [Member]",
        "documentation": "Warrants Expiring In February 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJuly2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInJuly2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In July 2027",
        "label": "Warrants Expiring In July 2027 [Member]",
        "documentation": "Warrants Expiring In July 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInJune2029Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInJune2029Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In June 2029",
        "label": "Warrants Expiring In June 2029 [Member]",
        "documentation": "Warrants Expiring In June 2029"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsExpiringInMay2027Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsExpiringInMay2027Member",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Expiring In May 2027",
        "label": "Warrants Expiring In May 2027 [Member]",
        "documentation": "Warrants Expiring In May 2027"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of warrants for payment of stock issuance costs",
        "label": "Warrants Issued",
        "documentation": "Warrants Issued"
       }
      }
     },
     "auth_ref": []
    },
    "ck0001824293_WarrantsNotExpiringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.vallon-pharma.com/20240630",
     "localname": "WarrantsNotExpiringMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYScheduleofWarrantsOutstandingtoPurchaseCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Not Expiring",
        "label": "Warrants Not Expiring [Member]",
        "documentation": "Warrants Not Expiring"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, equity impact",
        "label": "Warrants Not Settleable in Cash, Fair Value Disclosure",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r640",
      "r644"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.vallon-pharma.com/role/FAIRVALUEMEASUREMENTSDerivativeLiabilityMeasurementInputsDetails",
      "http://www.vallon-pharma.com/role/LIQUIDITYDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYEstimateoftheFairValueoftheWarrantsandAssumptionsDetails",
      "http://www.vallon-pharma.com/role/STOCKHOLDERSEQUITYNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "auth_ref": [
      "r306",
      "r346",
      "r446",
      "r447",
      "r473",
      "r655",
      "r657",
      "r660"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r143"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.vallon-pharma.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r143"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r532"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-25"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001824293-24-000105-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001824293-24-000105-xbrl.zip
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MJRF)Z^_P= 2MLQ-9O65\:YXDS;;-?MY:1P2"E<M)=YGE!;(+<,I,=UU@,&(
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M?&<>T>P45NSKA0!LMI@0Y&=(_,W\ZR9\]3'Z>:_;%"4I]JM64XS]/.E1(BQ
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MC0#VTRX5 _8 '] V+\T :*L@XN\<])N# :QT;CGT8.[21G3I+^33JZZY4Y]
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M)P!?NA/0H98 SIGE!Z4<MNE^2V:XQAOGMDY<?)$!+\)_8;F=5NO_I_2,+BV
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M.A@\W[[<;XHQGL?"E/![&?E-\#%_1Y_HBY[^$=S6 [S-B+O<B1G;/IJ:LR#
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MZB@UP.O N!X>"X9@/M5!2(&7_L[/]^DP/E!W_R8.%]%SCP6>%YK )>K4U/_
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M"@ZQ$ZEZ)"FUSEQX?<5E8^E]?B9LR+MC_NQ<>6?\&^OO^8WB%W:FGZ$3:J?
MS $5_J*G*KZG'+C._"ABZ2"8'73M82-+4Y@7]R_:*_FYD0M:'(=3B$/Y=G U
M)@B\+S*I0MA8SOO#["8@=VIQ<>O<"0SOA8FTP@0+,XF_/!R6P.0[*@D7?J.J
MVZHW0Q&J^BRH*LQ\0WN,O[B)C443* WK4 @5["$:B]7*/H=JJ.A#:\8H0NC@
M>(RY+T$*J6+R=J'KJ*7PO'KC-W&5I#JZ P;L^7ZJV#-%)1XU:_QPZ@7[]H.?
M[;O<+,!_2*BF/R8=>$,KG*:_ A[2X<B./#LNRX9:W&('K*"B>5I?,06$GO\Q
MWOX+T9Z1G*@$E#[18Q7,U:7;NL;&IPOA>/=J^L-4CZDC+Q;0_5#WLP:X@&::
M$%/$7W2:2,1%8!1KOGL<I%+2\O]%>&VE4332#Q?)R\( )&;P[KCWT*#"F%#Y
MS"0F/^A7Z!#YN642/[I)04M[A2L\%%9/>"@5):'$SJ6 A!4C]0-B#FY:D8C^
M^/G(JY:&C @>[:BI"%\,1?W5>%2G%IX2+0R5F:613+4L1XR[AQ*B@W0'FO+%
M(!(/#B O6C>["#M3U<%'JK]SG>&L!&<"J.NL7"+4@S(<ZF2J;2G^G"!REI*%
M6%X&MU[7:CO-(S[!F[Q)E^>0I1@Y9YB0[9F3<<F-E4"GQA.@OPL_T!Z*LR&:
M)@:+[_+[$^ 8!,!39/#D&0K^RL/Y5Z"S@ @2X[^#,L1__<WPHA._4XE 6Y44
MGL&#U3O!*&VZ>A57C]S+<^K"IRCL._C$8V<R/N$'GK7BNK8^]ER_=@+4S-RB
M)BSOW$+E^,*JX"1/'XL/4BE=@,!^5M"@I22ZT@"8LP&L;L[K4(-V-%028R@W
MOL?G4AIVE1BTB4!P*F65&51E!H4S@S+G %TK-A:/.WX179+$;[=*F%MQ2USA
M.PHGV%U0@(B[+%N2!9:)J*Q<3D=IQ5JL&U3N8F"#;8V=].O,*J=7+84G(G66
M;,##<B]P_U%4YUB+@G(_88&:CIA,VA2^%F4I=6%N> [/Z8 UH<YA71"84>4?
MP@?F)BB^,=GPR 2?6.JVZKPPJE!>L<_'E-27:/P8]$I=P'#)YE3!%O<!I6 B
M X*:VPK;Y<37TS$#M:)Q\"0XF6/*1\F7+Q?TTHF5'F^<SPB*$N;<0NG,3B("
M@@N7W^)I%US@?Y>G@0X.*_CYV/]I%'K#HA[I^HWY\MBQ_8KR'E41=Y-501\C
MXB,%=D4TBZ_"4B'<5X'PG2\R@3:3AZH8JF<HB]PJ6A^%F4Y.]%QY^)F9S8$M
MB0D3#=BWH<P=<NG_\DG3G;FAO%_J)ET]O>G3,OCPL!$D'PT(<E.2VA#LZX7I
MA<V#T/QR;?B_YK^9?]V$KSY&/^^UFV*O%_M5JRG&?I[T*+'5'/3E3(]*_ESN
M=/);U/I'?:3P8C #M" >:9?)P"2F)WN7+4$$,OZX?-D@<IDT?\,+HW;_*@H9
M]O+FB\$F4X>2"&TA!B(RH%I7VPT.B\LXH:,%!-<)--E-P U]*A6$4'<L06?;
MW9X-N.0LQ#16U%_/-M:6-O@*596 TERW:SQ:/\R>-RL7NFD6*.(68R*Q2)LW
MG8X(6D(,4.C0MD)!)6O7N*7.K:U5"V9'NV5$CXBS=HQN2]@QNM.*-E5;-N9]
M7.>#7_R*XCDM?I.%RB;NBA5*%:&N)=1^JX"$*M,.V(/H**FB$6IF?3"A_Y5*
M'_C'55NI@IC]GB@?B07DHW9MV*G++:G>%W<6^O&4NS?1OO*ZS*+]? A/*B#A
M=6K#=JLN=8I"=1ODM!^M@(629"+=YU75 O>\P'T;CSRH)<]=VJK.(,S .&?3
MLH@:L<LT(OQ?[.9K7>Y$ .5QDBHZC_KZ!:3S'BA@L0[_EIS(J53_2(\/<CDZ
M @H)]1FT+=/"QI<T(WU]M6\[6[5O,<[^<>B6Z88;T"UON6PI .%\S_!1-A8^
M\8';BQZJ.ES'3K^Q;=OH\6?05#K4=\!O$;[VH)4>T[+.>UC80 LRV?$Y+]JB
M=5Z+B=\XE<5O!@;7T4X@<!?R:K J<UUSV6W2PE(V9!V4J"%K.Z^&K+Q-^=5B
MY-C7H)PZAM4'T=9"[4&T]>J/ZX??KQ^$O]\\_47XG]'W[W>W6S5298^.>:%4
MS,/G.U,8S6W=$*2@:]IJGU#>GCV8-ESW/WGTQI219H1F4/)\:S[4&+ONA#ON
ML/XH2Q\*@+$7_<7G7K\-/&;.LV8^PFHS'S^]@HN-IG 3WU'^BF5D+L\V "JB
M<@&3O;%N@'4$I>EINJE:]IPGN]$]C-\-Y966B?O9T=A4&Y,NZ&$\;UJZKA[&
M;UVZ:'&ZU+>(?UWXI-T12XF]#F:PX-.SE*@O59UBC>ERU:EXO*U=*!^.EU*T
M4HW;'* A/Z3SCX*I/BOLLC1P()SK%9ZT1/L=^*R[C+7P- ?:B"5(3%OW(JYF
M5Z4"+SIZO!_5!<4#9"N4^ VJR]$"1,:U#$)[;_H%/;1;.:WGH.T],($J)DTN
MK@AT:4GD#X_-KDBT[=EC(]&UI3E9[=BI?.Q%]#U^$^0'!$N,7=YIT6E8<B]Z
MM,%JWH(NRO0)60ISB\PUXP)QC=P.N(:=<=,2 +]N,!V!7Z!%"$2\>M$=?>"'
M)4YC!32AP67I.(^7 ^$7R\WKI);8\5D)/L D/+CEGL[E047(5=:%?V=H>7C1
M!YQBPN9R6LQP?2'8PZ(>8D+*?52E$94F#9KK0;6)^Q;MQA;#5QPPD30A89$+
MJYMV?HJ%<EQR*LVCI/,M^*KBGDTA,^(+8,]R> ON.-&RA/C0>!FZO.7'K/H(
MXW=AYAFN/C=H8?>%_H'5;,6\91VUL3Y'A,X#"5Z?#!A*!IA<RK)_4TMZ6.V%
MSI>X+(88_FA88-&O#0L;\2^^&PT,KT51&F[+I2;99J RT"\&RJR4;/KIJ!$-
M0UVMR(RV=&@!0:K3O5R,/OC)KO&OQV5[D4?N N,O<2!>!^'$M7GS>(BKM.Z9
M==QGO6-H&:*Y7!%+FR._K\(J\$/\"8MLI OC2+9;GYD1H/7%'#[J>=>I.,%5
M.SQ)EQ$/OHE5N0=%O4X";-EUK[A$F\P4BC+/9,!:[:!95H6H%D@AALQ(OUQS
M"XT8(VT79?M;6)Z4:7TUL3JZBQ6++VFK#6N/+M8GNL4J.5W;A(V21W&])$W\
MP7]<*X8'4'*SE3;I656+P7L_+>3KUHK&7\,&33/:LZ8)IC_G+ :WU3150_6L
M=9-B53=9U4TN1R%C.JK#I_(FDHZHV2.1=#IK\Q.5,""(]0V&W[(LW\;Z3);5
M$?-SY=U+@YK7">PBBNE,1NIIF'-:@<PY%M_X?^R]^W?B2)(P^J_H>'KFL^_%
M%.)-U7YU#^5R]7BGJ^RUJWMV?]HC( %U"8G1PR[FK[\1D9E2Z@4(@RVPYIRI
M-J!'9KPC,A[H4GURS<F,*1.JOSD^T_H77,,S@5'>QB;>>2G$=F0<J685.NBS
MF<MF(A9>-&-MSQ/5D_/$BQZ6=_2SC^U:M]7,&:F^58R#>[$IP(7C>,+>C8_(
M=IX)=&"X(E@A^".)+^0Q/B06@QTFC<%,,%<8UMQI.&P<$:GAL#O.<B\(?)R^
M76NU&_5VQK#W4!">B-_'2B0HN-^'$RTHR.[Q$)IH6:*ESN/"6$+8C<5XHDEV
M)$VV]]2BEG\YCY.!O)0F3_I$V4^0CI 9K6;[4,M.P:SM1,-VT1*E4V,\4)+A
M7^=!<$_QDU?,\1#GNA0"2'9;PZ9J-"@ CX3X=&CSWX:0>>%D,[5JG<^*6(5]
M&J>RB]H3G_6<,Z2^CK.]8I,V Q?[!'FU)"(R4T,H*26ZV1A3;S)7]( @RS$5
MKI;GV2$-3$$0.JX7G<*]I[ $MQGY&8"8XI=A*>;:>>(U=%1.C8GGS)I(*8#!
M%+[66CBF,U3V2A]0>&C1L[1.IKK).TN[A>6YWMQ<@OI"8Q%\T5!_H*\B%0A.
M*>^D5,=?PZ%]2NRIP(%AXL0BO$B=G+@=A)\)M.Y!@-8&K;M_H%%\*T&%""O>
M@&)A_.E0/]CS-KX G]BA<:DCFH7J,<,/7S.F5!TFAB78JYKBML5?(,=7*J-S
M,EX)C_W!5N%8S;!!GG)7SIOKJ22>71I5R!2D(;*66,.GE?(IG8;4.9HYQ[Q;
M!&E3'@V=X[!/KCS]^/@@82;(?I[$)@520\Z.I/]$7Z]W"_:?>(&F$9UZI]L_
M6-.(G2\[BE8 \92W-]<4X"K/2MJFFT21DH0#UFJ7#JB_'*:0>>O\^I)55P3>
M)&G]8-9]9/U<MK;([+V7K>0G-S1%96JB[!^2[3_DANUD:$]^B[22B-<BB<,/
MUQ%MAY93*U+*W;./@[9>%::7@)#NQ)2#R%WB'MY.(JFJ-RX=/_))%?Q*@>MK
M/I "KK]%A//?LMBT=_:QA;UACZ'Z^"0,A.$V<T3V;2P4J5\\0LX\WP=KQB(%
M^^1/B?$[CG"X9LC1+9ATRW,8A6G[> ZC#])L>U%4L5;J<S-U?7>P6WJ.A_Z:
M.O2D:HF?R<,XJ '^.J2>_<:V+"]6.'6 G<0&K<$S.+40LBNMFV,"6X'W7ONN
M3*L=Q^8Z5'KVQ?1LDC65V"[.VKB=2B;DXY@4G-$HCJ(LV&T0"_;3A425LGQI
M92E:K^^%"]?HT"U%Z?X[=)0.&]L'SO8)FI,68@E#XV!> U@;-_(P^]DR4,=N
M/H-F.G%H5S.DC/U-UF:SE^48<$U:<8LF0B*<9 FA+Z=MJM(2:Q'QL'SDX+1D
M(ZN&O%8TT[ ]R,DTC)$WG5W?4,WR9^H,<D>3#RAESKOGR2;WB5R38CYNE.[6
M;:*/V^IFY+KE)!M3DHJHJ$XE9<G#;V48Z>31]!R7IR\S]Y&F$">F)/)CUWJ:
MLC+2<;=K*X)9?$?35J2SI[8B7PS3_0.GWD7-1+ST,7ZWE4ZK[[;2W42^#&_N
ML8W([]?:U^OAP^_WUU^OOWU_V*FE"']^QEM+VE)$[>M#?7083Q^8!2:O[C5M
M/HRUV>#Y211Y(AI/C>'%N&/F'-ZLR;MU[4LTN]!4A_9Z,G5LS$19E!-86!$M
M.Q$0-WG,LB@=6HY=IP,)9#,Q3#@VTA,KEFV-= G.;U<DH!QU+ 9S+PU4%^92
MSJJD3!5E*",.JZ3Q,ICT7U/G+YJ8(,>?<LDSS=3[:"-FO!I!CB12IT?2=5EK
MX4 (:)0S 8=7N*?'SB?39DI.= $-N<Z<MHGU\N9XKDU,RM0$GV[.HMG4*M1"
M4 K( 98,[5R9R\[GO%^(@EB-D2/X?SQ,$XL]Z#PVS5W<Q;-(0XX0LTX%KK*'
M=^(RU1'2?'86R2J>@^/8X<3.*(>GI6&/FYGC O<4Z=JBR/9N,@N[VTIF8;]:
MH="ZXB\^ME1_O1SMLX_O->UWVYC\&6!3!NU? 1E%)(;$B&JRACB%>=%P2Q")
M8*";=/"2+2](6IIDK(-14@/32<D?SAQA7J#3T'KD]^J=)/K;#?RNI 30?&4"
M^*\DUE/HIH9S1 J4O\M%A!!45#86BH^:[%$7CC^EZ^6G&C<497$*=>,A<8"5
M_Z@DI'Q(27@D$)0H5>EMT=+;9E5Z6Y7>QJWU37;YZ2C7UBO+UCLN5!U7G8W.
MQG/;_%<@K2EA6TFQNJ_1Z=JY66?U&DC;)4Z=Y_5)($E]WC+4=J3A2)(=3,,B
M[;]>;4 W]R30<.3J1QB/JVRW &!E6;S(2^2 1V/M0Y-6!?&?P62VH%)AU5YG
M''FH'0%!T2,FD2<N:\00U**+CNE,Z#$NXU$5._+3(HM>V( UK4D(;*G=8HL/
MHM^Q7" ,+8B(:BR2^E4XJ;<8A>7>+,[&]4@.900@VL=:1R"FNWO<2%&'I68Y
M:IJ%F/,D&4U$.9B(&]0RJU?40$'(YE$0(.989<4/\)(T#1SMV,QVN]X9M,M7
MMM!NEJZ6HEOOZ]VR+:I7;PRJ H_="CR$TW47.EU#[FI_%;[7N5 ,J:.E-P*?
M!T4I4_*M=AM9-C?<4A(P:E8PDC#Z7;7_XE!J79QP%5$V?!0CYOW!<I2VN/_Y
M\VVKE:U9V5M(")+-G4+/YJ6S?=Y ULX19=\42;[I][;(U!?T)27F*N.P.9Y[
M,#5_LLGEOYGK9&7*=,X^DM/3_%"2FIB*0RH.R>>0;6I9]LPAW8I#*@XY'@X9
MO#R'],K&(6_!9>*)YTJ<\I4:+E19Y0<"S0G)I!R[5AYO*-[_,R51?V^2Z/AG
MN%;\6_'O8:WN_?/OH.+?BG\K_GTAGV#O_-MKG K_;E%^15_RW8S<=^GZBQWJ
M1;;(Y5#/C>C8" ON[#'<961WB^RE"DJBE9<IEX/WV*1FQ&$33C7)@N=WB!.R
M*+I^M"D5_>*) KG'^XWZH+\^.V._Q_NO?.:ZI8<L3V+",(=VPN>JV5I"*6(R
MJ(+P,QLS:E3>RFI8^=;;+!9I9[$=(-KU;E'M4WY[8M!8;T^$^NQKE/3Z3].?
MIW27%U=>7ES5A7Q+S\HR-YIG']/ULD687.H N)_EB[WD5:_QT),X&[\2\\_M
M*,=Z)Q8\WIZ*A9HQ#/0MNS[MRG Y_/:K8=J_.9['^S&PR8U];;B8R9W54;'7
MRF+"PGT6CBWD_QHV=+9*3Z<9)TI,7M)I?C-Z_UE@.DVKH/DJ5L'VP8EV?G B
M;3.\N.^_94$'7/#-L=T82/Z0RO1[6*^44_+1ZZ2[/_0ZZ9X392T$^60!6UX^
MC''DDJ<4:BV<";-HW$[@\08,.#X)!ZODQ!&^&BL4E<UHJ%HX7BH*4/#E $49
MP)/&C*FU^"<XFZ+;J3?[ZZL$CKLT Q;5RO[I),,D_:VB)&@^:"G+X532\[>#
MP?JHR%L(%/WA8*7]SNG*Q6(BPO8IO;-6<"+7H*4:0"G[1VH:T.!\).9M-$M+
M,8G(!,H:S=7KGGW4>\UZ/^=HY:_E+IPX:<RW#XOY'F(>U-I6F'\+@23LLD?]
M::@3B6EK*V:X>^FK2KMOG2J=Q@8MIGR1G>@T:F'8ZY]];-;3PP,/UC*^0JM
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M@?9>ZI"^W\\]I(^J0-=QXA%4@'Z/.\E9B?B)ZLX="C-WP]@!"YCZ>477+U#
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M6"*UJ/-^*@E+3Q3^+XT5N:>P6APYZDY(VH5TDZ0+N!P$A@5"$LWN,?/J"JC
M4PAG?X.-I5G!8JEYP0+O(@"#/,&24Z?PU.%N(R>P&P.3.AGX.W K\S\Y=A Y
M$<KXWQZPBMYII+R(OTJL^G2_-L('\";M2!P3/MU\$HS)-0BP)8.$(,%,M!+"
MRR013&FFM@:2  0LN/D2&MYVAJ*0+E5?(#(Q!_E]@;:WJON=T*JNF@F58RV'
M:294)JLUVSZY\9DHOV^")#5L@X>M0GF+_D[@>5)-#FW#6GDF:;8O8.F!3P0"
M]2KLPL-5J1=8?#AT-)FZ#(8:/?&]Z8,<&:^G%;TC#/K(;)W$ 6$H@' "EZ:K
M<V",8\!P(V HD[(],+JM"0\!&1-A"?\9V FC*:G\HI<H,[CEM&\9DK,='YON
M+)?,X/$$RV-/&-/EUCHL^;\"PP4!8ZT 54O')5,'[2U-;US^%S>AC&""]0WY
M;^1OH5BQ[]2P8=03 [5LH)6>(J(UL"L&-Y,WB)I(QR,)H*%MHX)/;^L?8<\A
M##")&$K89$$$4J2=-P5-.8FP\ #&IPLK$ZV,KG\*_X6B!'Q7W#*\OKK =W[%
M,9""I_HB-D,7Q%8'-N.#LP@[%9HVMZ-XA-5&Q2VW:>8"L"8 @FA6'Y"T!#(-
M*0N8A0]IQ[DO;+8B$*&9. H\>+OG"41PLA*(LF?RI;R/$WIFEY;C_, U*#2"
M2Q!(6C##%G[=@W +FKUA9!N'T!V.R8G4!ZT641086(@GWL)0WJHWKS-N#9$2
M/:.M/H,C0+WJHB:ZC-F/C@66M6MZ/_B.@0VYY81/KFM#^%:0(SYY@9[%%*PU
MQXW!GS>/%#^ W^[3Z0HI&-[K2JP?H&/Z2%^(B6;CPSV\5_O";Z.O] \I,H\1
M3K:_)+JI2+89DWR9F-,IO!ZH F0B]:"<NLY"^F-T(:!Q[)HC_B[$/W@C)GSB
M<0#>P"T'QZ5POK>7Z3S2]'/,ECX2AH.RZPE[^I@@=ZB':PV@ O!B@']/0\F&
MX'<DHGZ]O]$^F4Y-(DG($_&KP$?X*ST)[Y:W:3?VN*Z194?WX=& Q:0?%[FP
MVKF!6)D2_U/[M8N:8,1P;?%%14HV]7)\;,C-\)KX8L"[=<++\M93![++>/$?
M0$Z.G7HA_UJ[FQL@B\8LH"-PK]#[=@U5]_M;A:I?@12S+:_;1SR+84]EX**U
M//-/1NTA#6T,OU%*@X<NKC8RG64,SX13$H\.:"O>I1<U%YYMD>(08Y'I;Q[/
M7"SP3!<@]F^NPVSGD;Q)LBR,I2E[00IO&'?@!*0/,5H#8L_S'+C?E_IZLO)<
M-@NXRC(7"\QM0T4(S %76V!LD:QV4%U:Q@(DH^.N:J#<1JX#>^#:-? =<2N\
MA_+90 W<!A@(A4V:GCB] TR Z A ?:[HR< !(#"B/:I[ )H'2\\7,C5:ODT.
M/0A=U^&;UBS8/?'J$@!!JM0+4(KC TEZ>\%X'CZA%#)X+?4@W! Z&-:>!&,,
M-8.\Q1[%-11'EXTNQM=,A 6(5(2O/3=')N"%Y,)JR31=^V;X ?[V#].R ,S?
MM7/SVS^^7VA8>PNXD<^AQV ,2#X+32(D!BEEC'\;@&=FP[O!]5S9 '#$.MBP
MINV8@/JQ2:VB04? ^\_OA_<7ER/F&X2H&=(+D* E6S7/'!R:)^T(LKD1C:':
M_MTF&_H!-:9H>@F$@8Q"Q+ 00?,ET)AI>*8(\XQM1D:'R/;0HG-YTZ>#A1%C
M8$;@$3ZG<IL?'NLUD#,1U1@11"7D<07!$@FNTP2DL1\ .L'<"M6&P)06<VRQ
M="#!(H:Q NX;<7HFVH0WFQ.0#098@&-M&5@+Q\; )-V#VSR_N?N"2@UH?<HN
M\8P3-D(F(JQT!NSJ(7C#5XBG2S5!;R20&\ 7>(Y"</]IHID#)H[>;M0:" GF
M+"V6B8L:%Q8<%N)R&\A]3)L =<J]A*Q;A=6.1Q7X/KX0V$^XF!8&VBPDN)GE
MC-#H B#/38N+- YM$;'%GN!/3D0VD;S(!#UM7 *Q!@LV\8:())*R4$@5;H\+
M*L%<(2\ O0/DPV4P"(BY\N:Y\<BR'X?Q>W,*Y(NA9CR?8F+'BE1=.GSA\##2
M"9HQF7/;@0Z.EN!,F'A !-0 $L#@ @W=9Q_M4Y*3U+V<7AA)!TIE,EPP3,,K
MZ0JB;I6IGQC?@#/"'L6P\I"8N<A&'_72=\3I42A^N<314*:02(DZW +8O&#T
M)^Z3\PK<09:C@!0X\D^VH$:\AW,D/@?Q'"P5960CF=30"%K@_KTQK (PB>T0
MYPXX8S/P9( W[AZN@#<6('1&CH74O_*F(C!PJ:#$\X$RG#E#?J?[O@X?_HY,
M98V=.=V(BL0-F>=\^-MG^-E;P8T+XMLEZ%'FKF SJ 4]^*2=/_QVC2\'S\!$
MWI%KQ,<_P ^!-69\1BBF1O+W_@Y.KRIT9!B H"1M:S1.B0*X_HNNC\.,Q#GG
M$,>5CB=A>H'Y:$+VB"WQOM._UQ_JX.4[')F?W6"F#95IIL"&R!^P#P//?I#4
M;BC)Q9SQ?:"6H[O.;[Y]OD!>M,2"B0G7"T/B>W@MD!VZT]3V6,AE12?9Z#_"
M9<X"$V9J(B?^<@2Z<B* ?<F#VF@W WB:!MI60"5XIN'YP00M%'@_GRGPQ+C=
M!$P%7&'C:0BM!]X3-HVD-!#MDQR5@-N6IT3*'2 >_N1>J4>L8SM/(D,)#\E
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M9 F*G^AQ(9H<\O+%P-U@YL@,>UD:PGLZ/+"ESQ$A6+)5E\N00+['4H!.I],
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MD]T DH\NL2_#+[ AHWD,?;2'%DYJG'%H3TR7J0C/U4'HLR#2?_"1#AD]N)]
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M_B?7G,PHXXW1<!UQM:@I45<0/<EP;64DC.'QX ?]@6S\B-E66(_&+#E$RO9
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M>[2"[ZG)<0*R+A3+2ER:?8)5)1EU?32M)J-)#EPN&^&$+55DV2:OO$\5RIU
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M63Y3(D0AJETDPBN)@/# 2_*LF1%HX^F?_8+9I#A&:FZ.YW1W@O^6@3N>(Q$
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M3H>U'92#%R$FPCBEG7"DRJ8?LEF3L'LV4T=-32]!%,&S_LTFTAY9Y=]GX\F
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MQ,1S^2Q*@^/R#^O(9*<TRXS.S,,30SX@79HWE$/)\$09Z0.4XJ?H550+9B.
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M>"I=2'F3Y+V9"23H(KQ ]A7%P6.A&QUN"5@.H?(#P?Y8+OB0;,_-LS ](;J
M-@36 @CE$Y1$.4H^;KP@D=!^D4RJG)='?L)P1 UST(HU,:!F2R;'T*)CW6S#
MY*CD.Y9"?*=^ LD^E6="K'8]LG(639BZKK]*U>_!J5GY?.>OU"7H#?MM">%E
MDUE^S,']=*,X]>,)OJY\@/.+_4OA:&>-;)B;)(QL*5DS:.BJV?89V5K6#%E2
M(//!R7E ! :3K\'3<6.,?V40_1K<]CR+ -PBY.QPOY/%'T!Y*UJT.90X]QM
MVJG:&D2>KN3[*=B?L-]*?+N*RFZ%%;;Q6&%K7AI<< FS.)I> 5!+ P04
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MP&7<M^O  A6"#Y<-RO&PD)>JMY '$\W*YH&+8!O_J;)@P6G9+' 19/UI$F!
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MIH[(SU6*K*RJ\UOX<3Y$SK4BCN$REU8)XGWVQ$7O74X)=*B-[(>P?#L"^$M
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MVM7#(L;]_ G#B<+L@*9LA<34BHD<B 27B,L8G@B33<Z99E"U,7XO0>MDUBK
MH9[P>\IP90@(0V9)E#YA^,@RP=\"X89:G9VR24,O-NX1;NRI*AT5]+V\</LL
M=U+F;/)H;9*2R!%#_QD$QU\Y,\8 ,&YK+_+ZI?NME(9%B7YT@#G1WGC;GPRG
M?E0J2,VX>]S )BH!%Q4!F7S1'/*91$!SZ[1Q1FL1:@=F#U.U3@YN16S<0'M=
ME50M],X(Z*HI^Z?3TL,LC6%<W2R9$,OJQM!4JFB)"RR1I+-":TRY$ZJ'0N\=
MY*R3NZL,CEI*J(:*0YCZX1C2KI^,D8AV*\;3XR)N2#N0AW&(V8;).NBN6!,P
M>?&V%&L4&FSFI;40+4^Q,C@>IFJ=7&1EC%1629])O^+46&<-X=8CFU1)@N[;
M87*KI0.,W+6L'2@]E/0OX4-C;$['T_; G_DP@CEO!JG/*$@24RA#*I:38)0C
MAL:4=.*)V]K-K]LI62=?N2(&;OC*U46_,KPO#[<,_O23">:H%X6V.47<1*:I
M!N*MP:3$@".!2TVX4BE&;Z,TU^JY=\_,+/+ =7*!E71>7<[UDK\8)Z>0;N&3
M9P6:8ZZ2HP,BT3V3H#DE0G'G40)1YMJN[TYBULGCU3<#%1304W'H!D9E-"PH
MX)C[.HJ^/2"GPI<N9%0,Z8I0?43J?HH608;\,9%14177X/'+YG5IO</?JTU8
M?ICBUVZ$H\DS)O"OM48M[[A[+S.7BW!2:?CR0MM[8R0%WC5M.U":48P'#''9
M9+0 CJ.*HR,.1$)3$)R5IJ_5]IV,:B9EUK9N!VBX9 S>$\HP39 \)N)YQ S!
M!*H"E4J"[HNO.1&/C"Q)KY9C5>7?:3J6$GE]9W)!AH8<1 ;3.3$B71GFHBX1
M2[V,W'NO>6_=A=LUOTS9H 443IG9V8$O,&JZ=L[L[@.'; B?@##%,'YW69>)
M'4V$$3%AB"=,K#U)>B]!ZY1!K8:'F[6"6GJH!OC?88P<CI"BK70\' _;:>'W
M"\R)XDQP#]P2='2&2!"2N%(&M5HFB:LZ!UW;\#U TCHE6W7A45,7U0#R'J:7
M3'QF,5@=-%%!A#+TC":>,4 ZJ 0,^ 7/M6W%%0)6Y69O/(4)M+,[S@3[OADW
M<T66'C<88WR)3JF4 D-@9TBPKF2Y60J,\114-XB+T+5.=G%Y5%P'?76-U(\%
M+G%*><C&\$QLUPXMM0_+,-A!;K-RPLD@:D\*/AC?/J\)K(>$5>5=M[:X?>3'
MGV%O_-8/)^?-GWR]##8(.2D:I2.9&8XAJL[$)1<(>+R)IU1;<\U0+%AG7.#A
MZU1@6AT#O8K^^6H)94+^[:CYVDLIX?O->Z\DW,%'I4("PJ<\X&#2?!GBW=Z<
M?6HA[8TO[,%6Q"CH?#13,E%::9PHGB6FF*531XTG640O0%&A?>T6UN+4K>IP
M=N!D G'8*6_ +948,BIB.8:/DAM%@A&>>$D1XR9&6GVJ[?+SURS8Z ,?U_W/
MTN*O%G%<&+RM]'^G;;>G[,+TM0/%++H[M''9*+2K"GGSFCIB PT^BP"J^LSV
MO02M613R%!"IIZ">\C-!$W?*:F)=B9>8$<0*KDC68(V/9: A/UU^]NQ1R5-@
M8GD%U&N)'C>3Z?#?G5#V\]OAV(\C,KC=M-V>U)UA>]ZX'UC5Q4>&, V92*T=
M"4D9X@PD#2G07'T"9%':UJDM]D3(Z45M]89P,3:$-QXYWVZ.2U9^[AAUX X2
MHP2C54UD+!F93@APAG^!$**)M?NIMU.R"&#4RP),!954@P?:O$GI\N[ ^?>]
M\6RKYPYDF$S@]BV? V.5U"7%L8A=(HTKF^S12"::T71F=)>Z-GR6HW01>.FG
MZK8]$;Z>0*<]XN_:>-H 4K1)HB1B+.U(;@6&8[;4XS.G-F=A0_]0NT;4(J@R
M+\MHU554C_BY8WIE$ W:4.,R24Z4^7^40(A*DRBH$#91[7SMW=,+$[<(GNQ+
MQU,-Q3W-7L7+$=^\JX>6THAL#&(^.B(A.^)%QL5@./="<RII;R,S"]*X",K<
MRT)9KVKLUPE>&\X<4&H"#Z#*R510FF>8/82$8O#.>F6S<+DVP!:A:Z$*(WU9
MJ*JNK[H]KWM!?P"389.&<;YC;@#<ZZXF"BXJ%$1(99,I(U)$P6C6+.9KM:8%
MNU^/(F,A&#W96%S/.'HB;=4L3MXFCHM2QR5Q1$V5--81K3(Z:T0'\=0D4JIF
M0N*:H*FVE5J<NI5/L_!G72=M/^] F.ZU[6DY&+4K] R8UH%RC%)B* =*"JF)
MLY*17 [F#2D&6]T\WT/.6@V9]@2?&P=>5-).O4/,+@CJ-BM>I2A(RQT7%&,,
M0(H<PT##L8B<!F:9H#S)ZH>?W$//([M +PPP*^JGXK%W301([5L4R:P?M?L-
M)G%89A(A.AH<QSPH(C&2>HH8YHR 4DQ9X$:EVE7_^^CY 7I$U0%32SV] .9]
M,X6+8DR@X"@-"%\91#D/7F%8(KI#1)('JQ7-M><.[J+E!V@)]0F4I=52-RF8
M&;O]? CE105P"/'\C(Q9 CRS>LD@UZ+@UV!X&;0DP65*A#74R!A5UGZI9&"A
MQS^R%_1#.Z&>E=.+A9E[R/U\^6"5R*QEWBF2\"O2E@7Q 3$MM',A9!]YK+VW
MX$&B'MGV^9&!U(^BZAH?%,'EP[N1NN,B@NUF/(981/CG<'IT!_8'TH.(F-V2
M4,9/,>7%GV*T1">,S#!T=][&I6S2*E0]L@/T<DS5DZFR+@(/X61N8[?2E[(V
MNH6R>WPR:LZ@G!9J?7#6<Q+P!R*SE,0;G@@O)X5R91F]OD%P090]].1']GY>
M#I*JJJ1RL'3)EMY.&_?9&>TTT3[Z<M809H8B2Y)5I-J6<V+]DH'20X_^ ;HX
M_<1(5752[X0WY/_:"?J'T$XGPSB%-#MA_^H'EZX\+^_>;"?$T6GJMB/&;@_%
MH9_";LYH7P?(E4E9EF($UT265WSY4@ZVGN:4E%(ZU0ZVGI;#)ZQ5<^.-"QD(
M"[&<>Q,X<<8RHE0.$( Z%/2:U*J?=W)_C3%^RQAO'^KONY5R6V<)DSR1$^-$
MQY"1/HG&D@$EY055V8+PWO>P27>I33+/NVO@QX?GJNKO&YY[XR\HOZOT66,I
M^E5%-!.*2*G*-HF@2)91N&18-KIVA7%QZM:I./WCPW-5]3\'/'V@20*3Y^]"
M/7_;#>1$=$!I:%P^3CZ1]7P0GLMW%C\V6Q&Q,H$[#_L?,/!*6I^)8.6M/$YD
M8CG+Q)6#P)P44LK:)VHN3MV/T*9>%5QW=1TKZZ[_W=%_[![^OGOXY]['__[G
MUKMW^^_+6WG3Z0B:/#V"6\M"PS'^Y0^8?(;)3CE?=[32!NHJSZ^VQ[J^-"IM
MPWYSV@['T+;;S7' J+>P=PBQ^3P>_AOAG!!7PSPLS:CSL?\9"!,"[R;)W:$=
MW!K)4R(\4L"L6EE2S@4@C'H>$B#V5>V]B)59J%(2JDG3M<GY<E+0^?S@Q?E#
MP0&5GCN"MJ2\K\$Q$J2A1&26C(6H6&9+E9>>E(VU,N_/N2YN+6BM+Z*JQ6LU
M69Q%RI=BXP$:RPQ@'8F*E@S>0FF(2H0_.DZ0H$SUB9A^.5JGK'H=ULL:XF@]
MU\;YT;SG5][WKLY!,M28C)$K+:_"DQE9=1HBP<RP'/-M4OTW[#X+H^M4 'BQ
M*ZD7U/T8B<R /7<J@Q2L53)S72)KFLYP<%FDU.UM1EM/4QE!0&1ZR9+P8#1E
MM>M"+SV=.3\ZY;P@^7'BQZV/WX?6+'@*.@-)60@T5IP3:[@AN!JL]UP$NP:9
MS'T<K%,C[CD70^\Y3#4850_1.K+;X9R:_3SG8Q?YFY[=(%:#D)SQB!F6+NXN
M:>)59$0CV4YQZ;.HW:1?DM27G' L ^ZGU'S_@<[;K;U#=.B?=O_8W?KPZ1"_
MO?_XX;MOOS@&[9+\_@#?GB)_G>PQOL.U^,:WP[9"_;8':JH%0'U+JE(P=.GQ
M%R25\Z5&32%E8$-@2B'ZHE*2R,@8L5&7:4NA=0X9M*^]!_%^BGIY/=AMG$,P
MH"-PPIR+Y36.9:.6!F)P+6JM./?7#\Q;\E5A#S*Y-J^*6Q4@"[U";%5=]&\#
M#P[W#W8//_[OUON=W?_YM'?0K>R+A3WOO?E+;;<*IF[YAU:S:)7XKF2X[GT9
MO34)9$8LFJ#0:5J*/MJZ0+13QF:M#$VU.TSWT5-AQ\SM]_Y]4HZ63,Z!8-$0
MH<O@A!"<8%1@2:8@G& &15&[ G<_1>MDOZKAY);=,;644O,5B-_?,?O]T&+\
M>02=_,?I\A$U=\\)4!Z#23(BN5D3"4H0+XPB'L HL$P;J+V :M&^5OO.>T/?
MLVBZ?]^ZM;U]^&EW9_>O@]WW'W8_5'"<=]RQFE=<A.)*+N_N]VLJKW4(7)(
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M"@\'Y5JSH[)-TC@+F239]5\1E'A6FOD@Z."R9,G4UO:3@'X<ZZ&>7AI4QCW
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MD:+CQ!*>Q:"Y=@(BEYO9DT\]]<"47TW K5[Z:X!\+D"KN<F!,9(#M40R5AJ
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M#Z="5)!YBY*.JQ%*%AU)7/+;_K?RW6S$DF*)&Y84L0'Q2,W0<\TYE="7 2=
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MC88M!%K10K@'[/@;&B^#1] $DRX5+ E<*5OTAH3(+?%,)*/1<@&^F:[G/^_
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M#TOI-:2Z\#18$-*X_NORI22Z_.>__?]02P,$%     @ MJ -65@_!$\32@(
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MKG[.VO_9<9V<_YY.4:)1_>&.54!J5+^O>RKUPYT;C77V;!N46/GAGFW:UD2
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M"P6RC!R(YA@KXC0,.G=3N;"EE1IH*.Q<E#@8%)1X+"L%"QS;K 919TI5+#X
MQ I8*NM\<NF>$(9H2LF.X><8%B=BZ1P%$MAWB"QQ_1GU";0A@@DY< ZM OR7
MB2IX@W:Y7V+'KGMC@,4HVRN8SF6A/[-@N^RES+%&E;%&3*%A#*ZK8S-G!*56
MY/KSJ8U-BBE"JZXE\Y\S9 JK&\D#D&(4ZA3[I;'E!TWG6AZ[;O>O0T19996Q
M:[ _DU"TW%"4LKEZR8&QD>52C#7X?A$8C%SBV)I@]H5HCMTO1]DZWX?'QP9-
M"0J5R_;OX_W[U501HG)C@&M6%K[5R 'QC2W7J2EY@[#@^&0^EJTFHBF-P,-P
MAJY6<U'66XJR8#D$9<< '>GJA7Q<)L+I;BD?K)549]U12A$\J7]R/ZR.2;O:
MEWRZ'H;3]8*1DGS6MX0TF*$ C>E3G&)2GA0M>](2:"?KX7])[-]5FX@C'&GU
M!=YC'&4?*U*E%!=1^'5H9)\=8\J]%F )<9KB=:B/(J\%&I0:CJ ,'^,4Z_Q:
MH*%<'X2L.1]&.R 7\^GZVC,,%OO+KO(Q"A3P9C?I+7O+-JP5N52GX*E^:U+K
M;CM0['5U^(FTVCC6G&%GS';Q@I6A"YXD3712N6"XR!5K9<X"B<B8X.HEC]4M
MYXFJX W6"AZFFLP%>XQ<#JT&_H\"KDW?TL-D)*X4&ZQ=Y.!Z,1?D>([U\ARL
MCNEN@]+*4:5;DH(#'I;^)QT,63EGIHK08#O]6;%]N_4HG:+M6(\'EOD\I94\
MOBK/^:IC@/^#]J^#@I[^#%==T!KIPR(1M.-8)SD&Z+ADW.]X@6 PY7CRM*".
M"3SR3V5U %(AMH Q8]5"!?9 2B'_#3NP[#?%=? P08[]4=-:T5[5'HHS1#0-
M"6IA=:-5/&&P4!4CL6 6BV8Q$0NE!H )1]$QG,#2)N;O-Z6RP0061ATG'"QB
M$1]6,(--+ IB0C7HQ6*FXV=#48QH.ZXSQ&+Q)J::(1E+R)A>#=F#&28%K(OA
M02Q5P&P3SV)I!O.8>!7+,!AB.GZ,+&!NT]FHLD(0SX9IC)*#,3.L8+EV,%4-
M^S#:%Z2RD13&$L$Q0"X;J6*<$"Q5(Q"6-X-5,YK$BD2P48W6,%X.MK-1&!/"
M03L;H["R'/1E8QI6(8+N*H%C53,4P8@R)A5"29/P#68HAT,Y,\Y@"A@JFG$+
M4YNA&I;(8%HUU*PFVIA>")G99!(SF) /2^I8EW%\MB- JX 3V92!]:IXUDR3
M&-3$![9<3=N8UX=+U0R'(02N5S,(A@HX:))59ZVX.YN-.AH0)K"L$<3;X1Q&
ML<%H*BQD*7>0,,.-:JX93!;"%D;38X#!3-@1 >T.9L%(#&/T(-V,Y+)L(<@)
MD;+)18/%0D2K<E!08")0-J\$*X5HL%K@@I(039L.;Q0YRE>+_F#3C(X!JEF^
M&VP[<LR6ZL$N$PN:0C%HMV-DMDP&/>%8&1.C05B.Z9@(! -$#,Y6?"&L3<3,
MJAT*%PBN6NN$"()0JE)K##"4]!%@M:Z&R'8\C,E*B&[&:5.10WDY7C<;<JC4
MC/=,50E5VHEPMJF&ZF""Q;16J!E.-+!6)]1F$EY,[X7,=G(,D*BVX1 43O+9
M#A:"J\DVUB5"[G#2G35S>*B9RIJ6@,>85+UJJW@*2WFRO1Z>!=/Q*H3A;#-=
MQCP9G)?3IND5QP#Q2C43-GT=7)8S10P&<*V=,:K^'-[QD:$LJN!@F,Q7 P@.
M%\BV"9"XV\R&**P1#J>R!2KH#L?;V0Z%Y\,D0XT!ABWG'X-2)<H1'=^D;"K6
M#%>%7+P6CX0;V5PMF*B'VZF<STKA83M%9RW'E?A2M!8D(V$WPP1K6342EAF^
MEALL.9( F5Z--B,4P::#+!?).Q[*X@(1$>,<76M$9)DK!7DRHA,<5"LA$0O,
M9ZFR$O')>;U6R44 H1"U:E@TRA3& *6:U(VFF8*[)E>C#%/DK085+0E%+]4,
M1Z4FSU":-ZKY>(O2VU$K6\I81CWJ:Y;:M2X?PP@A4;-RL5A;:%J]U!A@C&3*
ML1H4B^6Q<H/RXC'1%",U&(LUFJ(21-RQCEP)6Z@[YI$K2M -Q-S-:B07#!)1
ML]H(X6&"Q&JQ4(0@\DQM#+"9BV6(2EN*VW&6:!*2;B?+A-FL9T+I!@%GZZ9$
MFO$@*M,Y"HTGVK)'8N)QNJKP(2X?%P0E8!?4N.//:S;O'0.,=ZIJ-%2.Q[U-
MM657A 0&-DF[9B421!,*R=$$7=5XNU%.E+$6)C6A1*/::M@ZF3 )/2T96@(&
M=3!G1I*XW%ZUI]A2,BT8> @*)O,%HV5[:\E:H4.'D%!2%SI^"9634+,KYX!8
M$O"9:3K83B6RIJ<7SJ68IE6M1Y%4A; 3]?@@<DAI;1O"4^D46.A5>AE?"@B#
MB1ZEI.,^T(,S=)H!H5HO'TI70$^Z5[33+9\'H04Y[<&\*E[)9X)9'X-+J4RJ
M"@^< ZV$,GD4[N(JG*D7D#+>LC,=U)^D#3V#-/T(;JIDE$$UO%<G<T2@0'MJ
MI(BY"1RNDBW,[</1&ND) \TZ( T"SE :*X9#C6RF'$PPD5:6MX)^F3"S:CQD
M,$EOMJ?A%8;$*"P=IL!<@DK!CAZS+%74(EZY(%&-<K0%EDRJQ\;& $6P@N4<
M_YT#)2J7+L=CC%+/\4H<#3>].15*6'TS@=+)AMR5Z)"6$F0;H;/Q=$[VT'39
MRL09N$/K91(+!P9Y"@VG22^+J4PLDNU X2C#!JD&%&LP]4BN$DG&&"M-YZ%,
MBP&*3%;)D6S:8!,1%F*%.(=#18%M*5P *H=9.)X? _1%JETN!A5L2.8Y3BEV
M(LV8\X?7%!WB0+:DL%TEC[-"3>EQ^5RY+$:\\7Q-$TL1)) W Y4"Z^X5,+;*
M>D(#?U@@K1KMB4J%"BOEN(10Z ;K64\F7W ;<M9)SHH912$Y+E<4RPV2XW/%
M3DTE.9$NNI4FZ9$X/F-I64^#YRN1 6 NVJKPW;).>SHJ#P3:K,?NEK(UHQ#U
MP*5:O,-[_.&2!7?%*$ )(<.LJ7A5H#5+R<=,039L34T%!0CJ=6)99@RP' N"
MO1C3+!=8R.?,JZP9'G>LS)7]:5\X7^N(*0M.J(VX*)812FTIHDGY"]YNJ!**
MH-5\KU9A(H%FWA>L-.+N,4!31>L5'P7 A6"LFI""H69$KPJ>4(I(Y*K=',[Z
M,DC-V5RJ!%VO,6*DY2MD:FHB"OD$?PUV$T&BIDDI))[R-8H#]U5!$D5"3TB]
M4%)I=M%Z-).RFZ!5+TIIP <WZFV$3#?=HHSQV9*&<S+MIEIQ@I+55LX'I].R
MGV>(>"ZAD#EV## /Y^..YG$J+"04+Y?WQ6NI1E(JQN.-;*-B\WQ<9QM@HJ3#
MIJ 2#2$ 0[):3HC9.-)1+4]%@@&D&6U4/8G(0+&;)5Z*MQ)<T^3KY1;9T"*\
M;"&,3^,;C6B+3VI=CUIJ5:JM2*)I)61OBV^T8HD6V3(3>IGO:GK$;H,)**R7
MI,X88))':KK%=R6_DVS&.!/1(]5VF;=S_F2HW9-ZNIY5C+@-A?U<PJA&/6*I
M9!H>R>M+UHJ==!3.Z6JH4^\@1JD] .P@(DJ4[%*7X@)UOR_1;>;<@#^ =($\
M)J3PMLE5@CXT7C&-+LZE2,:*Q,*]-INTA'J4:I=P"XS%NF@U8"=[ ]/+M!NP
M7:\G#+3ML?VE5%JPH1Z=3QN"S]/32V0:=?M 7,UVC# *EOPY,I ,@B!-6P85
MAU)=EC;R%*3D.4^Z+(P!0FZ\4$S7FQZN5T3+FL?3[9:J:3/B)?1R..WAO+6>
MV#10S8L U70G%/ Q=*V7B=,^HULON$D=CI$RD.'"<-7;& -4.D[<C*C-5$="
M$::D@1FMA'3RNI#I^OU$R0B+'L$OU3M&)H#YT9[)D;B"YI,6 "12J*7V-" +
M!E))B"'S@\@AT/!ZW("8< =57XN4?6ZA@K" KKJ]%30(V 4@IP8Z73@)&#V@
M5 $ P.WK9YARR1-7L"@]"+<K0 DCLH,8.UC-.O$N$PY6F4BP*D>#V4(\9%:=
MD*V:Q+%F(F0V$_V &<?,_O\LCOG(,(9F\&"*C@2S=-@R2U&K+<0LM#+8EYW"
MV'\SW _ETC@&%IP1"M$:0T6H9N6?]W_$_[4!U_@/H$[ND*TZR3?.8&:8PC""
MPK(IREE:&!MDS#&LO[#LFEE7-C*(L4TBZB0OL1 F.\MS&O2#\6\WSF(A9[4.
M2P0BE&TFG3LA9P"\GV,X=0Y'' S'C0T JRG*F4J$H @KRX:C84]8$@IA)J5%
M:T&+L[(2&62,6"UE%24T1-G5;EC)]BA:;B7L@I<,I9FL*B.97KI6'OC#8HS&
MP0Y!Q)NI>*A6+=;B#NM:.9 UTFPBJ-L^@ Q#&1HLYOL'!!QDE?-*@"MZ:HZQ
M&^T2!W<+7@HJJV6?.-A3-'\E!KDKWDRX5N!C$M%(2#[;471W2(9SK**)A4:Q
M55+C'E&%$W4MP34T1-):K4Y;YY%NL\]?9_D$'LPRX8':9 OAD*,5I3[/:F$\
M&.J'&.$(0Z5K1+5H58MANUF*F9%4C/+ETJ$(&Y>$;K@7QRF\6N-SC,U)!<>1
M!+WDX-PF+<;#5:O,R&9U;,GQ>C$2E<IR.<)XT5:F9]I5#723O5H\)QLIFH%)
M2BD[N:I6RD<@,0]13FI>;O*<II<&:074*7E6\^![EX\K<6>+A:5B0^L(:A&I
MR*V,K/&\VDHT6BW$-O26NPOPJ]);$^^K1;BO9SB*!1A?"Y700*4!P: $I"B2
MJ#C!88EFTIQ4XT2WVFV40!!OQA,,EXM6N;02CY=$ R-C V^#Y-M 6"#K12U,
M(:P[!.4:I68:T$J FL"!ENWFNFZ\0[KM>LP,!(&,72FZM9(*QR-P!2!+O:XH
M4F3&8W@#RN#,H2VV1!9.B@FO5*NK@6!#5E*"VL)ZJ1ZC&5:A6&GX$Q;5*_@P
MV^<$K%Y$Q@F>E.N!$.IU3"J3XSI\V@G-"_S@B  6>+OK8SI)H5.J<8E<J 7E
M$<M0Q#R-Q&*$E6HK=6^EE8O3I*!T&[V> 5M0'57(M%\L=Y,A3Z;)%P5.IJK*
M(.#L-),9A-)M(MBL(Y*=-@ME1B$RW@)H>VDD'\'9 A!2"S+N#=<+0%VNVG&I
MA$-=M%,,*T#2:UN$G#,)M^Q)#O(4/,HE"+Q$9%N*IXPDP5A<JH1A+5!(]&A
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M$W@O"<-,/J"3\9;B+GGL>LV)GV7#2J;= 0;WYX!NQ!WGZY5(7/06FFLF!6.
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M9$DS4$;-GB^BNF%="^1-0^TZ.PMJ50)X!-"XOE7! W\H,0AM(#&$<NL53FP
M)%BI(NYH,1I#%=/=-=U)N],U"JJ$<"J@.%%#(HH!V1"@T8%X1<,1*)V',K$D
M6*%K W](:AY80(HM-TC:@(2;B(]'R@$%2;9IU#!S0(JU\D8IGFR0*)9J&[91
MJCL)+>CK(4([TK$"-%!NPGJ*K/E;@V\KR#9E,#[,1\8] MX$?#4)"12%CHJ2
M/2];:N"HF;-X3[>;"K5R!@&7<IY"M21TZQS,:0CH#E<L4U3M0E;1*@-+:?HJ
M@702D"I@LVYW40S54X!5+ #Y>BL(YDN(76I253801CO9K%J"R+8;2A712"F5
M+KII-)3'33$.MMQ @(8&QWVI,ES[?SMH=U>Z !9J>U&;=&LZI (=(I\'6)JD
M*G8&=Q=Q(%<S.ZF WV'7X#NI8A>6'??/0$C/<0Y6" &05@&0A1AJQ]Q*""WZ
MO5H,R)"D6NEIK2ZL(:4BK^EN+1]0XQ%!\?-(!X:;C829&:1F<<I;I+-2T]-C
M VT^'\%IV:J'8R4YZ#4:&2JEZC$8XOUZ0^6!@L576NE>T2)Y5,UY&[+$&$A=
MTD+A$FQ[!I$#08A00 VDZW9!BPH%FXQ &)DE21(MN$O.,EINWLGN@W'&"Z2Y
MO(#YU8H3$N.TDWYH)@ V <8/8,$ZW &000+>:%8"_=88SM9-O)-':YJC C5
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M/KO5Z1<>%BA5UO<63P@J['5K-)!PN%K9EJE5$(J0 8H&*'4,F Y_ #I5CAC
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MJ0RFM]MI4N\RTC(X.!*ONQ4Y(\"4Z^S+ XS713S<T5@#NM4WK#N>0HC28@9
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M4E:/T(I,V=;8,,Y:L17^=8D2MF4/TXYC%X9-4-O'W2.V3\/TK:60F5R%L0K
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M>R#F[HVI)T8[OVE! QU_FEI[TS#=4_?.L6 MWR<X1NIW922,YE$G'&ZU7QW
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M>9?&O@W]VI9OXC '.M*2E4B;NB^C RXXX8AC3A#U^!!O$X4_Z( I[2$C=!5
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M1,!^.%QI)11J'5^Y6H0.+[9;>S!<Y-7)Q0U!0BKQKDJVJ+<%\HD6^^'7UL-
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MP!G)J)M/(_MTOH]RGFEW+>/K:*[!F,:S9XA,(QX30R.0I;T93Y^1(DU!":3
MQ26HH!"E+>8LRC<9\Z,P0$M![83CLI8KOBD,D-GF7'5G8C2^/%#S22^HA<$Z
MZA+1W^ -Z4 H(5=39@S4TWS8,EO5 LDLZ9(@MTJ\<>+H<O,Y!5UZ9':G9:
M@'^[V_9E[23DJDL98Z9 RJTXOD#"ARCM'P_IL 1^'7+C=A&$XA./(Y,O+,W@
MITVVS[D_PP.TKSL,,"5^_<.=]>^D^Z![?3=Y2VT=3UI]2'N?O?)3V/1<_1<M
M4];1K07A3^MUI^Z-+%^P^%T9T^P^F6,Z_+OMC?ZSDY<D'G4AF.NT?D2VZ!8L
MG=-V0_F0;RU-06]]_(]KYW%VCA#Z:H"E!:A?G9G)3?+,W7F^FF$K;D0-(S,C
M%ETG/25JBAII?I75)'XFS%B!X,!K574W9":IWJ90XA;V_I5+FY8;8R.YZF($
MXQWEX$Y^AXAIVWZ)(E69&>P2#'GC3GP EV!VJFIXQ(W32?$)Q]?-KV;V K?)
M :R"CETAN?--J[PW=!O*/U?ISSOCBN?A9EZ8\VS7],88/T!I.3Q36F8D#5XY
M^E;%+WN5%MPV&<W(^'(*>G4C4MR%--J-FO)<-].!,+L+$S 0OXI66V9JDNOA
M^&F/&]C=;F@Y9+3Y]RXQA9WCXN(Z&89'2N\QQK;"DFJ6D^(9;E4>_,00OF5;
MLW>;?5,P@ \Z)4[D\4]_O#W_H_QC1_8S5>I!LYV/YGUS=LM>^]QH/_YJVN?&
M2(E $0FF*=GE[K#(YUBQPIE!*; 90QQ%.M'Z"<FM-CLL%+MAALQ7,(J1"O$,
M=M0=]D9W>6%J?4OG^0YK@WUTOY&_HOMUH&'3NH\M_MPR(S:=B(8D78/:4D'X
M%]!D)</)#WD%=:]W-PBR6:&^Q6PY:@H1VX[VCFF\$$F\654U$,QO!J+Y\#N8
M$M2>I'AUIE=8C4VRIZ2OWV0LBZ&-!T6E>S9V:B[&,RA!%?"8YD7S#O=2OGC"
M^ML&6=L<23(\<R.# 'K8!M=$OQ2/O>80[-,7P5#QF,P\X3A*_F[>-8?UN0?^
MK+7V9YS"D5>D@!<=TJ0&U]@V7;O869QUN,:SDAY4^JBW3F?T.46*\(_O!_N3
M4[8PR>Z1^AAU_;?%,@/![%[KUP,5A;#I;9?L;Z9E?6-]G&<(/J1UG0Q%^TY0
M(U>PFYNW*SAS@K;9IP!U^:Z(KG('AUZ@)-]_3-\FY$EMVU2*%O?EG6]V]4]K
M>[(!TTSR5'I1USYS=X<),ZRPE0CQ_Z65=1=V/CXC9$\P\6A4GV))85) [G@;
MLO5,L>FK'K0'31YI%N1&SR&C[^[!)2@9%$,S(\6FTZOOVND'C8NGZ<&_B=-Y
M8S<W?XS*1VC]'^ZH?R__V .+XSQN_\9H")VT$E8]L5(S@SV\4M]=-WOIVX+P
M$'T>;XH00LC;O:TJ1C877$3%.SKWOR$H!'K/!YODBYT7M;F[L]BEZ)*75[3D
MHE(XK4(HLDWJ2D=#88-%XGQD:'$.>>CMQ^>48$B9$O "?=%\*EK^W$QR9@.N
ME.$/O! *N+;HMVM:]_0.[^]L_Y.B^A?,&G(;6N2L?])1AUW^V\&%G!":#2HD
M>*1"8.^@8K<VTKZ%V?K$Y_I-[30J%1W];>N]:%4CF\F:7E.L-$,<9<4HE^$T
M'[+WE"K;E\&1%@:'-ZW)/AAU/-7<S#!(E(\&P9QSX2]RON&Z81\X_-*3Z%<D
MRO=$9-*$&7D]-#$HH-7>P%?!T:5$+;O2,\>RT-X>/A,KN*;\S23;7@58$94N
M:6L08IS(L%W*U0<,65IG+U;'N:*N5+_-$^KR:=$;%7[W9%O#<)H9,0I(58"+
M?M?AAG^^1'$OB)'GL8V;*&)<G<O"&$NI*&7B%> ^C.;NI+1 T1,.(=YG?#\P
M_W@G^GOY!WVA[/^5E3I4U;.1JL<+"M'P7Z;V4^][3B3I#*ATA&.)DD/==%LG
MJ")D)B@G&J+=ULA%GA"CTL;:Y?" PE&]R%YRQ;"KXA%U4$CWB9+5"<>+?FB&
M-$CU 9W;7H''KDC\60:DSJA-'61V>9H,Q:N JX%""@EN=1+3]/OHT,:DO6?)
MZW=9FPZF/5L^]_K64VA(E_ W;%4#F6??!6C>MJ@LN&53N12MVB5-%H]*W6X?
M%F[!> ?H="VQR=G=2C8:PM@7':,EP1@1*2@CP*=RXGF.FGDG=Y2+H-10?#'Q
M.3%/01X9ZA-1J/69D_ZL<WF_3!)&N<<IKAL4AT+\+4)*;7I_5+/%G:\):A(=
M2[ERL\T?R#U&-ZYQN=265KRL9@!/RQ<Q^PZ@GG?"P65TRZXY1)M[<*>9:#,1
M1Y+!/C0Y3G)7$A2R;K?%B:]F9FY<_G5ACRA-$+[HH!AZY,IO:O/K_T"W^'OY
MQZ9RCF^RZA(X0>/8^HM5@@K9K?L;0?-RORB$>5HD-C.)4"75*1^\?]T:S7B2
M*SDB,?&[=:J74,Z+K5OY/T>]W?I+S!@"<?'8<NQP^9)-DG$ND76[XT&3$]#+
MYGE)9I%Z$%",L3#;Y=@<"%:I%K-]H06):VS 7%N;:K!VPNK_^ID2?])2JK#/
MP@E',?U\@7$6-:^XTX @797'.<]G])*HQ<NS[!.L.;X>>@0TIC'QTOW3[6P$
M: LEV:MPGWH^NU54Y<E;I%.HUS<T2';CL(R&BV+H"0>F7T%Q./XM3:9GACB*
M$YV7'BJJ)@?"%(T%9:68X!((GNQO)K*;?#%)1"- YZ#?70$:J0E-LO!B_F5]
M;*7$M]KM_IZ>AQ'JPSIH_0I!?E/2'"\@K7-7OW?8VM9 1-P3K),KH7$SQ>I^
MMT7'$CNC5 .0,IAX>=REMY3/,UC&K&=ZN$@B#A<J3WRC!F*T@,Q.<V9;.]7>
MTC,[?:\XQ]Z8^$?_ _C/Y1\]4G_9?QPG9Q(4VM?$^<ON-\<G'.\_PC,G#.G2
M$=IM='$2E3?6QWV,/#1FK+"G/E;2[:/<95;--\%".%TS^&Y"^9>-E4')H%R&
MJW(10W6FW%L_#O=&DXX<"19XT4\[=(7G"&G>P7OLP-3B*-W$O )!+3$9D1<7
MJ)_I_6<%SY=RA7W,=+NBGB8M8;@P])7\4/-Y8>CLD'* T<T,@4L60S/M<8K#
M"Z7F6,WQIW= *P$9%F7M@',O6IT7[VE9Q#Y)\>^0"^;YT.J^4X*S2:+#(:W3
M;O"K\YDYC"&7_:WFJV"<F&12"QPC6>G!3W/AP\H >?RZ$H6UK?4>)+_^ZQ]O
MM_]$_L%CZ=G:,%DUH@]&\R'\#FN06%3:XFE_W[\VIB5(QJ,[44C%O\L6+%#3
M4\QI5GWT_8>5?#Z70>G5Y&"/!BZD57TX0DW NLKH9;<S!K0X9.R,]X]1'24_
M&"L[X<#[))])$D(6=K9DO:R+ @GY2.Q?1 I'\/[Z6=U_3@@]Z[C>)0X^%&\>
M2>X(>_;BD.NEOT4B>5UL*C6J% A(*BOZ<:5"<)0N&239DT*&ARZ%/^K#\K'6
M4[<-OFV0!P7*\#X> OB*E^V#A%+-NMR\K<A 8];"/.4!\*L)05P!7^-354<E
MIE&56%5-AX["A'SN0O7KVCY\Q"LJOMCA!XSOO*4"]&ICM8,US->NY]V')SXS
MJ8Z,-YY[D@J@Y@7UY?.&]J_<4-SPH=X\!&,YH;NNT0N5^Q8A@O4*3A=95P\V
M'<W,N8->*-*B0E_3_'#+K3B6G1:D^)VK Q6T2+;')Q4WSS8/3/Z=U<)OYI/S
MZTCJ'73S=YOO^KK$-X1L/:N"U:0[241FJN%OHP.I;2;Y92M[X)(J90( $O$F
M+PJJ7+L;WLE(KD"T?1 :<RU0J$!7& "+P"RSA^TO!O'/I[*#)5@.U;&Z)</X
MLTIX7E+GU6)TC7']Y99PY?WK "??@=VE%C/-O29[@ MQOKNR<B!(X )6Q7=;
MJ#[</[FMI[2V5U'*H/[@,J.TR]6C01XYFAI\SYK,[:5VZ'/"84"LJ:/-PXYL
MEA7D>649QL;-]I+%60G,&7552^?^35752:RG3JWEQ:&7>05:BN$\3+_QEV83
MU)<FY$H6H.LU,;#=0!H0?E^^^N.FD'%-]_)2(D;D_H \ I!6=D\[_%S6\/-]
MS*L?F3+YLZ.U1\:XUSUW]W6R7.;=$I3&JX4OAK!!/F%2BM7]'GN0L!&&^:YJ
M*$;_4;G<EYS?$E50>DKL&-54T7-0NG3)N,].$@A]!WUE0OCP,+^"S=V??<IR
M*D_<D"Z76A':_:G5SY6, ZKW!\3<5<H']^6WGI>AYB,N0I@&S?.= '3@8:ZF
MQ50C+<PZX_5;8<$Z$7ZR9#FY+AJN_D[/WW@HM]_?7F&U-MVVU8M5+%/NZ_FX
M=YJ ,$5* 4?1;_KHPYH]R\MH^<1T]-C,5AGCH36]:.A\&;<JE"PXTN32$F6T
M)"HH^O1.TK?S:BXRJ"2I0+C5NN"S7:ZYR YFH79V"Q?BER M,TKZ6JS=SK'G
M"FF,V;[7!I"&G5T5[3[AR"+I1ZHDW=CY2QC65VKJ$G7ED#EN_*\[_G4'[-(5
MRT:11K=:FW1\*"(08$,&?SJ[T"&U\FJA#1EBQ+=@7FP:_HT"4'-#1Q[I<HTF
M'U]HO$=Y9_A0<=FAMUG^V@,=;.YI(&=&!!,M!Y;WK=9%NN8:/IW/*2<;4P<.
M.\O^XF"]ITXN,=O@6"+W8&^(ZFA+F7=YKX64NPA<7Y_SG,GX+>(C)RIQ+<QK
MR''-<&6\D]&V/UIO(/S#IE,H)#(CX[ZC8MV9'8ZP<M^$*;?>$XYX]XCC_U47
M9\'Y1K/#FBK^O<)5D<HSK((P1P'EC$,SC9T-,K2.XMO;\DOX-0?^/!:KFTF7
M^^GH-Q$9@<G=P?+ZR:SQ^EQ\^E9U!$KSV>_UY=CS&.>ET0M/.'@ZCPZ7[4B$
MX<V2:1$=WACL'BQ0:</@H[;?V7:=W3IE;[G=HI"560@KW&>\,/DO^W=JE+3;
MV_-):,<O#G[2LE%I7BL#1S8KU$=J6$HM!A^=MD9/]$3QL8/]Q;#>7<Z1+_[E
ME_^Z7_R]L%$9T=L.ZX5;X[$[CP+Q#%1.F5["1V.U!NL&GFE43AU0*/HW*Y<Y
M.I_KP5RKOE67BI?;,M*%-[CS6*4O@W+U]1 A IP,R.VPU$)7+>#"U#[.:;F+
MIV&$6W1M1+3G(E?)&U_.FXWY&F\KM:\?U74EJL_6L?>QLV!7@$]2R:;VKLW>
MSX'%*RI8!']8O6_9E#%UI;KN];(TEM SH!5[PG'>\8YL.F!F<\4%F+&\'09F
M G9"&$*%:5M5ZBVG0W#"<^;K7FS-6.X2^&]/+R@OQ5!TK?9%#F7"?JLRW\GN
MJTW4<J0,KF'M=D;'S8-19@-SBR+W3SBB29F\^I@->$@)MGW[0$MQ$7-0O9#4
MVP8?%7+Y7'7%O8AQ=UINP'A(N,F0-="VX$TXY_'5NA_M)1'T^3%:GMSPTFX?
M$<%>P6D82"P&!B7GGW T,#O.%P)AM1H?^E@'X7G\05WAHUNZ_\QFETW,U/"&
M290=5VSM_&"O^G@+BUIW_#E0 ^!;SSK,B&1J]PQ5DAQVPI :&-LVF-9@=>[8
MYFCM&XIJ[BX+9I\ 48*QG))E#T<F6Q)*'UKYKT[$:%Z;BN)^T08\4(=W16\*
M[1K XOQ\-QP\!RGN.VGC%%HXL,]D020W/W6K"OCK2H-MA\&S2/2& SVOINBH
M3F$A IW\.#@&.#"O]:S^.U]YV8O'GG2$<L1Z]O9N5_$^!/##$)^V[:O]2X>W
M:IHJ5?9(2DN#!VV^PU-:V/G76V<]GASYI,YIK*(V+G\<GZEAEKFO2-3[(O?S
MB@KZA?YYJK1^%4KQMQ1:C8V3L](T:AK"2#V<2N3.@%H![C]^UX<WX/ZIR;1Y
MTM/L[5NL#0%>^CB% )N)$L-X;--%0/+9L4PE[U<CQUV+5<O[&S9UGM>-0GR8
M40Q[,Y!)&_[;YRW?)CUE=IH8U= #3:Z97?&[I\[G/? YM?\?>[OR2_<C83JG
M[G07[_&+P*1'?4K&/_1N1&+'&]5C5HB3RK6.<KLJ1<*0]JGZ[SXJ#(3LXD\X
MK%R];MN;K)=CURUYP/T9I;!;:/Z5SFKS_G+O=YY#J.3,^K1^[^WD&\O9Z4-4
MH)1):Y^E6)48NIAE!C+OY+[6I\#][NX*N+_/ 1H/>8X.#17O;C<B?=0]'60*
M#FG'OH(/V3]<%)$8;MMM)")..)1V&#U#>Y%JNJ>IX?@KN,B&TCQP9JW)89HS
M;9D5YL0$G'"@#^;_=<=_\X[KZPK"P@ .+W,)FR6ABX&PW(I\R_8>2D<@O8&J
MSN.Y(X9E%9O6]GKV82U;N_@0W5&B@]<:V0\_M*^XPV'Z137$/N^O<3-WL@I,
M.LT4A"0R:P6_8I5NM/@D&PC?3SKZ'31H1'Y&#?7_@IQ_$/@3$96? $Z\R,W7
M']MIG"V0Y)ECK/<:Q<Z7/2</K>51%7/3?<A'!GP!#AG!H2<<XIH;>L.#PIT?
M[MV9;5]I"1N$%%4C+,O-%*[!PN\K035O$Y=-N!G/F_?4#-^<<)05]#8F'7V>
M7*LC_Y9=P[;_[-3]?RNQY$G)?VR? .548,&(;ETC10DSDDQ3V<3N[!62'>U5
MVD)O%%DN:-=%3K(;22ZXUHM^!392O(6^2P.[(C7X(OR&5]LM5626=<J4#)U8
M&U?LDJ+6+-N>8RZI(D.G!,7TWK/$CW(![@*?Y]9ARM^2*V=G=^O^J'AWR(3,
MS*UW]708R:UKS"QBG&]+VTCWM<9]\<7 O!_&HRB9&=^<QO>9VFQMF-%!F'O_
MD9+PK\L7\@B]X6<C+H\YVPD<,M';7D<LE>6U/+/-?OBS\KL1%+W/>:CL;SAT
MZ<^J4XX.^^@R(1KNZ>_NF&]\-261+C'7C^D<=VNQ-[CU2,>ZP#<\^0.!Y"W9
MP'4PE(;3TRS9^G24GF\.[5C&DE=BR%L'4N0_D1VD&VMD,2.FGLK][^Z318W4
M"HR?O=@0U=OX*F^N<.>7E#&4F=&,3T@#,]]8;]$\JG<*.UU-AY-#NQP 9$]K
M$%[Q%LJ*/HKZ/KH%NU$[>Q;+2 ZI!M3XHWU8=T%-:^$JGLWODR[=)HHF^=$<
MKX"S)/8--;_+NR6L.3KW=/.'2IM1.S^@]M;7#5E#O2.P<PC+38W,S7:U(E3H
M$ WS99%X<D5;:4^QROHOQ25&_&FLJ+?(U!!LMK37N#9A>GZKS[AOWL:B,!TI
MOV2?(0&'1SBF1_2[=#<T.0%4/R:1Z?S-CBXXG'M#YEH-" 9OW70*>Z3NU,(*
M9LLW> K9KAW+1AL,)W3RX!' %.DWX'ND",+*92_%965IPC@\IQ8UM.S]M,;)
MU+KZ;91DB')C2,W&SOV*#(_WGBIR'NJ$@"@=J"AYIK@Q0<E7(+!EB]3\_&/F
MO(MQ?:&;MXZBDSW 6(OR(KX:YF5L>2;MO9-"9D<,K\+S6FJ+JS^?IU1.L!G?
M+V5X0"TKYE[#>JY M=2PS>9,2J%DBH'FITW2W^H()9:51- @=+X<<J!=^TB1
M9!'.[=,E'U^,DX^+2[J6F2.FFC88%]<0.@[H./S] JS(RX&%&=K,V';;9&TN
M*Q>N8I$13,;9C@R-#/>C".<3X)M%*81SFY*MW[W"6#6 W:)$OVVX$V;YD/=V
M=L@-28JYH:&A"S?W.WEY36YN0;\C[^1W@@GB=_PB+T)')<#MP+1*;-+>U9SR
M:A=]:Y7P^YQE>C*J=)TQC[XHJK991<Z+I=,HS$GE5#T OC+N6I8M^)61I":]
M=5C/*3+@P_3%:H5@M<[M4BQE1Y4V)\5)EP8>C__X9R_4?VT#D!HK$?O(C@IR
MR-JJ>3. (%DBFBK?U I 2@J#@,]52Z<N5K#)3C:Y:@NV[>G#LN21P%X=^./J
M4FHU=ECS%_S-$/?,@94I<$ANI%=9&K1\^8Q,VTLW^:2ACN;@-ZN!,.4"^0!!
M\51[Y=FGL+NO%G:JA1UD=-'$B"C_W8X1T\.*O_X'A;Y@:\6&J551U[BFSU6)
M&&K:_C+DX8P;-JA<O^H&VSJ6F5K@?8R&*^T QA:B#8.BZ?"[0--Q$=_S;\A+
M:;.)!$+$]%%F'\QVY .@#VR"\RX*3KABR?WAC0EK0V5&=9*>B0&9<$>![.VR
MS0U;9*O\8YUI-MMN1*/7+5C MZNN\!,.SO&'R041V:Q&WW";Z:+%,RCOPOP0
MH0 Y%T?[CS+0X^]1KSR&/$KM06W0KP;ZN@ 2>"]>D#PE;4)ZK6FX/[:8#]$_
M2ZD1(F6CW1I,1BZ>\T]J?6@2 (!B<L8:)$J2OYIPSJ0^F!+"5%J6[AME.]CL
M9)#F@JJT1*S= 9:FC$"C$.[78/[.^J*%T/-Z7G=LZO Q+9Y#[*LT/2S&0-J8
MF\O;/9$V9 #0*S@7"-:[*:KH,KA0W@[(ZX+ JK..]+=&:!'+=CBV/1&?(87'
M@H(Z&.9;;FX@J^=%:HI-#^[_HI[<_9]U@_^=/'&9BMTJ#QH^"&B/$&O YF6[
M=QAWA/$!&0-E&\<CU+D7CSLO97Y>X/_@5AKN]+FAH\#1:R<<H7FK^9T$\.S/
MA^K+O-N<O3#Q2,/M+6&1_G90N8CL?\WP^\#XY*>G1"TV%.&BEO5N:I=4O!1Q
MF5P7VR],2BSPS<0C/+T5[^QJF;38&NCG79^',E/T_;$!UYZ\N;U3ZQ+D.U9\
MRSYZ)%EUE#(RD.\KDU'M@/A_V'OON":S;7^8.<X,5A@'$:2.HB#=2.\SJ" U
M0PF1%@:14$+OA))Q%!0)H""AA]$(,0DA4D(+17H-" %"[SV$WB'PZKF?]W/'
MN>?,G9_W?:_W=\]\/_DO>S]K[;77LY^U]MYKK;N,4BZ$B \N]9)H:$6P*U:H
M.N2T$U]XL<UXOS/A>"K<LCPFIT>YXZN1A[L:RE"Q7EE=F]5W6'7W875_SM<]
M/=LQD!P9*4_BI!4#/+P9@N^9'U?*X%<RC2"K'V9E8MW5G<$/GR]T$HR)9*H$
MCY^,]+SATO+V_0)^:C^RLM<-?5=V/FGR1%2-C&7I60&*TNN&8![G!A7S20!
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M@ZN^!*O@,00'Y1;KP09:;Y2F4:'[:/-ZCSM[ZT?1"/\<-\60F1$>]R<B:*)
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MET/K7/GJ8WJUR2JN!A83YR[J),')^CY4QV5.#S_W03</A+M"_Q';TZ;^U%*
M,BA@VNS<0('NE[LAQ1+9C]-%Q:=]\#7)*;&P\ZY5 6GFP;C,([;^E30V/PR-
MA]O/G39Z?H->T^?B-82H3Z46G1)4T',)Y^JX-XO.VFHL7N2>:];/F*&6N/&
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MMX[\S5PC$>FF8I4GY3TV$/:-CJA3/O(*=_ZQ=/X$_H7>23;>J#7$5F)3^$C
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MTEX^O@OE/D+GUK%*,#INABXL>.]8']=3+%W/HX?<+]$(9W+;(Q1<VRV2&SG
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M<+VN+VV\N%X<+,RS!"TLC5'NK/;&?G4W;R7^MIY\46))ZU?I:&[H0T0BCG%
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MB"S^L&A,F&AOX4;XU@)#\OX,Q ?KZQLL=?FAZ&+#/3><668%;X.5[4B3]NV
MULQK-J..PZ+8!+QKZB+SS#PRZ&7J6HK4):VN[-+DA<E.:ZLV1!M-0U6D/M$D
MK>G51V3_U@]YS/.=:?7F>D=ZH*]=4^?H'I@ZO?@*&4\]53X2TWS@:3K0RV4
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MYD6AEN?;G,DC1+Z  Y?F229+1,FABYK3H8_X>K[QP;M4" DH*1ZG_SKSO'J
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M'TKET_"7#_9G\+E\L/>8@V27.8VC224&\/GU3'F&X&",RC%NL""JT:;9V.#
M<>H-<H>89-5LI$]T.T_/'0WTR-O>L#]91#\WG2KX9ME H3./XEBH=JPPQ9;0
M[U9OZ>X@:2>1BFGK>>_R3RO7@5VG'(Q:Q'[!0QVR (T!/3Q$*N59S/46SWK/
M&EI*J#3\%T)#6N&V6A*7A^GH;)!6"M$[,6=E<(FDO2!/N+L6WWH2%>2AW3-N
MFJC>+L/M%",LJ3/SW*FPK)B@/N&A%):F44E]'N-@]+B541IN=*'M50^7;70"
M;[WY!BS/-]+=I@90@Y>H*9/,EI8:,2W/:C>RD0>>VSABPV9'1\+\/W&V_@!_
MV15_"I_1KF!C3U*MGV/<+UL<<Z=@8U]L\EGKQ!6:1M3';)8[#S#Y=#IA.A7J
MHNL8Z,*/I;B?![VX99QB3J[$9TETXT%%I5F0KHKZ"FMZX&#U0%B_NT9,3K_:
MNI-I@3+(<%)QV3HEUC:MVT&  AKG;0   $9^(*,6%SQ:LM=]1OJ#XLMMJ.;U
M.&9.8,?5.BK/IU-9'*.XH64;N6*;(8OQ=GB]O0=@H&$S#BO5@[>_OG58TF32
MHW+JC([=0;@0D6KYXO)%;T_3BIPU"V3_THWP-.E**GHI,@F0.,!_]FQ:,\@&
MY$.UL2ES.@EE/IEMLWUR%["66*]0UU6X'FR0HK^KX-6I;D8[1+^4M*SH_L29
M^^?X2_5_#X[(::'797[C4BPTH;6<WG#@G7_OVM;^5[&<7@-Y=]0S>CF6MB_&
M%+6\*ZPLR;+(B@DY,*)><-46[.M^H5Y1D5]OWC27VI#EZCF_"Z/GU-NDX)]
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M57R<BML6"//:^OS;^,EN@P5^-TRSJ6>KSZ[$M=XQ18>Z;?7@O*P2Z8HE"H$
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MT=;9?J2VL8YX41]0XC3QR2BH=#A:XD J@R>8XTA!3SG66*E.$  OBUU=H7C
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M/ XN;?SF7<50[I=969DP+3F-_RVLK<7I^>^URW13&HKZ0V9+V,YG/\&SR__
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M^29HAG]!59R50VY,#&N/YPX'I&W['_F0TG F=#6RZ/M>Y7;(Z,(NU.SA\^M
M?NT6R"X&3:?W&>"&VO-T.#=3S"XR<:/.<U>#Y>QL1C/0*>CMY-MS5;7'"L?#
M<QCY,/=DMZ'@8PEN?/"!>DTZ74UI48'))+#,1];\]%8!O37LW*F;_EC"0!")
MV.F<]3&^8JYB\N7<#&]G;F)CZGQE]M'!%2A/)UT*:%9X9%07@&9/IZ#-J(7C
MW,"@S(%#N_2^2%]I>5F#:<<^N!K.E(=XD2$OU04:E^_/ ' R::H75*E&]3#)
MTD>[!8TV4210P)Z\7&W$DOU65V.UMM]CA_ <6X8:O"WN>7IDKT]9R/V7;4JB
M@&3#BP<"(I_/ B\W, R2QL.Z11\[A8!C$(TMXE8]LW@F%A"]611 IP+7MTG<
M$M?W%NN*?JTO=8\C7K0[9 UZ^]@+==.= >+#U$X<^0-%W,!NALQ:70^8!/([
M]'.6T)SZCHM=L )F9U*LRB)G;NDE+LV!&*NQ^%Q(\M.M*C1DD4HJ];OP@RBX
M:6Y]5KXV:,IZ]D5AW7[?K:Y(B.F'*5MOM4VB.OXNPK:;>_9BJUA5=)@\R1"F
MRI$6&O;/3K T' +Q?MC=2E0>1:BQ?:Y'V%?%KWLO=*^B?4R3M \>4&!R[SIB
M$2S5>4);86>CA@&OSM/=E/CW?_Y'<Y)_%ZXXHV>FW.=,R5HM<]RR##O'18+B
MS^I"2#-)L@S1N,:?/HF-L<6/#Y-@IHA7- ZFM@2;)G&K$RH4=F?W8:.C;F >
MRU/8DLZ;,?! K7(F5_N6-5/PZ0SP&N;1[F=KT!$5LDHL<>@;"/4+T_B-0'"9
M)8Q+U->?7;<?'Y2'M^RFEB59,$*5).9H[G,:A<]4I^V#3TAF#L$M7(<^YUSN
MNGUR4^NG&VC/J,7%K+7CQ<Z)MFMM->,(0(>H7\^B#[3]W<)F6UR":,C3A!Q#
MS(,:9GGX]W:/BRY5_C^(_3_Q3RGL^\>^'+A.>MZW&(0AX8+M&.[D-;9N249E
MSX_;ZEFYI$2G-??MNM#+ET8.4$SM&@.Q9>D,X.MP1S+BE$J.Q"+).GZ6C]Y_
M!NC<6%JQ<\HIFRN'-S0[T7U-&P4AB+T&Q<ER+2MS!RN0^7!66MZF'J;/.5P
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MRE&C\01(9Q P)&>.XJD/1LM/>9Z01.(;G@#V!Z@L7FUN\(:A(-^UI(]/UIO
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M1,B]1S,)M5U^;-[V)7)PW#-S#!OCWD5-)T_[@04F$<2(' U$W=AC&T"LN@>
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M**4H.719LT<\:;K@Z:^GN99F+9F873'B524)V(PS(( WWM]  "DCU10/UJH
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M@W0\BSUZN98W/?K+.<_JSZ?OU#L.:9#F[>)S'K+X>._A9+$/UZIU[/3!64I
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M_;[I'B*7N[(\)G^H4*[CG1M#60%R-JWO2R$.NLAJ!T%4!:B_]!N,:D[/Z$W
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M/0U/HI8'/G9+_:OL)3Y*W"/OD'U.__CC,C@2-/Y>NHB-@U[1(5Y56.3LU!P
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MG?R-P;UKHMD="P0?=Z\:Q[55086@ZL,KHKBP@*K/Y!Q'MR+(9=*M*C3+[W]
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M!JJ]HSLF2S7D8<> >?LJR]3.!979)5[%F:)',K0,O(AQR,?B0ERH0W/S2ZO
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M&4_)>GRB+'TR23\&G%XYA$UY,!:%(VI]\HY0?ER-<CW?!9S!!F:GC*88IXA
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MMT$'1:S2S@'O6^5&D/NS2]"H)R&>&^HVA.QO"3A/+*:C[2<+6[//\/[V=';
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M6 8^RTW,1=4GF<Q\.749YFWNM0>J)4Z--]CPI9:"LB/"G4VZ?1:D)^W0Z'G
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MX>642=UNDBG];;BGY)WF^*;EW$5R9H1"W8]3VOKC3)7G:-&J(73%=6$8=/F
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MUI[Y=/6:J7Q%6/J'2JWW@1'KZ-)< OFY5[<3B1^L*]1_\B%90][CP@LZF)K
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MM="S0D,NPN"ZGX7;+?=AU^%W63GJH79G;Y(UE1,4S^AMKO+RZ)"853!D9*F
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MV:8RA1P9 @#=?"X&+$#&"Z5^.IUB8#<Z_KDDNC]/#??DG-20!'#-:K$&-'S
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MMM3AAYBL3LV_#IS?6T<&P?*[(<!)ELN):&\%G-#-[EX'OR=>L/#T!RXC%^'
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M!?2:;OS>BC0-B4>52%NX^2:8(*2/.U:^-B7U:?0,B;%74/"\OBK3 Q2$RCZ
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MN5-J5HM64>RU,;]G+UIQ9!!UW97GQY"5FX3($L\MZ;-&C.=$WLIK-2WURTL
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MVWUM[W'IC:8BB=+:N'0B>CX.#109PW6A+\#ZO._.TYU48,(BERDKFLL=B!5
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MJ28<9C87$P95=G"!ROZ*8K,BJB>P!AD)$7':.):!'3!:JQ^-6Z$QZY6<0(.
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MV-VD;K%HH@Z6ZR<EVX[<2Z="[LJ\ >\.X:KIGC%Q&F4SX#ZA80UOR'5_=C^
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M9,W*U$&UWYSL%"#6NI&](O!F$O1ZY=?N-W9RH)$-QCH9]KNS,AP&V'5X#)/
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MDR!T72^%2>1Y$*6I ['G(\C"A,5!["2!G^@H_?[P$ZNX) 8D-?"UIJ<9*#C
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MIT?(S:8L2EQUM>@K$W^W7B[3=2Y?7#"'8Y^3&'(L;[0[B0L3RC%T& \)#M,
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M,6)JWLA!A(D$_U0'$2.FR/9!Q!A61F0.&M>)N%[1G(L?7J_J2A&RS7S^7#6
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MXQ]3OQF9%7SHGE/C=\M8I.XG5S'4G%BZ<&JFG&.NY@*7;]B+^DK4&O$C@'S
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M3QIVSXT8PL1/$/$##V$W<6-"O%3$H*[^^J0G-M:*,,HD91GJ5:2=7-*&V6H
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M89%5V<G'95$.?RPW0_E2$2&K.[*4#M<E>5[*H&4_5O*3E+FI4KG-FGV(AS3
M049)@CP:N0A3GZ#$%Q[R_=0E+.&IB#C88MOA;6*+7I-O=@2X*N/A-=-U"43#
MMO,L^4;+-6(5YTZVR?=E3O+F/YO=Q.5:?A36:U&5]OVYW'XOFT"TKY5!X9/\
M]R9_<]:;K5&UM*5G#_B8S/]$81^;L@BK8; :Y[M_>HI'=+U&-9?M^<&*SWWQ
MEK2U(_;#+3T5@P_6_$_'[(,VWU,R^^C9Q1'T4;1$>OZ/IEW,.C^JEDG AU8N
MY*O.U>O^:44>'_R,!SYE,LA)B8]PR#$B1#[<-"-Q1KU(ACE,=VKEP<I3[]0U
MM!Q%3']LY:'T_1^-43(!LPMZXH &5W:R;C2Y\G"EV497=@K0GEW9?0%<):[6
MV^7V[:MX+ OPUML;\B0>H@@3+W!#E HFPW]&*4H\-T,!]=PDB,,T%%I- L\1
MF'HOK23I[&DZBJB^HG1B,JPO8R4%;J7!A 2I3Y\D1EK4N>!LRM0G3ENG>J\S
M'82C(LCGYURP9>EC?5T^?M\6WQ9?O^GO2&LO-G7NK#P"V6; J3AP?I(\@#L8
M#T*CM_ME%15@:FP D E:*VE+:VURT!"]F<<':8I_.D-(]T:#;2S^M_O-C4H,
M;6[$1J6*/JW!0V-[%YG:H]P58CC;C2.90'=7M\Z-_/]!W^Q/F\U6I3H &UV]
MR&AL=MD"!>B2PO"88!"LEN!FVV&]*\^W):8CX,&VF-8-AGO0OZC/_4>R%;MN
MCJ =Z-/;)U;85B]44JAD9,F!HU@ [D)W2*ZAEN.%!BIDN0.]%[+5G]?BUO-Y
MB<PWGCO6G'?;^;Q0)YO./9?:&YCLU\Z=(#SR0TR1&PJ!<(H9(B+Q$8W"1(:?
MF(DH&SLPV9_'+5X^KI?9DJF7\W;[7>3.+2U$_EJ6#-?MB>NAR;Z%H<D^R#NV
M! M,7<\/3?9G&IKL3^(,]U%Z]Z')?K\#K'.+88R[WRNMQE;(?Y0C;53N5A6-
MM5HP/'AJ-'H<! C33#6?]T.4<.8B-_/E_SR>N%AKG]*$^)RE)2,F^T#@U R1
M)P()&"W7^-1E$!4GY0]*7IR*&;7UVF+'8N1L (*M(!I">MYXV@"4D]#:9 WS
MB39J!VFU44V2]Y$D3:F7>B%!3+H-"&>N:F 9<L1('$8XC05+"72J30>=B0W(
MW=?;+]??OMU^_=VYN;V_^@:?7=.%C9Z)L" QS!KL]I KBI9C:$VQ+$ZMZ:(R
M^^2:'E&[IM?T73[2XV_U,2]V/_RWI<CEDM_?/FZ>R%(Z QS[E'&"DB2C"',/
M2V> $B0\EB8^PXE'(J,80(?Z?"'ZCG!9CG2S^,WYHV(!V#P-!BXP/K -F6G$
M8(*6><@ D=IV$*%%^WW""@@L9P,-T"+PQ)VJ$WD5^=MM=I7G*A^XMV:?-=L)
MZBXSW7O?4%=NL*2_68O-2[&J3T@>SZUL?RT_VVPV",7!*!VF16"VW!A$W':B
M#'2?C;&-GP@3U2&;!]=U12C]6A0E 9=>+LX0);Z'N!>(R',SCWN@+F7G"$W\
M9:R:"^[H7CB9I.R0_H-$,*3T?=ZQ\ALXO=<MT151:V>H=.6:9%9CB\P[#FP\
M%;9_:F/']2,*/:J ]^.+:CI\)_+EAI??O!OQ9_F;XB%P(\RC+$ N4_U!LX A
M$@F,LBP@L1O@.(I _4&UJ$ZLSM>MFGBV>7J2'ZHJ Z;<MV?YJKVLU9>L75J_
M.T-M4#$RB+%F2LPV<L!<V*Z;N!K$4#+@5!Q<-(ESR45U@<6#TB"I;5:0#-*<
MOXI$%X;.2A+MFTTK,A><R]>GN-L46[+Z?\OGRPT7#U@D1!H)7SH D70 HI @
MDJ8>2H3\@<"$N Q8E]E%9F)[41<NUI0OG(JV(XD[BCJT3+,3J'X;8$]\F-*;
M2FY0N]DGV(@*SLYE9Z[C[!/MM)JS]VK#3WT]*UB& $_/J\V;$-]$_KIDXLS\
M]U7YP,J^8_NS#971*!L<[U.U+DM)B'F,1(P#A%//4P,$,A0RS\-A&#%?!"#W
M8"I.I]Y):TUC+LVMC'.*XVAXJ(?OS,].T^WX$9X(T%51G*&2->>.O)55<0=-
MT^H'P4N'KS[$H]B\J .;24<P3PZH+2]H,C[G]9RFAOO$VYJ<H-E'X*"_Y)W\
M&WO;VP(6NGX8)2'R7*IJFX)$^FENB!@.(YRY'A&I5OL,'6)3[TE*#Y<MGU>B
M+#,\8 1F>7L!TS.>MF" V;\#JLII4W2=/^H_)S%J.H):LDN]I&8U+3I"'UL'
MK7M,MA:*IB^L*H<LY_YJU@-WW#JQAK8H.A^%FG:^7-?[!?+'_ZI?#]PEM<[^
MR2B!H=LE?;):&W<\()?A]L?I>C/N=IP5YG!SX_QE\$1&W;SJS?/I_7*[$C*\
MH8P*CR)&"5.?197]S#"BGL<%Y=C''M9-7QPO/K&2E334%]#S?Z(_-PW0WO23
M%2=@#*<HQH@(4RNH=*"$Q#DQC-(0)XO-EGPX)T8[Y7#VFM%#3#YXEV5J_6A$
M!>7"34*2H,AWJ4H8")3$4JWB((YC'*2$^EH3![4I3AWX5W,L/B#/J:B/GVMR
M!KE^]9L$#V#8?1:*\:-.SF!B//!D/#:CQIY 7I<QTT_ZQ328@7)FP?>:A-(O
M7\\\E($;#<L@=H45MUD[Q*^'.Y;1?)D$*'.#=68*.@YE')%W2[I-,N+$#A:V
MB@O&,3-O"8(5X$X*%>RL:IC>(L7WQ9JK/U3/_E>R*A??7DH-5RV JY.B&0V3
M1/@49<S/U*QXB@@3/J*"!HGK9XE/0?6[6E0G=D'*)N8JD\W47\2>#6"Z2PM
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M8WGN_JD#Q,?'7#RJ62)W$K=2 W=14^'4HZ<<U7L7$"*>@T(C1K2  C!(U ;
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MZIWB91RE"16(!"2@:9@R#S:QJ(?6U"F&IL*ZF<BXR9V2NN$DN3[4-+,+=K
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M-DZ-H+ZMF_=>.#6@Z@=[0.M(7++43L?. JI)+F-*< T3&O9!-LQJF&(#2VV
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MN&GJI/2N>9 :R=+^5@*&:AQ*J9&*-A40F($^*YO5R1J=TIBEG0]6FB_;W"7
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MJ6%2$ZN[(NP<4-:;3P0%3$_1[<  TW)3!,!J/2R<)9WN(32K0@\+?*S-&G?
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M&2@:SG#6$&A3F%BZS$LF++>B).R!2(5"(=R!HR@9ZYV-AF5O9$U4W%EZLW>
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M,-M+=WMH3.9N5,GN3+ZFZ?S'&08F<P1[L:A?B]=XDN8#R3B)6I2WVRF#X):
M$:X\OW/!ZI #BJBZP5E/3PN6IHI35$WH#=B64^3$E>K*C\G-TGEIE7F:?T/#
M6<0U* 79RED%.H4$(CN,+Z@FH$GPC-ALO="5$?0L02W8GBH0JB?V!C"TE,N
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MZ $/[R>7;C@>:$6TR)3@3I(:8V(9P20M0%JM5<)XF5A6&3M/$M((9G97],.
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ME9\-X]!-?URX4;KN>+5H-.-98BG[##JSDOO+R(C2 I0-B9#LDJG_6'T=,8U
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M$;7%]4=7X.E:V\]>@+Q&]%OCYEN:^DD7KY)+:POT]4;I'E.?)J^6)\O6""Z
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MF;GGR:QDNMY=S8;C-)L=3BX]GM#7B%BV22]-BF;#>[D9QAW)T49P2F,((D4
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M%L*!MIR 4 S/<D8L1$THA@8L*E_;?KZ*P)V;MFRRV)TM8ZD4S#BPQI9'>M*
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M2#R!49:!5D0'YCQU>J,&AYM@J$^7?0=E/53W%I+K6>%_365\4(H'W]+4W3#
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M_; 9UZN.L_NK-8B2;?2Y_OC:0;BMH.3H.QZ[XT>L<"IL++3'9$OK*:?!!V;
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M9<ECBDQZV- X@B6J&;,D=_A2=B'*WB+\4DME$#]J62#VL +LI@*6^3SKCO4
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M)12?O(I.+TG>]!UJ%S8?,<ZJ+S$JL#[RIV5ZKK056"&B4@5[90P<;]0CT["
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M(5G3559+916$=-VG]-%P3PU+]X#8I_7SR[%;@5C+!=9>]12W=C8L[Z'+;^N
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M+[;/D^P3?^82S*=,RU.?+A3V?QRNOE)I9ZP50U<&7:($I.%Y%D_&OA0 C:)
M3X\Y(\'OL.*Z+HUJ+O67=*<YN?QY%N"*$XF[35C!:3R B49,*6TM.(NN%*8
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M$%H"]8@TD(6E%$3-7/@JB#A!M(-!MWBU.)9R!L@2"^;1THCY4%C%%2M12!1
M%"J$"BUGR)Z FYA%4HW,!*(:!L+DFN-"W'[I[$8K*W-(,Q-CEJS]BW!=<[NP
MUE\(S)O=MPWOY-24:"I+L.4&%44"'RED5XQK('!@L(4O@2H9(")]*4QLQ:U8
M@KQHN=$^A\($4ID"YUG&U$HZE&1:!1#BUX;M(2A"0)2YR'<?@IBG V =)*->
M(5&"VL.C/=BGJ=0>VB?W*&RGECIT6OW,,M8<:!V(K"T;+Q0M+!3A0I.*/0]E
ME+"5_SDMRF(<Z+"Q+?#DVP//VC&YX1(,MN(8*RIDGP=2Q=;8@!=F\RFVV/F
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MWU_V^@&U<5M[BCIPOQD]H-^J_A]02P,$%     @ MJ -61%[6_W"!0  #QD
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MR;U>0@(D:*XWE]RY\=9^%_^0V+7_"/D74$L#!!0    ( +:@#5F\ZS=AM@4
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M7V-A;"YX;6Q02P$"% ,4    " "VH U9WV8Z4#)'   P% , '0
M    @ %@ 0$ 8VLP,# Q.#(T,CDS+3(P,C0P-C,P7V1E9BYX;6Q02P$"% ,4
M    " "VH U96#\$3Q-* @#Q8 , '               @ '-2 $ 8VLP,# Q
M.#(T,CDS+3(P,C0P-C,P7V<Q+FIP9U!+ 0(4 Q0    ( +:@#5EXA)[PK<$
M '#1!P =              "  1J3 P!C:S P,#$X,C0R.3,M,C R-# V,S!?
M;&%B+GAM;%!+ 0(4 Q0    ( +:@#5G827W4NG8  )*)!0 =
M  "  0)5! !C:S P,#$X,C0R.3,M,C R-# V,S!?<')E+GAM;%!+ 0(4 Q0
M   ( +:@#5GDXF,/9 @  +HJ   9              "  ??+! !E>#,Q,5]C
M96\S,#)C97)T-C,P,C0N:'1M4$L! A0#%     @ MJ -6381-69:"   LBH
M !D              ( !DM0$ &5X,S$R7V-F;S,P,F-E<G0V,S R-"YH=&U0
M2P$"% ,4    " "VH U9$7M;_<(%   /&0  '@              @ $CW00
M97@S,C%?8V5O<V5C=&EO;CDP-F-E<G0V,S N:'1M4$L! A0#%     @ MJ -
M6;SK-V&V!0  ^A@  !X              ( !(>,$ &5X,S(R7V-F;W-E8W1I
F;VXY,#9C97)T-C,P+FAT;5!+!08     "P + "H#   3Z00    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>ck0001824293-20240630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ck0001824293="http://www.vallon-pharma.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ck0001824293-20240630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-08-06</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:ThroughFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-01-29</startDate>
            <endDate>2024-01-29</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2024-06-17</startDate>
            <endDate>2024-06-17</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesA1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-20</startDate>
            <endDate>2024-05-20</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-26</startDate>
            <endDate>2024-06-26</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ck0001824293:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesCCommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesCCommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC2CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesTWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:GRIOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ck0001824293:PrivateGRIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <instant>2023-04-20</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">ck0001824293:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-13</startDate>
            <endDate>2022-12-13</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-14</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-09</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-14</startDate>
            <endDate>2022-12-14</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:BridgeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-09</startDate>
            <endDate>2023-03-09</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ExchangeWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ck0001824293:BridgeSecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesB1CommonAndSeriesB2CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-21</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:PreFundedAndSeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ThePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:ThePlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-26</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:SeriesC1CommonSeriesC2CommonWarrantsAndPlacementAgentWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsNotExpiringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInAugust2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInDecember2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInMay2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJuly2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInApril2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInFebruary2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringInJune2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn18MonthsAfterTheWarrantStockholderApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ck0001824293:WarrantsExpiringIn60MonthsAfterTheWarrantStockholderApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:GRIOperationsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-21</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ck0001824293:AmendedAndRestated2018EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001824293</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ck0001824293:FormerChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-21</startDate>
            <endDate>2023-04-21</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="closing">
        <measure>ck0001824293:closing</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-29">0001824293</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-31">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-32">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-49" decimals="4" id="f-267" unitRef="number">0.0333</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-50" decimals="4" id="f-268" unitRef="number">0.14290</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="c-51" decimals="4" id="f-269" unitRef="number">0.07690</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentType contextRef="c-1" id="f-2">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-3">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-7">001-40034</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-8">GRI BIO, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-9">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-10">82-4369909</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-11">2223 Avenida de la Playa</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-12">#208</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-13">La Jolla</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-14">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-15">92037</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-16">619</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-17">400-1170</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-18">Common Stock, par value $0.0001per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-19">GRI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c-1" id="f-26">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c-1" id="f-27">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-28" unitRef="shares">2927707</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-34" unitRef="usd">6353000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-35" unitRef="usd">1808000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-36" unitRef="usd">531000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-37" unitRef="usd">1126000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-38" unitRef="usd">6884000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-39" unitRef="usd">2934000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-40" unitRef="usd">6000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-41" unitRef="usd">8000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-42" unitRef="usd">141000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-43" unitRef="usd">14000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-44" unitRef="usd">7031000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-45" unitRef="usd">2956000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-46" unitRef="usd">1236000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-47" unitRef="usd">1410000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-48" unitRef="usd">935000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-49" unitRef="usd">1270000</us-gaap:AccruedLiabilitiesCurrent>
    <ck0001824293:WarrantLiabilityCurrent contextRef="c-3" decimals="-3" id="f-50" unitRef="usd">0</ck0001824293:WarrantLiabilityCurrent>
    <ck0001824293:WarrantLiabilityCurrent contextRef="c-4" decimals="-3" id="f-51" unitRef="usd">3000</ck0001824293:WarrantLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-52" unitRef="usd">45000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-53" unitRef="usd">14000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-54" unitRef="usd">2216000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">2697000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-56" unitRef="usd">96000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-57" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-58" unitRef="usd">2312000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-59" unitRef="usd">2697000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-60" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-61" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-62"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-63"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-64" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-65" unitRef="shares">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-66" unitRef="shares">801914</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-67" unitRef="shares">801914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-68" unitRef="shares">49663</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-69" unitRef="shares">49663</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValueOutstanding contextRef="c-3" decimals="-3" id="f-70" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding contextRef="c-4" decimals="-3" id="f-71" unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-72" unitRef="usd">40389000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">31792000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-74" unitRef="usd">-35670000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-75" unitRef="usd">-31533000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-76" unitRef="usd">4719000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-77" unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-78" unitRef="usd">7031000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">2956000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">877000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">880000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-82" unitRef="usd">1811000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-83" unitRef="usd">997000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-84" unitRef="usd">1380000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">5054000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-86" unitRef="usd">2342000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-87" unitRef="usd">5926000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-88" unitRef="usd">2257000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">5934000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">4153000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-91" unitRef="usd">6923000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">-2257000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">-5934000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-94" unitRef="usd">-4153000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-95" unitRef="usd">-6923000</us-gaap:OperatingIncomeLoss>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-5" decimals="-3" id="f-96" unitRef="usd">1000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-6" decimals="-3" id="f-97" unitRef="usd">122000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-1" decimals="-3" id="f-98" unitRef="usd">3000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <ck0001824293:ChangeInFairValueOfWarrantLiability contextRef="c-7" decimals="-3" id="f-99" unitRef="usd">122000</ck0001824293:ChangeInFairValueOfWarrantLiability>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">6000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">-934000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-102" unitRef="usd">13000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-7" decimals="-3" id="f-103" unitRef="usd">-2095000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">-2250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-106" unitRef="usd">-4137000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-107" unitRef="usd">-8896000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-4.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">-4.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">-239.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-239.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-8.82</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-8.82</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">-433.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-115"
      unitRef="usdPerShare">-433.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-116" unitRef="shares">457742</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-117" unitRef="shares">457742</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-118" unitRef="shares">28181</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-119" unitRef="shares">28181</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-120" unitRef="shares">469100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-121" unitRef="shares">469100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-122" unitRef="shares">20536</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-123" unitRef="shares">20536</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-124" unitRef="shares">10987</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-125" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-126" unitRef="usd">16871000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-127" unitRef="usd">-18496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-128" unitRef="usd">-1625000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-129" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-130" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-14"
      decimals="INF"
      id="f-131"
      unitRef="shares">5</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-12" decimals="-3" id="f-132" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-13" decimals="-3" id="f-133" unitRef="usd">532000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-134" unitRef="usd">-2150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-135" unitRef="usd">-2150000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-136"
      unitRef="shares">10992</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-137" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-138" unitRef="usd">17416000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-139" unitRef="usd">-20646000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-140" unitRef="usd">-3230000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-141" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-142" unitRef="usd">13000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="c-21"
      decimals="INF"
      id="f-143"
      unitRef="shares">1802</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-21"
      decimals="INF"
      id="f-144"
      unitRef="shares">480</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-20" decimals="-3" id="f-145" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodValueWarrantExercises contextRef="c-6" decimals="-3" id="f-146" unitRef="usd">12000</ck0001824293:StockIssuedDuringPeriodValueWarrantExercises>
    <ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing
      contextRef="c-21"
      decimals="INF"
      id="f-147"
      unitRef="shares">13350</ck0001824293:StockIssuedDuringPeriodSharesPreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-20" decimals="-3" id="f-148" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">11721000</ck0001824293:StockIssuedDuringPeriodValuePreClosingFinancing>
    <ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt
      contextRef="c-21"
      decimals="INF"
      id="f-150"
      unitRef="shares">596</ck0001824293:StockIssuedDuringPeriodSharesSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-20" decimals="-3" id="f-151" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt contextRef="c-6" decimals="-3" id="f-152" unitRef="usd">3333000</ck0001824293:StockIssuedDuringPeriodValueSettlementOfDebt>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-21"
      decimals="INF"
      id="f-153"
      unitRef="shares">335</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-20" decimals="-3" id="f-154" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">1875000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalizationExpenses>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization
      contextRef="c-21"
      decimals="INF"
      id="f-156"
      unitRef="shares">4930</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-20" decimals="-3" id="f-157" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization contextRef="c-6" decimals="-3" id="f-158" unitRef="usd">-2940000</ck0001824293:StockIssuedDuringPeriodValueReverseRecapitalization>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-159" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-160" unitRef="usd">-6746000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-23"
      decimals="INF"
      id="f-161"
      unitRef="shares">32485</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-162" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-163" unitRef="usd">31430000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-164" unitRef="usd">-27392000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-165" unitRef="usd">4038000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-27"
      decimals="INF"
      id="f-166"
      unitRef="shares">49663</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-167" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-168" unitRef="usd">31792000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-169" unitRef="usd">-31533000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-170" unitRef="usd">259000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-171" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-31" decimals="-3" id="f-172" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-32"
      decimals="INF"
      id="f-173"
      unitRef="shares">19</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-32"
      decimals="INF"
      id="f-174"
      unitRef="shares">25419</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-175" unitRef="usd">4389000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-176" unitRef="usd">4389000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-32"
      decimals="INF"
      id="f-177"
      unitRef="shares">170812</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-3" id="f-178" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-31" decimals="-3" id="f-179" unitRef="usd">-1887000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-34"
      decimals="INF"
      id="f-180"
      unitRef="shares">245875</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-182" unitRef="usd">36218000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-183" unitRef="usd">-33420000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-184" unitRef="usd">2798000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-38" decimals="-3" id="f-185" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-186" unitRef="usd">37000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment
      contextRef="c-39"
      decimals="INF"
      id="f-187"
      unitRef="shares">187</ck0001824293:StockIssuedDuringPeriodSharesFractionalShareAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-39"
      decimals="INF"
      id="f-188"
      unitRef="shares">353892</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-38" decimals="-3" id="f-189" unitRef="usd">4134000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-190" unitRef="usd">4134000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise
      contextRef="c-39"
      decimals="INF"
      id="f-191"
      unitRef="shares">202334</ck0001824293:StockIssuedDuringPeriodSharesWarrantExercise>
    <us-gaap:NetIncomeLoss contextRef="c-40" decimals="-3" id="f-192" unitRef="usd">-2250000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-193" unitRef="usd">-2250000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-41"
      decimals="INF"
      id="f-194"
      unitRef="shares">801914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-195" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-196" unitRef="usd">40389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-197" unitRef="usd">-35670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-198" unitRef="usd">4719000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">-4137000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-200" unitRef="usd">-8896000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-201" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-202" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-7" decimals="-3" id="f-204" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">74000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-206" unitRef="usd">26000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-3000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-7" decimals="-3" id="f-208" unitRef="usd">63000</us-gaap:FairValueAdjustmentOfWarrants>
    <ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">127000</ck0001824293:OperatingLeaseRightOfUseAssetPeriodicAddition>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-3" id="f-210" unitRef="usd">26000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">-370000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-212" unitRef="usd">750000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">-400000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-214" unitRef="usd">4179000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-215" unitRef="usd">-250000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-216" unitRef="usd">1157000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">127000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-218" unitRef="usd">-30000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-4344000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-220" unitRef="usd">-2119000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-221" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-222" unitRef="usd">8000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-223" unitRef="usd">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-224" unitRef="usd">-8000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">0</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:ProceedsFromAdvancesFromEmployees contextRef="c-7" decimals="-3" id="f-226" unitRef="usd">190000</ck0001824293:ProceedsFromAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">0</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <ck0001824293:RepaymentOfAdvancesFromEmployees contextRef="c-7" decimals="-3" id="f-228" unitRef="usd">195000</ck0001824293:RepaymentOfAdvancesFromEmployees>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-44" decimals="-3" id="f-229" unitRef="usd">9499000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-45" decimals="-3" id="f-230" unitRef="usd">12250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-46" decimals="-3" id="f-231" unitRef="usd">961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-47" decimals="-3" id="f-232" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">1250000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">12000</us-gaap:ProceedsFromWarrantExercises>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">0</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">2939000</ck0001824293:NetLiabilitiesAssumedInConnectionWithReverseRecapitalization>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">0</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <ck0001824293:PaymentOfReverseRecapitalizationCosts contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">2984000</ck0001824293:PaymentOfReverseRecapitalizationCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">1571000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">517000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-7" decimals="-3" id="f-244" unitRef="usd">150000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">8889000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-246" unitRef="usd">6917000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">4545000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">4790000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-249" unitRef="usd">1808000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-250" unitRef="usd">9000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-251" unitRef="usd">6353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-26" decimals="-3" id="f-252" unitRef="usd">4799000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">0</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:StockIssuedForRepaymentOfNotesPayable contextRef="c-7" decimals="-3" id="f-254" unitRef="usd">3333000</ck0001824293:StockIssuedForRepaymentOfNotesPayable>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">0</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">532000</ck0001824293:DebtDiscountAndAdditionalPaidInCapitalRecognizedFromIssuanceOfWarrants>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">0</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">1875000</ck0001824293:StockIssuedForPaymentOfReverseRecapitalizationCosts>
    <ck0001824293:WarrantsIssued contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">0</ck0001824293:WarrantsIssued>
    <ck0001824293:WarrantsIssued contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">18000</ck0001824293:WarrantsIssued>
    <ck0001824293:StockIssuanceCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">367000</ck0001824293:StockIssuanceCostsIncurredButNotYetPaid>
    <ck0001824293:StockIssuanceCostsIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">0</ck0001824293:StockIssuanceCostsIncurredButNotYetPaid>
    <ck0001824293:NoncashMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">0</ck0001824293:NoncashMergerRelatedCostsFinancingActivities>
    <ck0001824293:NoncashMergerRelatedCostsFinancingActivities contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">72000</ck0001824293:NoncashMergerRelatedCostsFinancingActivities>
    <us-gaap:NatureOfOperations contextRef="c-1" id="f-265">ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date of inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders. The Company&#x2019;s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases. The Company&#x2019;s lead product candidate, GRI-0621, is an oral inhibitor of type 1 Natural Killer T cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). The Company&#x2019;s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 Natural Killer T cells and is being developed for the treatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease (SLE) or lupus and multiple sclerosis (MS).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reverse Merger with Vallon Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, pursuant to an Agreement and Plan of Merger, dated as of December 13, 2022, as amended on February 17, 2023 (the Merger Agreement), by and among the Company, GRI Bio Operations, Inc., formerly known as GRI Bio, Inc. (GRI Operations), and Vallon Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Merger Sub), Merger Sub was merged with and into GRI Operations (the Merger), with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company (Note 4). In connection with the closing of the Merger (the Closing), the Company amended its certificate of incorporation and amended its bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recapitalization                              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, and immediately prior to the effective time of the Merger (the Effective Time), the Company effected a reverse stock split of its common stock, par value $0.0001 (Common Stock), at a ratio of  one-for-thirty (the April 2023 Reverse Stock Split). On January 29, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-seven (the January 2024 Reverse Stock Split). On June 17, 2024, the Company effected a reverse stock split of its Common Stock at a ratio of one-for-thirteen (the June 2024 Reverse Stock Split and together with the April 2023 Reverse Stock Split and the January 2024 Reverse Stock Split, the Reverse Stock Splits). Unless otherwise noted, all references to share and per share amounts in these consolidated financial statements reflect the Reverse Stock Splits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 4, the Merger was accounted for as reverse recapitalization under which the historical financial statements of the Company prior to the Merger are the historical financial statements of the accounting acquirer, GRI Operations. All Common Stock, per share and related information presented in the consolidated financial statements and notes prior to the Merger has been retroactively adjusted to reflect the Exchange Ratio (as defined below) and the Reverse Stock Splits for all periods presented, to the extent applicable.&lt;/span&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-48"
      decimals="INF"
      id="f-266"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c-1" id="f-270">LIQUIDITY&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and, as a result, has incurred $35,670 in accumulated deficit through June&#160;30, 2024. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June&#160;30, 2024, the Company had cash of approximately $6,353. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, the Company, GRI Operations and Altium Growth Fund, LP (Altium) entered into a Securities Purchase Agreement, dated December 13, 2022 (the Equity SPA), pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes (as defined below) in return for the issuance of shares of GRI Operations common stock (GRI Operations Common Stock) immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued 74,584 shares of GRI Operations Common Stock (the Initial Shares) to Altium and 298,339 shares of GRI Operations Common Stock (the Additional Shares) into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 2,789 shares of the Company&#x2019;s Common Stock and the Additional Shares converted into an aggregate of 11,157 shares of the Company&#x2019;s Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Company&#x2019;s Common Stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into a securities purchase agreement (the February 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering, (i) 25,419 shares (the February 2024 Shares) of  Common Stock, (ii) 359,196 pre-funded warrants (the February 2024 Pre-Funded Warrants) exercisable for an aggregate of 359,196 shares of Common Stock, (iii) 384,615 Series B-1 common warrants (the Series B-1 Common Warrants) exercisable for an aggregate of 384,615 shares of Common Stock, and (iv) 384,615 Series B-2 common warrants (the Series B-2 Common Warrants, and together with the Series B-1 Common Warrants, the Series B Common Warrants) exercisable for an aggregate of 384,615 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The Series B Common Warrants together with the February 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#x201c;February 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $14.30 (less $0.0013 for each February 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain ownership limitations, the February 2024 Warrants became exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0013 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for an 18-month period after February 6, 2024 the date of issuance. As of June&#160;30, 2024, all of the February 2024 Pre-Funded Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the February 2024 Shares and February 2024 Warrants pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright &amp;amp; Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, shares up to $10.0&#160;million of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company has sold 293,892 shares of Common Stock in the ATM Offering at a weighted-average price of $3.27 per share, raising $961 of gross proceeds and net proceeds of $923, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, the Company filed a prospectus supplement to its registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $2,644, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $961 that have been sold under the ATM Offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into a securities purchase agreement (the June 2024 Purchase Agreement), pursuant to which the Company agreed to issue and sell, in a public offering (the June 2024 Offering), (i) 60,000 shares (the June 2024 Shares) of  Common Stock, (ii) 2,125,793 pre-funded warrants (the June 2024 Pre-Funded Warrants) exercisable for an aggregate of 2,125,793 shares of Common Stock, (iii) 2,185,793 Series C-1 common warrants (the Series C-1 Common Warrants) exercisable for an aggregate of 2,185,793 shares of Common Stock, and (iv) 2,185,793 Series C-2 common warrants (the Series C-2 Common Warrants, and together with the Series C-1 Common Warrants, the Series C Common Warrants) exercisable for an aggregate of 2,185,793 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The Series C Common Warrants together with the June 2024 Pre-Funded Warrants are referred to in this Quarterly Report on Form 10-Q as the &#x201c;June 2024 Warrants.&#x201d; The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $1.83 (less $0.0001 for each June 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2024 Pre-Funded Warrants are exercisable for one share of Common Stock at a price per share of $0.0001, are exercisable immediately and will expire when exercised in full. Each Series C Common Warrant is exercisable into one share of Common Stock at a price per share of $1.83 and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Series C Common Warrants (Warrant Stockholder Approval). The Series C-1 Common Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the 18-month anniversary of the Warrant Stockholder Approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the Company&#x2019;s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025. &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Series T Warrants issued in connection with the Merger are not presently subject to forced exercise by the Company as the equity conditions for their forced exercise, which include (among other things) a requirement that shares of Common Stock have a value weighted average price of at least $838.11 per share for the periods specified in the Series T Warrants, are not met. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements, but there can be no assurances any such financing will be available when needed, even if the Company&#x2019;s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of one year from the issuance of these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-271" unitRef="usd">-35670000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-272" unitRef="usd">6353000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-52" decimals="-3" id="f-273" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-53"
      decimals="INF"
      id="f-274"
      unitRef="shares">74584</us-gaap:CommonStockSharesIssued>
    <ck0001824293:CommonStockHeldIntoEscrowAccount
      contextRef="c-48"
      decimals="INF"
      id="f-275"
      unitRef="shares">298339</ck0001824293:CommonStockHeldIntoEscrowAccount>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-49" decimals="-3" id="f-276" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-49" decimals="-3" id="f-277" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-54"
      decimals="INF"
      id="f-278"
      unitRef="shares">2789</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted
      contextRef="c-54"
      decimals="INF"
      id="f-279"
      unitRef="shares">11157</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-55"
      decimals="INF"
      id="f-280"
      unitRef="shares">25419</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-56"
      decimals="INF"
      id="f-281"
      unitRef="shares">359196</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-56"
      decimals="INF"
      id="f-282"
      unitRef="shares">359196</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-283"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-57"
      decimals="INF"
      id="f-284"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-58"
      decimals="INF"
      id="f-285"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-58"
      decimals="INF"
      id="f-286"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-55" decimals="-3" id="f-287" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-55" decimals="-3" id="f-288" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-289"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-56"
      decimals="INF"
      id="f-290"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-291"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-58"
      decimals="INF"
      id="f-292"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-59"
      decimals="INF"
      id="f-293"
      unitRef="usdPerShare">14.30</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="INF"
      id="f-294"
      unitRef="usdPerShare">0.0013</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-60"
      decimals="INF"
      id="f-295"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="INF"
      id="f-296"
      unitRef="usdPerShare">0.0013</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-61"
      decimals="INF"
      id="f-297"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-61"
      decimals="INF"
      id="f-298"
      unitRef="usdPerShare">14.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-61" id="f-299">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-62"
      decimals="INF"
      id="f-300"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="INF"
      id="f-301"
      unitRef="usdPerShare">14.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-62" id="f-302">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-63"
      decimals="INF"
      id="f-303"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-64" decimals="-5" id="f-304" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-64" decimals="3" id="f-305" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-65"
      decimals="INF"
      id="f-306"
      unitRef="shares">293892</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-66"
      decimals="2"
      id="f-307"
      unitRef="usdPerShare">3.27</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-65" decimals="-3" id="f-308" unitRef="usd">961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-65" decimals="-3" id="f-309" unitRef="usd">923000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-67" decimals="-3" id="f-310" unitRef="usd">2644000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-65" decimals="-3" id="f-311" unitRef="usd">961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-68"
      decimals="INF"
      id="f-312"
      unitRef="shares">60000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-69"
      decimals="INF"
      id="f-313"
      unitRef="shares">2125793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-69"
      decimals="INF"
      id="f-314"
      unitRef="shares">2125793</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-70"
      decimals="INF"
      id="f-315"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-70"
      decimals="INF"
      id="f-316"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-71"
      decimals="INF"
      id="f-317"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-71"
      decimals="INF"
      id="f-318"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-68" decimals="-3" id="f-319" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-68" decimals="-3" id="f-320" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-72"
      decimals="INF"
      id="f-321"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-69"
      decimals="INF"
      id="f-322"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-70"
      decimals="INF"
      id="f-323"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-71"
      decimals="INF"
      id="f-324"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-72"
      decimals="INF"
      id="f-325"
      unitRef="usdPerShare">1.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-73"
      decimals="INF"
      id="f-326"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-73"
      decimals="INF"
      id="f-327"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-73"
      decimals="INF"
      id="f-328"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-74"
      decimals="INF"
      id="f-329"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-75"
      decimals="INF"
      id="f-330"
      unitRef="usdPerShare">1.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-76" id="f-331">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-77" id="f-332">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharePrice
      contextRef="c-78"
      decimals="2"
      id="f-333"
      unitRef="usdPerShare">838.11</us-gaap:SharePrice>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-334">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2023 balance sheet was derived from the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, the unaudited interim consolidated financial statements furnished herein include all normal and recurring adjustments considered necessary to present fairly the Company&#x2019;s financial position as of June&#160;30, 2024, and the consolidated results of operations and consolidated stockholders&#x2019; deficit for the three and six months ended June&#160;30, 2024 and 2023 and consolidated cash flows for the three and six months ended June&#160;30, 2024 and 2023. Consolidated results of operations for the three and six months ended June&#160;30, 2024 are not necessarily indicative of the operating results that may be expected for the year ending December&#160;31, 2024. The unaudited interim consolidated financial statements, presented herein, do not contain the required disclosures under GAAP for annual consolidated financial statements. The accompanying unaudited interim consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December&#160;31, 2023, included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March&#160;28, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the six months ended June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As the Company had a net loss in each of the three and six months ended June&#160;30, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,302,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,305,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2024 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-335">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States (GAAP) for interim financial periods and pursuant to the rules of the Securities and Exchange Commission (the SEC). Any reference in the accompanying unaudited interim financial statements to &#x201c;authoritative guidance&#x201d; is meant to refer to GAAP as found in the Accounting Standards Codification (ASC) and Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The December&#160;31, 2023 balance sheet was derived from the Company&#x2019;s audited consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim consolidated financial statements include the accounts of GRI Bio, Inc. and its wholly-owned subsidiary, GRI Bio Operations, Inc. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-337">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Estimates and assumptions are primarily made in relation to the valuation of share options, warrant issuance and subsequent revaluations, valuation allowances relating to deferred tax assets, accrued expenses and estimation of the incremental borrowing rate for the operating lease. If actual results differ from the Company&#x2019;s estimates, or to the extent these estimates are adjusted in future periods, the Company&#x2019;s consolidated results of operations could either benefit from, or be adversely affected by, any such change in estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-338">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820), establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The three levels of fair value hierarchy defined by ASC 820 are described below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company&#x2019;s financial instruments included cash, cash equivalents, prepaid expenses and other current assets, accounts payable, accrued expenses and certain liability classified warrants. The carrying amounts reported in the balance sheets for cash, cash equivalents, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair value based on the short-term maturity of these instruments. The Company recognizes transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. At June&#160;30, 2024, there were no financial assets or liabilities measured at fair value on a recurring basis other than the liability classified warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Vallon Pharmaceuticals, Inc. (Vallon) issued warrants (the May 2022 Warrants) in connection with a securities purchase agreement. Vallon evaluated the May 2022 Warrants in accordance with ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging &#x2014; Contracts in Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 815-40), and concluded that a provision in the May 2022 Warrants related to the reduction of the exercise price in certain circumstances precluded the May 2022 Warrants from being accounted for as components of equity. As a result, the May 2022 Warrants were recorded as a liability on the balance sheet. Vallon recorded the fair value of the May 2022 Warrants upon issuance using a Black-Scholes valuation model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to revalue the May 2022 Warrants at each reporting date with any changes in fair value recorded in its statement of operations. The valuation of the May 2022 Warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The change in the fair value of the Level 3 warrant liability is reflected in the statement of operations for the six months ended June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c-1" id="f-339">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred Stock Issuance Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred stock issuance costs represent incremental costs incurred that are directly attributable to proposed offerings of securities. The costs are charged against the gross proceeds of the respective offering upon closing.&lt;/span&gt;&lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-340">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Common Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year. Diluted net loss per common share is computed based on the weighted average number of shares of common stock outstanding during each year, plus the dilutive effect of options considered to be outstanding during each year, in accordance with ASC 260,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As the Company had a net loss in each of the three and six months ended June&#160;30, 2024 and 2023, diluted net loss per common share is the same as basic net loss per common share for the period because the effects of potentially dilutive securities are antidilutive.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-341">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common stock equivalents excluded from the diluted net loss per common share calculations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.177%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.983%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.985%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,302,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,305,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-79" decimals="0" id="f-342" unitRef="shares">2503</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-80" decimals="0" id="f-343" unitRef="shares">1094</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-81" decimals="0" id="f-344" unitRef="shares">5302813</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-82" decimals="0" id="f-345" unitRef="shares">40253</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="0" id="f-346" unitRef="shares">5305316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="0" id="f-347" unitRef="shares">41347</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-348">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the applicability and impact of all ASUs issued during the quarter ended June&#160;30, 2024 and each was determined to be either not applicable or expected to have minimal impact on these financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-349">MERGER WITH VALLON&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, pursuant to the Merger Agreement, Merger Sub was merged with and into GRI Operations, with GRI Operations surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Closing, the Company amended its certificate of incorporation and bylaws to change its name from &#x201c;Vallon Pharmaceuticals, Inc.&#x201d; to &#x201c;GRI Bio, Inc.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Effective Time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each share of GRI Operations Common Stock outstanding immediately prior to the Effective Time, including any shares of GRI Operations Common Stock issued pursuant to the Equity SPA, automatically converted solely into the right to receive a number of shares of the Company&#x2019;s Common Stock equal to 0.0374 (the Exchange Ratio).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Each option to purchase shares of GRI Operations Common Stock (each, a GRI Operations Option) outstanding and unexercised immediately prior to the Effective Time under the GRI Bio, Inc. 2015 Equity Incentive Plan, as amended (the GRI Operations Plan), whether or not vested, converted into and became an option to purchase shares of the Company&#x2019;s Common Stock, and the Company assumed the GRI Operations Plan and each such GRI Operations Option in accordance with the terms of the GRI Operations Plan (the Assumed Options). The number of shares of Common Stock subject to each Assumed Option was determined by multiplying (i) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Option, as in effect immediately prior to the Effective Time, by (ii) the Exchange Ratio, and rounding the resulting number down to the nearest whole number of shares of Common Stock. The per share exercise price for the Common Stock issuable upon exercise of each Assumed Option was determined by dividing (A) the per share exercise price of such Assumed Option, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio and rounding the resulting per share exercise price up to the nearest whole cent. Any restriction on the exercise of any Assumed Option continued in full force and effect and the term, exercisability, vesting schedule, and any other provisions of such Assumed Option otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Each warrant to purchase shares of GRI Operations Common Stock (the GRI Operations Warrants) outstanding immediately prior to the Effective Time was assumed by the Company and converted into a warrant to purchase shares of Common Stock (the Assumed Warrants) and thereafter (i) each Assumed Warrant became exercisable solely for shares of the Common Stock; (ii) the number of shares of Common Stock subject to each Assumed Warrant was determined by multiplying (A) the number of shares of GRI Operations Common Stock that were subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting number down to the nearest &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;whole number of shares of Common Stock; and (iii) the per share exercise price for shares of Common Stock issuable upon exercise of each Assumed Warrant was determined by dividing (A) the exercise price per share of GRI Operations Common Stock subject to such GRI Operations Warrant, as in effect immediately prior to the Effective Time, by (B) the Exchange Ratio, and rounding the resulting exercise price up to the nearest whole cent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;The Bridge Warrants (Note 8) were exchanged for warrants (the Exchange Warrants) to purchase an aggregate of 4,632 shares of the Company&#x2019;s Common Stock. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $1,340.43 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;All rights with respect to GRI Operations restricted stock awards were assumed by the Company and converted into Company restricted stock awards with the number of shares subject to each restricted stock award multiplied by the Exchange Ratio and rounding the resulting number down to the nearest whole number of shares of the Company&#x2019;s Common Stock. The term, exercisability, vesting schedule and other provisions of the GRI Operations restricted stock awards otherwise remained unchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Merger was accounted for as a reverse recapitalization under GAAP because the primary assets of Vallon were cash and cash equivalents. For accounting purposes, GRI Operations was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i)  the equity holders of GRI Operations immediately prior to the Merger owned, or held rights to acquire, in the aggregate approximately 85% of the outstanding shares of the Company&#x2019;s Common Stock and the Company&#x2019;s stockholders immediately prior to the Merger owned approximately 15% of the outstanding shares of the Company&#x2019;s Common Stock (ii) GRI Operations holds the majority (4 out of 5) of board seats of the combined company, and (iii) GRI Operations&#x2019; management holds the majority of key positions in the management of the combined company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;In addition to the transaction costs noted above, at the Effective Time, 4,363 shares of Common Stock were issued to GRI Operations&#x2019; financial advisor for services related to the Merger.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <ck0001824293:CommonStockExchangeRatio contextRef="c-83" decimals="4" id="f-350" unitRef="number">0.0374</ck0001824293:CommonStockExchangeRatio>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-84"
      decimals="INF"
      id="f-351"
      unitRef="shares">4632</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-84"
      decimals="2"
      id="f-352"
      unitRef="usdPerShare">1340.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-85" decimals="2" id="f-353" unitRef="number">0.85</ck0001824293:CommonStockOwnershipPercentage>
    <ck0001824293:CommonStockOwnershipPercentage contextRef="c-86" decimals="2" id="f-354" unitRef="number">0.15</ck0001824293:CommonStockOwnershipPercentage>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-355">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the net liabilities assumed in the Merger:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.568%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;April 21, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,190)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: Transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,984)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net liabilities assumed plus transaction costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,923)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-48" decimals="-3" id="f-356" unitRef="usd">941000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-48" decimals="-3" id="f-357" unitRef="usd">310000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses contextRef="c-48" decimals="-3" id="f-358" unitRef="usd">4190000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccountsPayableAndAccruedExpenses>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-48" decimals="-3" id="f-359" unitRef="usd">-2939000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-48" decimals="-3" id="f-360" unitRef="usd">2984000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts contextRef="c-48" decimals="-3" id="f-361" unitRef="usd">-5923000</ck0001824293:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetIncludingTransactionCosts>
    <ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses
      contextRef="c-49"
      decimals="INF"
      id="f-362"
      unitRef="shares">4363</ck0001824293:StockIssuedDuringPeriodSharesReverseRecapitalizationExpenses>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-363">FAIR VALUE MEASUREMENTS&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies the guidance in ASC 820 to account for financial assets and liabilities measured on a recurring basis. Fair value is measured as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity's own assumptions (unobservable inputs). The guidance requires that fair value measurements be classified and disclosed in one of the following 3 categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:67.5pt;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:6pt;padding-left:63pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period. There were no transfers between Level 1, 2 and 3 during the six months ended June&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the May 2022 Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.8&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-364">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents, for each of the fair value hierarchy levels required under ASC 820, the Company&#x2019;s liabilities that are measured at fair value on a recurring basis at June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.594%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets (Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs (Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant Other Unobservable Inputs (Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-87" decimals="-3" id="f-365" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-88" decimals="-3" id="f-366" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <ck0001824293:WarrantLiabilityFairValueDisclosure contextRef="c-89" decimals="-3" id="f-367" unitRef="usd">0</ck0001824293:WarrantLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-87" decimals="-3" id="f-368" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-88" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-89" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-371">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the fair value of the Level 3 liability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.984%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Warrant Liability &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of June&#160;30, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4.6pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-90" decimals="-3" id="f-372" unitRef="usd">3000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-91" decimals="-3" id="f-373" unitRef="usd">-3000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-92" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-375">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes valuation model was used to estimate the fair value of the May 2022 Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.288%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.427%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172.8&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.3&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.65&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants and the Placement Agent Warrants with the following weighted-average assumptions:&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.1&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-93" decimals="3" id="f-376" unitRef="number">1.728</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-94" decimals="3" id="f-377" unitRef="number">1.710</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-95" decimals="1" id="f-378" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-96" decimals="1" id="f-379" unitRef="number">2.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-97"
      decimals="INF"
      id="f-380"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-98"
      decimals="INF"
      id="f-381"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-99" decimals="4" id="f-382" unitRef="number">0.0462</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-100" decimals="4" id="f-383" unitRef="number">0.0412</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-384">PROPERTY AND EQUIPMENT&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense related to property and equipment was $2 for each of the six-month periods ended June&#160;30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-385">&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.122%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.511%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.512%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-101" decimals="-3" id="f-386" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-102" decimals="-3" id="f-387" unitRef="usd">21000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-103" decimals="-3" id="f-388" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-104" decimals="-3" id="f-389" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-390" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-391" unitRef="usd">34000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-392" unitRef="usd">28000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-393" unitRef="usd">26000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-394" unitRef="usd">6000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-395" unitRef="usd">8000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-396" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-397" unitRef="usd">2000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-398">ACCRUED EXPENSES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-399">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll and related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;632&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;736&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-3" decimals="-3" id="f-400" unitRef="usd">236000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedResearchAndDevelopmentCostsCurrent contextRef="c-4" decimals="-3" id="f-401" unitRef="usd">93000</ck0001824293:AccruedResearchAndDevelopmentCostsCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-3" decimals="-3" id="f-402" unitRef="usd">67000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-4" decimals="-3" id="f-403" unitRef="usd">441000</ck0001824293:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-404" unitRef="usd">632000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-405" unitRef="usd">736000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-406" unitRef="usd">935000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-407" unitRef="usd">1270000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-408">PROMISSORY NOTES&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bridge Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, GRI Operations entered into a Securities Purchase Agreement, dated as of December 13, 2022 (the Bridge SPA), with Altium, pursuant to which GRI Operations issued senior secured promissory notes (Bridge Notes) in the aggregate principal amount of $3,333, in exchange for an aggregate purchase price of $2,500. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were issued in two closings: (i) the first closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on December 14, 2022; and (ii) the second closing for $1,667 in aggregate principal amount (in exchange for an aggregate purchase price of $1,250) closed on March 9, 2023. The Bridge Notes were secured by a lien on all of the Company&#x2019;s assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, upon the funding of each tranche, Altium received warrants to purchase an aggregate of 13,763 shares of Common Stock (the Bridge Warrants). The Bridge Warrants had an exercise price of $121.03 per share, were exercisable at any time on or after the applicable issuance date and had a term of 60 months from the date all shares underlying the Bridge Warrants were freely tradable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The $1,250 of proceeds from the first closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $679 and $571, respectively. The $1,250 of proceeds from the second closing were allocated to the Bridge Notes and Bridge Warrants based on their relative fair values as of the commitment date, resulting in an allocation of $718 and $532, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the Bridge SPA, and also in connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered into the Equity SPA (Note 9) pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#x2019; Common Stock immediately prior to the consummation of the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the Company completed the Merger and the outstanding principal and accrued interest on the Bridge Notes was cancelled and the Bridge Warrants were exchanged for the Exchange Warrants. The Exchange Warrants contain substantively similar terms to the Bridge Warrants and have an initial exercise price equal to $1,340.43 per share subject to adjustments for splits and recapitalization events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Bridge Notes were accounted for as share-settled debt under the accounting guidance in ASC 835-30 and, as such, the initial net carrying amounts were accreted to the redemption amounts using the effective interest method. The Company incurred $205 of debt issuance costs related to its issuance of debt under the Bridge SPA, of which $90 was incurred during the six months ended June&#160;30, 2023 related to its issuance of debt under the Bridge SPA. Interest expense stemming from amortization of debt discounts and issuance costs was $1,161 and $2,104 for the three and six months ended June&#160;30, 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-105" decimals="-3" id="f-409" unitRef="usd">3333000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-106" decimals="-3" id="f-410" unitRef="usd">2500000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <ck0001824293:DebtInstrumentNumberOfClosings
      contextRef="c-106"
      decimals="INF"
      id="f-411"
      unitRef="closing">2</ck0001824293:DebtInstrumentNumberOfClosings>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-107" decimals="-3" id="f-412" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-108" decimals="-3" id="f-413" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-109" decimals="-3" id="f-414" unitRef="usd">1667000</us-gaap:DebtInstrumentFaceAmount>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-110" decimals="-3" id="f-415" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-111"
      decimals="INF"
      id="f-416"
      unitRef="shares">13763</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="2"
      id="f-417"
      unitRef="usdPerShare">121.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-111" id="f-418">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-108" decimals="-3" id="f-419" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-112" decimals="-3" id="f-420" unitRef="usd">679000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-113" decimals="-3" id="f-421" unitRef="usd">571000</us-gaap:ProceedsFromNotesPayable>
    <ck0001824293:DebtInstrumentAggregatePurchasePrice contextRef="c-110" decimals="-3" id="f-422" unitRef="usd">1250000</ck0001824293:DebtInstrumentAggregatePurchasePrice>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-114" decimals="-3" id="f-423" unitRef="usd">718000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="c-115" decimals="-3" id="f-424" unitRef="usd">532000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-52" decimals="-3" id="f-425" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-116"
      decimals="2"
      id="f-426"
      unitRef="usdPerShare">1340.43</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-117" decimals="-3" id="f-427" unitRef="usd">205000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-118" decimals="-3" id="f-428" unitRef="usd">90000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-6" decimals="-3" id="f-429" unitRef="usd">1161000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-7" decimals="-3" id="f-430" unitRef="usd">2104000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-431">STOCKHOLDERS&#x2019; EQUITY&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with signing the Merger Agreement, the Company, GRI Operations and Altium entered the Equity SPA pursuant to which Altium agreed to invest $12,250 in cash and cancel any outstanding principal and accrued interest on the Bridge Notes in return for the issuance of shares of GRI Operations&#x2019; Common Stock immediately prior to the consummation of the Merger. Pursuant to the Equity SPA, immediately prior to the Closing, GRI Operations issued the Initial Shares to Altium and the Additional Shares into escrow with an escrow agent for net proceeds of $11,704, after deducting offering expenses of $546.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Closing, pursuant to the Merger, the Initial Shares converted into an aggregate of 2,789 shares of Common Stock and the Additional Shares converted into an aggregate of 11,157 shares of Common Stock. On May 8, 2023, in accordance with the terms of the Equity SPA, the Company and Altium authorized the escrow agent to, subject to beneficial ownership limitations, disburse to Altium all of the shares of the Common Stock issued in exchange for the Additional Shares. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;February 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 1, 2024, the Company entered into the February 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the February 2024 Offering, (i) 25,419 February 2024 Shares, (ii) 359,196  February 2024 Pre-Funded Warrants exercisable for an aggregate of 359,196 shares of Common Stock, (iii) 384,615 Series B-1 Common Warrants exercisable for an aggregate of 384,615 shares of Common Stock and (iv) 384,615 Series B-2 Common Warrants exercisable for an aggregate of 384,615 shares of Common Stock for net proceeds of $4,389, after deducting offering expenses of $1,110. The securities were offered in combinations of (a) one February 2024 Share or one February 2024 Pre-Funded Warrant, together with (b) one Series B-1 Common Warrant and one Series B-2 Common Warrant, for a combined purchase price of $14.30 (less $0.0013 for each February 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to certain ownership limitations, the February 2024 Warrants were exercisable upon issuance. Each February 2024 Pre-Funded Warrant was exercisable for one share of Common Stock at a price per share of $0.0013 and expired when exercised in full. Each Series B-1 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for a five-year period after February 6, 2024, the date of issuance. Each Series B-2 Common Warrant is exercisable into one share of Common Stock at a price per share of $14.30 for an 18-month period after February 6, 2024, the date of issuance. The February 2024 Warrants were classified as equity and the allocated fair value of $4,279 is included in additional paid in capital. As of June&#160;30, 2024, all of the February 2024 Pre-Funded Warrants have been exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the amount paid for the February 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series B-1 Common and Series B-2 Common Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.3&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.65&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the securities pursuant to the February 2024 Purchase Agreement, the exercise price of the Series A-1 Warrants issued in connection with the Merger was reduced to par, or $0.0001, per share pursuant to the terms of the Series A-1 Warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;May 2024 At The Market Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 20, 2024, the Company entered into the Sales Agreement with Wainwright, pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement,  shares up to $10.0&#160;million of Common Stock from time to time in the ATM Offering. Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company has sold 293,892 shares of Common Stock in the ATM Offering at a weighted-average price of $3.27 per share, raising $961 of gross proceeds and net proceeds of $923, after deducting commissions to the sales agent and other ATM Offering related expenses. On July 26, 2024, the Company filed a prospectus supplement to its registration statement on Form S-1 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $2,644, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $961 that have been sold under the ATM Offering.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;June 2024 Securities Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2024, the Company entered into the June 2024 Purchase Agreement, pursuant to which the Company agreed to issue and sell, in the June 2024 Offering, (i) 60,000 June 2024 Shares, (ii) 2,125,793 June 2024 Pre-Funded Warrants exercisable for an aggregate of 2,125,793 shares of Common Stock, (iii) 2,185,793  Series C-1 Common Warrants exercisable for an aggregate of 2,185,793 shares of Common Stock, and (iv) 2,185,793 Series C-2 Common Warrants, exercisable for an aggregate of 2,185,793 shares of Common Stock for net proceeds of $3,172, after deducting offering expenses of $1,057. The securities were offered in combinations of (a) one June 2024 Share or one June 2024 Pre-Funded Warrant, together with (b) one Series C-1 Common Warrant and one Series C-2 Common Warrant, for a combined purchase price of $1.83 (less $0.0001 for each June 2024 Pre-Funded Warrant).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The June 2024 Pre-Funded Warrants are exercisable for one share of Common Stock at a price per share of $0.0001, are exercisable immediately and expire when exercised in full. Each Series C Common Warrant is exercisable into one share of Common Stock at a price per share of $1.83 and are exercisable beginning on the effective date of the Warrant Stockholder Approval. The Series C-1 Common Warrants will expire on the five-year anniversary of the Warrant Stockholder Approval. The Series C-2 Common Warrants will expire on the 18-month anniversary of the Warrant Stockholder Approval. The June 2024 Pre-Funded Warrants and the Series C Common Warrants were classified as equity and the allocated fair value of $2,908 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to an engagement agreement (the Engagement Agreement) with Wainwright, the Company, in connection with the June 2024 Offering, agreed to issue to Wainwright, or its designees, warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153,006&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of Common Stock (the Placement Agent Warrants). The Placement Agent Warrants have an exercise price of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.2875&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share, will expire on June 26, 2029 and are exercisable following the Warrant Stockholder Approval. The Placement Agent Warrants were classified as equity and the fair value of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$229 is included in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the amount paid for the June 2024 Pre-Funded Warrants approximates their fair value. The Black-Scholes option-pricing model was used to estimate the fair value of the Series C-1 Common Warrants, the Series C-2 Common Warrants and the Placement Agent Warrants with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.012%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159.1&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term in years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92&#160;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had the following warrants outstanding to purchase Common Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,125,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Do not expire&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384,615&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,950&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,117.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$27,300.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2,561.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5,586.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384,615&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,185,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18 months after the Warrant Stockholder Approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,185,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after the Warrant Stockholder Approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:InvestmentCompanyCommittedCapital contextRef="c-119" decimals="-3" id="f-432" unitRef="usd">12250000</us-gaap:InvestmentCompanyCommittedCapital>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-49" decimals="-3" id="f-433" unitRef="usd">11704000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-49" decimals="-3" id="f-434" unitRef="usd">546000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c-54"
      decimals="INF"
      id="f-435"
      unitRef="shares">2789</us-gaap:ConversionOfStockSharesConverted1>
    <ck0001824293:ConversionOfStockAdditionalSharesConverted
      contextRef="c-54"
      decimals="INF"
      id="f-436"
      unitRef="shares">11157</ck0001824293:ConversionOfStockAdditionalSharesConverted>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-55"
      decimals="INF"
      id="f-437"
      unitRef="shares">25419</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-56"
      decimals="INF"
      id="f-438"
      unitRef="shares">359196</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-56"
      decimals="INF"
      id="f-439"
      unitRef="shares">359196</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-57"
      decimals="INF"
      id="f-440"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-57"
      decimals="INF"
      id="f-441"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-58"
      decimals="INF"
      id="f-442"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-58"
      decimals="INF"
      id="f-443"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-55" decimals="-3" id="f-444" unitRef="usd">4389000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-55" decimals="-3" id="f-445" unitRef="usd">1110000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-59"
      decimals="INF"
      id="f-446"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-56"
      decimals="INF"
      id="f-447"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-57"
      decimals="INF"
      id="f-448"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-58"
      decimals="INF"
      id="f-449"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-59"
      decimals="INF"
      id="f-450"
      unitRef="usdPerShare">14.30</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="INF"
      id="f-451"
      unitRef="usdPerShare">0.0013</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-60"
      decimals="INF"
      id="f-452"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-60"
      decimals="INF"
      id="f-453"
      unitRef="usdPerShare">0.0013</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-61"
      decimals="INF"
      id="f-454"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-61"
      decimals="INF"
      id="f-455"
      unitRef="usdPerShare">14.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-61" id="f-456">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-62"
      decimals="INF"
      id="f-457"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-62"
      decimals="INF"
      id="f-458"
      unitRef="usdPerShare">14.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-62" id="f-459">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-120" decimals="-3" id="f-460" unitRef="usd">4279000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-121" decimals="3" id="f-461" unitRef="number">1.563</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-122" decimals="2" id="f-462" unitRef="number">1.63</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-123"
      decimals="INF"
      id="f-463"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-124" decimals="4" id="f-464" unitRef="number">0.0465</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-63"
      decimals="INF"
      id="f-465"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-64" decimals="-5" id="f-466" unitRef="usd">10000000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <ck0001824293:SaleOfStockAgentCompensationPercentage contextRef="c-64" decimals="3" id="f-467" unitRef="number">0.030</ck0001824293:SaleOfStockAgentCompensationPercentage>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-65"
      decimals="INF"
      id="f-468"
      unitRef="shares">293892</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-66"
      decimals="2"
      id="f-469"
      unitRef="usdPerShare">3.27</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-125" decimals="-3" id="f-470" unitRef="usd">961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-65" decimals="-3" id="f-471" unitRef="usd">923000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:SaleOfStockMaximumValueOfSharesOffered contextRef="c-67" decimals="-3" id="f-472" unitRef="usd">2644000</ck0001824293:SaleOfStockMaximumValueOfSharesOffered>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-65" decimals="-3" id="f-473" unitRef="usd">961000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-68"
      decimals="INF"
      id="f-474"
      unitRef="shares">60000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-69"
      decimals="INF"
      id="f-475"
      unitRef="shares">2125793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-69"
      decimals="INF"
      id="f-476"
      unitRef="shares">2125793</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-70"
      decimals="INF"
      id="f-477"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-70"
      decimals="INF"
      id="f-478"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-71"
      decimals="INF"
      id="f-479"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-71"
      decimals="INF"
      id="f-480"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-68" decimals="-3" id="f-481" unitRef="usd">3172000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ck0001824293:StockIssuanceCostsOfferingExpenses contextRef="c-68" decimals="-3" id="f-482" unitRef="usd">1057000</ck0001824293:StockIssuanceCostsOfferingExpenses>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-72"
      decimals="INF"
      id="f-483"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-69"
      decimals="INF"
      id="f-484"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-70"
      decimals="INF"
      id="f-485"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction
      contextRef="c-71"
      decimals="INF"
      id="f-486"
      unitRef="shares">1</ck0001824293:SaleOfStockNumberOfSecuritiesIssuedPerTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-72"
      decimals="INF"
      id="f-487"
      unitRef="usdPerShare">1.83</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-73"
      decimals="INF"
      id="f-488"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-73"
      decimals="INF"
      id="f-489"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-73"
      decimals="INF"
      id="f-490"
      unitRef="usdPerShare">0.0001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="c-74"
      decimals="INF"
      id="f-491"
      unitRef="shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-75"
      decimals="INF"
      id="f-492"
      unitRef="usdPerShare">1.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-76" id="f-493">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-77" id="f-494">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-126" decimals="-3" id="f-495" unitRef="usd">2908000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-127"
      decimals="INF"
      id="f-496"
      unitRef="shares">153006</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-127"
      decimals="INF"
      id="f-497"
      unitRef="usdPerShare">2.2875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="c-128" decimals="-3" id="f-498" unitRef="usd">229000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-129" decimals="3" id="f-499" unitRef="number">1.591</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-130" decimals="2" id="f-500" unitRef="number">1.65</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c-131"
      decimals="INF"
      id="f-501"
      unitRef="number">0.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="c-132" decimals="4" id="f-502" unitRef="number">0.0492</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, the Company had the following warrants outstanding to purchase Common Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,125,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Do not expire&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384,615&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;August 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,950&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1,117.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;December 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$27,300.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2,561.65&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;May 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$0.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;July 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$5,586.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;April 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;384,615&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$14.30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;February 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,006&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$2.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;June 2029&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,185,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18 months after the Warrant Stockholder Approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,185,793&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60 months after the Warrant Stockholder Approval&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-133"
      decimals="INF"
      id="f-504"
      unitRef="shares">2125793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-133"
      decimals="INF"
      id="f-505"
      unitRef="usdPerShare">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-134"
      decimals="INF"
      id="f-506"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-134"
      decimals="INF"
      id="f-507"
      unitRef="usdPerShare">14.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-135"
      decimals="INF"
      id="f-508"
      unitRef="shares">8950</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-135"
      decimals="INF"
      id="f-509"
      unitRef="usdPerShare">1117.48</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-136"
      decimals="INF"
      id="f-510"
      unitRef="shares">42</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-136"
      decimals="INF"
      id="f-511"
      unitRef="usdPerShare">27300</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-137"
      decimals="INF"
      id="f-512"
      unitRef="shares">271</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-137"
      decimals="INF"
      id="f-513"
      unitRef="usdPerShare">2561.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-138"
      decimals="INF"
      id="f-514"
      unitRef="shares">13</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-138"
      decimals="INF"
      id="f-515"
      unitRef="usdPerShare">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-139"
      decimals="INF"
      id="f-516"
      unitRef="shares">26</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-139"
      decimals="INF"
      id="f-517"
      unitRef="usdPerShare">5586.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-140"
      decimals="INF"
      id="f-518"
      unitRef="shares">384615</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-140"
      decimals="INF"
      id="f-519"
      unitRef="usdPerShare">14.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-141"
      decimals="INF"
      id="f-520"
      unitRef="shares">153006</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-141"
      decimals="INF"
      id="f-521"
      unitRef="usdPerShare">2.29</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-142"
      decimals="INF"
      id="f-522"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-142"
      decimals="INF"
      id="f-523"
      unitRef="usdPerShare">1.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-142" id="f-524">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c-143"
      decimals="INF"
      id="f-525"
      unitRef="shares">2185793</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-143"
      decimals="INF"
      id="f-526"
      unitRef="usdPerShare">1.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-143" id="f-527">P60M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-528">STOCK-BASED COMPENSATION&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2015 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GRI Operations adopted the GRI Operations Plan, which provided GRI Operations with the ability to grant stock options, restricted stock awards and other equity-based awards to employees, directors, and consultants. Upon completion of the Merger, the Company assumed the GRI Operations Plan and 982 outstanding and unexercised options issued thereunder, and ceased granting awards under the GRI Operations Plan. As of June&#160;30, 2024, no options remain outstanding under the GRI Operations Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended and Restated 2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 21, 2023, the stockholders of the Company approved the Amended and Restated GRI Bio, Inc. 2018 Equity Incentive Plan, formerly the Vallon Pharmaceuticals, Inc. 2018 Equity Incentive Plan (the A&amp;amp;R 2018 Plan). The A&amp;amp;R 2018 Plan had previously been approved by the Company&#x2019;s board of directors, subject to stockholder approval. The A&amp;amp;R 2018 Plan became effective on April 21, 2023, with the stockholders approving an amendment to the A&amp;amp;R 2018 Plan to, among other things, (i) to increase the aggregate number of shares by 1,856&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,381&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; shares of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company&#x2019;s Common Stock &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for issuance as awards under the A&amp;amp;R 2018 Plan, (ii) to extend the term of the A&amp;amp;R 2018 Plan through January 1, 2033, (iii) to prohibit any action that would be treated as a &#x201c;repricing&#x201d; of an award without further approval by the stockholders of Company and (iv) to revise the limits on awards to non-employee directors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The A&amp;amp;R 2018 Plan provides the Company with the ability to grant stock options, restricted stock and other equity-based awards to employees, directors and consultants. Stock options granted by the Company under the A&amp;amp;R 2018 Plan generally have a contractual life of up to 10 years. As of June&#160;30, 2024, awards granted under the A&amp;amp;R 2018 Plan representing the right to purchase or contingent right to receive up to an aggregate of 2,503 shares of the Company's Common Stock were outstanding and 4,367 shares of the Company&#x2019;s Common Stock were reserved for issuance under the A&amp;amp;R 2018 Plan. The number of shares reserved for issuance under the A&amp;amp;R 2018 Plan may be increased pursuant to the A&amp;amp;R 2018 Plan&#x2019;s &#x201c;evergreen&#x201d; provision on the first day of each calendar year beginning January 1, 2024 and ending on and including January 1, 2033, by a number of shares not to exceed 4% of the aggregate number of shares of the Company&#x2019;s Common Stock outstanding on the final day of the immediately preceding calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures equity-based awards granted to employees and non-employees based on their fair value on the date of the grant and recognizes compensation expense for those awards over the requisite service period or performance-based period, which is generally the vesting period of the respective award. The measurement date for service-based equity awards is the date of grant, and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity-based compensation costs are recognized as expense over the requisite service period. The Company records expense for performance-based awards if the Company concludes that it is probable that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2024, all of the outstanding and exercisable stock options were out of the money and therefore had no intrinsic value. At June&#160;30, 2024, the unrecognized compensation cost related to unvested stock options expected to vest was $313. This unrecognized compensation is expected to be recognized over a weighted-average amortization period of 2.47 years &lt;/span&gt;&lt;/div&gt;No equity-based awards were granted during each of the three-month periods ended June&#160;30, 2024 and 2023.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-144"
      decimals="INF"
      id="f-529"
      unitRef="shares">982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-145"
      decimals="INF"
      id="f-530"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-146"
      decimals="INF"
      id="f-531"
      unitRef="shares">1856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-147"
      decimals="INF"
      id="f-532"
      unitRef="shares">2381</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-148" id="f-533">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-149"
      decimals="INF"
      id="f-534"
      unitRef="shares">2503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-149"
      decimals="INF"
      id="f-535"
      unitRef="shares">4367</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum contextRef="c-149" decimals="2" id="f-536" unitRef="number">0.04</ck0001824293:ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInSharesReservedForIssuanceAsPercentageOfAggregateCommonStockOutstandingMaximum>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-537">&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded stock-based compensation related to equity-based awards issued under the GRI Operations Plan and the A&amp;amp;R 2018 Plan in the following expense categories of its accompanying consolidated statements of operations for the three and six months ended June&#160;30, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.261%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.264%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-150" decimals="-3" id="f-538" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-151" decimals="-3" id="f-539" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-152" decimals="-3" id="f-540" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-153" decimals="-3" id="f-541" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-154" decimals="-3" id="f-542" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-155" decimals="-3" id="f-543" unitRef="usd">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-156" decimals="-3" id="f-544" unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-157" decimals="-3" id="f-545" unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-546" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-547" unitRef="usd">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-548" unitRef="usd">74000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-549" unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-550">&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below represents the activity of stock options granted to employees and non-employees for the six months ended June&#160;30, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.816%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:8pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted average remaining contractual term&#160;(years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 4pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,655.14&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.56&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 4pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 4pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-551" unitRef="shares">2503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">471.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-158" id="f-553">P9Y6M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-554" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-555" unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="INF" id="f-556" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-557" unitRef="shares">2503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-558"
      unitRef="usdPerShare">471.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-559">P9Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-560" unitRef="shares">456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-561"
      unitRef="usdPerShare">1655.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-562">P8Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-3" decimals="INF" id="f-563" unitRef="shares">2503</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-564"
      unitRef="usdPerShare">471.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-565">P9Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="-3" id="f-566" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="-3" id="f-567" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-3" decimals="-3" id="f-568" unitRef="usd">313000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-159" id="f-569">P2Y5M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-570">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment contracts with its officers that provide for severance and continuation of benefits in the event of termination of employment by the Company without cause or by the employee for good reason. In addition, in the event of termination of employment following a change in control, the vesting of certain equity awards may be accelerated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Separation and Release Agreement&lt;/span&gt;&lt;/div&gt;In connection with the resignation of David Baker, the Company&#x2019;s Former Chief Executive Officer, pursuant to the Merger, the Company and Mr. Baker entered into a Separation and Release Agreement on April 21, 2023 (the Separation Agreement). Pursuant to the terms of the Separation Agreement and his employment agreement, Mr. Baker will receive continuation of his current salary and certain COBRA benefits for 18 months payable in accordance with the Company&#x2019;s payroll practices. Mr. Baker also received a lump sum payment equal to 150% of his target bonus and agreed to reduce amounts payable with respect to certain future milestone payments.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ck0001824293:COBRABenefitsPaymentPeriod contextRef="c-160" id="f-571">P18M</ck0001824293:COBRABenefitsPaymentPeriod>
    <ck0001824293:PercentageOfTargetBonus
      contextRef="c-160"
      decimals="INF"
      id="f-572"
      unitRef="number">1.50</ck0001824293:PercentageOfTargetBonus>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-573">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-5" id="f-574">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-575">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-576">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
